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ABSTRACT
Formulating healthcare evidence: case studies in medical techno-practice
in the UK, 1990-2000.
The development of multidisciplinary Health Services Research and Health
Technology Assessment in the United Kingdom in the 1990s informs government
R&D policy for a 'knowledge-based health service'. This thesis comprises health
service case studies focused on medical techno-practice in a collection of eight
publications and an original critical review essay. A wide variety of primary and
secondary research methods are used in separate empirical studies. Perspectives
from sociology applied to medicine and health care, science and technology studies
(STS), and the multidisciplinary field of 'health services research' are combined to
offer a detailed and reflexive account.
Health care is a field of policy and technical practice marked by complex, hybrid
problems, as well as being associated with a wide variety of physical hazards and
socially perceived risks. The case studies are drawn from three substantive fields of
healthcare technology and practice affecting large proportions of the population:
human implant technology (total hip prostheses); cancer detection (testing for early-
stage prostate cancer); and outpatient care. The inter-related objectives of the work
are, firstly, to analyse variability in patterns of health care. This enables, secondly,
analysis of observed techno-practice variations in terms of their implications for
effectiveness of interventions, social patterns of health care consumption, risks to
patients and health care policy. Thirdly, explanations for variability in practices and
policies can be offered, which suggests the need, fourthly, for sociologically-
informed approaches to analysing policy for the introduction of 'new technology'
into healthcare systems. The final objective is to make the case for, and contribute to
a sociopolitical analysis of the advance of the new healthcare sciences and their
articulation with public policy in contemporary advanced health care systems.
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The results of the three case studies show the following. The proliferation of costly
artificial hips evoked a national policy response that draws heavily upon health
technology assessment evidence and processes. Early detection of prostate cancer
presents dilemmas associated with surgical specialisation, and conflict between
policy, clinical beliefs and practices. Outpatient care demonstrates tension between
modernisation, evidentiality and the obduracy of shared socio-clinical practices. The
common threads drawing the case studies together are the observed variability in
patterns of health care delivery and practice; underlying patterns of medical beliefs,
professional work organisation and socialisation; the shaping of healthcare risks for
patient populations; and linkages between healthcare innovation, modernisation
and counteracting controls.
The review essay builds upon the published work to develop a reflexive
understanding of the activity of healthcare science as a policy-related enterprise,
and argues that healthcare evidentiality as represented by the new healthcare
sciences, its proponents and its institutional vehicles, should be considered as
having legitimating and regulatory functions. Evidentiality should thus be
considered one of the societal forces that must be embraced by a socio-politics of the
dynamics of healthcare innoyation and governance. The original critical review
essay accompanying the published work contributes to this enterprise.
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1. Introduction
1.1 Aims of the critical review
This review essay summarises the aims, methods, results, conclusions and
contribution to knowledge made by eight submitted publications. A statement is
given ofmy contribution to the multi-author publications presented (Appendix 2).
The majority of the publications present 'evidence' about the variability of different
medical techno-practices, which I define as healthcare provided with the deployment
of technical knowledge or material technology, or both. The essay analyses the
disciplinary underpinnings of the work, and its foundations in the expansion of the
new health care sciences geared toward high-priority health care policy problems
during the 1990s in the United Kingdom. In this essay I combine frames of reference
associated with multidisciplinary 'health services research' (HSR) and 'health
technology assessment' (HTA) with more sociological perspectives associated
especially with science & technology studies (STS) and the sociology of scientific
knowledge. I treat HSR and HTA as examples of newly emergent healthcare
sciences susceptible to the latter approaches.
Three case studies ofmedical techno-practice are presented in the published papers:
artificial hip replacement, early detection ofprostate cancer, and evaluation of
outpatient services. These are chosen because they affect large proportions of the
population and a wide cross-section of it. They have been ofhigh priority within
National Health Service research and development policy in the United Kingdom in
the 1990s, and they demonstrate different patterns of the relationship between
material technology and clinical practice (ranging from high salience of material
technology in artificial hip replacement, through the clinical use and interpretation of
blood testing technology in prostate cancer, to a complex mixture of technologies
and shared clinical practices in outpatient services when considered at a high level of
generality).
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The common themes across the studies taken as a body of work are demonstrated in
detail in this essay. They are summarised in section 1.3.2 below and are drawn out at
the end of each case study chapter. By way of introduction, the first thread drawing
the case studies together is the observed variability in patterns of health care delivery
and practice, which can be interpreted as pointing to organisational 'inefficiencies'
and possible inequalities in social access to healthcare services. Secondly, underlying
observed variability, the case studies exhibit patterns ofshared, collective medical
beliefs, professional workpractices and socialisation at a variety of levels ofmedical
organisation and aggregation. Thirdly, patient populations experiencing these
patterned techno-practices are exposed to particular shaping of healthcare risks, in
other words risks to health and other aspects of citizenship that are attributable to the
healthcare system itself. Finally, I argue that the case studies should be analysed as
demonstrating linkages between the phenomena of healthcare innovation,
modernisation and counteracting controls.
Further, I take the opportunity in this essay to extend the previously published work
by reflecting in particular upon the role of the growth of 'evidentiality' and the new
healthcare sciences as phenomena in themselves associated with the social
legitimation and governance of contemporary public healthcare systems. I argue that
it is important to formulate the societal phenomenon of varieties of scientific
'evidence' as one key discourse in the study of healthcare system innovation.
1.2 Disciplinary perspectives, perspectives on interdisciplinarity
In this introduction it will be useful to discuss the question of the disciplinary
perspectives which I am drawing upon in the submitted publications and in the
critical review presented here. The body ofwork presented in the publications is
diverse both in subject matter and in the disciplinary perspectives that have shaped
the research questions that have been addressed and the methodological approaches
to analysis and interpretation that have been adopted. I suggest that to some extent
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this is symptomatic ofwidespread trends in the institutions of a 'knowledge
economy' and of practices of scientific research as manifest in contemporary health
care systems. The interplay of disciplinary perspectives is a theme that I return to
periodically and build upon in this essay.
The body ofwork presented and discussed here sits somewhat uneasily in the context
of existing, conventional disciplinary and academic-institutional boundaries. It spans
both social science and clinical science, and much (but not all) of the work could
legitimately have been defined as falling within the remit of either. It is the case that
these disciplines and boundaries carry with them a wide variety of different
conventional assumptions and expectations about research methodologies, definition
of research questions, appropriate styles and methods of analysis, and modes of
academic presentation. Thus, for example, in this essay I will occasionally use the
first person to describe aspects ofmy work, in the knowledge that this is a far more
acceptable practice in 'social science' than it is in 'medicine', where third-person
reportage in the passive voice is the norm. I do not dwell here upon the
philosophical, political and methodological issues invoked by this particular
difference.
This thesis embraces, in particular, the academic discipline of sociology, applied to
medicine and health care, and the multidisciplinary areas ofwork commonly known
now as 'health services research' (HSR) and health technology assessment (HTA)
which typically in the 1990s was focused upon research agendas of effectiveness and
cost-effectiveness of public healthcare. The latter I take to bring together in varying
combinations the disciplines, sub-disciplines and practices of epidemiology; public
health medicine; health economics; medical statistics; psychology; organisational
analysis; medical/healthcare sociology; 'qualitative research'; and general practice
and the many specialties ofmedicine and clinical science. Note the inclusion of
sociology and qualitative research in my list. Not all conceptualisations ofHSR/HTA
in the 1990s would have incorporated these. For example a typical handbook of
health service evaluation listed the required 'skills' as: "..biological sciences, clinical
science, clinical practitioners, managers, health economists, statisticians and
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information officers" " (St Leger et al, 19921). And in Paper 1 analysing the
disciplines and epistemology of Health Technology Assessment, I cited a prominent
history of 'medical research' which noted the bringing-together of 'strange
bedfellows, ranging from psychology and the social sciences to biomathematics'
(Weatherall, 1995). HTA, nevertheless, can be characterised as having a rather stable
core methodological programme (Woolf& Henshall, 2000). As these varying listings
suggest, HSR and HTA have become fields of knowledge production marked by
uneasy and unclearly-defined partnerships.
In this essay I will switch between a disciplinary, broadly sociological, perspective
and a 'multidisciplinary' perspective, less clearly aligned with any one
conventionally-defined academic discipline, which I take to be addressed to the
evaluation of health care 'problems'. Health services research is a very good example
of a problem-driven area ofmultidisciplinary research expertise.
At the time ofwriting (2003-4), the academic world has been witnessing for some
years a notable increase in discussion of notions ofmulti-disciplinarity, inter-
disciplinarity and trans-disciplinarity, and a variety of activity representing attempts
to bring disparate disciplines together (e.g. Klein, 1996). The institutionalisation of
this activity can be observed in the creation of a plethora of research institutes,
centres, networks and partnerships in and around the academic world, typically with
a form ofmatrix organisation around broad problem-themes. This development is
evident in (and across) the physical, engineering and medical sciences as well as in
the social sciences. The roots of this trend are themselves a topic worthy of the
attention of social scientists. An analysis of them might point to the roles of science
in a 'knowledge-based economy' (Ravetz, 2001); increasing concern about the
articulation points between research-based knowledge and public policy ('evidence-
based policy and practice', e.g. Davis & Nutley, 1999); increasing movement toward
client and patient-oriented public services (e.g. Mead & Bower 2000; Greener 2003);
the putative advent of a (global) 'risk society' (Beck, 1992; Beck 1999); the rise of
the 'regulatory state' (Moran, 2001) and the movement from government to
11 use the Harvard system of referencing in this thesis.
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governance (Rhodes, 1997); increasing efforts to address the complexity of
sociotechnical issues such as 'the environment' and 'transport'; increasing recognition
of the local and personal expertise of non-academic citizens (Irwin, 1995);
increasing concern about the legitimisation of science (Fuller, 2000); and the effects
of'cognitive revolutions' such as biochemistry, molecular biology and genomics, and
perceived needs to bring different sciences together to engage in practical problem-
solving activity.
In the interdisciplinary field of science and technology studies and in the sociology
of scientific knowledge, some of these trends in the contours of scientific disciplines
and in the application of expert knowledge have been described - in widely quoted
studies - in terms of "Mode 2 Knowledge Production" (Gibbons et al 1992), and
"post-normal science" (Funtowicz and Ravetz, 1992).
Firstly, "Mode 2 knowledge production" is defined as a set of changes characterised
by complexity, hybridity, non-linearity, reflexivity, heterogeneity, and
transdisciplinarity in the cognitive domain. As suggested above, this form of
'knowledge production' involves new configurations ofwork, and a new social
distribution of expertise amongst a wider constituency ofmultiple stakeholders than
previously acknowledged as participants in science. In these circumstances previous
organisational boundaries aligned with mono-disciplinarity start to blur, and
underlying notions of competence may be redefined.
Secondly, "Post-normal science" can be understood as an attempt to conceptualise a
set of developments as a reaction against reductionist and mechanistic assumptions
about the partitioning of physical and social reality, the assumed value-neutrality of
science, the social segregation of science from stakeholder and community
participation, and the belief in science as a vehicle of precision and certainty.
Postnormal science is associated with "unstructured" problems that embody complex
cause-effect relationships crossing traditional domains of enquiry and thus promoting
transdisciplinarity. Such problems typically exhibit a high plurality of social values
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and factual knowledge in contexts where there is pressure to arrive at societally
acceptable policy decisions.
Trends such as those outlined above, I would like to suggest, produce an increasingly
institutionalised tension between mono-disciplinarity and cross-disciplinarity which
is having far-reaching consequences in higher education and research institutions,
both in relation to research and to teaching and learning. These tensions are also to
be felt at the individual level. Strong arguments can be mounted in favour of cross-
disciplinary approaches to tackling 'problems' in public policies and social practices.
For example it has been argued in the case ofunderstanding risk-related behavioural
phenomena, that mono-disciplinarity has a negative impact because of its
'decontextualising and reductionist tendencies' (Horlick-Jones and Sime, 2004).
Health care is a field ofpolicy and practice marked by complex, hybrid problems, as
well as being associated with a wide variety of physical hazards and socially
perceived risks.
Thus it is reasonable to expect that the body ofwork presented and discussed in this
review essay embodies some of the disciplinary tensions from which it arises. This
section has highlighted a concern with the boundaries of disciplines. As well as
embodying disciplinary tensions this essay seeks to challenge these boundaries in a
manner that can engender dialogue, and point toward possibilities for the
constructive development ofmulti-dimensional evaluation in healthcare organisation
and policy processes. Such a challenge to conventional boundaries is echoed, for
example, in calls to 'de-monopolise' the assessment paradigm of Health Technology
Assessment (Webster, 2004) by making policy networks more open to societal
participation and by seeking, in the terms of this essay, to make their assessments of
innovative techno-practice more multi-dimensional.
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1.3 Medical techno-practice: case study topics in health care and
technology
In this section the substantive topics of the published papers are introduced, and the
initial introduction to the relationships and common threads between them (sketched
above in section 1.1) is further described.
In a total of eight research papers (referenced 1 to 8 below, see Appendix 1 for
bibliographic listing), original contributions are made to three substantive health care
topics: human implant technology (total hip prostheses, also referred to as 'artificial
hips' or surgically as 'hip arthroplasty'); cancer detection and care (testing for early-
stage prostate cancer); and outpatient care. This work forms part of the massive
development in multidisciplinary Health Services Research and Health Technology
Assessment which has been characteristic of government R&D policy in the United
Kingdom of seeking to move toward a 'knowledge-based health service' (DoH 1993)
during the 1990s. Part of this policy agenda was increasing awareness of a need for
'good evidence' on which to base an efficient deployment of resources to produce
high-quality patient care. This phenomenon is analysed using approaches drawn
from the sociology of scientific knowledge in one of the papers (Paper 1) which can
be read as an introduction to the epistemology and methodologies ofmuch of the
content of the remaining seven pieces.
As noted above, the three substantive case study topics are all in areas which have
been ofhigh priority within National Health Service research and development
policy in the United Kingdom during the 1990s. The detailed backgrounds to these
topics are outlined in the introductions to the case study chapters 2 to 4 of this review
essay, and are summarised briefly here for convenience.
Artificial hips
Total hip prostheses were by the 1970s a very successful high-technology surgical
procedure, but the health services policy community identified a 'problem' in the
1990s. This was seen as a proliferation of new and often expensive designs of the
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technology, and a parallel variation in patterns of clinical choice ofmodels, for
which the evidence on which to base decisions about clinical effectiveness was
weak. Occasionally devices appeared to fail. This problem required analysis of the
performance of different models of artificial hip. and in this author's view, analysis
of the innovation environment which produced new technologies, and of processes of
the production of'evidence' and regulatory control. The methodology ofHTA
systematic review was required in order to assess and compare existing research on
performance, while historical and sociological approaches were needed to
conceptualise and analyse innovation processes, clinical practices and regulatory
policy.
Detection ofearly-stage prostate cancer
Rates ofmortality from prostate cancer, and the incidence of its detection, were
rising dramatically during the 1980s and early 1990s internationally. However, it was
clear that part of this trend could be attributed to increased rates of detection of the
disease in its early stages, especially through a relatively new diagnostic test which
became widely available to medical practitioners. For the NHS the key question was:
should a population screening programme be introduced utilising this test? The
policy response to this question required knowledge of the performance of the test in
appropriate populations and of how the medical profession was using it in clinical
practice. To address these questions required a combination of clinical science
(urological) knowledge ofpatient profiles and the testing technology, together with
identification of social and organisational 'variables' relevant to clinical practice in
this field. Also helpful would be a sociological understanding of the importance to
the construction ofmen's risk experience of interpretive practices in professional
work. This is offered in this essay.
Outpatient service delivery
In the case of outpatient service delivery, there had been a strong feeling amongst
some commentators and health care practitioners as early as the 1970s that a
phenomenon of 'recycling' of patients through outpatient clinics was common.
Sometimes described as a 'merry-go-round', and often attributed to young doctors
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unable or unwilling to discharge patients, there appeared from these critical
comments to be a degree of unjustifiable use ofNHS hospital resources. The
evidence for this phenomenon and its possible causes, however, was weak. Analysis
of the institutional settings and conventional clinical practice in and through which
outpatient care was delivered, was largely absent in the empirical research record.
Multiple disciplines were again useful in tackling these questions and interpreting the
resulting research.
It is worth noting that what I have described in the paragraphs above as a
requirement to combine sociological perspectives and understandings with
perspectives from HSR/HTA and clinical sciences was not necessarily recognised in
this way by other research participants. My academic-institutional locale was
primarily a department of epidemiology and public health, and my own experience
was that it was difficult to claim (successfully) as sociological certain research
questions, topics or agendas - for example what I formulate in this essay as 'shared
clinical belief systems'. Indeed, in the analysis I present in Paper 1 in this thesis, I
imply that the experience of sociology as a discipline in such environments was often
one ofwhat might be termed de-disciplinisation in which it lacked the authority to
frame research questions and frequently became synonymous with 'qualitative
research' (an unfortunate development in this author's view. However, I suggest that
since the 1990s this situation has altered to some extent with the increased attention,
especially, to patients' experience and the acceptability of healthcare innovations).
Having presented these thumbnail sketches of the three case study topics, and the
methodologies required to address the research questions, I now turn to a synopsis of
the aims of the thesis.
1.3.1 Summary ofAims and Objectives
Given this summary of the substantive themes of the work presented here, in the
submitted papers I have the following objectives:
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A. To apply rigorous, multidimensional, methods of health care evaluation to
three substantive topics, drawing upon a variety of disciplinary perspectives;
B. To analyse variation in patterns of health care delivery at a variety of levels
(in orthopaedic surgery, prostate cancer detection and outpatient services);
C. To analyse observed practice variations in terms of their implications for
effectiveness of interventions, social patterns of health care consumption, and
health care policy;
D. To offer explanations for observed clinical practices and health care policies;
E. To suggest alternative models for analysing policy for the introduction of
'new technology' into the health service, and to suggest specific changes to
health care policies following from the study results;
F. To suggest implications of the case studies for future research - understood
as the 'production of new health care knowledge';
In addition to the case study objectives, this essay has two further objectives:
G. To make the case for, and contribute to a sociopolitical analysis of the
advance of the new healthcare sciences and their articulation with public
policy in contemporary advanced health care systems;
H. To assess the roles and inter-relationships of different disciplines in
producing knowledge relevant to healthcare.
1.3.2 Common themes introduced
As advertised above, a number of common threads draw together the submitted work
when viewed as a whole. These are reprised briefly at the end of each case study
section (chapters 2 to 4) and are discussed at greater length in the context of the
advance of healthcare science during the 1990s, and of the need for a 'sociopolitics'
of healthcare policy, in the final section. Here, I provide some amplification of these
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inter-related themes in order to pave the way for a reading of the case study sections
below, and the published works included in this thesis.
As noted above, Paper 1 presents an analysis of the phenomenon of the growth of
healthcare technology assessment considered as a multidisciplinary problem-oriented
scientific enterprise. HTA and its overlapping movement in healthcare science,
health services research, have a primary concern to assess the quality, effectiveness
and cost-effectiveness of healthcare interventions and systems. A key method of
identifying the existence of possible ineffectiveness is the comparative method. This
has been adopted widely in HSR and HTA. Early illustrations of this method, which
might be termed the 'method of variations', to assess the delivery of health care can
be seen in the work, for example, ofWennberg in the USA and McPherson in the
UK (Wennberg and Gittelsohn, 1982; Wennberg, 1988; McPherson 1988). This has
been and remains a widely used and highly influential approach to assessing the
possible variations, and thus inequalities in health service provision and possible
inefficiencies in modes of service delivery.
In the papers presented in this submission, effectiveness and quality of health care,
represented in patterns of variations, are at issue in a number of dimensions of care
delivery: in the design and composition of different material technologies; in
aggregated professional practitioners' clinical beliefs and practices, and in patterns of
clinical service rate variations within and across secondary care settings. Data and
analysis of such variation is especially to the fore in Paper 3 (variations in
performance of artificial hips), Paper 5 (clinical beliefs and practices in detection of
early prostate cancer) and Paper 6 (variations in re-attendance rates in hospital
outpatient care). Group and hospital-level variations in practice are metaphorically
described later in this essay as 'institutional signatures' by which might be
recognised systematic differences in medical practice at different levels of analysis.
Related to this focus upon care delivery is a concern with medical work organisation
and professional development aspects ofmedicine that underpin observable
variations in the delivery of care services. In particular, a number of the submitted
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papers draw attention to the phenomenon of specialisation and sub-specialisation
within the medical profession. This is evident in the case of orthopaedic surgeons
who specialise in hip prostheses and who practice either in specialist orthopaedic
centres or in general hospitals; in the case of urologists who specialise in prostate
disease and whose work also may be organised through specialist centres or in
general surgical care settings; and in the case of hospital outpatient care considered
broadly, where specialisation and sub-specialisation are seen to be associated with
patterns of variations in service delivery rates some ofwhich are more readily
explicable than others.
One of the important early contributions ofmedical sociology to the understanding
ofmedical practice variations has been to note the 'conventional' and routinised
nature ofmedical encounters, in which the clinical practices of health professionals
employ 'recipes' in negotiating interactions with patients (e.g. Bloor, 1976). While
the detailed analysis of outpatient assessment practices provided by Bloor provides
an argument for the 'local' constructed nature ofprofessional health beliefs, practices
and behaviours, this may be contrasted with both the avowedly cosmopolitan nature
ofmedical knowledge and professional orientation, and the identification of broadly-
defined, shared patterns of institutional and professional practice demonstrated in the
work presented in this thesis. As already noted, the published work included in the
thesis provides examples of patterned variability in collective medical beliefs and
practices in a variety of dimensions, locales and levels of aggregation. As the case
studies show, this includes for example variability between consultant teams and
between organisational units such as hospitals (outpatient services), between age-
cohorts of clinicians across clinical centres (detection of prostate cancer), and
between specialists and non-specialists in particular medical conditions (hip
replacement).
Health hazards and the societal apprehension of 'risk' have assumed an
extraordinarily large place in analysis of contemporary healthcare systems and public
health (e.g. Lupton, 1995; Petersen 1996; Howson 1998; Robertson 2000) and of
course in social theory more broadly, as noted above in the case of Beck's hypothesis
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of the risk society (1992). The papers presented here share a concern with hazards
and the social distribution of risk associated with healthcare itself, sometimes termed
iatrogenic risk (and given its most extreme formulation, perhaps, in the early work of
Illich (1975) but highly relevant to contemporary healthcare (Edwards, 1999)). As
will be demonstrated, this thread runs through all three case study topics, evidenced
in the differential performance and occasional failure of hip prostheses, in the
differential exposure ofmen to the early detection ofprostate cancer and to
psychological risks of appraising the tests for the disease, and in the vagaries of
patients' experience of hospital outpatient care systems. Alongside risks to health
should be set risks to the healthcare system itself, as demonstrated in an analysis of
the research agendas of healthcare science (see Paper 1), and thus the framing of
some of the research questions in the papers presented here, which shows a major
focus upon risks to healthcare budgets and the organisational efficiency of systems of
healthcare delivery.
Technical innovation and innovative healthcare practice, at a general level of
analysis, are central to the substantive topics investigated in the body of work
presented here: innovation in the design and material composition of artificial hips,
innovation in the testing technology available for the diagnosis ofprostate cancer,
and innovation in the organisation and culture of outpatient care. As the case studies
show, and as I try to capture in using the term 'techno-practice', the social and the
technical should be seen as closely interwoven in developing understandings of the
dynamics of healthcare activity. Such activities are, broadly, 'sociotechnical' - as
with other fields of human endeavour (cf. MacKenzie,1999). Of course,
governments and healthcare executives espouse to some degree at least a doctrine of
modernisation that promotes innovation in medical techno-practice. Innovation holds
the potential to engender improved quality and effectiveness of healthcare services.
But as May et al have pointed out (2001), this commitment in contemporary
healthcare culture is often in conflict with the commitment to a strong evidence base
for policy decisions. Indeed, it may be seen as somewhat paradoxical (as noted in
Paper 1: 203) that a high level of innovation in the many facets of healthcare
provision is central to the growth of the new healthcare sciences during the 1990s,
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which brings a radical questioning of the evidential basis on which innovation
decisions are made. This leads us to an analysis of healthcare innovation that accords
the new healthcare sciences themselves a prime position in conceptualising the
dynamics of state attempts to regulate and control innovation in the healthcare
system. Thus I argue that 'evidence-based healthcare' should be conceptualised as a
regulatory and credentialist phenomenon as well as a scientific movement. This point
is developed and discussed further in the final discussion section of this essay.
This brief discussion has sought to draw attention to the main threads which interlink
to draw together the body of work submitted in the published papers presented here.
These interwoven threads can be summarised as analysing and theorising:
• observable variations in patterns ofhealth care delivery and practice;
• patterned variability in medical professional clinical beliefs;
• variable patterns ofmedical professional work organisation and socialisation;
• the shaping of health risks associated with healthcare delivery and policy;
• healthcare innovation, 'evidentiality' and regulatory control;
• reflexive understanding of the activity ofhealthcare science as a policy-related
enterprise manifest in Health Technology Assessment and Health Services
Research.
1.3.3 Methodologies
Overall, the case studies combine substantive empirically-based analysis of selected
aspects of healthcare technology, service delivery and policy, with interpretive
analysis of the methodology and epistemology of health services research. The three
case studies employ a variety of research methods appropriate to each. Each of the
three case studies has its own detailed objectives which are outlined in the respective
sections below. To take up the theme of interdisciplinarity again, it can be noted that
in the text of the published papers the sociological dimensions of the subject-matter
and the analysis are not conspicuous or explicit. This testifies to the fact that much of
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this evidence-producing work was framed in the context of the generic
multidisciplinary field ofHSR and HTA, rather than from the standpoint of research
agendas shaped by social or sociological interests and organisations. It is one of the
tasks of the commentary on the case study chapters presented in this essay to remedy
this by highlighting a sociological framing and interpretation of their subject-matter.
In this respect I suggest that what is distinctively sociological is not whether research
designs and methods of one type or another are used, but rather the institutional
embedding of disciplinary perspectives and the concepts brought to bear, especially,
in the framing of research questions and the interpreting of research results in terms
ofparticular 'literatures'. Thus the argument I develop later in this essay reflexively
builds a socio-political analysis o/HSR/HTA as well as pointing to the
social/sociological elements that were framed originally within HSR/HTA
approaches.
2. Variability in orthopaedic technology: total hip
replacement
2.1 Background
Total hip replacement became a major subject of critical attention in health policy
communities during the 1990s, a development which was in many ways unlikely. By
the 1990s this surgical procedure was hailed generally as one of the success stories of
twentieth century technological medicine (Lefanu, 1999). By the mid-1990s about
40,000 artificial hips were being implanted annually in the United Kingdom. The
general perception, therefore, was that it was a procedure that had reached maturity,
with a very-high success rate in terms of improving mobility and reducing pain for
the many patients, suffering mainly from osteoarthritis or rheumatoid arthritis, who
underwent the procedure. Yet at this time the national NHS R&D Health Technology
Assessment programme rated it as one of the top ten priorities requiring the
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production of robust research-based evidence. Why should total hip replacement
have become such a cause for concern?
An (over-)simple answer to this question can be summarised as being that the
procedure had become a 'victim of its own success'. The papers (Papers 2-4) which I
have submitted here illustrate some aspects of this analysis, and I will elaborate upon
it here. I would like to suggest here that a particular constellation of circumstances
led to the "problematisation" (see e.g. Blume, 1992: 71) of artificial hip replacement
as a controversial techno-practice within contemporary healthcare policy
communities.
As noted above, the observation ofpatterns of variation in healthcare delivery has
been one of the springboards for the upsurge in Health Services Research generally
(Wennberg & Gittelsohn, 1982). Patterns of variation of use of different hip
technologies became apparent both in the United Kingdom and between different
national health care systems during the 1990s. A survey published in 1993 (Newman,
1993) showed that 70% of orthopaedic centres in the UK used both the more
conventional 'cemented' and less conventional 'uncemented' modes of fixation, and
that there was also significant geographical variation. As noted in Paper 4,
uncemented models were more frequently used in the south of England. Thirty-
percent of centres stocked at least two types of the (generally less frequently used)
uncemented models. Thus, before the term 'postcode lottery' became current in
public debate, it appeared that geographical factors would play at least some part in
determining what type of prosthesis patients in a particular population might receive,
and that this was to some extent independent of standards of clinically-defined need.
Similarly, in spite of the internationally shared nature ofmany hospital surgical
procedures, there were also variations in patterns of use of different types of hip
prostheses between countries. One of the most conspicuous examples of this was the
fact that in Finland over 50% of hips implanted were non-cemented, while in
neighbouring Sweden and Norway the percentages were 4% and 15% respectively,
strongly suggesting the influence of non-clinical forces shaping the orthopaedic
marketplace.
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At the same time, a certain amount of concern about the surgical procedure of hip
arthroplasty inflamed the mass media imagination. It appeared that some junior
surgeons had implanted some of the pieces of the implant 'the wrong way round'.
This was reported in newspapers at the time (e.g. The Guardian, 'Shooting at the
Hip', 23.2.93- 'Shoddy material and inept surgeons mean that up to 30% of hip
replacements have to be redone'), and a television programme focused upon 'The
High Price OfHips' (BBC2, 1993), drawing attention to the relatively high cost of
the procedure as well as surgical risks. Concern was also expressed by leading
spokesmen (yes, men) within the orthopaedic profession itself, suggesting that there
were potentially risky trends in hip implantation developing in some parts of the
health service and the profession (Murray et al, 1995; Bulstrode et al, 1993). These
trends were described derogatorily as trends toward 'designer hips', and seen as
marked by commercially-driven innovations. As noted at the end of Paper 2 on the
history of artificial hips, it is ironic that a technology that is invisible to the user
should be shaped in part by social, or at least socio-medical, fashions. This raised the
question of the effect of commercial orthopaedic engineering companies upon
surgical practice, and in particular, in this author's view, pointed to a need to
understand better the development of the technology itself and the routes by which
different technologies reached clinical practice in the National Health Service. This
indicated a need to draw upon perspectives from sociology and science & technology
studies.
Costs of the apparently proliferating new models in particular were high, and
occasionally devices appeared to fail. In 1997 the 3M 'Capital hip system' appeared
to fail dramatically, and was recalled amidst public consternation, though not without
the manufacturer claiming that in some centres the surgeons had used inappropriate
procedures and that they had withdrawn the product anyway, prior to the
controversy, for commercial reasons. My favourite quotation from the media focus
upon this event came from a member ofParliament who was reported to have said
that compared to orthopaedic device design and manufacturing 'quality control is
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better on a lawnmower'! (The Capital incident is described in some more detail in
Kent & Faulkner, 2002).
For total hip prostheses, therefore, the 'problem' as appraised by the health services
policy community, was that there was a proliferation of new designs, and a parallel
variation in patterns of clinical choice ofmodels, for which the evidence on which to
base decisions about clinical effectiveness was weak. The total hip replacement
procedure itself, aside from the technology, was very expensive and with an ageing
population increasingly large numbers of potential implantees appeared to be coming
forward. Thus it appeared to the healthcare policy community that here was a
technology whose design, adoption and diffusion were, essentially, out of control.
2.2 Objectives
Given this background, in Papers 2, 3 and 4 presented here the objectives are to:
- outline the history of innovation in the technology of hip prostheses from earliest
experimentation to current developments (Paper 2);
- describe the range of hip prostheses available in the marketplace of the advanced
(primarily Western) healthcare systems; and to submit the published evidence of the
variation in their clinical effectiveness to critical review, using structured methods to
appraise study quality and to summarise clinical outcomes; to make healthcare policy
and research recommendations (Paper 3);
- to analyse the contribution made by clinical effectiveness studies to the National
Health Service policy for total hip prostheses, to analyse the policy environment
around artificial hips, and to propose further research which would shed light on the
sociopolitical forces at play in that policy environment (Paper 4).
2.3 Methodology
The work on artificial hips comprises: Paper 2, providing an account of the history of
the development of artificial hip technology, using mainly secondary written sources
(a fuller account would require extensive archive research which was beyond the
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scope of the study); this provides the historical context for Paper 3 which is a study
taking a 'health technology assessment' (HTA) perspective to examine knowledge of
the performance of the wide variety of hips available in the NHS and elsewhere,
using a 'systematic review' methodology to examine existing studies. The systematic
review method maps medical knowledge on the subject and subjects its methodology
to critical appraisal; Paper 3 thus represents a 'classic' HSR/HTA research approach
and methodology, but Paper 4 takes a more critical stance and argues that the HSR
approach has certain limitations as a tool for analysing the constituent forces
involved in policymaking about new health technologies and generating
recommendations for health service policy. This paper, therefore, presents a
sociological analysis of the policy context of the regulation of innovation in artificial
hip technology in the UK and in the context of European Union medical device
directives.
2.4 Results
The historical account and the systematic review provide evidence of the
proliferation of innovations in the technology, and of the relative weakness of the
evidence for clinical effectiveness as judged by strict HSR methodological criteria.
Evidence for some models is better than for others, but there is a fundamental
difficulty in attempts to use clinical evidence to evaluate new designs, which the
HTA programme and NHS policy has focused on. The domination of policy
discourse on artificial hips by the HTA agenda of 'clinical effectiveness' is
interpreted, in the third paper, as a limitation of current policy development, and a
sociological research framework is developed to address this bias, drawing especially
upon theory in the sociology of science and technology, 'risk' and regulatory science.
A notable feature of this analysis is that the knowledge, produced mainly by
orthopaedic surgeons themselves, about the performance of artificial hips comes
mainly from specialist surgical centres, rather than general hospitals, an observation
that may suggest the existence of positive publication bias in the 'evidence base'.
Thus the generality of results from published evaluations of the technology may
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indicate a higher level of overall efficacy than would be found in non-specialist
orthopaedic centres. This analysis of the distinctiveness of collective practice
patterns is taken up again in the final discussion section in this essay.
2.5 Conclusions and contribution
These papers taken together as a case study focus to a large extent upon the
technology of artificial hips/hip arthroplasty, and variations in its use and
performance. This is important to emphasise because there are advantages and
disadvantages entailed in this focus. Given an interest in understanding the processes
whereby new technologies enter the healthcare system resulting in variations in
healthcare delivery, I would like to suggest that a major advantage of this work is to
highlight the fact that artificial hips are part of a large and fairly globalised
orthopaedic products industry. This dimension, and any analysis of it, has been
conspicuously absent in work within the conventional 'HSR/HTA' mould, as
illustrated in Paper 3 here (though this work does allude in passing to some of the
alliances to be observed between orthopaedic surgeons and the orthopaedic products
industry). It is thus part of the contribution, especially of Paper 4, to focus attention
on the healthcare products industries as a relatively 'invisible' actor shaping the
patterns of variability in clinical healthcare delivery. However, bringing some
topographical features into focus through one lens inevitably diminishes the focus on
others. Thus the papers presented here have not concerned themselves with another
key feature of the variations in hip replacement services, namely the socialisation
and professional/working environments of surgeons themselves. Indeed, in reviewing
the body of research represented by mainly clinical studies of performance of hip
prostheses (Paper 3), mostly conducted by orthopaedic surgeons themselves, it was
apparent that very few studies existed of the working practices, surgical procedures
and prosthetic choices made within the sub-specialty. This would perhaps be
methodologically difficult, but would certainly shed further light upon the observable
patterns of hip implantation, and the relationship of these to the orthopaedic medical
products industry. It is thus interesting to note that the systematic review method in
HSR/HTA can also be regarded as a partial, though unintentional, sociology of
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healthcare knowledge, in which the interests and knowledge-practices of
stakeholders can be observed.
Thus the three papers presented have made contributions to UK health service policy
regarding hip prostheses, to the field of knowledge of hip prosthesis performance and
its sociopolitics, and to the conceptual broadening of health technology assessment
as a healthcare science.
Developments in 'knowledge-based' health service policy
Total hip prostheses became a site for increasing attempts at regulatory activity in the
UK during the 1990s. The historical account of the development of artificial hips
(Paper 2) shows that continual innovation has been characteristic of this aspect of
healthcare technology since its inception. Some commentators within the clinical and
orthopaedic engineering professions themselves described a "trial and error culture"
within contemporary orthopaedics (Huiskes, 1993).
During the 1990s it became clear that national HTA was being deployed as a sort of
'regulatory science' (e.g. Irwin et al, 1997; Lehoux and Blume, 2000), in other words
the scientific production of evidence was becoming undertaken in an institutional
context which involved negotiating control over the boundary from the scientific and
R&D worlds of innovation into that of health service application. HTA
organisations can be conceived of as intermediaries at the interface between, crudely,
science and policy. Also at this interface, though acting most strongly on processes
of control over the initial approval of the safety of new health technologies are the
formal regulatory agencies - represented primarily at the time in question by the
Medical Devices Agency, an agency of the Department of Health in the UK.
Regulation of medical devices, ofwhich hip implants are an example, became more
controlled and Europeanised during the 1990s (see Paper 4; Altenstetter, 1996; and
Kent & Faulkner, 2002 for further detail on medical device regulation in Europe). In
contrast to medical device regulation, HTA has been concerned primarily with
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control over the introduction and diffusion in the healthcare system of prostheses
which have already been approved in terms of safety and biocompatibility.
Since the publication of Paper 3 in 1998 (and a companion report commissioned by
the national HTA programme - Fitzpatrick et al, 1998) there have been a number of
further developments in regulatory policy in relation to artificial hips. The National
Institute of Clinical Excellence (NICE), introduced in 1999, is a major example in
the UK of an institution combining processes of appraisal of scientific evidence with
the formation of public policy, the attempted embodiment of the ideal of 'evidence-
based policy1. Paper 3 contributed directly and explicitly to the knowledge on which
was based NICE'S guidance to the health service, issued first in March 2000. The
primary guidance is that "the best prostheses (using long term viability as the
determinant) demonstrate a revision rate (the rate at which they need to be replaced)
of 10% or less at 10 years. This should be regarded as the current 'benchmark' in the
selection of prostheses for primary Total Hip Replacement" (NICE, 2000). This
guidance was in line with (though not explicitly cross-referenced to) the principle
introduced in 1998 that revision of primary hip replacement due to aseptic loosening
within 10 years of implantation should be reportable to the Medical Devices Agency
(MDA, 1998). NICE's guidance was challenged on a variety of grounds by two
orthopaedic engineering companies, and following the quasi-legal consideration of
evidence presented, no change to the guidance was made. A further notable
development is the closer working reported now between NICE and the NHS
Purchasing and Supply Agency (PSA) which NICE depicts as enhancing the
implementation of its guidance (NICE, 2000), and thus strengthening overall
regulatory control.
The apparent failure of the Capital Hip was noted above in the introduction to this
case study section. The Royal College of Surgeons (RCS) of England, following a
massively detailed investigation, produced a report of the alleged failure of this
model of hip (properly the '3M Capital Cemented Hip System') in 2001. It is worth
noting that initial concern amongst clinicians had appeared around 1997-1998, and
that due to this timing and the reliance upon published data, neither Paper 3 nor the
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companion report by Fitzpatrick et al (1998) had included any published clinical
evidence about this hip system in their reviews of evidence. Remarkably, though
perhaps less remarkably given the key position accorded to scientific uncertainty in
the sociology of scientific knowledge, the RCS report was unable to identify
unequivocally the technical cause of the failure - ofwhat was in fact one of four
versions of the technology going under the name of the same hip system. The Capital
hip was a variation of the classic 'Charnley' model of hip and had not required de
novo clinical trial for marketing approval. The ensuing controversy led the British
Orthopaedic Association, in new professional guidance (1999), to make a point of
referring to the possible risks to safety associated with even small variations to
existing models of implant. The Royal College of Surgeons' investigation, led by a
clinical epidemiologist/statistician, can be understood as a good example of the
enrolment of evidentiality into social processes of accountability and legitimation.
The British government has also concerned itself directly with artificial hips. The
National Audit Office, the investigatory financial 'watchdog' of the British
government, produced a wide-ranging report (not confined to, though highlighting,
the issue of the performance of the technology) on many aspects of hip replacement
in the NHS (2000). This report was followed by an update (2003). These reports note
some progress but continuing weaknesses including in regard to systems of
surveillance of implanted hips, NHS Trust policies for introduction of new
prostheses, variations in performance across the NHS, concerns about the use of
incentives by manufacturers, surgical training and expertise, conflict between
waiting time targets and clinical urgency, under-reporting of adverse incidents, and
compliance with NICE guidance in NHS Trusts.
Finally, it should be noted that there had been a variety of calls from various
quarters, increasingly strong since the mid-1990s, for the introduction in the UK of a
'registry' system for the recording of all hip (and knee) replacements along the lines
of that noted above for some of the Scandinavian countries (Norway, Sweden and
Finland). The Capital controversy certainly added fuel to the debate about this. The
Department of Health issued a formal consultation document (DoH, 2000) and a
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system, after a great deal of debate and negotiation between the stakeholders
involved, was announced in July 2001 and launched in April 2003 (reported in
National Audit Office, 2003). It is a voluntary system, funded by a levy on NHS
Trusts.
Thus innovation in artificial hip technology led to 'problems'. In such a widely used
and relatively high-profile surgical procedure (waiting lists for orthopaedic surgery
are always high on the health policy agenda in the UK) which employs high-tech
material technology public confidence is ofmajor concern in healthcare policy
networks. Interestingly, the problems were due to technological success which led to
some technological failure. The responses, in the shape ofHTA research,
professional body investigation, assessment by government bodies and regulatory
guidance from the quasi-regulatory authority of the NHS have been extensive and
searching. A re-legitimation of total hip replacement, with a major focus upon
essentially modernist marshalling of evidence, has been sought. This response may
be understood as in keeping with the putative cycle of 'reflexive modernisation' in
which modernisation is interpreted as turning back on modernity itself (Beck et al
1994).
Broadening ofHTA
It should be clear from the previous section that the papers on artificial hips
presented in this submission have contributed to the development of a multi-faceted
analysis, drawing upon different disciplinary perspectives, of the problem of total hip
replacement in the NHS. The expansion of HTA/HSR approaches to embrace an
approach that permits a sociopolitical analysis of innovation and regulation of new
hip technologies has been suggested particularly in Paper 5, and also illustrated
above. This type of analysis could be extended to the more recent developments in
policy and evidentiality in relation to total hip replacement noted here. Paper 1 also
has contributed to the development of approaches to the analysis ofHTA as a part of
the phenomenon of contemporary evidence-based healthcare policymaking that draw
upon academic threads in the sociology of scientific knowledge, and science and
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technology studies. Explicit reference to this work can subsequently be found, for
example, in the important work of Lehoux and Blume (2000), May et al (e.g. 2001
and 2003) and Webster (2004), where further extension and theorisation of the field
ofHTA is to be seen.
I end this section by summarising the key threads of the analysis of this case study,
threads which are picked up again in the following two case study chapters. There is
clear evidence of variability in the performance of different hip technologies,
implying inequitable population access to orthopaedic surgical care; this uncertain
and variable supply of technologies and surgical expertise presents the service user,
the potential implantee, with a healthcare environment in which personal health risks
associated not with illness but with the medical system itselfmust be addressed;
patterns of differential availability of different models of hip prostheses suggest that
relatively stable, shared institutional practices exist within healthcare provider
organisations and within their associated (orthopaedic) professional networks; the
public, mass media and government attention to controversial aspects of the
technology and service delivery shapes the context in which health service users may
understand and meaningfully construe their health and healthcare; regulatorypolicy
as a form of governance is seen to emerge from a complex of actors in a policy
network including clinicians, commercial organisations, formal and quasi-regulatory
bodies, citizens and other actors claiming to represent them. These themes from the
study of the socio-technology of artificial hips may be seen to run through the case
studies on prostate cancer detection and outpatient service delivery presented below.
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3. Variability in cancer care: locating early prostate cancer
3.1 Background
Detection of prostate cancer has become an important topic, and in some senses a
resource, in the development of healthcare science in the UK for several different
reasons.
Rates ofmortality from prostate cancer, and the incidence of its detection, had been
rising dramatically during the 1980s and early 1990s internationally. It was also clear
internationally that approaches to treating the disease varied dramatically. In
particular in the USA a much more interventionist approach was evident compared to
the policy most prevalent in the UK namely "watchful waiting", in other words
active monitoring to detect signs of progression of the disease.
However, it was clear also that part of the upward trend in incidence could be
attributed to increased rates of detection of the disease in its early stages, especially
through a relatively new diagnostic blood test, the prostate-specific antigen (PSA)
test. Various versions of the PSA test were used from the mid-1980s for monitoring
prostate cancer progression, but in 1994 the Food & Drug Administration (FDA) in
the USA, became the first regulatory agency in the world to approve a commercially-
produced version of the test (the "Hybritech Tandem PSA Assay") for detection of
the early stage disease - in conjunction with DRE (digital rectal examination).
In the early to mid-1990s in the UK, prostate cancer was the subject ofmass media
and public attention, and controversy, as the issue of screening for the disease
became prominent. Media headlines such as "Rising fear of prostate cancer 'could
cost the NHS £400m'" (The Guardian, 31.10.95) were frequently to be seen. It was
common to hear about public figures who had contracted the disease, such as
General Norman Schwarzkopf and the musician Frank Zappa. Such personalised
references undoubtedly contributed to raising the public profile of the disease and to
increasing the public perception of risks associated with it.
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The fact that prostate cancer is a disease affecting men is also significant in its rise as
a topic of healthcare science and policy. The absence of national screening
programmes for men, compared to breast cancer and cervical screening for women in
the UK was noted in public debate at the time. The perception of this gender
disadvantage (whether it is a disadvantage to health in this instance is open to doubt)
was reflected also by some academic work (Cameron & Bernardes, 1998).
Contemporary societies have been diagnosed as undergoing an institutionalisation of
'risk' (Giddens, 1991). Medical discourse and the incursion of the healthcare system
into everyday life may be one instance of this form of social infiltration. Diagnostic
and screening techno-practices can be considered to play a part in the shaping and
experience of health risks. In sociologically-informed theoretical work on 'the new
public health', Lupton has suggested that diagnostic testing is seen as offering people
control in the face of the disorder represented by possible disease (1995:78). The
knowledge provided by diagnostic testing in principle enables protective action to be
planned. Thus the apprehension of risk and individual testing of asymptomatic
people to determine if a disease is present are part of a process in which both are
mutually supportive, constituting a process of personal knowledge generation. In a
context of socially amplified risk and uncertainty, it is understandable that screening
and early detection technologies are becoming not only an increasingly important
part ofmodern healthcare services, but also a growing source of ethical and social
concerns from public health perspectives (Stewart-Brown, 1997). Needless to say the
advance of genetic testing further develops a trend in which social - personal,
familial, and societal - apprehension of potential disease risks is exacerbated.
Pressing the sociological analyses further, Howson (1998) has analysed cervical
cancer screening as a healthcare site where the practices associated with risk and
with population surveillance are brought together. Thus organised forms of screening
for disease may increase the stock of knowledge of health and health behaviour held
by health services and authorities, at the same time enhancing concerns about health
risks in certain population groups. Howson has described the understanding of the
'relationships between the subjective articulation of risk and the processes shaping
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those articulations' (my emphasis - 1998:210) as an essential task of the social
scientific study ofpublic health and disease prevention. Thus the emergence and
uptake ofPSA technology in health services, and the production of evidence about
prostate cancer detection by the healthcare sciences, should be seen as part of a
societal process in which the contours are being constructed within which men's
personal appraisal of risk ofprostate cancer is delineated.
Therefore, early detection and treatment ofprostate cancer may be seen in retrospect
to have many of the ingredients to attract the attention of the new healthcare sciences
in pursuit of evidence-based healthcare. The issue of screening for prostate cancer
was identified as one of the highest priorities in the first research agenda produced in
the early deliberations of the UK national Health Technology Assessment
programme. The importance of population screening issues in the NHS R&D agenda
was evident in the fact that one of the Standing Group on Health Technology's
(SGHT) advisory panels was assembled specifically to examine population screening
(note: I am drawing here upon my own participatory experience during 1993-4 as
'Scientific Secretary' to the Acute Sector Panel of the HTA of the NHS SGHT).
From an epidemiological point of view the prevalence and incidence of the disease
were large and apparently growing. However, the disease was marked by great
scientific and clinical uncertainties - the natural history of the disease was not clear
or predictable, the best treatment was not known, and there was doubt as to whether
the tests available for early detection of the disease could be used as population
screening tools. This made for a considerable burden both on clinicians and on men
who might have the disease or be worried about it. Healthcare science in the form of
Health Technology Assessment was enrolled into the process of policy development,
with the avowed aim of providing a solid basis for policy decisions. In other words,
policy looked to science for legitimation.
In retrospect the HTA programme was described by the government as having 'a
carefully structured portfolio of research designed to provide the evidence base for
policy and practice'. Two systematic reviews (Chamberlain et al, 1997; Selley et al,
1997 - the current author was a co-author of the latter report) concluded that there
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was inadequate evidence to support the introduction ofmass screening using the PSA
test and that the comparative effectiveness of alternative treatments for early prostate
cancer was unknown. These conclusions, it was stated, were subsequently supported
by HTA reports from several other countries and awareness of the conclusions
'helped to contain the uncontrolled dissemination of PSA testing'
(http://www.dh.gov.uk, 09/2003).
Thus the crucial issue from the perspective ofNHS policy was the question of the
possible introduction of a formal population screening programme, and a threat of
possible diffusion of testing in the face of a lack of evidence of public health benefit.
As seen above, apart from the risk of the disease, there were also financial
implications of a possible screening programme. A National Screening Committee
for the UK first met in 1996 with the remit to advise the Department of Health by
examining all existing and possible national screening programmes which might be
of value. In keeping with the philosophy of the knowledge-based health service, its
first report contained a strong statement about appropriate methodology by which
strong evidence on which to base its conclusions and policy recommendations might
be arrived at (NSC, 1998). The methodology of systematic reviews, the method by
which the two HTA reports on prostate cancer had been produced, was highlighted.
The degree to which a systematic approach was sought to forging a 'link between
research evidence and the formulation of national screening policy', including a
major role for the HTA programme, was described at the time in a strong statement
of the aspirational role of healthcare science in policymaking by members of the
NSC secretariat (Sherriff et al, 1998: 58).
Given that the evidence for the comparative effectiveness of treatments for the
condition was deemed to be equivocal, and a policy for national screening
programmes was not to be espoused, it was important, therefore, to know the extent
of variation in then current clinical practice in using the diagnostic (PSA) test
because this would have direct implications for the pattern and volume of different
types of further diagnostic activity and of treatment undertaken. It would also be
crucial to building the social and clinical contexts in which asymptomatic men would
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appraise their wish to be tested for prostate cancer - in more sociological terms, to
shape the context for men's subjective articulation of risk - and their subsequent
experiences of testing and treatment processes. It was thus the aim of the study
reported in Paper 5 to produce evidence about the variability in current clinical
practice, to ascertain possible reasons underlying it, and to suggest implications for
men who might be considered by medical interpretation or might consider
themselves to be at risk from the disease.
Although not presented in this thesis because I was not the lead author of the
publications, I contributed to several others arising from the same research. The aims
of these related studies were primarily to assess the performance of diagnostic and
screening technologies for early-stage prostate cancer (Selley et al, 1997) and to
describe the treatment strategies envisaged by urologists in the face of diagnostic
uncertainties and lack of convincing evidence about the comparative effectiveness of
alternative treatments (Donovan et al, 1999).
3.2 Objectives
Given the background outlined above, the objectives of the study described in Paper
5 are to:
- describe possible variations in current (1995-6) clinical practice of consultant
urologists in use of the prostate-specific antigen (PSA) test in detecting early-stage
prostate cancer;
- to analyse practice variations in terms of potentially predictive characteristics of
urologists' socialisation and hospital settings;
- to assess the implications of practice variations for men undergoing the PSA test,
and for further research in the subject.
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3.3 Methodology
Paper 5 thus reports a national postal UK questionnaire survey of urologists' views
about the use of the PSA test. It was able to survey a large proportion of the
urologists in the UK. It used a custom-designed questionnaire. The study might be
criticised for relying upon a case vignette method rather than empirical observations.
However, the internal coherence of the results suggested that it produced strong
evidence that there was significant, systematic variation amongst urologists in their
interpretation of PSA cut-off points, in other words the threshold above which
further investigative action would be advised. The study did not include general
oncologists, unless they were also urologists as defined by membership of the British
Association ofUrological Surgeons (BAUS). Plausible factors predicting this
variation were identified by multi-variable analysis, though the interpretation of the
implications for patients, on the basis of this study alone, remains speculative.
3.4 Results
The paper analyses UK urologists' views about the use of the blood test - the PSA
test - to detect the disease in men without symptoms. Analysis shows that it is highly
likely that aspects of the organisation of urological services, which vary between
geographical areas and health care centres, and the socialisation of urologists, will
lead to an unequal social patterning of detection of the disease amongst men in the
UK. Centres where there was a urologist specialising in prostate cancer were more
likely to use lower cut-off points in interpreting PSA levels, thus making it more
likely that further action would follow in these centres. The extent of this variation
has important implications for the use of the test by the medical professions, in
primary and secondary care, and for the conduct of research in which the PSA test is
used as a marker for the disease in asymptomatic men.
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3.5 Conclusions and contribution
Subsequent to the early HTA work on prostate cancer, ofwhich the paper discussed
here formed a part, national healthcare science in the form of the HTA Programme in
the UK has devoted further large amounts of resources (over £13 million) to research
with the aim of producing evidence on which to base NHS policy.
The policy on PSA testing in Britain was conservative, and research needed to tackle
the problem of low recruitment rates to clinical trials if the HTA approach was to
produce the knowledge about treatment comparisons that was seen as necessary.
This dilemma in research policy led to innovations in HTA methodology: 'New
methodological approaches are required urgently to investigate this issue and to
bridge the gap between clinical practice and the need to acquire evidence. Such
approaches need to retain the essential principle of randomisation while
incorporating more fully patients' perspectives and preferences' (Donovan et al,
1999). And in the meantime '....until more evidence accumulates, patients and
urologists should use the information available from recent systematic reviews to
reach shared decisions about treating localised prostate cancer and provide
information that highlights uncertainties about the potential effects of such
treatments on survival and quality of life' (Donovan et al, 1999).
Thus an innovative feasibility study was mounted to try to assess how to improve
recruitment to a future full scale randomised trial of alternative treatments (given the
earlier failure of a Medical Research Council trial). This used qualitative methods to
assess men's reasons for participation or non-participation. The design of this study
necessitated offering the PSA test to several thousand men in order to identify a
small number with the early stage disease who might be randomised to one or other
treatment. The design of the study focused particularly on the initial offer of the PSA
test. There was an ethical concern that men offered the test should be fully informed
about the test and possible treatment side-effects, the favoured approach being that
this should be in the context ofprofessional counselling, rather than the conventional
information sheet and consent form. The feasibility phase thus examined the
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performance of PSA testing in the screening context, men's attitudes to screening,
preferences for treatment of early-stage prostate cancer, and their willingness to
accept treatment randomisation (the above comments draw upon the author's
involvement in the planning of the study in question).
This development, toward a 'counselling' model of men's decision-making about
consent to participate in a randomised control trial, is clearly consistent with the
direction of both the NHS Centre for Reviews and Dissemination (NHS CRD, 1997)
and British Association ofUrological Surgeons' recommendations to constrain use
of the PSA test, though perhaps elevating the degree of information provision and
magnifying the health service incursion into asymptomatic men's appraisal of
personal risk and healthcare decisions. This can be contrasted with the prevailing
approach in the USA, expressed here by David Kessler, Commissioner of the
regulatory body for new medical devices the Food and Drug Administration (FDA)
at the time the PSA test was approved for use in early detection. At this time
screening programmes were already widely diffused, bolstered by public health
campaigns such as 'Prostate Cancer Awareness' weeks: 'This test - used with other
procedures - can help detect those men at risk for prostate cancer early on when more
treatment options are available..But for the test to help, men must be aware of the
importance of early checkups and get them on a regular basis' (FDA, 1994).
The feasibility study mentioned above led to the support of a primary research
project in 2001 in the UK, a randomised control trial to compare treatment strategies
for screen-detected early prostate cancer (radical prostatectomy, radical radiotherapy
or 'watchful waiting'/active monitoring). This is known as the ProtecT study. The
trial involves prostate checks and PSA blood tests for 230,000 men aged 50-69, with
the expectation that 2,000 would be detected as having signs of early prostate cancer.
It is still under way at the time ofwriting. It is notable in the context of the
discussion in this essay about interdisciplinarity, that this study is stated to combine
'the qualitative traditions of sociology and anthropology, epidemiological and
statistical disciplines informing randomised trial design, and academic urology and
nursing', and the study 'contravened conventional approaches by being driven not by
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the randomised trial design but by the qualitative research' (Donovan et al, 2002).
Regardless of the interpretation that we might give to possible power-shifts in the
inter-disciplinary and inter-methodological relationships of stakeholders in
healthcare science, one outcome of the methodological innovations claimed here has
been to increase recruitment rates to the large-scale trial of alternate treatments for
early stage prostate cancer from an estimated 30-40%, to 70% (Donovan et al, 2002).
The ProtecT study forms part of a wider NHS Prostate Cancer Programme as part of
the broad policy initiative known as the NHS Plan launched by the Department of
Health in September 2000 (NHS Executive, 2000). This takes the form especially of
a risk management programme aimed at providing asymptomatic men with
information about testing in order for us to make 'informed choices' about
proceeding with the test; and upon speeding up access to diagnosis and treatment.
The Programme also included provision to increase the number of urologists in the
NHS by nearly 100 by 2005.
In the context of a policy NOT to introduce a public screening programme, it is clear
that at the beginning of the 21 st century there is considerable ambiguity in the
existing policies and practices, and confusion amongst both the medical profession
and men concerned about the disease. Men with urinary problems in the UK are
likely to be PSA-tested either by general practitioners or by urologists. Self-testing
kits are available commercially. Unsurprisingly perhaps, men with suspected or
confirmed prostate cancer are generally in favour of testing and a policy of screening
for the early-stage disease (Chappie et al, 2002). Thus as Donovan et al note,
screening may be creeping in through the back door (Donovan et al, 2001) - exactly
what policymakers have been seeking to avoid. One implication of this is that more
men than is justified by the existing science will be exposed to further investigation
and to radical treatment, in other words surgery or radiotherapy with their associated
side-effects, which include relatively high proportions of incontinence and
impotence. As the contribution made by the study presented in Paper 5 has shown, it
is highly likely that this trend to increased testing is associated with urologists at a
relatively early stage in their careers and with clinical centres where there is sub-
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specialisation in prostate cancer. This suggests that increased clinical specialisation
in the disease by younger urologists at an early stage in their careers is likely to
promote pressure for men firstly to undergo the test in the absence of symptoms, and
secondly to undergo radical treatment in conditions of uncertainty about disease
progression. Thus this case study contributes to describing professional risk-shaping
dynamics which are deeply embedded in contemporary social processes ofmedical
professional education, controversy within the frame of evidentiality, and the
collective organisation of care in healthcare settings.
The example discussed here of early detection of prostate cancer shares common
threads with the previous case study of artificial hips. As with hip prostheses, the
study presents evidence of variability in patterns of outcomes of care delivery with
clear implications for inequalities in the delivery of care to different populations and
patient groups, and thus concomitant inequalities in the social distribution of
healthcare risks. Men exposed to the British National Health Service have unequal
chances of detailed investigative testing for the presence of early prostate cancer. As
with orthopaedic surgeons, specialist urologists display collective patterns of clinical
knowledge and beliefs which are expressed in their clinical decision-making and are
associated with features of the professional organisation of care and local
institutional patterns. These institutionalised practices ('institutional signatures' - see
case study of outpatient services below) contribute to shaping the context in which
risk of prostate cancer may be appraised by men exposed to the healthcare system.
Regulatory policy - resistance to mass screening programmes - in this field shows
signs of underlying ambivalence related to tensions between a search for robust
evidence about the comparative effectiveness of different treatment approaches for
the early-stage disease, and the attitudes ofmen and the medical profession toward
the relative benefits and harms of early detection.
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4. Variability in outpatient care: collective socio-medical
practices
4.1 Background
Hospital outpatient clinics in the United Kingdom are the point of entry to the
healthcare system at which the majority of people with a health problem encounter
specialist clinical expertise. Diagnosis, testing and treatment may all occur in the
outpatient setting. In the UK system, typically the person has been referred to the
specialist by a general practitioner who in principle acts as gatekeeper for these
services. It is in the outpatient setting that the full range ofmedical and surgical
specialisation and sub-specialisation, and a range of diagnostic technologies is on
display. It is well known that the styles of behaviour produced by professionals in
these settings can be characterised by their routinised nature, and that the interactions
in these settings contend with a wide variety of tensions arising partly from the
uneasy institutionalisation ofmedical authority within 'bureaucratic' organisational
settings. This has been the topic of one ofmedical sociology's most well-known
works, which detailed the 'ceremonial order' of interactions in outpatient clinics in
the UK and the USA (Strong, 1979). Thus it is important to recognise that the
techno-practices of outpatient care are expressed through a very complex mixture of
expertise, knowledge, organisation, management, routine, interacting participants,
interests, material technologies and so forth. It has also become one of the sites in
healthcare organisation where broad movements such as contemporary policies in the
areas of evidentiality, patient participation and resource use may become activated
(e.g. Sanders & Harrison, 2004). But it is also important to recognise that outpatient
clinics have functions other than to provide services to patients. They also function
as sites for training of staff and for research and development. Outpatient services
attracted increasing attention amongst healthcare policy communities in the early
1990s, and this provided the impetus for a broad HSR research agenda which aimed
to improve knowledge about the characteristics of the outpatient care system and its
underlying dynamics. The case studies discussed here formed part of this agenda.
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Outpatient care has always been the poor relation of inpatient care within the British
National Health Service. The number of single outpatient attendances in the NHS is
massive, on average nearly one per head ofpopulation per annum. A National Audit
Office study published in 1991 (NAO, 1991) found that outpatient visits varied
between English districts in 1988-9 by 352 to 1726 visits per 1,000 resident
population. Towards the end of the 1980s and in the early 1990s increasing policy
concern began to manifest itself at the general effectiveness of outpatient services.
Unlike the longstanding and politically debated 'waiting list problem', which refers to
inpatient waiting lists, waiting times for initial outpatient appointments became a
political issue only in the early 1990s with the arrival of the Patient's Charter
symbolising the growing movement toward standard-setting and consumerisation in
healthcare. During the early 1990s the NHS introduced a set of Outpatient
Demonstration Sites in an attempt to highlight perceived shortcomings and to
introduce innovative improvements (NHS Executive, 1995).
An analysis of the rationality of the operation of outpatient services produced the
trenchant conclusion that '..the system seems to be geared to bringing back for
consultation patients who have neither the clinical need nor the inclination to attend
hospital, whilst blocking the way for new patients to undergo speedy assessment'
(Frankel and Robbins, 1993: 93). The particular focus of concern was thus the
phenomenon of patients' re-attendance at outpatient departments. In 1989-90 only
8.5 million of over 36 million attendances in England were 'new', first-time
attendances by patients referred from outside the hospital system (Department of
Health, 1990). There was thus a strong perception that re-attendances were a burden
on the services available and this was acknowledged by some well-known views
within the medical professions that supported notions of a 'merry-go-round' of
patients being recycled from one outpatient visit to another because of some form of
institutionalised inertia. A structured review of research in outpatient services noted
that a number of studies suggested, though not unequivocally, that high re-attendance
rates might be especially associated with the subordinate roles and statuses ofjunior
hospital staff in relation to senior, consultant staff in hospital outpatient practice
(Faulkner and Frankel, 1993). Junior staff it was suggested may not have had the
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confidence or authority to discharge patients to the community or to primary care.
'TCA' (To Come Again) written in medical notes, became synonymous with this
alleged lack of authority or initiative ofjunior doctors.
During the early 1990s, cost pressures and the introduction ofGP fundholding
responsibilities provided stimulus for general practitioners to question and for
specialists to have to justify long term re-attendance at the hospital outpatient clinic.
It was recognised that clinical activity delivered by the major acute clinical
specialties was more dispersed than popular beliefmight suggest. Around 10-20% of
outpatient attendances in some regions in high volume specialties were
acknowledged to take place outside major hospitals, in community hospitals and
other settings. This 'outreach' model of specialist care was supported by the
government policy ofmoving toward a 'primary care-led NHS' (Coulter, 1995). Day
case surgery developed largely in a research vacuum as regards evidence for
population requirements for services, and there was negligible evidence of it
substituting directly for equivalent inpatient procedures. Relatively minor procedures
which had been provided previously, but not counted, in outpatient clinics were
moving toward being provided, counted, and paid for as new episodes of day case
care. Contract incentives for general practitioners to undertake minor surgery further
challenged the outpatient department as a site for surgical treatment.
Such developments indicated moves toward a blurring of boundaries, in which the
once clear lines between general practitioner and hospital specialist were becoming
less easy to discern. This fragmentation of roles, settings, expertise and activity
around the primary-secondary care interface suggested that the traditional concept of
hospital outpatient services was itself becoming outmoded, and that a more flexible
model of the complexities of'ambulatory care' was required.
The organisational phenomenon of outpatient visits thus became increasingly visible
to the healthcare policy community. Three published papers (Papers 6-8) are
presented which report on three separate empirical studies examining aspects of the
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outpatient problem with a primary focus upon aspects of the re-attendance of
'season-ticket holders'.
4.2 Objectives
In summary, given the background outlined above, the three studies encompass a
description of the range of variability, especially with regard to re-attendance at
outpatient clinics in one English region, an assessment of the scope for improvement
in a single department, and an analysis of the obduracy of the socio-medical settings
in which health professionals' outpatient care practices are embedded.
More specifically, the objectives ofPapers 6 -8 were:
- to describe variation in re-booking rates between a set of consultant firms and
'provider unit groups' in surgical and medical specialties across the south west of
England; to assess possible reasons for variation observed; to assess the value of
'routine' NHS data for this type of study (Paper 6);
- to assess the scope for reducing 'unnecessary' clinic attendances in a 'benchmark'
department in the UK (Paper 7);
- to explore the experience and views of patients, general practitioners and hospital
clinicians which might underlie the observed variations between long-term and short-
term outpatient clinic attenders (Paper 8).
Taken together, therefore, the studies describe the extent of variation in re-booking
practice in a wide range of hospitals/specialties/ consultant teams; analyse the extent
of'avoidable' re-bookings in an already-efficient setting; and paper 8 offers social
and organisational reasons for the types of practices and clinical routines suggested
by the analyses in papers 6 and 7.
4.3 Methodology
Two of the studies are based upon primary data collection, an interview study (8) and
a clinic-based survey using a custom-designed questionnaire (7), and one uses NHS
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'routine' datasets (6). Given this essay's introductory comments about disciplinary
and cross-disciplinarity, it can be noted that Paper 8 draws upon a sociologically-
informed frame of reference in investigating the sociomedical and organisational
aspects of the networks of relationships in which participants in outpatient care are
embedded. The paper reports work that formed part of a larger, cohort study. Thus
this can be regarded as exemplifying two of the major types of contributions that
'qualitative research' can make to 'quantitative' studies, namely the capacity to
generate hypotheses and the capacity to offer explanations for their findings
(Black, 1994), through interpretative analysis. In Paper 7 a quantitative analysis of re-
attendance rates is presented, and this is supplemented by analysis of open-ended
questions which were, again, able to produce valuable insights about the reasons
underlying and constituting the clinical behaviour which was expressed in patterns of
clinicians' outpatient decision-making. The study on which Paper 6 is based is
primarily descriptive in its approach to quantitative data-gathering, and here the
possible explanations for the observed patterns of behaviour are limited because data
that might have provided explanatory resources were not sought. Nevertheless, it was
possible to discount some possible confounding variables, for example sub-
specialisation by clinicians.
4.4 Results
As a body ofwork, the case study of outpatient services explores the extent of
variability in rates of outpatient care delivery in different medical specialties, the
potential avoidability of re-attendance, and offers accounts of 'good organisational
reasons' (Garfinkel, 1967) for these apparently non-rational practices.
Paper 6 shows that there is substantial variation in 'new to old' attendance ratios at
different levels of analysis, that this variation cannot be accounted for by
epidemiological factors - disease prevalence - alone, and that although there is
evidence of individual consultant variations (a 'consultant signature' - suggested in
previous research on service rate variations (Wennberg, 1982)), there is also the
suggestion that shared cognitive and behavioural factors are operating at the
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institutional level (I term this the 'institutional signature'). An important conclusion
of the analysis in this paper was confirmation that surgical specialties can be
expected to have lower rates of re-attendance than medical specialties. This in turn
highlights the conclusion of Paper 7, which shows that there may be significant
scope for reduction in 'unnecessary' clinic attendances even in a surgical centre
known to operate relatively efficiently in terms of re-attendance rates. Finally, the
results of paper 8 suggest that while there are complex social and cultural aspects of
both clinical and patients' experiences of outpatient care, a dissonance in 'power
perceptions' between general practitioners and hospital clinicians might offer an
opportunity for effecting clinically acceptable change to some of the conventional
practices of outpatient re-attendance illustrated in the other two studies.
4.5 Conclusions and contribution
Outpatient services have continued to be an object of concern in the healthcare
policy community (e.g. CSAG, 2000). These studies taken together show tensions
between evidence ofpotential opportunities and locales for intervention in health
professionals' conventional beliefs, practices and organisations, and the resistances to
these opportunities represented by deeply embedded social and collective inter¬
professional networks and meanings. The 'outpatient problem' is, in a sense, a
construct that reflexively supports the conventionality of the healthcare system and
the professional work that sustains it. Such tension between intervention and
convention is evident also in debate about the changes in organisational structure and
responsibility implied by UK government policy ofmoving toward a 'primary care-
led NHS'. In the mid-1990s, the NHS R&D programme launched an initiative in 'the
primary-secondary care interface', which examined the feasibility of shifting the
balance of care in the direction of the primary care sector. However, it was noted
from an increasingly consumer-oriented perspective, that the examination of the
feasibility of structural change should not be made without recognising the needs,
values, perceptions and attitudes of patients (Coulter, 1995). It is in furthering the
understanding of this aspect of the primary-secondary care interface that Paper 8
presented here has contributed.
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Moves toward the dismantling of traditional, conventional patterns of follow-up of
outpatients in hospital clinics following surgery can be found in subsequent research
which has examined inter alia the follow-up ofpatients after surgery for breast or
colorectal cancer. Kievet (2002), for example, performed an extensive meta-analysis
of the impact of traditional follow-up regimes on patients' outcomes (mortality rates)
after surgery for colorectal cancer, concluding that continuing routine surveillance
should focus primarily upon patient support and was best carried out by a general
practitioner or nursing personnel. Likewise, Brown et al (2002) reported a small
randomised control trial in the United Kingdom that concluded that patient-initiated
follow-up is a potential alternative to standard clinic follow-up for women following
treatment for Stage 1 breast cancer, with no adverse effects. This case study can also
be regarded as contributing to the research literature investigating the modernising
trend in contemporary health care toward shifting the balance of services at the
primary-secondary care interface, and, indeed, toward a larger measure of self-care
(cf. Department ofHealth, 2001). Papers 6 and 7 presented here can thus be read as
contributing to the understanding of conventional clinical practices whose
foundations may not meet criteria of clinical rationality nor even produce the best
outcomes for particular groups of patients.
Re-structuring of services at the primary-secondary care interface points the way to
another way in which the outpatient problem may be tackled, albeit by default. The
outpatient problem as conventionally formulated rests largely upon methods and
attitudes of professional working that seem, as they are challenged, increasingly
archaic. Research and development priorities provide a good indicator of the new
directions of 'outpatient' health care. Both the Primary Care Development Fund and
the recent priorities for research in the interface between primary and secondary care
in the NHS research and development strategy confirm the demise of the traditional
model of outpatient services. The themes highlighted are transfer of follow up care to
general practitioners, direct access of general practitioners to some services,
reorganisation of diagnostic and investigative services, extension of primary care
roles for care of people with chronic conditions, treatment in the primary care setting,
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specialist outreach, and shared care. Candidates for shared care are being extended
from people with diabetes and asthma to those with rheumatological,
ophthalmological and orthopaedic problems. Clinical guidelines are reaching further
into the taxonomy of illness, for example, to cancers and other endocrine problems.
The growth of such innovative services around the primary-secondary care interface
can be understood to be re-defining the conventional notion of outpatient services in
such a manner as to define the outpatient problem and its attendant mythology out of
existence (Frankel and Faulkner, 1994). However, it appears that the notion of
'ambulatory care' mentioned above, which is more associated with the American
healthcare system, has not gained significant ground as a shaping concept in UK
policymaking.
Thus the case study of outpatient re-attendance shares a number of features with the
previous case studies of artificial hips and prostate cancer detection. The papers
discussed show evidence of substantial patterned variability in care delivery,
associated with conventional clinical practices in secondary care settings. The
institutionally patterned nature of these techno-practices I have termed the
'institutional signature' (Paper 6; the significance of this concept is further discussed
below: section 5.1). So patients' risk of being re-booked for re-attendances at
outpatient clinics is associated with factors other than rationally-defined clinical
need. The demythologisation of conventional clinical practices, many associated
with specialisation and sub-specialisation in particular clinical fields, in this area
contributes to a contextual re-structuring of the sites in which health risks may be
managed by patients and health professionals. This is illustrated, in turn, in moves to
shift responsibility for monitoring of chronic or recurring conditions to ourselves as
citizen-patients in 'the community' and to primary healthcare teams. Regulatory
policy here attempts to balance efficiency of care delivery with timely access to
appropriate services by patients. Behind regulatory standards such as outpatient
waiting times targets (for first referrals from GPs), for example, can be seen a
plethora of tensions between clinically defined needs for hospital outpatient
attendance, uncertainties about the healthcare science evidence for optimal follow-up
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regimes for many medical conditions, political pressures for a 'primary care-led
health service', and collective forces ofmedical professional power.
5. Discussion/Conclusions
Contemporary society is characterised by some sociologists as being in a phase of
'late modernity' in which the application of technologies and technical knowledge
has become of the essence. In this review essay I have drawn out the common
threads in three fields of healthcare, with a focus upon the delivery of diagnostic and
treatment services. I note that these three case studies have as their major focus
material technology and patterns of clinical practices. As discussed above, I take it
that technologies and practices are inextricably linked and are 'social'. They are
'socio-technologies' (Brown & Webster, 2004:27 and passim). In recognition of this,
while I do not use the broad metaphor of 'technologies' as a conceptual tool in this
essay (or elsewhere), I have introduced the term 'techno-practice' to denote these
practices that can be seen as underlying and indeed partly engendering the patterned
and institutionalised structures of the healthcare system. This approach giving high
priority to socio-technologies is akin to that adopted in other theorisations of
HSR/HTA, for example Lehoux & Blume (2000) and May et al (2001; 2003) who
argue that 'the institutional superstructure of health care rests largely on the
application of technologies to problems of understanding the nature and distribution
of disease, its diagnosis, treatment and management, and the organisation of service
provision'.
To re-visit this essay's introductory comments about disciplinarity and inter-
disciplinarity, I point out here that this essay can be read, with an eye to the title of
my thesis, as re-formulating the disciplinary pedigree of those case study papers
originally framed within the HSR/HTA paradigm. During the 1990s, the new
practitioners of healthcare science became strongly enrolled in the problem-oriented
agendas of health policymakers. A discourse of effectiveness and cost-effectiveness
shaped much of the healthcare science produced, and (as noted in Paper 1) the
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epistemology of biomedicine and disease epidemiology was extended outside its
earlier disciplinary boundaries to be applied to the science of healthcare evaluation,
as 'clinical' epidemiology and HSR/HTA. The disciplinary agendas of this early
HSR/HTA are embodied in much of the case study work included in this thesis and
published during the 1990s. Reformulating this healthcare knowledge in the way I
am attempting now in this essay draws attention to the tensions between
disciplinarity and problem-oriented, multidisciplinary HSR, and to the shaping of the
endeavours of healthcare science by the institutional authority and rich resources of
co-ordinated, powerful healthcare policy communities. Thus the multidisciplinary, or
a-disciplinary analysis of outpatient service variations, of factors associated with
variability in prostate cancer test interpretation, and of artificial hip technologies,
originally framed primarily in terms of the 'effectiveness and efficiency' agenda, I
re-conceptualise here through the concepts of techno-practice and socio-technology
to point to their significance within a new and different agenda for a sociology of the
dynamics of healthcare.2
The discussion in this concluding section of the thesis recapitulates the nature of the
'problems' which were taken during the early 1990s to provide the rationale for the
research agendas of which the case studies form a part. It discusses the work
presented in the three substantive areas of techno-practice relevant to patterns of
health care delivery and technology, summarising the original contribution to
healthcare knowledge which they have made in toto (section 5.1). Following from
this, I adopt a more explicitly sociological perspective in order to consider the
contemporary phenomenon of evidentiality in healthcare of which, again, the
submitted studies form part (section 5.2). Finally, in section 5.3,1 argue that
healthcare evidentiality as represented by the new healthcare sciences, its proponents
and its institutional vehicles, should be considered as one of the social forces that
must be embraced by a sociopolitics of the dynamics of healthcare innovation and
governance.
2 It is interesting to note that one of the early and foundational texts ofmedical sociology, 'Medical
Sociology' by David Mechanic (1968) includes epidemiology as a small sub-topic.
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5.1 Patterns of health care techno-practice: beliefs, practices and
healthcare risk
In this section I discuss the generality of the contribution made by the case study
papers which I associate with the Health Services Research model of the
multidisciplinary study ofhealth care. From the perspective of the disciplines of
clinical sciences the subjects addressed in this thesis appear diverse, but seen through
the lens of a sociological perspective their commonalities can be brought into view.
Thus this essay has enabled a number of common analytic aspects of contemporary
healthcare to be highlighted.
The 'problem-oriented' nature of the multidisciplinary production of healthcare
knowledge in the new healthcare sciences was discussed in Section 1 of this essay. In
the case of outpatient care the problem was voiced by NHS hospitals and health
authorities, and took the form of concerns about, in essence, the efficiency and
quality of outpatient care services. In the case of early prostate cancer the issue of
screening and diagnostic testing had been identified as a policy issue of national
priority by the NHS Executive and the national Health Technology Assessment
research programme; concern was also expressed in public forums as the public
profile of the disease increased. In the case of total hip replacement, this also had
been identified by the national HTA programme, had evoked adverse media
comment, and orthopaedic waiting lists were a government and public concern. In
summary, therefore, all three fields of healthcare techno-practice affected large
proportions of the population, and raised questions of efficiency of healthcare
organisation, effectiveness of interventions, and risks associated with exposure to the
healthcare system itself.
Turning to the case study papers themselves, each of the three case studies describes
variability and patterning in aspects of the collective delivery of healthcare by health
professionals. By comparing the framing of the research questions in the different
papers, as formulated in their stated objectives, it can be seen that the majority of the
papers have addressed themselves to concerns with aspects of health care practices
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and technologies whose patterning and variation has obvious implications for the
quality and effectiveness of health care delivery. In each case study one implication
of the variability shown is that patients receive treatment or diagnostic services based
to some extent on vagaries of their access to some health service settings rather than
others, which vary for reasons not connected with epidemiologically-deflned 'need'
or requirements (e.g. Coast et al, 1996).
The case studies have demonstrated the importance, for example, of underlying
institutional professional practices that shape variations in patterns of healthcare
delivery - 'institutional signatures' in outpatient practice; specialist centres in
urological practice for prostate cancer, and centres for hip replacement favouring
certain commercial models of prosthesis over others. I am not claiming here that
such variations in access related to patterns of service provision are obviously or
necessarily harmful for patients. At the level of the healthcare system, the variation
shows that some patients receive services or technologies that others do not. The
healthcare implication of this is a different question. Often it will be the case that
technically 'more advanced' practices will be of greater benefit to patients, but it is
clear, for example from the case of early detection of prostate cancer, that access to
services which might be regarded as the most 'modern' or specialised cannot always
be interpreted as unequivocally in patients' best health-related interests. Underlying
the descriptions of healthcare patterns produced by the comparative 'method of
variations' are analyses of the institutional beliefs and local medical socialisation
practices that result in the outcomes of variability in healthcare and technology
choice. In the terms adopted in this review essay, these 'outcomes' can be interpreted
as potential risks arising from encounters with healthcare that as citizen/patients we
experience as part of our participation in particular local systems of practice.
The concept of 'institutional signatures' represents an attempt to capture the notion
of sources of variability in healthcare techno-practice that do not stem from
individual practitioner preferences, beliefs and recipes for practice. Some variability
in healthcare patterns is doubtless due to 'clinical uncertainty' about optimal
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treatments. Numerous studies emanating from the clinical sciences attempt to
identify factors that might account for sub-optimal service delivery when assessed
against standards. Some of these studies which may combine consideration of patient
morbidity, resource factors, geographical area, and individual practitioner beliefs
may also assess some aspect of'practice patterns' such as size of a healthcare team
(e.g. Wauters et al, 2004). Variation attributable to individual factors is, of course,
important but is not the focus in this thesis. The concept of the individual 'consultant
signature' was first introduced, as mentioned above, by John Wennberg whose
research has led to a gamut of 'small area variations' studies (Wennberg &
Gittelsohn, 1982) . However, the organisational, professional and institutional
aspects of healthcare have remained under-researched and under-conceptualised in
sociological studies. The recent silver anniversary edition of the journal Sociology of
Health and Illness published overviews of 'organisational research' in the field, and
they note the relative neglect of the area and a failure to build upon existing research
(Davies, 2003; Griffiths, 2003). Although related concepts such as distinctive
'ideologies' in different clinical teams have been shown in early work in the field
(Strauss, 1964), it is surprising that there appears to be no real equivalent of the
clinical science 'practice patterns' concept in the sociological/organisational research
literature, and certainly not as a widespread concept. It thus appears that this concept
should be used to frame further empirical investigation and should be tested for its
utility in relation to more established concepts in the sociological understanding of
clinical practice, organisation and change. It is notable that quantitative and
comparative research methods were used or re-analysed in the case studies presented
here, and it may be that such approaches are required to further develop research in
this field.
I now move on from formulating the contributions to healthcare knowledge of the
three case studies, to assess the phenomenon of healthcare evidentiality as a key
aspect of contemporary healthcare policy processes within contemporary society.
3
Adequate exploration of the complex theoretical and empirical questions of linkages between
individual and collective behaviour patterns is beyond the scope of this essay. It can be noted here that
the variable power of individual consultants in the NHS - to influence clinical teams' practices, to
control categorisations of patients (cf. Griffiths, 1997 & 2001), and to access resources for patients
will account for a degree of the articulation between 'individual' and 'collective' characteristics.
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5.2 Health care evidentiality: credibility and regulation
In this section I discuss the production of healthcare knowledge as 'evidence' in the
healthcare science movements represented primarily by HTA and EBM. This is
conceptualised as 'evidentiality', the term denoting the rhetorical and actual
increased commitment to scientific empirical knowledge in contemporary healthcare
policy-making. Firstly the epistemology of healthcare evidence is discussed, and
secondly consideration is given to the institutional locales which process evidence
and are involved in processes of healthcare policymaking. The role of evidentiality in
regulation of healthcare innovations is then explored. I argue that the new
evidentiality has emerged in parallel with (in response to, but also, paradoxically,
engendering) the legitimation problems of healthcare/medicine. I suggest that the
evidentiality movement has the twin functions of highlighting tension between on the
one hand, credibility claims, and on the other hand evidential uncertainty, and of
contributing to societal attempts at control over innovation in the healthcare system
via 'regulation'.
The epistemology ofhealthcare evidence
The studies submitted with this essay are illustrative of the methodological variety in
the development of the healthcare sciences during the 1990s. Many different
research agendas and designs, within the HSR/HTA paradigms, can be used to
produce evaluations of health care delivery issues, but the core methodologies for
assessing causal effectiveness of interventions use experimental methods in the form
of controlled trials or the systematic review. Knowledge about healthcare is highly
diverse but the professional scientific movements ofHTA and EBM are quite
focused in their research agendas, question formulations, research methodologies and
modes of organisation of 'expert' knowledge.
The nature of evidence in these movements has been subjected (as suggested in
Paper 1) to a massive amount ofmethodological self-scrutiny by its proponents and
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practitioners. This can be regarded as an attempt to strengthen the scientific
foundations upon which the results of investigations into healthcare are based. Paper
1 analyses the core epistemology ofhealthcare science which is clearly an
application to healthcare systems and practices of the experimental bias-elimination
principles of biomedical and epidemiological quantitative and comparative research.
The terminology of'outcomes measurement' and HTA's focus upon generic
outcomes such as 'quality of life' indicate the clinically-driven framing of research
questions in which causality is framed by the primary focus upon medical conditions
and 'interventions' which produce effects on the health status of patient populations.
The nature of this epistemology has been elaborated by Tanenbaum (1994) and
Harrison (1998) 4
It has been argued that high degrees of emphasis on standardisation and
quantification are symptomatic ofprofessions/organisations suffering loss ofpublic
trust (Porter, 1995). Thus the movement toward the aim of knowledge-based
rationalisation of healthcare systems can be regarded, as suggested at the end of
Paper 1 presented here (1997: 203), as an essentially modernist response to the
legitimation crisis well-documented as 'challenges to medicine' that have been
observed over the last two decades in medicine/healthcare (Gabe et al, 1994). Within
this perspective, therefore, it is possible to understand the numerous efforts to
standardise the methodologies for the production of healthcare knowledge, for
example through handbooks of systematic review methods (NHS CRD, 1996) and
guidelines for the conduct of randomised controlled trials. As citizens and patients,
therefore, we are invited to renew our trust in medicine/healthcare because of the
reinforcement of its scientific underpinnings. As also noted in Paper 1, it is
paradoxical that a movement to restore public trust proceeds by a process that
involves a heightened questioning of the evidential basis ofmedical techno-practice.
It thus appears that the evidentiality movement attempts to 'manage' both scientific
Harrison in this article, like many other authors subsequently, tends to equate 'evidence-based
medicine' (EBM) with all manifestations of the broader growth of what I have termed in this essay the
healthcare sciences. While I cannot explore this point in detail here, it is important to distinguish the
different strands within the healthcare science movement. HTA as a movement and as a practice, for
example, does not share the ideological and professional discourses ofEBM focused on 'individual
clinical expertise' (cf. Sackett et al, 1996).
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uncertainty and public confidence. I suggest that it does so via an institutional
positioning between the practitioners of healthcare science, policy processes and
patients and publics. Thus it exhibits a form ofwhat might be termed 'bounded
uncertainty' in attempting to negotiate between actors that produce uncertainty on
the one hand, and actors that seek credible and evidentially robust public services on
the other (see sub-section below on the 'organisational sites of evidentiality' for
discussion of the related topic of the intermediary role of 'boundary organisations').
Generally, the knowledge-producing approaches ofHTA and EBM can be criticised,
from a sociological or 'policy analysis' point of view as being, by virtue of their
methodology, impervious to various important factors in the policy environment of
healthcare, such as manufacturers' interests, the concerns ofpatient advocacy
groups, and existing regulatory policy. This point is taken up in section 5.3 below. A
caveat to this assertion is that the HSR/HTA paradigm is now increasingly according
some recognition to the importance of 'patients' preferences' in its research agendas,
though perhaps in ways that could be regarded as constructing 'patients needs' in
narrow ways (e.g. Haynes et al, 2002). The Medical Research Council's 'Health
Services Research Collaboration' national centre poses 'How can we gain an
understanding of people's needs and the population's expectations and experience of
health care?' as a key question in its research agenda (MRC HSRC, 2004). These
aspects typically require 'qualitative' research methodologies. It can be noted that
integration of these with experimental and quasi-experimental methods, and varieties
of survey methodology, is seen by the practitioners of the new healthcare sciences as
important to the development of HSR/HTA methodology (e.g. Pope & Mays, 1995).
The organisational sites ofevidentiality
The relationship between science and policy is a central concern in contemporary
regulatory states, as it is in the academic field of science and technology studies.
Under the conditions ofmode 2 knowledge production/post-normal science (see
53
section 1), this relationship is changing. It is argued that society in general is moving
from an era of technocratic policy-making towards a more inclusive regime (Abels,
2002), though this is not a universal observation across all technology sectors
(Abraham & Lewis, 2000: 205). Interaction between science and policy has been
conceptualised in terms of'boundary organisations' (Guston, 1999) which are
interpreted as stabilising the boundaries at the interface between the two spheres of
activity. Analysis of the structure of interactions between evidence-producing
institutions and healthcare policy communities suggests that they have such an
intermediary role, though below I note reservations about their stabilising function.
Examples of evidence-producing and processing institutions in healthcare R&D in
the UK are the NHS Centre for Reviews and Dissemination, the Cochrane
Collaboration, the National Co-ordinating Centre for Health Technology
Assessment, and the National Institute for Clinical Excellence (NICE; the latter
conducts its own 'technology appraisals'). These newly-designed institutions can
usefully be seen as boundary organisations acting to promote the generation and
processing of healthcare science in the service ofpolicy but at the same time acting
as buffers between the evidence-producers and the evidence-consumers. These
hybrid organisations permit healthcare governance processes, drawing upon
scientific appraisal of new techno-practices, to design into the policymaking process
other actors such as manufacturers, health service managers and patient advocate
groups. In other words these organisational sites of evidentiality allow for 'the
politics' of the results of healthcare science to be considered. In a similar manner, an
intermediary role of research commissioners and producers has been suggested by
May et al (2001) who apply perspectives from actor-network theory (e.g. Callon,
1986) to conceptualise funding bodies for evaluation of service development
initiatives as 'points of passage' which clinical innovators must pass through in
attempts to gain support and legitimacy for their innovations. Thus the production of
evaluative evidence under the principles of HSR7HTA methodology mediates the
processes of the policy appraisal and subsequent adoption of new healthcare techno-
practices.
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However, while boundary organisations introduce apparent structural stability, the
boundaries between science and policy that they embody remain permeable and
malleable (cf. Gieryn, 1983). They are better conceptualised, in my view, as
boundary zones, rather than clear lines. Such zones become sites for contestation of
interests and evidence, suggesting that the uneasy enrolment of HSR/HTA and
clinical science into the disciplines and structures of healthcare policymaking should
be viewed as a dynamic process that shapes and re-shapes such boundary zones. In
the case of the NHS in the UK, a focus on boundary-work draws attention to
conflicting role-definitions amongst stakeholders and to their interdependencies and
power-relations. Drawing upon my own participant experience in UK national HSR
and HTA, I suggest that the activity ofmaking 'policy recommendations' was an
issue of contention that highlighted boundary-definitions in the early history of the
national HTA movement. At this time, in the case of Paper 3 (systematic review of
total hip replacement) and Selley et al (1997; review of diagnostic and screening
tools for early prostate cancer) it was unclear the extent to which healthcare policy
recommendations might be offered by researchers, in other words by the healthcare
scientists including myself. Attempts so to do, in fact, met with the disapproval of
the NHS policy community who commissioned the research. A similar phenomenon
can be observed in the case ofNICE. NICE has the status of a Special Health
Authority, and operates in a quasi-legal manner. Decisions about guidance to the
NHS on adoption policy for new pharmaceuticals or technologies are made by a
select group of individuals. But the evidence they refer to and their interpretation of
it can then be challenged by interested parties. Multi-stakeholder 'hearings' for the
consideration of the evidence - now in both the 'scientific' and quasi-legal senses of
the word - about particular new techno-practices are therefore part of the modus
operandi ofNICE. Often, 'appeals' from industry are presented. Such processes as
these can be seen, therefore, to be at the same time threatening and constitutive of
boundary zones between healthcare science and healthcare policy. It is inevitable,
and perhaps socially beneficial, that such controversies are generated in and around
boundary organisations such as NICE and the national HTA enterprise.
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The institutional vehicles of evidentiality thus represent key actors in analysis of the
healthcare innovation process for any given techno-practice. This suggests that
evidence produced under the epistemological and organisational auspices of the new
healthcare sciences has a regulatory function with respect to innovation in
healthcare. This point is discussed further below.
Evidentiality and regulation
As argued above, and in submitted papers 1 and 4,1 suggest that 'Evidence' (as
embodied in the HSR/HTA and EBM movements) has a quasi-regulatory function.
National HTA constructs distributed laboratories in which new healthcare
technologies are tested in comparison to existing technologies. Paper 1 showed that
the application ofHTA to an innovative healthcare technology could provide a sort
of 'safety zone' for the technology - and for the risk-related national policy decision
about its deployment - while scientific uncertainty was considered. As I wrote in
Paper 1 'Laboratories harbour uncertainty while engaged in projects to reduce it.'
(p203). This principle has subsequently been demonstrated even more strongly in the
working of the National Institute of Clinical Excellence, which routinely issues
guidance that technologies are to be regarded as experimental pending the production
of new knowledge in the form of appropriate clinical trial evidence. Meanwhile,
patients should only be exposed to the technology in the context of such evaluation.
Clearly, therefore, the new healthcare sciences are enrolled by the state into
regulatory control over the diffusion of healthcare innovations.
One of the responses to risky healthcare variations has been the development of the
movement to produce 'evidence-based guidelines' with the aim of standardising
techno-practice (clinical practice patterns). This can be regarded as a modernist,
rationalist response which has emerged with the possibility of restoring legitimation
to the healthcare system. Evidence-based guidelines are clearly also part of the new
regulation of healthcare. Many health-professional representative bodies produce
their own guidelines. NICE itself produces a wide-range of authorised guidelines in
the UK with its own stamp of credibility as the National Health Service's central
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body for the assessment of the science of healthcare interventions. Guidelines
represent an explicit attempt to shape frontline medical techno-practice by translating
the evidence produced by healthcare science into working rules and routines for
decision-making and clinical policy. However, guidelines represent a form of
attempted standardisation of clinical behaviour that has to contend with evidential
uncertainties as well as the vagaries of individual and institutional working practices.
The standardisation associated with guidelines in the context of the Evidence-Based
Medicine movement, in a sociopolitical analysis that to some extent exemplifies the
approach that I argue for in this essay, at the level ofmedical practice, has been
explored in detail by Timmermans and Berg (2003b).
The importance of the link between governance and evidentiality is increasingly
recognised within professional networks ofmedicine. To give an example from the
case studies discussed in this thesis, in the controversial case ofpolicy for detection
of early prostate cancer, 'Stronger and braver governance is required to ensure that
responsible decisions about risk management emerge for areas such as screening,
which have such potentially enormous individual and societal consequences. These
decisions must be based on sound research and proper partnerships' (Thornton &
Dixon-Woods, 2002).
This analysis is echoed elsewhere in recent research literature on scientific expertise
and policy formation. At a transnational level of analysis 'regulation by information'
for example has been suggested as characteristic of the (European) regulatory state
(Majone, 1997), and Lehoux and Blume (2000) have conceptualised HTA explicitly
as a 'regulatory science'. Majone's analysis suggests that information can only
change expectations and behaviour if it has credibility. The evidence-producing
movement in health care has a number of features that that may be regarded as more
or less 'designed' to build and enhance societal credibility. These features are evident
in the organisations that have been considered above as the key national
organisational sites of healthcare evidentiality in the UK. These institutions have
claimed and been accorded a high degree of authority within healthcare policy.
Perhaps most obviously they lay claim to credibility through processes of
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centralisation. This applies both to the processes by which evidence is brought
together and summarised, in particular through the use of systematic review
methodology, and to the institutions' organisational forms as symbolic 'national'
centres.
I have characterised HSR/HTA in this essay as being healthcare sciences engaged in
scientific activity focused primarily upon issues ofefficiency, quality and
effectiveness of healthcare delivery. These sciences produce knowledge using the
epistemology discussed above and organised through some of the institutions
identified in this discussion. Regarding these as 'regulatory science' (Jasanoff, 1990;
Irwin et al 1997; Lehoux & Blume, 2000) recognises the relationship between
knowledge processes and societal control. It draws attention to 'the politics' of the
linkages between science and policy: for example, regulatory institutions vary in
their appraisal and decisions about techno-practices (cf Abraham & Lewis, 2000);
expert scientific knowledge may be challenged by citizen-experts (e.g. Epstein,
1996); and innovations in scientific knowledge may be shaped by the commercial
interests of industry (Blume, 1992). These considerations make it clear that the
production and deployment of knowledge about healthcare should be regarded as in
part a process that concerns the regulatory control of new healthcare techno-
practices.
I argued in Paper 1 that HTA shapes the production of knowledge using
methodologies that effectively exclude the social, political and ethical agendas that
HTA makes programmatic claims for. It is thus left to other disciplinary
perspectives, such as sociology of science/science and technology studies, to explore
sociological and political analysis of healthcare techno-practices, including the
intermediary boundary between the various actors producing healthcare knowledge
about innovative practices and those formulating healthcare policy which may or
may not promote innovation. This leads us to an explicit consideration of the
dimensions of a sociopolitics of the dynamics of healthcare innovation and
regulatory policy. This is developed in section 5.3 below.
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5.3 The sociopolitics of health care innovation and policy
The previous section considered the production and organisation of healthcare
knowledge as a form of 'evidentiality'. The final section of this essay reflects upon
the components of a 'sociopolitics' of the dynamics of technology/practice (techno-
practice) innovation in healthcare systems, ofwhich the evidentiality of the new
healthcare sciences constitutes a significant part. The intermediary knowledge-
processing organisations are an increasingly important actor in the sociopolitics of
healthcare innovation. The argument builds upon glimpses of such concerns that are
to be found in submitted Papers 1 (HTA), 2 and 4 (artificial hips innovation and
policy) and 8 (power dynamics at the primary-secondary care interface).
A number of trends mark the development of the contemporary healthcare system in
the United Kingdom. These are associated with broader movements in public policy
and service delivery, and structural and cultural developments at a societal level.
These broader trends were alluded to above (section 1.2) in considering the origins of
transdisciplinary knowledge production. Thus societal changes are in train that have
been conceptualised as the regulatory state, the knowledge-based economy, network
governance, risk society, citizen science and consumerisation, finding expression in
part in a re-structuring of healthcare and healthcare policy processes. In healthcare
trends are to be seen toward shared medical decision-making; participatory
governance; 'patient pathways'; 'knowledge-based' service/evidentiality;
technological modernisation; lifelong learning; risk-based regulation; standards and
targets-setting; and intensification of specialist services and 'outplacing' i.e.
devolution to primary, community or 'self care. Naturally, these trends are not
always acting in harmony.
It has been the aim of this review essay to set the substantive topic areas in their
sociomedical and policy contexts. Throughout, the concept of collective techno-
practices has been emphasised. Paper 8 was able to show dissonance in the 'power
perceptions' of hospital doctors and general practitioners across the sociomedical
interface of primary and secondary care. Paper 1 drew on sociological perspectives
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to analyse Health Technology Assessment as one strand of the broad movement in
the new healthcare sciences - part of 'evidence-based healthcare' - whose growth
characterised the 1990s. Further, Paper 4 introduced ideas about the need to extend
analysis of clinically-defined policy issues to embrace broader, sociopolitical
analysis of the policy environment in which the clinical problems are embedded.
This perception is paralleled also in recent analysis of health technology assessment
other than my own (Lehoux and Blume, 2000). This extension of the toolkit for
analysing clinical/healthcare policy into the realm of the sociopolitical has been
echoed by May et al who note 'looking at telehealthcare through the lens of clinical
studies means that other substantial sectional interests are excluded from analysis'
and in terms of the organisation of 'policy-related clinical science' (2001:905), the
interests ofmultiple stakeholders including not only clinical constituencies but also
manufacturers and patient groups should be taken in to account (2001:133).
This review essay, therefore, points to tensions between state or professional forms
of control over healthcare practices and countervailing forces of innovation. Such
forces of innovation come both from within modernising medical professions and
from 'outside', for example commercial organisations or societal demands.
'Modernisation' is enshrined in the policy of the NHS, and may run counter to the
institutionalised processes of evidentiality discussed above in terms of the
intermediary boundary between healthcare science and policy. These two policy
directions may conflict with each other in ways which determine the experience at
the boundaries of the healthcare system of specific innovative techno-practices. An
empirical analysis of such an effect has been produced in the case of telehealthcare
(May et al, 2001) and its constituent elements in the practical conduct of healthcare
technology evaluation conceptualised in a contingency model (May et al 2003).
The silver anniversary edition of the journal Sociology of Health & Illness contained
two chapters on health technologies intended to review the field (Heath et al 2003;
Timmermans & Berg 2003a). One might expect that such a professionally high-
profile degree of attention to technology would highlight the importance of a
politico-economic analysis of healthcare technologies, their production, processes of
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adoption and diffusion, interface with healthcare systems and their health and social
consequences. However, this is not the case. The chapters that deal with technology
do so almost entirely by viewing them in a context ofprofessional-patient
interaction. While this site of technology is, of course, important, it is a testimony to
the neglect of socio-political analysis of health technology innovation that these key
review articles take the focus that they do. In this review essay, therefore, I hope to
have argued the case for formulating healthcare science as embodied in HTA/HSR as
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7. 'Strange bedfellows' in the laboratory of the
NHS? An analysis of the new science of health
technology assessment in the United Kingdom
Alex Faulkner
Introduction
A recent disease-focused history of the development of medical research in
the United Kingdom, written by a professor of medicine, refers in passing to
a new type of health care research. The author notes the multidisciplinary
nature of this type of 'medical research' and draws our attention to alleged
difficulties of research methodology:
This new branch of medical research brings together some strange
bedfellows, ranging from psychology and the social sciences to biomathe-
matics. It presents many difficulties, not least the uneasy amalgamation of
the relatively 'soft' science of interviewing techniques with some fairly
sophisticated mathematics (Weatherall 1995: 312).
Current developments in the National Health Service suggest that
research knowledge is seen amongst state authorities in the United King¬
dom as a means of improving and controlling the development of healthcare
services. The new type of health care research known as Health Technology
Assessment (HTA) has emerged as both the largest financially and, symboli¬
cally, the highest-profile of the research programmes within the new NHS
R&D strategy (Department of Health 1993). The NHS Executive has spear¬
headed the state's co-ordinating action in this area, in spite of the existence
of other agencies with kindred health policy interests in the Department of
Health. HTA is a multi-faceted movement constituted in the interactions of
state policymaking bodies, the medical and healthcare professions, acade-
mia, hospital management and healthcare commissioning authorities.
Overall the NHS R&D strategy aims to increase the proportion of annual
NHS expenditure on research and development from 0.9 per cent to 1.5 per
cent. It explicitly advocates the development of an evaluative culture within
the NHS, aimed at developing a 'research-based' or 'knowledge-based
NHS' (Department of Health 1993). The 'exploitation' of knowledge as a
resource generated through research is one of the most important require¬
ments of contemporary industrial capital (Webster 1994). New structures
and management in public sector services are accompanied by expansion of
research and other knowledge generating practices (Hoggett 1991, Hughes
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and McGuire 1992). A consequence of this is the formation of new strategic
alliances between the various producers and consumers of research know¬
ledge, in which research disciplines participate in the strategic action of
healthcare policymaking agencies.
The scope of the national health technology assessment movement brings
into view many healthcare issues of interest to a sociological analysis. It
raises issues to do with interests, values and inter-organisational relation¬
ships. It raises questions about the shaping of research agendas, healthcare
policies, regulation of health technologies and, indeed, about the evolving
patterns and methods of healthcare which we might have to call upon as
health service users. It also raises issues germane to some of the prime con¬
cerns of the sociologies of medicine/healthcare and science/technology,
including trust and contestability in medical authority, construction of
health and healthcare risks, rhetorics of scientific projects and knowledge
claims, relationships between the disciplines of medical and healthcare
knowledge, and relationships between healthcare experiments, laboratories
and technology tests.
In this chapter I am concerned with only a limited set of the possible
themes. The focus, therefore, is upon the use of rhetorical discourse in the
construction and shaping of a 'need' for health technology assessment
around new constellations of institutions and disciplines - 'strange bedfel¬
lows' - which are negotiating agendas in healthcare knowledge. I locate this
analysis by developing the notion of the NHS as a massive laboratory in
and around which healthcare knowledge is produced. Implications for key
themes in the sociological study of science/technology and health/illness are
discussed. I confine myself largely to considering some of the key activities
and developments which are part of the formal national NHS HTA move¬
ment in the United Kingdom, with some reference to related activities in the
Medical Research Council (MRC), rather than the wider range of health¬
care research activity much of which might also follow a broadly health
technology assessment model.
Before moving on to consider the main themes of the chapter, I sketch
briefly the state-co-ordinated formal structure which has been created for
national HTA activity in the United Kingdom, followed by a description of
the methods used in producing the analysis of HTA presented here.
Formal organisation and function of national HTA
Health technology assessment is the only one of the many research pro¬
grammes, set up under the new NHS Research and Development
Directorate, to receive support through the formation of a permanent
standing group to oversee it, the Standing Group on Health Technology
(SGHT). The SGHT identifies priorities for assessment through nation-wide
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consultation, inviting topic suggestions from health professionals, represen¬
tative bodies and others. Suggestions are considered by six advisory panels
designed to reflect the full range of different sectors within healthcare. Five
panels deal with healthcare sectors or types of technologies: the acute sector,
primary and community care, pharmaceutical, diagnostics and imaging, and
population screening panels. The sixth is concerned with the methodology
of HTA. These groups score and rank technologies suggested for assessment
which are then passed to the SGHT. SGHT performs a similar exercise to
reach recommendations for commissioning assessment projects from
research organisations. Membership of these panels and the standing group
are of importance when considering the constituencies represented in
national HTA. The major criteria for assigning priorities to assessments are
stated to be: benefits in terms of improved outcomes for patients; method¬
ological gains; timescale of potential benefits; value for money of assess¬
ment; importance of early assessment; and factors relating to Health of the
Nation policy, prevalence and social/ethical considerations (Department of
Health 1995: 46).
Methodology
For data about HTA in the United Kingdom, I draw upon reports pub¬
lished by the major new institutions representing the HTA movement, min¬
utes and papers relating to meetings of advisory groups, comment and
debate in the medical and health services press, discussion and communica¬
tions with some key participants, and upon my own participation in HTA
activity, akin to the 'participant comprehension' which Collins (1984) has
described. Collins assumed that the researcher adopting this approach
would have a single, clear professional identity as sociologist, but neverthe¬
less describes how he and colleagues 'became scientists ourselves' (1984: 60).
My professional affiliations are both to sociology and 'health services
research'. For one year, in the capacity of a health services researcher, I
became a 'scientific secretary' to one of the six advisory groups working
with the major group charged with co-ordinating national HTA, the Central
Research and Development Committee's Standing Group on Health
Technology. I have also been involved in academic research work much of
which can be described as health technology assessment, and some of which
forms part of the national HTA programme. I thus also reflect upon famil¬
iarity with the practices, discourses, networks and institutions of HTA to
inform the account presented here. Particular 'data' drawing on this experi¬
ence are presented in the text in quotation marks and noted parenthetically
as being 'author observation'.
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Laboratories, experiments, technology testing and rhetoric
There have been recent calls for and signs of a rapprochement between the
sociologies of medicine/healthcare and science/technology (Bartley 1990,
Berg 1995, Casper and Berg 1995). The notion of a 'knowledge-based NHS'
is of dual interest because it signals a bringing-together of scientific know¬
ledge, which has been investigated in social studies of science, with health¬
care practice, which has been investigated by sociologists of medicine and
healthcare. Central to the practice of science are laboratories. Recent devel¬
opments in the sociology of scientific knowledge and the history of science
have regarded laboratories as both empirical (e.g. Latour and Woolgar
1979) and metaphorical (e.g. Macleod and Rehbock 1994) locations for the
study of scientific activity and the production of scientific knowledge.
Bartley (1990) suggested that medical sociology, using the tools and con¬
cepts of the sociology of science, might investigate medical scientists' empir¬
ical laboratories as the locations where medical knowledge is constructed.
The notion of the NHS itself as a massive laboratory enables such
approaches to be applied to the broader fields of healthcare practice and
policy which come under scrutiny in the HTA enterprise.
The primary form of scientific activity which takes place in laboratories is
the experiment and its interpretation. In social studies of science the vari¬
able relationship between experiments and laboratories is an important sub¬
ject (Knorr Cetina 1992): ' . . . laboratories and experiments combine
differently in different fields' (1992: 114). The sociological focus upon labo¬
ratories has permitted a view of science which goes beyond taken-for-
granted notions about the ability of experimental methodology to support
or negate hypotheses by applying bias-eliminating designs, to allow consid¬
eration of experiments in the context of the resources and practices
employed in conducting them. Laboratories are not merely the location in
which experiments are conducted, but they also involve, for example, the
deployment of equipment and measurement instrumentation, the formation
of strategic inter-individual and inter-organisational alliances, and the use
of persuasive literary techniques in the presentation of 'findings' of experi¬
ments in scientific publications.
MacKenzie (1989) has drawn attention to the similarity between scientific
experiment and technological testing. The approaches developed for the
understanding of scientific knowledge can be applied also to the examina¬
tion of the testing of (hardware) technologies. While the construction of sci¬
entific knowledge typically involves interpretation of particular observations
in terms of theory, technology testing involves such interpretation in terms
of predicted 'real-world' performance. Knorr Cetina (1992: 116) has
described the laboratory as an 'enhanced environment', in which often
obscure underlying processes are rendered legible by means of instrumenta-
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tion and measurement. Thus experimentalists and technology testers work
with 'traces' of processes rather than the processes themselves. Technology
testing involves 'projection' from the test to observed performance (Pinch
1993). Observations produced 'under laboratory conditions' or under test
conditions, are projected by interpretive techniques as predictions of how a
technology would perform if applied in the real world. Thus* the concepts
which have been developed in social studies of science and technological
testing can be used in the sociological investigation of the 'assessment', in
other words the testing, of medical technologies. Health technology assess¬
ments enact various forms of projection, which construct health profession¬
als, healthcare technologies and ourselves (as patients) as participants in the
experimental laboratory of the NHS.
The sociology of scientific knowledge (SSK) has also drawn upon social
constructionism to show how scientific facts are constructed through the
manifold practices of scientists (Latour 1987). Key to this approach to science
has been the concept of rhetoric. Having been historically regarded as anti¬
thetical to science, rhetorical discourse is seen in SSK as an intrinsic aspect of
the methods used by scientists not merely in publicising the results of science
but in the constitution of scientific theory and fact (Beer and Martins 1990).
Rhetoric in this context can be defined as discourse which implicitly or explic¬
itly persuades or proposes. Here the term has no pejorative connotation.
Disciplines have disciplinary rhetorics, and fields of science characterised by
the activity of several disciplines, such as health technology assessment, are
likely to have multi-disciplinary or inter-disciplinary rhetorics. We can thus
speak of the rhetorical constitution of disciplines or scientific fields as an
aspect of the production of scientific knowledge.
The deployment of disciplinary rhetorics constitutes 'boundary-work' in
Gieryn's sense (Gieryn 1983). In this conception, disciplinary discourse is to
be seen as laying claim to professional territory by defining appropriate
methods, concepts and agendas for a scientific programme. Such rhetorical
work may be especially characteristic of new, changing, weak or interdisci¬
plinary fields of scientific activity, where shared meanings and concepts
are lacking (Porter 1995: 228). Tension between disciplinarity and inter-
disciplinarity is likely (Good 1993). Health technology assessment in the
United Kingdom is just such a field of scientific activity.
The relation of disciplinary knowledge to the NHS is a matter which discipli¬
nary activists play a part in constructing. This has been shown, for example, in
the work of Ashmore et al. (1989) in their discussion of health economics in
relation to the medical profession. The authors regard health economists as
engaged in an 'educative strategy' (1989: 186) using programmatic discourses,
in other words, discourses describing and promoting programmes of desirable
change in NHS practices, which might be achieved by the adoption of lessons
from the discipline of economics. Similarly, Pinch et al. (1992) discerned rhetor¬
ical devices at work in the social processes inherent in the introduction of
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clinical budgeting technology in the NHS. In this chapter I focus primarily
upon 'formal' rhetoric produced in policy statements and 'public' professional
scientific debate to analyse the project ofnational HTA.
Constructing and supporting a legitimate 'need' for health technology
assessment
In the late 1970s and early 1980s, a repertoire of accounts emerged in the
discourse of international healthcare policymaking which might be drawn
upon by different actors in constructing rhetorical justifications of a need
for HTA. The first strand in this repertoire is a construction of policymak¬
ers' 'concerns'. In the late 1970s, a concern to promote cost containment as
the key issue was paramount amongst policymakers' discourse on medical
technology. For example:
Technology has been identified as a major cause of increasing health care
expenditures,. .. controlling new technology is required to contain health
care costs (Committee on Technology and Health Care et al. 1979: 14).
Such accounts referred frequently to the uncontrolled proliferation of 'new
medical technology', especially novel, high-cost, high-tech diagnostic equip¬
ment such as the CT scanner and magnetic resonance imaging (Jennett
1986). As the above account indicates, part of the policymakers' agenda was
to control diffusion of this type of equipment because it caused escalating
expenditure. In the perspective adopted here, this 'cost-containment' justifi¬
cation of a need for HTA is regarded as a rhetorical device which is consti¬
tutive of the boundaries of HTA, enabling certain interests and disciplines
to lay claim to a stake in its activities. It does not follow that financial
expenditure is the aspect of 'costs' which will necessarily be dominant in the
evolving model of HTA practice. While concern for expenditure might have
been presented as the primary cause, a set of 'concerns' has now come to be
portrayed in healthcare policymakers' discourse as underlying the need for
assessment of technologies:
There is growing concern relating to the health benefits and risks of
technology, its financial costs, and its social implications (Banta and
Gelijns 1987: 255).
The first of these authors is a high-profile international adviser on health tech¬
nology policy who was involved in meetings such as a seminal and symbolic
multi-interest 'Tidal Wave' conference held in England in 1991 (Hoare 1992).
The set of concerns Banta cites is notable for its reference not only to health
benefits and risks, but also to social implications, a theme which can be traced
back to the birth of the original technology assessment movement in the
United States, where the concept emerged in the mid-1960s associated with
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liberal political movements. Prominent in this early concept were notions of
the unintended consequences and indirect effects of technologies such as
industrial processing (O'Brien and Marchand 1982: 7). This model has been
taken up within the programmatic discourse on HTA in the United Kingdom.
Another high-profile expert and early proponent of assessment of medical
technologies, Barbara Stocking, conducted case studies of expensive health¬
care technologies in the United Kingdom. Then Director of the King's Fund
Centre for Health Services Development, one of the United Kingdom's major
independent research centres for research and consultancy on health services
issues, she described technology assessment as including:
the technical and clinical evaluation of a technology, as well as its
economic, social and ethical implications (cited in Hoare, 1991: 1).
Rhetorically deployed concerns about these different dimensions of tech¬
nology support a 'need' for HTA activities in the NHS. The grouping of
'concerns' of healthcare policymakers also promotes a particular model of
the disciplines which might appropriately participate in it. In an article in
the Lancet aimed at a medical audience, the current (1997) Director ofNHS
R&D explicitly makes a case for combining specialist disciplines:
The need to reassemble these fragments and to define their limits is
central to the successful incorporation of science into health care (Swales
1997: 1319).
He identifies the major topics of this science as being medical outcomes, cost
and quality of life (1997: 1320). The second rhetorical strand is thus a pro¬
gramme to amalgamate diverse disciplines: multi-disciplinarity. Linked to
multi-disciplinarity is the 'discovery' of common ground between disciplines
via the dusting down and applauding of new 'founding fathers'. This is seen
in the canonisation of individuals who according to HTA activists espoused
and promoted experimentalism and the monitoring of the effects on patients
of healthcare practitioners' work. Individuals who are being acclaimed in
this rhetorical discourse include, notably, the epidemiologist Archibald
Cochrane who is discussed below in relation to the role of epidemiology and
methodology in HTA. For example, Cochrane has been commemorated
recently by the publication of a collection of essays in his honour (Maynard
and Chalmers 1997), and 'a large photographic portrait of Cochrane has
pride of place in the reception area of our (academic) department' (author
observation). Two other individuals have been elevated in this way. Ernest
Codman, an American who in 1900 instigated a hospital system for moni¬
toring the end results of surgical care, was praised by the Director of the
NHS Centre for Reviews and Dissemination (Sheldon and Faulkner 1996).
And the 18th-century surgeon John Hunter, credited within the surgical
profession as being the first scientific surgeon, received a strikingly titled
homage from the chairman of the SGHT (Irving 1993).
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Appeals to common ground can be seen in the heart of the state-promoted
definition of 'health technology' itself. What counts as technology? The
meaning of'technology' is indexical (Pinch et al. 1992), that is, it is related to
the occasions and contexts of its use. It is also a metaphor. Some metaphors
become more dominant than others, and thus can be interpreted as traces of
the workings of power across communities, networks or disciplines (Leigh
Star 1991: 52). Whereas earlier policymakers' discourse concerned expensive
new medical equipment, health technology has been promoted in the pro¬
grammatic discourse of the state-orchestrated HTA movement in the United
Kingdom as a highly abstract, all-embracing metaphor. Far from being con¬
fined to high-cost high-technology equipment, it has been promoted by the
NHS Executive (and this was a usage already common amongst healthcare
policymakers in a number of other countries) as being:
. . . deliberately defined as broadly as possible. It encompasses all meth¬
ods used by health professionals to promote health, prevent and treat
disease and improve rehabilitation and long term care. It includes the
activities of the full range of health care professionals, the use of equip¬
ment and procedures, and the administration of pharmaceutical products
(Department of Health 1995:8).
Health technology is the experimental matter in the laboratory of the NHS.
It forms part of the discourse of the 'knowledge-based NHS'. The bound¬
aries of health technology are being drawn very broadly, by the NHS
Executive arm of the state.
It is possible to characterise in a number of ways the range of topics
which fall within the purview of health technology assessment. In order to
draw attention to the metaphorical and cross-disciplinary deployment of
health technology terminology, I present below a typology which charac¬
terises technologies from the viewpoint of a healthcare practitioner, with
examples mostly drawn from the HTA programme.
A typology of 'health technologies' from a health professional's perspective
Type of Technology Examples
Information systems Picture Archiving and Communication System (PACS)
Material artefacts Drugs, bronchodilator, hearing aid
Organisations Regionalisation (of intensive care), specialised versus local
access service (for vascular surgery), primary care-based
emergency centre
Interpreted techniques Diagnostic technologies and screening tests
Technique-assisted Physiotherapy, laser treatment, coronary artery bypass graft,
interventions knee prosthesis
Interpersonal communication Counselling, psychological treatment, health visitor
domiciliary visiting
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For Pinch et al. (1992), health technologies are 'social technologies' in
that they are intended to change human behaviour. This notion can be
extended by asking what sorts of behaviour might be changed. Here the tar¬
gets of intended change are health professionals and healthcare policies.
Examples would be modes of organisation of healthcare delivery, healthcare
techniques, or practitioners' choice between alternative healthcare options.
The majority of HTA topics focus upon a condition (such as stroke or low
back pain) and its corresponding technologies (such as rehabilitation tech¬
niques or spinal surgery) (Department of Health 1995). Some topics include
questions of organisational models for the utilisation of technologies, divi¬
sion of labour, job design, and skills. The National Co-ordinating Centre
for HTA is charged with developing an inventory of existing health tech¬
nologies and briefings on their effectiveness and cost-effectiveness (Research
and Development Directorate 1995). This re-interpretation of the earlier
principles of HTA is commensurate with the radical approach to creating a
'knowledge-based' health service which the state has promoted. The move
from new hardware-embodied technologies to a more general notion of
interventions having health .effects is again evident.
Further rhetorical discourses take the form of'horror stories'. First, iden¬
tifiable primarily with the health care purchaser's perspective,1 it has been a
frequently quoted statistic that only some 15-20 per cent of health care
interventions had a firm basis in research evidence (Hoare 1992). The editor
of the British Medical Journal greeted the launch of the first annual report
of the Standing Group on Health Technology with the words: 'Few deci¬
sions made in health services are made with good evidence' (Smith 1994). So
a vast array of healthcare practices are being performed, in this account,
without the 'evidence' to 'support' them. This has been countered by propo¬
nents of 'evidence-based medicine' amongst the medical professions who
uphold the need for individual clinical expertise alongside a commitment to
draw on the best available evidence in making care decisions (Sackett et al.
1996). This counter claim can be viewed as a version of the conventional
medical professional strategy of appeals to a need for clinical freedom.
The second type of horror story takes the following form: unevaluated
health technologies can be dangerous and a risk to health. This is illustrated
by the construction of the need for assessment of health technologies by ref¬
erence to previous health technologies which, allegedly unassessed, found
their way into routine medical practice only for their deficiencies then to
become apparent. The classic example, frequently quoted, is that of gastric
freezing (Challah and Mays 1986, Department of Health 1995: Foreword),
in retrospect a painful and ineffective treatment for duodenal peptic ulcers.2
There are thus several linked strands in the rhetorical repertoire at the
disposal of proponents of HTA. A rhetoric of broad rational concerns,
employing appeals to medical, social and economic values is linked to
appeals to cross-disciplinary common ground; this is supported by a
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rhetoric of appeal to possible danger and risks from healthcare provided in
the absence of an adequate evaluative knowledge base. These appeals are
not specific to particular disciplines within HTA, and so they promote
multi-disciplinary participation in it. Appeals are both to clinical and eco¬
nomic concerns and to a need to produce new healthcare knowledge. Health
technology is a 'trans-disciplinary' concept, like other such notions
'metaphorically encompassing the several parts of material handled sepa¬
rately by specialised disciplines' (Good and Roberts 1993: 6). However, as
the above interpretations suggest, these rhetorical resources are flexible in
their potential use, and are contestable. This draws our attention to power
relations at work in the negotiation by the various disciplines for positions
in the multidisciplinary world of HTA.
Consideration of these persuasive discourses would be important in a
sociological history of the emergence of HTA in the United Kingdom.
Alongside them should be set an historical account of the 'official' policy
development which identified a need for nationally co-ordinated HTA. This
of course would be another, but different, rhetorical discourse. It is thus
worth noting the appearance during the 1980s and more recently of commit¬
tees and advisory groups, and reports from national bodies, which would
doubtless form part of such an account. These include: a call from the
Council for Science and Society in 1983 for evaluation of all expensive new
medical technology; a Medical Research Council (MRC) committee dealing
with research on health service delivery; a national Health Technology
Assessment committee established in the Office of the Chief Scientist in
1987; a House of Lords Select Committee on Science and Technology which
reported on 'Priorities in Medical Research' in 1988, noting a wide disparity
between the research needs of the NHS and the activities of the MRC; and a
government advisory committee reporting on 'Medical Research and
Health' in 1993, explicitly supporting the concept of health technology
assessment.
Research alliances and institutional co-ordination
Via HTA, the NHS is gaining access to the means of production of research
knowledge, and knowledge-producing disciplines and institutions are gaining
access to the laboratory of the NHS. Research alliances are emerging in inter¬
actions and negotiations between state orchestration, healthcare organisa¬
tions and the disciplines of healthcare knowledge production. It is not possible
here to analyse the full range of processes which constitute the organisational
and disciplinary membership of HTA. In this section, therefore, I give exam¬
ples of alliance-formation, co-ordination and centralisation which are evident.
In doing so, I am aware that I am glossing over many of the tensions which
undoubtedly exist around the state-promoted HTA project.
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The participating constituencies in HTA are broad. The ways in which
individuals and institutions become engaged in HTA networks include
memberships of the SGHT and its advisory panels, location of co-ordinat¬
ing bodies such as the National Co-ordinating Centre for Health
Technology Assessment within academic institutions, involvement of
'acknowledged experts', often researcher-clinicians, in the process of defin¬
ing assessment questions prior to funding, consultation within the NHS and
more widely amongst representative groups such as medical royal colleges
and the Patients' Association, and the advertising and award of assessment
project funds. The SGHT and its advisory panels have multi-disciplinary
membership, including healthcare purchasers and providers, clinicians and
other health professionals, health economists, and individuals seen by mem¬
bers of the R&D Directorate as methodology specialists.
Closer alliances between academic researchers (from the disciplines of
epidemiology, medical statistics, public health medicine, human sciences,
psychology, sociology, social anthropology and economics), clinician-
researchers and purchasing authorities (especially in the form of public
health departments) are being developed. Novel forms of collaboration are
arising between academic researchers and health service practitioners.
Examples are the location of health service research centres in NHS hospi¬
tals, and formal collaborations between NHS public health departments
and academic research centres.
At inter-institutional level, long-standing co-ordination between the
MRC and the Health departments has been extended (Medical Research
Council 1991). In 1992, health services research funded by the MRC was
seen to need its own managerial Board, the Health Services and Public
Health Research Board (HS&PHR) (Medical Research Council 1992,
Medical Research Council 1995). The research councils, the Department of
Health, the MRC HS&PHR Board and the SGHT are all linked by cross-
memberships.
Thus there are multiple signs of new inter-institutional networks, alliances,
co-ordination, and centralisation in the broad institutional development of
national health technology assessment. The growth of co-ordination of health
technology assessment activity attests to the orchestrating role being played by
state agencies. However, the term 'health technology' has not been strongly
embraced by academic producers of HTA knowledge - 'they generally prefer
to describe their organisations, as we do, in different terms, such as "health
services research" or "health care evaluation" or "health science"' (author
observation). This terminology can be interpreted as signalling an independent
position in preserving a capacity for determining local research strategies with¬
out becoming over-dependent upon the NHS-driven agenda of HTA.
Given these organisational developments, the following section considers
the relationships between the disciplines and methodologies of HTA.
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Multidisciplinarity, experimentalism and accuracy of projection
In health technology assessment, projection - the extrapolation of findings
from the test environment to the real world - takes a number of forms
depending on the methods adopted by the different disciplines of healthcare
knowledge. The current incarnation of HTA in the United Kingdom com¬
prises a multi-disciplinary approach drawing upon both quantitative and
qualitative methodologies, with a distinctive mixture of disciplines and
skills. The research commissioning groups of the HTA programme and the
MRC have a preference for research teams made up of certain disciplines.
Informal discussion with HTA administrative support staff confirms that
projects lacking clinical specialists, elements of economic evaluation or
access to expertise in medical statistics are unlikely to be supported. In seek¬
ing tenders for a National Co-ordinating Centre to manage and support
national HTA activity, the NHS Executive sought a single centre capable of
providing: 'Multidisciplinary scientific skills . . . [which] should include clini¬
cal (medical, nursing or therapy) and epidemiology, health economics, soci¬
ology and other social science disciplines' (Research and Development
Directorate 1995).
As Pickstone (1993) argues, until very recently the experimentalism of
basic biomedical research has been the primary world of medical research,
clinical medicine a 'poor, confused imitation' (1993: 452), and research has
been discipline-driven. The impact of scientific research on health service
delivery was relatively indirect and long-term (Austoker 1989, Booth 1989,
Medical Research Council 1995a). With the arrival of HTA, the organisa¬
tional changes described above have been implicated in a re-alignment and
shifting of power across and between professional disciplines, and a disrup¬
tion of the previously strong boundary between high status experimental
biomedical science and the scientifically lower status clinical research.
Exponents of epidemiology and medical statistics have been the leading
disciplinary activists in linking experimental science and clinical practice.
The primary form of projection ('generalisability' in the language of HTA),
promoted as the vehicle of this linking, is the randomised controlled trial
(RCT). In principle the RCT enables valid generalisations to be made
because it eliminates sources of bias. In promoting the RCT as the preferred
methodology for what he called 'applied medical research', Archibald
Cochrane - in what proponents of HTA now regard as a core text in the
application of the experimental method to health service research (Cochrane
1971) - aligned clinical research with the experimentalism of the more pres¬
tigious biomedical sciences. Skills in experimental research design for causal
analysis of disease patterns are strongly claimed within the disciplinary
boundaries of epidemiology. Its practitioners have advanced their influence,
applying the same methodological concepts to questions of technological
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cause and health effect within health services. Cochrane's name is now used
rhetorically to symbolise an international search for bias-free evidence
about the effects of health technologies, gained by the collection of results
only from RCTs. This is known as the Cochrane Collaboration.
Further entrepreneurialism in the discourse ofepidemiology can be seen in the
'systematic review', a second methodology aimed at identifying bias-free, gener-
alisable relationships between health technologies and their effects. In strong
programmatic statements from policy centres for HTA, this assessment method
is also construed as a scientific method owing its principles to epidemiology. The
method has been enshrined in the Cochrane Collaboration handbook on
'Preparing and maintaining systematic reviews' (The Cochrane Collaboration
1994). Its introduction, entitled 'The science of reviewing research', begins:
The scientific principles that apply to epidemiological surveys apply also
to systematic reviews: a question must be posed, a target population of
information sources identified and accessed, appropriate information
obtained from that population in an unbiased fashion, and conclusions
derived. Often statistical analysis can help in reaching conclusions (1994:
VI-1).
Here the information sources referred to are the results of existing, com¬
pleted RCTs. The epitome of the method, referred to above as 'statistical
analysis', is meta-analysis, the statistical summarisation of the data from
several empirical studies deemed to be comparable (Dickersin and Berlin
1992). The formal commitment to elimination of bias has resulted in an
attempt to construct the systematic review also as an experimental scientific
procedure, along the lines of the randomised controlled trial.
However, a purely quantitative approach to systematic reviews is implic¬
itly criticised by the NHS' national centre for this activity in the formal
guidance it has issued (NHS Centre for Reviews and Dissemination 1996).
It commends an approach which:
considers all the results taking into account not only the methodological
rigour, and therefore reliability of these studies, but also helping to
highlight and explore differences. A qualitative analysis of the evidence is
therefore an essential step in the assessment of the effectiveness of a
health technology (1996: 46).
The document bemoans an exclusive focus upon the 'narrow' methods of
statistical pooling of data. These passages suggest that rather than being a
matter - for those with appropriate statistical expertise - of cumulation of
results from separate studies, the review requires qualitative judgements to
be made about the homogeneity, or otherwise, or studies. Thus what is at
issue is the basis on which accurate projections from 'results' of experiment
(or combined experiments) might be made: in other words of how bias or
subjectivity might best be controlled.
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Thus the contribution of epidemiological discourse to the construction of
the HTA agenda powerfully promotes scientific experimental methodology.
However, even around this formal programmatic agenda, conflict is in evi¬
dence, for example over the status of the RCT (Black 1996) and of meta¬
analysis (Eysenck 1994) as methodologies of knowledge production.
Epidemiology also figures in the framing of the national HTA agenda
through its focus upon the prevalence of medical conditions. Whereas his¬
torically clinical science has been greatly occupied with relatively rare condi¬
tions (Frankel 1989), epidemiological analysis of the distribution of
remediable conditions has paved the way for a re-distribution of clinical sci¬
entific research attention to some of the most common afflictions. And, as
noted earlier, prevalence is one of the criteria explicitly used in the for¬
malised priority-setting processes of the SGHT in identifying topics for
assessment.
There is increasing interest on the part of medical practitioners in so-
called 'qualitative' research methods, coming from within the arena of clini¬
cal research. For example, there has been a series of editorials, appearing in
the most prestigious medical journals, including the British Medical Journal,
presenting the case for qualitative methods in healthcare research, and
analysing the interface between qualitative methods and clinical experimen¬
tal research designs. Programmatic statements from a medical viewpoint
shape the relationship between qualitative and experimental research.
Qualitative research is held to be especially relevant for hypothesis genera¬
tion, explanation of experimental or quantitative findings and understand¬
ing of factors affecting implementation of research results (Jones 1995).
Papers written by sociologists have also been published in medical journals,
outlining some of the main qualitative research methods which can be
applied in healthcare research (e.g. Mays and Pope 1995).
The definition of medical symptoms and outcomes of treatment for
research purposes has, historically, been largely the preserve of medical spe¬
cialists performing clinical research. In the new model of health technology
assessment, the boundaries of this territory appear less clear. New contribu¬
tions are being made predominantly by research techniques derived from
sociology and psychology. This is embodied in the increasing development
of measures of health status and health 'outcomes' measures, in particular
measures informed by our own experience, as health service users, of our
symptoms and health states. Patient-derived measures of the 'outcomes' of
'interventions' - are being increasingly incorporated into the array of mea¬
sures used in experimental tests of health technologies. The novelty is that
they are constructed from 'qualitative' research, usually interviews, into our
experience of symptoms. A typical example is the development of an 'instru¬
ment' to assess the outcomes of total hip replacement surgery - one of the
highest priority technologies identified in the early HTA programme - from
patients' perspectives: 'Many questionnaires . . . intended for general use . . .
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may be . . . insensitive to the specific changes in health produced by a partic¬
ular intervention . . . Questionnaires are needed therefore which address
patients' perception of a single disease entity . . . ' (Dawson et al. 1996: 185).
These authors' disciplines combine sociology and orthopaedic surgery.
Psychometric statistical methods in particular are being used to 'validate'
such measures. Validation in this sense is another form of 'projection', akin
to the testing ofmeasurement instrumentation technology in laboratory set¬
tings. The construction and validation of such measures are presented as
processes establishing the scientific accuracy of the representation of
patients' subjective experience. This enterprise results in calls for the 'stan¬
dardisation' of such measures (McDowell and Jenkinson 1996), because the
generalisability of results depends partly upon having reliable methods of
enabling the effects of the application of health technologies to produce
'traces', to use the SSK term described above, which can be apprehended,
quantified and interpreted by statistical analysis.
The proliferation of measures of health status and quality of life extends
the definition of what counts as an effect of clinical intervention, and
thereby re-shapes the meanings which health and illness might have in the
discourse of healthcare policymaking. This process is being strongly sup¬
ported by the involvement of proponents of health economics in HTA.
Health economics has established itself as a core discipline in the health
technology assessment repertoire. Economic evaluations are increasingly a
part of clinical trials, and it is policy to encourage this development both in
the HTA programme and in the MRC. The performance of economic evalu¬
ations alongside clinical trials is promoted by professional economists
within the discourse of NHS R&D policymaking as a matter for profes¬
sional health economists rather than as an activity which can be accom¬
plished by 'doing-it-yourself (Drummond 1994: Foreword). Assessing costs
and benefits in health technology assessments enhances the perceived need
for health status measurement tools, because changes in health status, mea¬
sured either as survival or quality of life, are the 'effects' against which dif¬
ferences in costs between alternative technologies are evaluated in economic
analysis. Ashmore et al. (1989) have drawn attention to the processes by
which economists, in interaction with others, construct quality of life mea¬
sures (QALYs) as representations of generalised public preferences for
states of health. Here it can be said that this too, like the discourse of epi¬
demiology and medical statistics, is a methodology for controlling bias and
attempting to take a viewpoint which might somehow make it possible for
judgements based on social values to be expressed on behalf of a popula¬
tion. This is explicit in the texts of health economists who state that they
perform their analysis 'from the perspective of the NHS' or from the 'soci¬
etal perspective'. Utilitarian philosophies are preferred. But here too, within
the expert system of health economics, conflict and debate can be found.
It has been questioned, for example, whether the focus upon the health
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benefits of health technology is too narrow. Health economics might fail to
take account of other benefits or costs which, as citizens rather than as
patients, we might derive from healthcare (Ryan and Shackley 1995).
In interdisciplinary fields, expertise from more than one discipline comes
together to seek common goals (Good and Roberts 1993). Within the con¬
stellation of HTA disciplines, the clinical sciences and health economics are
the ones most clearly delineated. Some interdependencies suggest a blurring
of boundaries between the constituent HTA disciplines, reflecting research
alliances which have been formed. These include, for example, an interde¬
pendence, centred on outcome measurement, between the disciplines pro¬
moting expertise in interviewing and questionnaire design and the
corresponding clinical specialisms and body systems. A further interdepen¬
dence may be discerned around cost-effectiveness between the disciplines
concerned with health status and quality of life measurement, and health
economics. On the other hand, conflicts and tension exist between discipli¬
nary and inter-disciplinary rhetorics of HTA. For example, 'adherents of
qualitative methods commonly criticise HTA's emphasis on the randomised
controlled trial' (author observation); a public health consultant reports
that, in a leading teaching hospital, 'powerful clinical scientists' believe that
'the HTA side is contentious, as there is an obvious link to rationing . . .
[though] . . . formalising an HTA process in the NHS Trust would certainly
ring the management bell' (Ayres, P. personal communication); and leading
voices in the formal programme of health economics criticise the clinical
professions' agenda of applying scientific evidence to healthcare practice
(Maynard 1997).
The rhetorical claims of health technology assessment constitute the
activity of health technology assessment as having the legitimacy of science
at a time when novel alignments of professional disciplines are developing,
when professional identities and disciplinary authorities exist in tension with
each other, and when research communities are being invited to respond to
a culture of health service 'needs'. Those involved in the disciplines of HTA
perform experiments in and around the laboratory of the NHS. These
experiments use measurement instruments to test health technologies. In
these tests projections are made from the laboratory world to the 'real-
world' of health technology in healthcare practice. The different disciplines
of HTA are able to mobilise their technical, methodological and rhetorical
resources to different degrees in constructing the HTA agenda.
The assessment agenda
The rhetorics of HTA discussed above might be taken as a guide to the
assessment agenda which we would expect to find embodied in the national
HTA programme: 'concerns' for benefit and risks to health, for cost and for
© Blackwell Publishers Ltd/Editorial Board 1997
PAPER 1
Health technology assessment in the United Kingdom 199
social implications. We can examine the HTA programme to see what form
these concerns might take, shaped by and shaping the organisational and
disciplinary processes described above.
Turning to the aspects of health technologies which are typically assessed,
it is clear that 'effectiveness' and 'cost-effectiveness' are the two hinges on
which the formal NHS HTA world-view swings. Strong statements confirm¬
ing this abound: for example, 'The aim ... is to help those conducting and
funding trials to ensure that their work tackles the issues of cost-effective¬
ness as well as effectiveness whenever it is feasible to do so' (Drummond
1994). The MRC approach is essentially the same. Its studies 'measure effec¬
tiveness and efficiency in relation to health outcomes' (Medical Research
Council 1995b: 107).
Turning first to costs, in what ways are 'cost implications' being con¬
structed in the HTA agenda? A concern with economic implications might
suggest that encouragement of potentially income-generating technologies
might be high on the agenda, or that high-technology high-cost equipment
would be of priority for assessment, but the voice of commercial exploita¬
tion is noticeable by its absence from the formal discourse and practices of
national HTA, in spite of policymakers' early plans to create collaboration
between the NHS R&D strategy and industry (Department of Health 1993),
and attempts by commercial interests to stimulate alliances via national
'research foresight' in health-related technologies.3 It appears that the
strength of the clinical and academic economic discourses on benefits and
costs of health technologies have resulted in an institutionally bounded, cir¬
cumscribed agenda which is relatively impervious to commercial networks
and interests. This is not to say that practitioners of HTA research, for
example, might not transact with both national HTA and commercial
organisations in seeking to negotiate favourable conditions for themselves
locally, but the clinico-economic discourse of health costs and benefits effec¬
tively excludes commercial interests.
Concerns for risks to health were part of the policymakers' early rhetoric
of a need for HTA. Examination of the topics of national HTA suggests
that absolute safety and risks to health are not the major issues in the HTA
agenda. Rather, safety and health risks are aspects of outcome measurement
in assessments where different technologies are being compared. Of course,
in the case of pharmaceuticals and 'medical devices', statutory agencies exist
with responsibility to ensure safety: the Committee on the Safety of
Medicines, and the Medical Devices Agency in the Department of Health.
But the over-riding focus upon comparative effectiveness and cost-effective¬
ness in the HTA disciplines projects quite different definitions of risk. The
major dichotomy evident here might be characterised, if somewhat glibly,
as one between risk to the public health and risk to the public purse.
Like processes of risk assessment (Carter 1995), health technology assess¬
ments construct boundaries between safety and danger. However, unlike
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discourses of risk to the healthy body, the discourses of health technology
assessment amalgamate concerns with transgression of boundaries of health
with concerns regarding transgression of boundaries of financial budgets.
They thus generalise and extend the notion of risk. The influence of epi¬
demiological and economic perspectives results in the construction of risk at
the level of society as a whole.
In HTA health benefits and costs are aspects of both clinical and eco¬
nomic discourses. The agenda of health status measurement and quality of
life measurement has been referred to above. 'Costs' and 'benefits', like
'health technology', themselves develop metaphorical meanings. Discourses
of clinical research, incorporating assessments of the effectiveness or effi¬
cacy of healthcare technologies derived in interactions with patients, refer to
effects of technologies such as complications, mortality, and patient 'out¬
comes'. Health economics constructs costs and benefits in both financial
terms and in terms of the health outcomes of quality of life and mortality.
Experimental science, as embodied in the epidemiological and statistical
methods of HTA, requires standard, reproducible forms ofmeasurement so
that stable comparisons between different patients or groups of patients at
different times- may be engineered. The other disciplines of HTA deploy
techniques which enact this requirement. Economists' cost-effectiveness
analyses frequently proceed by constructing a model of a typical health dis¬
trict or general practice population in order to examine cost and benefit
implications (e.g. Bachmann and Nelson 1996). This represents another
form of testing of health technologies, in this case projecting from simula¬
tions to actual populations.
Turning to the shaping of 'social implications', it has been argued by
leading HTA proponent David Banta that: 'The social implications of a
new or existing technology can be the most challenging and difficult aspects
of evaluation . . . the methods for assessing social implications are relatively
undeveloped . . . ' (Banta and Luce 1993: 132). The implication is that when
methods are better developed, HTA will be able to address these issues bet¬
ter. However, it could be argued that if HTA practitioners are to focus on a
scientific agenda built around generalisability, elimination of bias, and the
representation of a form of aggregated public interest, this would preclude
examination of substantive social and ethical issues. Economic evaluation is
leading to consideration of ethical issues in healthcare provision, but this is
focused upon questions of choice between alternative services (the rationing
debate), rather than the examination of the substantive social and ethical
issues arising with particular technologies such as, for example, animal to
human organ transplantation. 'Xenotransplantation was considered by the
Acute Sector Advisory Panel of the SGHT, but not accorded priority, in the
first year of operation of the national HTA programme' (author observa¬
tion). It may be that mechanisms outside health technology assessment,
such as the investigative activity of the mass media and specially convened
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groupings of state-identified experts (Advisory Group on the Ethics of
Xenotransplantation 1996), will be the major means by which those tech¬
nologies, with apparently broad social and ethical implications, are
addressed within society. This would be despite the HTA claim to this
agenda.
The discourses of epidemiology, statistics and economics construct the
population's health status as the indirect aggregate of many individual out¬
comes of health technology. The current HTA agenda allows directly for the
patient's voice in closely limited ways. Users' representatives such as the
College of Health are included in the consultation process on priority topics
for assessment. A few health technology assessment topics include lay or
patient attitudes or actions as a major strand in the assessment question.
One example is the study of the effect on treatment rates of patient partici¬
pation in care decisions, using interactive video disks containing personal
testimonies of former patients and information about the probability of dif¬
ferent outcomes following surgical treatments (NHS Executive 1996). As in
this case, projects which do incorporate users' voices contain them within
the design of the project. They give priority to measuring the outcomes of
that participation by the experimental methods of bias-elimination and in
terms of aggregated health outcomes. Multidisciplinary HTA defines the
healthcare user population as the object of more or less cost-effective
healthcare interventions.
Lay incursion into the expert domains of design, conduct and interpreta¬
tion of assessments has occurred with AIDS activists in the United States
(Epstein 1995). Such engagement is not evident in HTA. And, as Elston
(1991: 82-3) has noted, experimental treatments and illnesses where curative
medical science has little to offer are specific, limited areas perhaps not rep¬
resentative of the overall capacity of healthcare consumers to challenge the
authority ofmedical science.
The embryonic agenda of HTA, considered at this general level, is not
about what the sociology of scientific knowledge is most often concerned
with, the processes of building particular facts. It is, rather, about preparing
the ground which makes it possible for some sorts of facts - rather than
others - to grow, what sorts of facts are going to be important. This is per¬
haps the reason why so much of the early funding in the national HTA pro¬
gramme has been put into study of the methodology of HTA itself. A
reflexive emphasis on methodology reflects and facilitates the engagement of
the different professional disciplines 'taking part' in HTA. This is also a
debate about what is the appropriate instrumentation for the laboratory
of the NHS. It again reflects the tension between disciplinarity and inter-
disciplinarity in HTA. While the major emphasis has certainly been upon
the bias-reduction methodologies of the controlled trial and meta-analysis,
no exclusive coalition can be said to have emerged. The voices of non-
experimental assessment methodologies and non-population oriented
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disciplines have also negotiated places - at least for the time being - in the
emerging agenda. Tensions are evident, for example, in the small number of
studies funded on topics such as the role of qualitative methods and action
research in HTA (NHS Executive 1996). 'Similar conflicts occur routinely in
informal discussions about the respective status of the randomised con¬
trolled trial in comparison to non-experimental assessment methods'
(author observation). The effect of such internal ambiguities is to enhance
the authority of health technology assessment discourse and its participat¬
ing voices by retaining control over its agenda. This indeterminacy in turn
can be seen as a boundary-constructing control strategy (Jamous and
Peloille 1977, Gieryn 1983).
Conclusion
'Health technology' is an abstract metaphor shorn of specific disciplinary or
methodological signification. As the quotation at the beginning of this chap¬
ter suggests, unresolved tensions between disciplines can exist in the interpre¬
tative elasticity which this creates. HTA may or may not be interpreted by
different interests as an extension ofmedical research. The trans-disciplinary
concept of health technology has been promoted by the state, and the health¬
care knowledge disciplines orient themselves to it in different ways. The
metaphor enables these diverse actors including HTA research policymakers
and research knowledge producers to shape their activities in diverse ways in
and through the production of healthcare knowledge. The workings ofpower
are evident within and between the disciplinary discourses of HTA. The
health technology metaphor serves the state by enabling the participation of
the agencies of knowledge production required by the vision of a knowledge-
based health service. The elasticity ofHTA's metaphors enables uneasy part¬
nerships to exist between disciplines and methodologies, such as qualitative
and experimental methods, and clinical science and sociology.
In health technology assessments, such as clinical trials, the application of
technologies in healthcare provision and the testing of them are conflated
for a proportion of health care users. Patients are entered into trials of alter¬
native treatments, and models are built to project the effect of health tech¬
nologies on real patient populations. Thus HTA defines the NHS, its
patients and health professionals, as a research laboratory for the field-
testing of the effectiveness and cost-effectiveness of healthcare technologies.
The inclusion of 'patient preferences' in health technology experiments (e.g.
Torgerson et al. 1996) suggests that, as consumers, our intimate feelings
about treatment or other healthcare choices can be incorporated into health
technology. If the exercise of choice itself might affect health, then personal
healthcare choices become part of the material from which some health
technologies are manufactured.
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The different combinations of the variable relations between experiments
and laboratories in health technology assessment, such as the multi-centre
randomised controlled trial combined with cost-effectiveness analysis, pose
methodological and analytic challenges for the sociology of healthcare
knowledge. For example, HTA projects construct ad hoc laboratories in the
healthcare environment, which are not marked by separate physical space,
and resources for experimental work are widely dispersed between organisa¬
tions and disciplines. Analytically, a challenge is presented by the perception
that, in HTA, health professionals and patients themselves constitute part
of health technologies and the measurement instrumentation employed in
experiments.
Health technology assessment provides a locus in which relationships
between rational science, scientific uncertainty, trust and authority may be
examined. Its processes constitute and define areas of expertise characterised
by scientific uncertainty. The negotiable 'boundaries' between acceptable
and non-acceptable risk, conventionally if implicitly conceived of as lines of
demarcation, might better be re-conceptualised as broad bands where ques¬
tions of comparative risk to health and budgets are held, pending expert,
political and public actions related to scientific evidence. Laboratories har¬
bour uncertainty while engaged in projects to reduce it. National health tech¬
nology assessment policy exemplifies a rational-planning approach to the
dynamics of science and health care. From the perspective of the sociology
of scientific knowledge, it is an activity which is open to analysis as a scien¬
tific practice, with associated contestable knowledge claims. Contestability of
expertise is frequently taken to be one of the defining features of health-
related issues in contemporary societies, and it is associated with a decline in
trust of medical authorities (Gabe and Bury 1996). However, it is not obvi¬
ous that this is a clear, unopposed trend across healthcare. The HTA move¬
ment, in its engagement of expert disciplines, its research alliances, its
encompassing metaphors, its containment of uncertainty, its consultation of
public voices, its bias-elimination methodologies, and its use of a rational
aggregated voice speaking for the good of the public health, might be seen as
part of a dialectical process involving decline in traditional medical authority
and a reconstruction of a new framework of scientific authority. We are
invited to place trust again in this new form of scientific expertise. It is para¬
doxical that this invitation to place our trust in science is associated with the
radical questioning of more established forms of healthcare knowledge
which the health technology assessment movement promotes.
Acknowledgements
I should like to thank the editor and the anonymous referees for comments on previ¬
ous versions of this chapter, and Caroline Brown for comments and advice.




1 Since 1991, the NHS has been organised by a division between health authorities -
'purchasers' or 'commissioners' - which contract for health services with
'providers' (called NHS Trusts) in the form of hospitals and community health
service agencies.
2 The use of the example of gastric freezing to support the case for assessment is
something of a selective reading of the assessment history of this particular opera¬
tion. It was invented and unevenly diffused primarily in the USA, after testing
with apparent success on animals. At least thirty-six trials of the procedure were
published in American medical scientific journals during the 1960s, the early stud¬
ies being at least 'qualified favourable'. With hindsight, many of these studies are
regarded as having methodological flaws. The negative results of the only multi¬
centre randomised controlled trial were not published until the procedure had
fallen out of favour (Fineberg 1979). Gastric freezing spread in spite of assess¬
ments, rather than because of lack of assessment.
3 For example, a multi-interest conference 'Planning national research priorities:
foresight and the science base in wealth and health creation', held in Cambridge in
1994, organised and supported by SmithKline Beecham Pharmaceuticals and
attended by the NHS Director of Research and Development.
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7 CasingtheJoint TheMaterialDevelopmentfArtificialH ps AlexFaulkner INTRODUCTION Hundredsofth usanpeopleworldwialkiththidda
ofentirelyartific alhips.M nyavedartif cialreplacementsin¬ stalledforb thftheirhipjoin s.T esdevices,implan dyortho¬ pedicsurgeonsinriskyanexp nsiveoperati ,r torelocomotor functionandreducepainfromarthr tictherwisedam gedjoi ts. Indeed,artificialhipsrpe c v dtobonhsuc sst ie moderntechnologicalsurgery.Mostpe plwhfuncti nphy ica ly withtheseinvisiblaids,how v r,reunawarfthe rm t ri lcom¬ position,thepr c ssbywhicht yhaveenmanufactured,orve theirbrandname.Fortuse ,heis ccessidefi edytheirfunc¬ tionality:aslo gitworksandreducesp in. Today,t t lhipprostheses,aorthopedicsu geonsandman fac¬ turerscallthem,areonfmajorproductsfm ltin tionalco pa¬ niesthatspecializeimed caltechnology.Ico t mporarymedi ne, designsandmaterialfr quentlych geasinnovatingsurgeonsand manufacturersseekimprovederformance,abro derr ngfpoten¬ tialimplantees,a dimprovedr fi abilityforthe rdevices.Inn v tion inmaterialsanddesignshouldthusbeunderstooit co textf commercialenvironmentaswelloniwhichm d apractitioners andpatientsse ktechnologiesalleviatpa dimprohysic l functioning.Thises aydiscussest evariousm ter als dimod rn devicesthatreplaceh pjoincompletely.Btracingthr ngfma-
199
terialsusedathprosthetictechnologyasev lved,t ssaywillut¬ linethmaterialsusedinthdiff renttypesofd signsproducedto ay.Inmedicalterminology,thefor ationfrtificialj tbe weenbonesisknownaarthroplasty.T ehipjoi ties entiallyball-and- socketjoin ,th"ball"eingtherou deda fthighbone(femur),thesocketbeingacavityinthipbo e( etabulum)its lf.Humanimpl tm terials,tobsucces ful,mu txistihetis eofthehumanbodywithoutcausingversereaction,ith rthtis ue orthemat rials.Thme nst tthesearchfosuitablematerials
in partsea chfor"inert,"biologicallycompatibleateria sswell materialsthatwi lwithstandtheforc sex rtedojoi tsbyphysicalac¬ tivity.Asthise aywillhow,urgeonsandengineershavexp ri¬ mentedwi haidevarietyofm te ials—includingm ta s,plastics, andceramics—duringtheevolutionfthisypefi pla t.Somefth majordevelopmentsinindustrialengineeringa dmat rialssciencei thewentiethc ntury,aso emightexpect,havcontributedthis-
-Otoryfartificialhips. Thises aydividesitaccountofhedevelopmentfartificialips mintofourbroadchronologicalstages:earlyhistoryf mhenineteenth centurytohearl1940s;"premodern"phaseofacceleratedctivityfromthemid-1940stoheid-1950s;a"mod rn"phasef omt mid- 1950sthroughthe1970s;andrecentdevelopmentsovertla ttw ntyyears.Sinceclinicaldevelopmentsartificialh preplacementw re takingplacearoundthworldsimultaneously,thisistoricalacc unt organizedarounddevel pmentsthainvolvesimilarmat rialsnd similarsurgicaltechniques.Itsworthyingth tnys udyfhed ¬ velopmentfartificialh pim la tsu tcontendwiththef ctt at whateverhistoricalrecordalreadyxistsab nmpiledprimarilybymembersofthprofessionresponsiblef rdevelopinga dimpla t¬ ingthesedevices.Thus,lar elyorthopedicsurg onsandd ignershavedeterminedhexistingliterature.Bycontrast,lynowav ew ofthesedevic sm rgingfromtheperspectiveofthoswhoavre¬ ceivedimplants,especiallyr sultofmul idisciplinaryresearchi o theefficacyofh althcarete hnologiesitWest. Aleadingcommentatorthesta eofdesignandm t rialsi ipimplanttechnologyt ee doftwentiethcenturyasdescribed theprocessforthopedicinnovationi ippro theses"tr ala d errorculture"(H iskes,1993).Thu ,t ichapterconcernedwithth productsfthaculture,whichischara terizedbyont nualinn vation
andexperimentation.Itisasytogivehm sleadingimpre s nt technologyhaslear,unilinear,predominantlytec icala dw th hindsight,predictabletraj tory,whichonecandis erthratio al marchoftechnologicalpr gress.A ditsce tainlyse,ed above,thatmanyperceivartificialh pintsva iousformtb highlysuccessfutechnology,developmentwhichipu ctuated byheroicindividualsandbr akthroughm ment .Tlite at reo ¬ thopedicresearchcont nsm nyxamplefthisypehistory.F asociologicalperspe tive,however,techn lrtifa srepres nt theproductofnetworksr lati nbetweegro ppeo leho havebeenabletoestablishh rs keint tt chnology.T"success" or"failure" ftechnologicaldev lopmentssequaimp rtance seekingexplanationsforwhyomebecdomin nta dcc pt d routineus ,andwhythersdnot.Thhis orfrtificialips manyexamplesofm terialsth tdidno"work"w l,bualsosome wheresatisfactoryexplanationsfoc ngingmat aldes gnrl ss obvious. Thehistorypresenteder ,t niaccou toftiviti s rangeofactorswhoh vproduc ddusetificialpreplacement technology.T hn logy,ieffect,scietymadet riala dtpr ¬ ductionoftechnologiesisacc mpa i dbye"producti n" smar¬ ketsanditsusers.Theradicalnatureoft ahipreplacem nt generalsuccessico t mporaryhealtharepr iceavcreat d highdemandanindeecr asinglyla gerk tfothiypof prosthesisasboty ungerdoldggroupswithdegenerative jointdiseasea dotherf rmsfj iam grseen,rthe ¬ selves,aspotentialimplante s. Inordertillustratehpe hapsunexpectedvari tym t r al historyproducedbythisrialanderr rculture,Ihoev s alim¬ agespresentedinthise ayartsimplbecau yhowome¬ thingoferangemat rialtechnolo sus dv ri .Iaddi¬ tionhis,however,eydrawatt ntionifferentm dian whichtheseprosthesesarrepre ent dit insociety.No mally,nly theinhabitantsofconfi edworldbiomechanicallaboratories, manufacturingplants,orhospitalseeart ficiali s.Butf erl k ng attheseim g s,onsr mind datdevicesh vbeenrwill be,insertedsidethhumano yanttemptmmicfunctio ofhumanskeletaltis u s.Th rei ,ur ly,omethingrath runs tl aboutlookingtb dypar sth treusuallyhiddefr mview.T is
1
raisesquestionsab uthowwedi c ssthn ermate ialndmechan¬icsofthehumanbody.S ciety'sco cernwitht chnologicalmedi ineensuresthats chim gessom timesreacht publicdomain.Butheseimagesalsochallenget econv ntionalperc ptionfthext r alfab icofhumanb dies,andthuschallenget materialfo ndationofev ry¬daylife. FIRSTEXPERIMENTSW HSURGICALH PPLANTS ThedevelopmentfartificialipsisharedbetweenEu opendhUnitedStat s.Inthel tnin teenthandarlytw n iethcenturies,widevarietyofmat rialswausednplantsurgeryge erall ,in¬ cludingmetalssuchazi c,copper,dndaluminum.However,noneappearedespeciallyuitablendiwascustomaryoregardthe astemporarymeasures,sometimesinsert din othbo ywithhehopeofstimulatingsel -repairbyheodytissues.Thefirstr corded successfularthroplastyoft ehumanipwcarriedouti1822WestminsterHospitaliLondon,butthisdidnotinv lveanypros¬ theticcomponents.Thfirstkn wnca efin ertionofforeignmaterialbetweenbonendsoccurredi1840,wh nwoodwasusedi nt¬ tempttoobilizeast ffjaw one.Inthl t1880s,experimentswithhipjointswerebeingconductedFra cewithtechniquesusingmus¬ cletissueasthmplantationm terial,andiG rmanywithvariousnaturalndfabricatedm erials.ThomasGluckin1890d s ribedb ll- and-socketjointsmadefr mluxurious,h rdnat ralma erial— ivory—andfixeint rnallywithnickel-platedste lscrews.Hh l odevelopedagluema ewithcolophony(der vativefneresinx¬ tract),pumicepowder,andplastertoachi vefix onwithintb dytissue.Lat r,whenthismethodledoextrusionft ej ints,nesur¬ geonemployedg lfoi . In spiteofGluck'sropheticexperiments,t r yyearlapsedb ¬forethnextsignificantdevelopmentrosthetichipsurgery.Sus¬ tainedexperimentationtookplaceduri gth1920sd1930s,when surgeonssedavarietyfmaterialsi natt mptodesigndurableinvertedcup—calleda"flo tingcup" rmol —tofitverthshapedheadofthet ighboneandbetw entandeacetabulum.Thiswasthefirsttypeofhipim lanttobusedinnysignificantumbers.Osur¬ geon,OttoAufranc,wasreporti1956hathedc n uctedov r
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thousandiparthroplastiesoverfifteen-yearperiod.Aufr ncss ted thatemoldorcupmethodwasthebests lutiontcon tionsfthe hipresultingfromrheu ato darthritisndt aticdegenerative arthritis(Aufranc,1957). ThefloatingcupwaspioneeredbyM riusN.Smith-P t rsen, eminentsurgeonfromB st n,Massachusetts,w omScalesd bb dt "doyenfarthroplastyofthehip."1Smith-P tersen,aemigrant UnitedStat sfromN rwayihise ns,madeani nov tionsor¬ thopedicsurgeryandbecamrofessofo thopedicsurgerytH ¬ vardMedicalSchoolanchiefofrt op dicstMassa husettsGe ral Hospital.ew sacclaimedintheU dKi gdom,whereh as electedanhonorarymemberofthR y lS ci tyfMedic nei1952.2 TheprincipleofSmit -Pet rsen'smoldwasr storefuncti nbyi ¬ troducinganrtificialc pintothej t,atheranctuallyreplacing aremovedpartofthjoint.Ex erimentingwi hdive sema rials, Smith-Petersenmadsucce sivesofgla s,viscaloid,Py xBake ite, andVitallium.3 Vitallium,metallloyofcobalt,chro ium,andtungsten,ap¬ pearedtobhmostbiocompatibleat rial.By1940over,200Vit l¬ liumfloatingmoldoperat o sbyversixtyu g onswerep esentedt theTexasSurgicalociety(Howm dicaIn .,1998).fa trthfi st— butnotthelast—timeithistoryfppr s h ses,hismaterialwa transferredoorthopedicsf mapplicationsitc gnatefie f dentistryanddentalimplantation.Aeqrlthe1870s,onefcellu¬ loid'sapplicationssh dbeenintheroductionfd n all es;i ¬ deed,Smith-PetersenborrowedVitalliumfr mhidentist.While manyofthesematerialsappearwithhinds g tunlikelyca dida sfo theirintendedfunction,h yareextr melyi t stingfowhath emphasizeabouttherangof"man-made"materials,d wnf mv r¬ iousembryonicoro eestablishednufacturingindustries,w th whichitaspossibletexper m ntw tht eboundari sfth ma bodyduringthefirstdeca esftwenti thcentury.E cofth se materials,infact,didhavele stonet ractivep op rtytjus ifte t¬ ingtthisenvironment.Forxa ple,aft rb rvingthagl ssstim¬ ulatedtissuegrowth,scientistsassumedthaoth rr latm terials wouldbeothin rtanmalleableu derthappropriatema ufactur¬ ingtreatment. Thefirstrecordedartificialr placementnpjo nbym nu¬ facturedpartoccurredin1922,wh nforty-one-year-oldmi
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Britainsufferedf actureohneckffemur.Agraftw staken fromhisotherfe ub ne,a dheafas ionedfromv rywasat¬ tachedoitbeforesurgeonsin e t dinhh stipsock t.4M re thandecadep ssed,owever,befordoctorsimplantedthfirst known,andsoothefirstsuccessful,m tallicreplacementfthh d andpartoftheneckfthefemur.5Possiblythefi tartificialmet lp socketfixedntoahumanacet bulumwasintrod cedbyGerman,E. Rehn,w oinsertedasteelcupwithspikesoni st rs rfacefa en thedeviceintothrefashionedostb ni asesfcong nitaldisl ca¬ tion.Thiswasco ceivedatemporarydevicethatwouldnablew bonetof rmithhipsot atsecurej ntw uldxistwh nthm tal cupwasremoved.Ataboutthsametimperhapsthf rstalac¬ etabularcups,madeofVital ium,wereintro c dyPre tonn AlbeeinthU itedStat saround1940,whicherekn wnasAlbee
TiandAlbee-Prestoncups(HowmedicaI c.,1998). M̂eanwhile,i1938P.Wiles,asurgeontMiddle exHospitaln
l-nEngland,hadbeenexperimentingforthefirsttimwithgrou dc m¬ asponentsfstainle ssteeltor placeb hcupandb lel mentsoft joint,preciselyengineeredtofiachth r,thfir ttt mpttotali jointreplacement.Wil sinser dsixuchdev es,bol -a dscrew-fixed tohefemoralandac tabu arbo e.Atths metim ,ithUnit d States,E.JHabou hinNewY rkdev lopedthc nceptfhmold arthroplastyfur erandintroducedh llowballwith"skirt"th t wouldfitaroundtheshapedhean ckftf mur,adefromVi¬ talliumalloy.InthecaseftA bcup,fix tionfthadthe prosthesisprovedpr bl matic;Haboushc ncludedt tanrtifi ial headanneckofthef murndnarti icialsocketwere essary.H organizedtestsihisNewYorklabo atoryu ingVitalliumhe dand anacetabularsocketmadefacrylic.Unf rtunately,exc ssivew arnd abradingresultedfromtheset s s. Thedevelopmentfipprostheses,ther fore,throughtharly1940ssawthebirthoft ialnderrorcultu eorthop dicimplant surgery,inwhichaiderangeofmaterialsd wnf omvarietyof sourceshadbeent st dindiff r ntdesigns,producingala eumber of"errors."Neitherthmoldn rpartialjointbo ereplacementshowed greatsuccess.Thlat1940sandrly1950s,bycontrast,werenespe¬ ciallyfertileandproductiveperiodf rthevolutionfpmp a t technologies—thoughnotwit utrror,fcourse—asn wmaterials
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andmodificationstkn wmaterialsw ebr ughti htest-bedf humanipimplants.• EARLYMODERNDEVELOPMENTS
Inthemid-1940sanewdesignignaledtfirstuofplasticsijoi t replacementtechnology,a dbroughwitittfi stiome ha ically designedhipimplant.I1946twoParisianbroth rsn medJud tintro¬ ducedthisv ryinfluentiali novation.TheJ d tsbeli v dt tos¬ teoarthritiswasp imarilydise seth ttt ck defemo alhe d; thus,beca seitwafittedod seasedound tion,"mold"ar hro¬ plastywnotaviabledesign.Thebrotherssign dtheiprosthesis inmethylmethacrylatepolym r,aglassythermopla ticc nbas ormolded,ostcommonlykn wnacrylic,butlsopr duc dn r otherproprietarynamessuchsPe s x,l xiglasandLuc t .Thm ¬ terialwasfirstp oducednGe manye rlthecentu y,buind stri l productiondevelopedfrom1932onwardwhacrylicshe tdmold¬ ingtechniquesb cameavailable.T crylici dustryprog es dr p¬ idlyduringWor darII,whenthm terialasusf gl zing aircraftbodies.LikeVitallium,ylicwasf rstu dinmedicaltre t¬ mentasdentalimpla t.Haboushh dstudiedtwear-resistance propertiesin1940whenc ns deringhiart roplastyork,budt useditnhisurgicalexperiments.ThJuddesiacryliccons sted ofanenlargedhemisphericaldshortthicktemxt nal neckofthefemur,designsometimesb i greferredas"mu h¬ room."Toinserttotheb dy,urg onne dedamock t intotherecipient'shipbone. TheJud tacrylichipjoinwastfirstmas -producedsurgicalim¬ plantofa ysortusetherm plastic.By1952,urgeonsh dinsert d morethanfourhundredJu timpla tsanddesignb c mwid ly usedthroughoutEurope.Inspitefgo dbioc m atibilityhmate¬ rial,however,theatofsubsequ ntfracturessigh.Toombatis surgeonsoftembeddedarofstainlesst lrchromium-plate brassinthestemoreinforcer constructedhip.Th emodifications resultedinproblemsa sociatedwi hthbrittlenessofacrylics n; consequently,thdevicwasproducedi"block" rs lidnylon.Al¬ thoughisreducedthocc rrencefstemfract s,parti l
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nylonmaterialprovedtb edestructiveho ytissuf hipthaneacrylicdbeen.Somesurg onsi ilard imade
incobalt-chromeal oysndst inlesste l ,butwhilgainreducing fractures,andh vingimprovedwearharacteristict ticulating surfacesofballndocket,itgen rallysuffer dfr mexcessiveloo en¬ ing.Nevertheless,nt restthiypofd signti lxists.I arly 1980sGermansurgeo simplantedversiofthJudet- tylendo¬ prosthesis(i.e.,onthatiu edf rrepairinghe dfhighbone), thefairresultsofwhiche epublish dinrt opedicr s 1990s(Bettintal.,3). Awell-knownmericansurgeon,M.d'Aubig ehproducedhis owndesigusingacrylicre imaterial,l os dthJud tpro thesis. Thisfeaturedv rylongstemritt nin idetmuran —in
-^3highlyunusualdeparture—afl tplatethweig t-bearingrt, whichlooksratherikspatula.S l desinsereu ednomat r d̂esigns:intheearly1960s,forxampleocketc mponentf 30modelproduc dinItalyusedthpolyacetalresinDe r ,whi hs factmanufactureditheUnit dSta sbyDuPon .Igene al,how ver 's®despitethepopularityfacrylicresinJud tvic ,g n rali ofpinionam ngsurge sturn dgainsth smat riali1950be¬ causeofhighlevelsfa lurduetooseningsedbyexc ive wear.Withhindsight,ther foreeJu tdesignifr qu ntlyregarded asdis terinthorthop diccommunity,butaneregardeds firstartificialh ptobeimplantednumb rsfp tients ff ci nt suggestthataotallyar ificialh pjoinfomedesi nc uldb regularandacceptedpartofsurgicaltre tmenjoidis sfrac¬ tureinpopulationsnalargscale. Thepost-WorldWaIIyearswitnessedsuchanexp ionit developmentfpolymerplasticsforc nsu rg odth titsome¬ timesknownash"AgefPlastics."Orth p dicimplantutiliz d solidnylonasmaterialicupimpl ntsw llthJud tb n stemdevice.Thmaterialwasus dforybearinginengineeringap¬ plications,anditsrelativesiliencw sppealingspo sibleme s to spreadhweightl adthroufem r.Amallnumberfpr s¬ theseswereimplantedi hsm t rial;odesignfoll w d Smith-Petersenmod lwhilan th rdesignafixth aof femurbythreesplines.Neith rde ignwasucc ssful:likJud t hip,bothdesignsinducedev rewearresultingti suea tioni abradedparticlesofnylon.Ithlate1940s,polythe ewus di
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non-weight-bearingprosthesisandis cketcupim lardesignt theSmit -Pet rsenfloati gcup.Tlatt r,whichaseight-b arin , soonsh wedignsfdeteri rationanweari hp ly hene,lik nylon,reactingadverselyndproducingfiparticlethwerou embeddedinbo ytissue. Atapproximatelythesameimein1950,erwerajordevelop¬ mentsinthU itedStauseoftalsf re or lcompo¬ nentofthehip.AustinM ore,f example,asurgeontU iv rsity ofSouthCarolina,hadbeeinvolvedwitthfi stkn wnme allicr ¬ placementofthhe danartn ckfemurihu aip. Moore'snameiscloselylink dwiththatfu geonF.RThomp n
intheU it dStates.Bothsurg onsconsideredatuitablyshap stemcomponentouldbinsertei idthupp rsectiofon ofthefemur,inrelativelysofthoneycomb-likeb ne"i ¬ tramedullarycanal"insidet.Moore'sitialc nceptw f"self- locking,"straightdeviceth tachiev dt bilityi idli tl curvedfemurbythpressu eofja mingitir lyn(lat r,such methodwastoberme"press-fit")(M ore,1957).Moaidy professorfengineeringatthAust alLabo atori siN wY rk, producedthetotypefisdesignincobalt-chromealloy,r bably Vitallium,ndthedesignincludedb llcomponentatw sffs fromthepffemoralstem.Figu e7.1illu tratesde ignandts development.Thisty fcollaborationbetwesurg o s,eng neers, andtestinglaboratorieswabecomeinc e si glyrucialfutu¬ novationsiorthopedicimplants. TheMooredevicwast chnicallysuccessfulinm nyys,b tm- planteessufferedfromunstablemov m ntatthhipd,a thoughi didnotcompletelyloosen,im stases"migrati n" ftheviceoc¬ curred.Inloselyrelatedw rk,F.RThompsonbeli vithsame conceptfintra-femoralmplantation.His1951des gw squiteimi¬ larinappea ancetoheMoo edevic ,h ughThompsonfe r dbr k¬ agenddifficulti sofremovingthstemfwasingrownithb tissue.Thompsonalpreferredcobalt-chromest lndus dVit ¬ liumforhisdev ces.Habou hexperimentedfurth rw ll,and1951 heinsertedacastVit lliumb llnpsocket,fixewithden alcrylic cement,intoapatienttthHospitalf rB ndJ i tDiseas s NewYork. WhileVitall umh dbeenmostpro isingetalloyforp implantsduringthe1940s,betw ent oworldarlargnumber
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FIG.7.1.SequenceofAustinM ordesig s.Thiignwasftfirst useemb ddingofataperstemin idehb nfemur.Tir tit sequencehowst prosthesism rgingfrot pfae rieved,decay d thighbone.Thloopsim talw rentendedft attachmentfmusc e tissues.Thmat rialicobalt-chromeal oy.enitias raighttw sn modified.Thwindowsit stem—"fenestration"—werede ignede bl thecanc llousbo effemurogrowt r gh,usixingdevice position.Fr mM ore,1957Re rintedbypermissionfthJournalfBa JointSurgery(Ame ican). ofstainlessteela dte llloyw recr atedusinidange ofengineeringapplicationsithendustrializednations:"18-8" ain¬ lesssteel(18perc ntch omium,8p rni kel)hadbe nfirstint o¬ ducedintosurgery1926asnal er ativtvanadiumteel,wh l theadditionofmolybdenumproducedevorcorrosion-resist¬ antsteel.Thus,ttensiles r ng ha din r n sofai lesste l helpedthemb co e,afterWorlaII,m inalternativeb lt-
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chromealloyssthemat rialfotload-bearingfemoralcomponent ofartificialhips.IntheUnitedS a site rly1950 ,st inlesste l wasusedbothinstemde ignsandnewdesig softhm ldrfloat¬ ingcupconcept.F rexam le,J.CAdamsproducedfirstholl w stainlesss e lcup,follow dbyasolidcwi hsmallaperturef tightcontainmentfaresh pedfemor lhe danne k.Thdesig provedtbeunstablea do ewasre bso bearo ndthedevic .A Judet-stylestemprosthesisal owaconceivedistain esse lar und thisime,butfa ledtoga np pularity,andEic rprod cehead- neckreplacement,firstiastainlesss la dtheinc tcob lt- chromealloy(Sca es,1967). Stainlessste lsw relsobeingus dinEngla dyG.KMcKei Norwichinhisfirstattemp stproducedesignfot talballn sockethipimplant.McKeehaddesign dafabri atemodelsoft t hipprosthesesaearly1940.Likehicounte p rtsintUnit d States,hefoundthatisstainlesse ldevic squ cklybecamlooin vivo,whileacobalt-chromel yversionsurvivedwfoaperi d. FollowingavisittheUnitedS a s,McKad pt dthedesignform oftheThompsons lidtemprosthe s.Tt isheaddedthree-clawe cupthatw ss rewedintothacetabulum,llpartsowm dfroma cobalt-chromiuma l yca ledvinertia.6Ispiteofthedevel pm ntsin stainlesse lalloy ,McKh dcomethebeli fth tmetaland itsalloyswereinsuffici ntlyi ertfohum nimplantation.Halsbe¬ lievedthattitaniumh dtend ncyto"self-weld"(McKe ,1971:50). Thusheusedcobalt-chromeforc pandsock tandfemor lcomp ¬ nentsthaw reproducedaspaiforimplant tionisinglhire¬ placement,andhemark de hco o entwithanu berform t h¬ ingpurposes. Despitethefacthalong-l s ingstablr ifi ialhremained thehorizon,kn wledgefsuitablematerials—intermofb ti - compatibilityandstrength—hadincreasedsignifican lybyth1950s. Vitalliumndsomeformsofs in ess e lw r le tabl shed,and manyoftherialanderrordesignsdesc ibedab vewconceivedi anttempttopreserveandutilizeund magoreshapedhis ck s, wheresurgeonsinsert dth mi toei herar placementfemoraln k andheaordwithcup/moldpositioneoverit.Ontoth r hand,thelackofsu cessfulipreplacementdesigw ss rti gtolend supporttoheidea,alr adysuggestedbysomsurg ons,th tforahi implanttobefunctionalwithoutcausingda geeith rtohehum n
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bonetissurheprostheticmaterialsthem lves,surg onsw u d havetoproducedesignfighlywear-resistantcomponentsinhich thearticulatingmovementbetwellandsock tit elfasachi ved throughheusefotallyartificialma erials.Wi hbenef thindsig t, inthedesignsofM ore,Thompson,andcKtfuturftalh replacement,thconc ptowhi hcurrenartifi ialhjointsisbased, canbediscerned. Inreviewingth searlyhipimplantswc nst eyri¬ oneeredtypicallybyasi glurg onnsma lnumberfp ti nts usingc stom-madecomponents.Iiinteres i gtnothr nd namingdevicesaft rtheisurg on-inventor,trendatco tinu dint the"modern"phaseofdev lopm nt.T elativefai urs¬ signswhenimplant dmorewid ly,hichahavseemedpromis- ingnitiallywhenimplantedbythsurgeon-inventor,mightex-
-Oplainedtosomeextentbyor rmanufac uringtechniq esusedwh n t̂hedevicewassubje tedomaspr ductiontechniqu(Williamand Roaf,1973).Howeverprogressabeingmadeinthunderstanding is)andproductionoforthope icmaterialsins itfclinicafailu e . "MODERN"HIPI PLANTS WhilestainlessteelandVitalliumw re tablish dle dingcon¬ tendersiartificialh pfabricat onbyth r y1950s,ometal—tit ¬ nium—hadyettomakeanppe ranc .Alth gti a iumisn w commonlyusedmaterialinhipimpl nts,tfirste rd duvivo wasbyLeventhali1957,sixyearafterh dorigin llypr sented caseforitsu entheJournalfB na di tSurgery.Ti a iumh oxidelayerrfilmnitssurfacethatreducestissreactionmini¬ mum,akingithighlynert,likeaceramic.Titaniuislsoresist ntto salineenvironm nts,whiche han esitsuitabilityfomplant t onin¬ sidethebody.Cobalt-chromend"316L"stai lesse lrc rrosion- resistantme lalloyswithsi larproper iesinthires c .Mat r a s suchasgold,ilverandplatinumlsohavei hcorrosion-resistance buthavepoormechanicalproperties,renderingth moflittlin e s forheavy-dutyimplants.Titaniumh slesl s icitythcobalt- chromealloys.Infact,tit niu( di sl s)stheo lymetallic¬ terialofsignific ncebeintrodu edimplantsu gerybetween1950 and1970.Bycontrast,manydifferentpl s ic ,rubbers,fib rs,andfa ¬
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ricswereintroducedduringthesampe i d.TheU.S.Departmentof Defensesupportedthdevelopm nttitaniutechnology,w ichre¬ quirednewm ltinga dfabricationtechniques,i stitaniumetal¬ lurgylaboratory.7 Givenitsemerg nceatthit m ,isstrikingth ttitaniumalloys werenotconsid redbytheartificialhip'smostsuccessfulsurgeon-in¬ novator,JohnChar ley,fromLancashire,England.Ch r leyisbest knownforintegratingthescientifics udyofjo tlubricati nandbio¬ mechanicswiththprobl msassociatedwithprost et chijointsur¬ gery.Indeed,irevi wingth"first32years"oftotalh preplacement in1991,WilliamHarris,le dingcontemporaryU.S.surgeon-desig er, singledoutCharnleyinhiappraisaloft epr gressofhijo ntre¬ placementtechnologi s.Charnl yhadinfactdevelopeprelimi ary arthroplastyasearly1946,buhadabandonedt eideanthrough¬ outmosfthe1950hadremainedpessi isticabouttprospectsof asuccessfuldesign.Them ireasonforhiskepticismath stimlay inhisv ewthattfrictionalpropertiesofa ylicormetalinthpr s¬ thesisandbonea dcartilaginthehumbodywerincompatible. Cartilagelubricatedwithsynovialfluidinhumajoi tshaex¬ tremelylowcoefficientffric ion,moreslipp rythansk teonice(a hisbiographernotes),whichartificialm ter alscannotm tch.Witcol¬ laboratorsinengineeringCharnl ybuiltrigstogaugethefricti nin jointsfb ea dtheartificialmaterialsthenm inlyinus :s ainless steel,cobalt-chrome,andacrylic(andperspex)(W ugh,1990:104).Fric¬ tionwasshowtbemuchgreaterwitthesartificialm t rialsev , whenanimalsynovialfluidw sealubricant. Charnley'simt usbec mtofindtwodifferentartifi ialmateri¬ alsfortheballnds ck tth twouldslidefree yincontactwiteac other,butnorequireartificiallubric tion.Charnleyturnedomanu¬ facturersofsyntheticplas icsinsearcfosuit blesocketmaterial.H foundacompanyinBolt ,Lancashire,thknewhowtapplyne polymersinengin eringapplications.Char leybelievedth ttb st materialforhispurposeswapolytetrafluorethylene(PTFE)—b st knownunderthebranameTeflo ,butsometimesmarketedund r theproprietarynamFluo —thesamemateri lnowfamousoritsu e innonstickcookingute sils.Noto lydiditn tstick,butCharnl ybe¬ lievedttobethm stin rtplas icthenknow ;inde d,htest dhis byinsertingmallpiecesintohiownleg.Heexperimentedwitha floatingcupdesignc mbinedwithaso ketcup,bothinTeflon,bu
quicklymovedontamoreradicappro ch:su gicalr movalfthe femoralhead,replacingitwithMoo e-stylefemoralc mponent, whichasthenfix dwitt eadditionof"cement"ins detf mur. Todaythiscementingpr ncipleith instayoforthopedicpre¬ placementractice,espe iallyforimplantsielderlyople.Th MoorestemwasthfirstusetTeflonocket.McK einN rwich andothers,swh vese n,eu i gprimarilym tal,cobalt-chrome orstainlessst el,f rthfemo alhead,butthisf il di patientswith arthriticsocketbonesthacouldotwithstandt ebrasionft ism ¬ terialandd sign.I1962,however,thPTFEsockets,madebyCharn- leyhimselfandinsertedntoomethhu dr dpati nts,begaf il becauseontissuebeganod terioratereactionworparticlesf themat rial.C nleynotedthatex remeg ti udeexpress db hispatientsinthearlystagesfollowingthperat ondelayedh recognitionfthefailure.C ar leysoughtm rc anicallybust̂ formsofpolyethylenewithhigden ity,andtf r thighmolecular
~T3weightpolyethylene(HMWP)f rthartificialh psocketwasintro- rnducedattheenof1962.Sincethatim ,td v lopmentfthsocket componentfor ingthbearingsurfacewi htheb llh sedom - f<onatedbythuseofsuccessiverefin mentsofplasticm terials. Charnley'searlytotalj intd viceappearedpromising,nhc¬ ceptedadvicefrommechanicalengin ersth tsmal erf oralhe d wouldbeanimpr vement,partlybecauseitwoulde ablethick r, morerobustsock tc ptbeused.Thiswast iginfhso-called lowfrictionarthroplasty(Char ley,1979).harnleyredesigned Moore-stylefemoralcomponentandhianufacturedi st i less steelbyThackrays,nengineeringompanyfroL ds,Y rksh re, withexperienceinmakingsu gi alinstr ments.Althoughhb li ved thatcobalt-chromewouldprovtbethepref rablem tal,n v r adopteditnhisownsurgicalpractice.Cha nley'sl wfrict onesig isillustratednfigur7.2.Iworthn tingthateometalssp o¬ ducedatthimehdifferentworkingcharacterist cs:c balt-chrome artifactswerec st,hilstainl ste lwarought.T idiffe ncere¬ flecteddiffer ntmodesofpr duction.Wh r ascobalt-chromerequired largenumbersofrelativelyunskilledfe lela or,stainl sswa producedby"menwho[w re]t engi eringcraftsmen."Tmas¬ culineimagofstainlessste lma ufacture,skillede gine ringcraft stronglyassociatedwithnorthernE gl nd,mahaveelsomeappeal forCharnley,dmaypartlyexp inwhcontinuedtusrtificial
FIG.7.2.EarlyCh rn eyprosthesis.Tfem ralcomponentisnstainless steel,thcupinhigh-d nsitypolyethylene.Tw r s" rialprosthesis"ar inscribedonthetem;namfmanufacturers(Thackrays,t emedi l instrumentengineeringco panyiLe ds,England,boughtithearly1990s byDePuyInternational,onefthemajormanuf cturersofr pedicim¬ plantsworldwide)isalsolegible.Th"trial"prosthesiswinfactmanufac¬ turer'smodelatesthfabricationproc ss,andwoulnh vebe implanted.Asc nbes en,thmallfe or lheadwaabsolutelyspherical andproducedwithhighdeg eeofshi ,w icC arnl ybeli veessential tolowfrictionperformance.FrOwe ,1971,6 .Rep int dbype missiono ProfessorRobertOw n. hipsproducedinstainlesss e l,additiontofact titwasal cheaper.Bythlat1960s,Thackraywasproducingnintethou¬ sandstainlesss e lartificialhipsp rye r.Infact,thcompanydidpr ¬ duceacobalt-chromeversionofthehipinte rlymid-1970sfot U.S.market,butthepl nw snofinanciallysuccessfula dwaab ¬ doned. Atthesameimth tCharnleyw sdevelopinghidesigns,o er surgeonsinEnglandweredesig i gpro thesesthatwerbim¬ plantedverywid ly.Forexample,inthlate1950sanear60sth widelyused"Stanmore"devic s,nam dfort wniEssexwh reth country'sNati alOrthopedicHospitaliloc e ,u edbalt- chromiumalloysthematerialchos nfoalrelatedparts.An t er
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FIG.7.3.TheRinghipprosthesis.B thcomponents,i cludingb ari gur¬faces,ncobalt-chrome.Notethv ryl ngs ckets rewfix di totheacetab¬ ulum.Thenameofthepati ntothx-rayremindsusth tesed vic sreimplantedithinteriorofap rson'sb y,utheimageambiguousi thisrespect,because,althought p rsonnamed,lypartft ep sonisshownandt ex-rayimagesogenerallyav ilableontohspecialistor¬ thopedicsurgeonandotherhospitalstaff.Whilelargnumberofx-raym¬ agesofhipprostheseshavb npublishednacad micjournalsyorthope¬dicsurgeons,itelativelyunusualsehepatient'samein crib donthem.FroRing,1971.ReprintedbypermissionofDr.PARing. individualorthopedics rgeon,P.ARing,dev lopedcem nt-free prosthesiswithanovelm ansfattachingt eso ketcompo ent.Again,intheRi gprosthesis,c balt-chromiumlloywasem terial used.Ascanbseenfromfigure7.3,thsocketdesignf aturedl gscrewforfixingtheprosthesisupin othib ne.Awithhearly
Charnleyprosthes s,clinicalre ultsfth sim la tsrs i lb ng publishedtoday. RECENTD VELOPMENTS Overthepastenofifte ny ars,enormouinstitutio ala dfin nci l resourceshavbeenmarshaledfothepurposefx loringn wmat ¬ rialsanddesignsforartificialhips.I pitefthemanya par td¬ vances,thecurrentstateofimplte hnologyh sbd crib dy oneleadingcommentators"inn vatioimpasse"a dbyno her ashavingit"glassceiling."Theproliferationfwmodels,c mb ¬ nationsofmaterials,nddes gnvariation ywhichreco sid¬ erablymoreexpensiveth narli rm d ls,hl s mcomme tators toexpressconcernabouttre dowar"d signerhips"(Bulstrode al.,1993).Inthe1960smostpati ntswhomsurg onsawforreplace¬ mentsw rerela ivelyeld rlp oplehosuffe dfroms verjoi t painduetoarthritis.Buhischaract rizationfend-userhb expandedastheechnology,d m ndfor,hipprostheses changed.Treportsofgocli icalsulf pro th sesfift enyear orlongeraftimplantationh sencouragednexpa sionfthmar¬ kettoolderandsp ciallyy ungerimpla t s,s chsth swhoh v sufferedjointdamagefromsports-relat dinjurydeteri tion.Th s if artificialhipsvereachedpl teaunth ircurrenttechnologicald ¬ velopment,thismaybecauef llictieirownsuccess duringthe1970sand80s. Perhapst ecentralissuenhontemporarydevel pm ntfhi implantssthedivisionbetwehoseari lantedhcrylic "cement"andthoseatrnot.Ispitfesuccesscem nted models,thedevelopm ntfcementl ssdelhasb enspurr dy twomainfactors.Theirstilooseningfcomp ents,whichn the1970swaattributedo"cem ntdiseas ,"c nditionhosenat r andexistencerestilldispu d.Iwasbelievth tad rr actions occurredbetweentissuandcem nt,a singparticl sftg¬ gravatethesurroundingi su ,whichinu nloosen dimpla t.Re¬ gardlessofthveracityish ory,itc rt inlysnforcebe¬ hindthedevelopmentfcementlessmodelat,iurasencour¬ agedsearchfoalternativemat rialswithhictcre ed qu t fixationtohehostb n .Tothermaireasosc ntinuedpo r
performancefthes ck tco pon ntsfcem tedimpla ts.Mor ¬ over,therehasbeentr ndtowarddivi ingtheprosthesisosepa¬ ratefunctionalparts.Thiiskn wnmodularity,theprimeexample ofwhichistheproductionft eheadf moralcomponentse a¬ ratelyfromitsstem,whichgivesurg onsgr aterch iceins kingb t¬ teranatomicalfitofthed vice. Surgeonsandengineersh vthussoughtmat rialsnddesigns thatmightimprovethettachmentfthimpla tt sb ned tissue.Avarietyoftechniqu sfe couragingt surroundingbonet s¬ suetoactuallygrowin othpr sthesis,t ac ievingw atikn wn as"biological"fixation,h veemerged.Surgeonsdinotintr duce theseuncemented"porous-coated"d ignsu tilharly1980s,al¬ thoughtheconceptadbe ninvestiga edasrlyth1960s.T e e arenowmorethanw ntydifferenmodelsfthisypefd signth
"Omarket(Griffiths,PriestndKushner,1995).Tdesignusuallycon- ŝistsof"micro-p res"ofthebasicimplantmetaladdedsv rythin enlayertohebasicdevice.Thadditionallay rif rmedofmi ute S3sphericalbeadsincobalt-chrome,wiremeshohoneycomb-likel t- ticeint tanium,requiringadvancedproductiot chnologiestfix thebasicsurfa e.Thet m/h adantcupaybt eated,usuallyallorpartfthe"shoulder"ofthefemoralc mponent,andllfth outers rfacefthsock t.S hdesignseincrea inglywidemar¬ ketedbutr mainso ewhatcontroversialclinica ly,p rtlybecausef concernsaboutth irlo gevityithb dandpar lybec usepa ni theighappearstobf i lycommonwiththet odffix i nof thefemoralc mponent(Faulk rta .,1998). Theconceptfbiologicalf xat onwastestedithb ratory earlyasthelat1960s,snotedbove.Thin wb nextendedt theconceptfabo dwhere,ratherthansimplingrowthfbo einto theinertprosthesis,abiol gicalnteractionb tw eoneandprosthe¬ sisisought.Thisrepre entst ltimatef offixationw thint bodyshortfhumancell-basedtissuengine ring.Thbio ct vema e¬ rialisappliedsfurth rcoating,u uallyinceramicmater alsp yed onthesurfaceft porouscoat.Hydr xy patite(HA),alc um phosphateceramic,i fparticularimport nce.T iscanbderived fromnaturalb ne,utcanlsoproducedsynthetically.Itsc mical andcrystallinestructureithemst majorralconstituentf humanbone.Dentistryagainpl ysrithepedigreeofthmate¬ rial,sinceitwasoriginallyus di ralnfaci lurger ,forexample,
FIG.7.4ABGIIhipwithydroxyapatitebioceramicco ting.Thes em madefromVitalliumcob t-chrome- olybdenumll y,nts cketand stemarecoat dwi hthc ramichydr xy patite(HA),ch racteristically white,forcementlessfixation.Nott"macro-interlock"bobblinglif sh gillsontheupperpartftst moenhancefixa io .Thm gfr 1998advertisement.Thb ckdropofalmsc e"N ture" mphasizesth appealbeingmadetosmooth,rg nicn turalfuncti .R ro ucedbyr¬ missionofHowmedicaOsteonics. assyntheticbof rar ific altee h,uinsuit blef rw ight-bear¬ ingbecauseoftbri tleness.Advancedf rmofnd strialt chnology arerequiredfosprayingHA,thco tb inu ltpass riesf layersblastedonthh stm talyacomputer-controlledrob tic spray-nozzle.AexampleofnHA-coat dd vicifigur7.4. Long-termresultsoftheperfo mancefHAinthumipar stillawaited,buiecomingincreasinglydelsed.E rlstu i s suggestthatitmayblesa socia edwi hthigpainm nyfth earlierporous-coatedd vic s(Fau kn rel.,1998).Th eisome technicalcontroversyaboutt ep imalmetuswi hHAcoa ing.
^IOrtLCAyHULN/\tK Titaniumh sigherelasticityth nmostothermetalsbuis sitivet thesurfacedisturb nceintrodu dwithcoa ing.Ch mium-cobalt- molybdenumalloysremainstr ngerwhencoat d(L armo thSpi¬ rakis,1989),butonthetherh ndtitaniummaybpr ferablebecaus
itformsachemicalwelmechanicalbondwithHAo ting(Geesink,1990). Thematerialsusedfortfemoralst mandhei c mentlessim¬ plantsintherec ntperiodh veb nmainlystai lesssteel,c balt- chrome-molybdenumalloy,ntita iuahiminumvanadiumlloy(Head,BauknEmerson,1995).However,stainlessste lrmuch lessusednowfortht m.Theorthopedics archliteraturedisputes therelativeadvantagesofthh rtwolloys.Ag inthe eisupport fortitaniumlloybeca seoftbio ompatibility,hdegreeofin-
| ĝrowthofb neintothimplantwhenpor us-coated,di elasticity,T5whichisimportantf ruseinsmalleremsiz s.Titaniumwasup-
j|',T,portedextensivelyinEurop anc tersforthopedicsduring1980 (Sterntal.,1992).Otheotherh d,isaiobaninf riormate- r»orialfortheload-bearingsu facefthhe dftf mur,sorepr e toabrasivewear,andco veysgr terstres es,m kingilessuitable forusewiththparticle-structureofac ylicment(H ad,Ba k,n Emerson,1995).Ceramicsndcobalt-chromea loysreb thsup riori theirw arproperties.Infact,thmo tw delyusedem ntlessrtificial hipintheU it dStates—andprobablyworldwi e—ishAML (anatomicmedullarylocking)dev e,produc dbyDePuyanma u¬ facturedincobalt-chrome-molybdenumalloy.W rtitaniustems areusedth yregenerallycombinednowi dulard vic swith stainlessste lorcobalt-chromell yheads,w ichcapableofking ahigherdegr eofpolishandrl spronetcratching(Lea month andSpirakis,1989).Thehe dcomponento ulardesig s yb coatedinanttempttachievethsmoothn ssfc ramic,f rexample bytheuseoftitaniumnitride. Metalmaterialsandsurfacefinishes,therefore,sp ciallyfo femoralcomponentfthartificialhi ,rest lbei gdeveloped."Su- peralloys" ndcompositematerialsbeingt stedi a t mptt achievebett riologicalandb mechanicalm t hingofl x bility ofthefemur.Polyacetal,polyethylene,ca bondacr licrmong themat rialst athavebe nemployedforthipurposeimetalc m¬ posites(LearmonthandS irakis,1994).Ia o ertechniquete ¬ hancefixation,ths emsofdevicf rc me tedimplanta ionayb
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Executive summary
Objectives
To review available evidence on-the comparative
effectiveness of different prostheses types in total
hip replacement (THR) for adults suffering
primarily from osteoarthritis.
To develop an economic model, using cost data
from two NHS orthopaedic centres, to model the
cost-effectiveness of alternative prostheses under
varying resource input assumptions.
Methods
The reviewers had the benefit of a large in-house
database. Additional searches were conducted in
Medline, 1980-95, using a modified Cochrane
strategy for identifying randomised controlled
trials (RCTs). Separate searches were conducted
in Embase, 1990-96, to identify studies with
comparison or control aspects. Further details
are given in the full report.
For inclusion, studies had to provide clinical
outcome data for specified prosthesis designs,
comprising functional assessment, radiographic
data or time to failure. There were very few
RCTs. Priority was given to studies with an
element of comparison. Checklists and simple
rating scales were used.
NHS price data and data relevant to costs were
obtained directly from two NHS Trusts and
their associated orthopaedic centres. The total
expected costs of THR included an element
for revision of the primary operation.
Results
Appraisal of studies
Most of the studies came from specialist
orthopaedic centres; this has a bearing on the
generalisability of the results of individual studies.
The methodological quality of the studies was
generally poor, for example, lack of sample
size calculations.
Comparison of prosthesis types
The following tentative conclusions can be
drawn about the performance of different types
of prostheses. The various designs are described in
the full report.
Cemented designs in general show good survival
results at 10-15 years plus. Models with good,
published, comparable results (at 10 years or more)
include the Stanmore, Howse, Lubinus, Exeter
and Charnley. The rate of acetabular revision in
cemented implants remains problematic. Newer
('second-generation') cementation techniques
usually give better results than more
traditional techniques.
In comparing short- to medium-term longevity
between non-cemented porous-coated and
cemented prostheses designs, there is no clear
advantage for either type. Thigh pain is a problem
associated with non-cemented porous-coated
implants to which cemented designs are
not prone.
The small number of studies of cemendess
hydroxyapatite (HA)-coated models report mild
to moderate thigh pain in between 0% and about
5% of patients at 2-5 years' follow-up, a good
result compared with porous-coated implants.
Hybrid designs are comparable with the best
cemented designs for early survival (6-7 years),
superior both in terms of survival and thigh pain
to porous-coated implants.
The uncoated press-fit and resurfacing types of
hip prosthesis have survival results that are notably
inferior to those of other types. Little evidence is
available on fully modular prostheses.
Economic modelling
Using the economic model developed in this study,
the general conclusions under our assumptions are
summarised below.
Prosthesis cost, hospital costs and revision rate
are the components of the model with the greatest
impact in terms of changing total expected costs
for THR procedures.
Very high and veiy low estimates of hospital costs
change the total expected costs for individual
prostheses but have little effect on their relative
cost-effectiveness compared with each other.
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Compared with survival data for the Charnley
cemented prosthesis from 'centres of excellence',
and assuming a prosthesis cost of £353 including
cement, even a 'no revisions' prosthesis should not
cost more than about £650 (at 1997 prices) to have
equivalent total expected costs over 20 years. Only
cemented prostheses are currently available at
this price.
In 70-year-old men, for example, a low price
prosthesis is generally more cost-effective than a
high price prosthesis, even with a very low revision
rate. In 40-year-old men, prostheses with high
prices and low revision rates can be more cost-




• The major concern is the proliferation of novel
designs of prostheses whose effectiveness is un¬
known. Mechanisms for improving use of appro¬
priate prostheses could be examined. Aspects to
consider are suggested in the full report.
• Healthcare commissioners could model costs of
alternative prostheses, using their local input
resource assumptions and outcome data, along
the lines of the model described.
• Commissioners and providers could also:
- ascertain the range and extent of use of
routinely used prostheses known to have
results poorer than the best cemented designs,
distinguishing different design types and
taking account of age-groups, and seek audit
of outcomes, including revision rates
- in the case of significantly new designs, satisfy
themselves that appropriate monitoring and
evaluation is carried out.
Research recommendations
Some of the key recommendations from the main
report are as follows.
General
• Improvements are needed in the design and
reporting of research studies in this area.
• Further inclusion of patient-derived quality-of-
life measures in studies of hip prosthesis
performance is essential, as clinical hip-scoring
systems do not take the patient's views into
account when assessing outcomes.
• Patients' values and choices regarding
quality of life in relation to THR should
be investigated.
Prosthesis types
• Reporting of longer follow-up studies,
especially of hybrid and cementless HA-coated
models, is required in order to assess further
their early promising outcomes. Follow-up
of the coated acetabular component of
hybrid implants is required to ascertain the
medium- and long-term performance of
this prosthesis design.
• Results for thigh pain and longevity in
HA-coated models require longer follow-up
periods. The extent and significance to
patients of thigh pain associated with porous
and HA-coated implants should be assessed.
Longer follow-up assessments are also required
for porous-coated cementless and fully
modular designs.
• Further exploration is required of the
associations between radiographic signs
of loosening/migration and later
mechanical failure.
• More up-to-date information is needed on
the use of new cementation techniques, so
that their use can be encouraged.
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Chapter I
Introduction
Total hip replacement (THR) has, since,the 1960s, be o e one of the most frequent
orthopaedic procedures undertaken in the
NHS; it is, in general, extremely effective in
pain relief and improved physical funcdon in,
typically, patients aged 60 years or more who are
suffering from osteoarthritis. It is an expensive
procedure and substantial resources are devoted
to it. In the UK, in the year 1994/95, some
32,500 primary replacements were performed
within the NHS (according to Hospital Episode
Statistics). THR performs very favourably in
cost-udlity studies that compare it with other
surgical procedures.
In assessing prosthetic technology, it is easy to
believe that if an optimal design for the implant
could be created in bioengineering laboratories,
then a standard optimal effectiveness could be
defined and implemented across health services.
However, THR is a clinical service and such a
technical solution, even if it could be engineered,
would not have this effect because of the wide
range of other factors which necessarily contribute





• operating theatre environment
• effects of prophylaxis for thrombosis and
pulmonary embolism
• rehabilitation procedures
• patient factors such as bone quality and
severity of disease.
Interpreting the evidence on the performance
of different prosthesis designs is thus difficult.
Hip prostheses technology is continually changing
and many new designs and methods of fixation
have been experimented with since the original
Charnley Low Friction Arthroplasty cemented
concept of the 1960s. Some prosthetic designs
have identifiably better outcomes than others,
and some fail early and spectacularly. THR
technology has been, to some extent, a victim
of its own success as its use has been extended
to include younger age groups and as increases
in the longevity of implants are sought. Repeat
THRs (revisions) perform notably less well than
primary replacements and, clinically, revisions
are regarded as something to be avoided
if possible.
The rationale of supply and demand underlying
the proliferation of alternative designs, fixation
methods and surgical instrumentation is difficult
to interpret. There is no statutory or nationally
coordinated professional monitoring of pro¬
cesses of innovation and diffusion in the UK
Factors contributing to the difficulty of
interpretation include:
• the commercial interest ofmanufacturing
companies active in supplying the
orthopaedic profession
• orthopaedic surgeons' creativity and ingenuity
• difficulties in interpreting the comparative
results - especially short-term results - of
different hip technologies.
In a somewhat critical discussion, orthopaedic
innovation in THR technology internationally
has been referred to as a 'trial-and-error culture'.1
Interviews conducted by our research team have
indicated that manufacturers exert, in various
ways, a degree of influence over the prosthesis
models which surgeons might prefer and the
choice available to them. Some orthopaedic
surgery departments, for example, are supplied
by a single manufacturer.
It is known that over sixty different models of
THR prostheses are used to at least some extent
in the UK Recent trends in new prosthesis
technology have been towards new methods
of cemented fixation and various designs of
uncemented component. In most cases,
uncemented components are significantly more
expensive per unit than cemented components
(in part, at least, reflecting more complex pro¬
duction processes), the price range in the UK
being of the order of £300-400 to £1500-1600
in 1996/97. Such differences have major impli¬
cations for the comparative cost-effectiveness
of alternate technologies and, hence, for the




The major interrelated issues in the use ofTHR
technology in the NHS are:
• the proliferation of new models in the market
for prostheses
• the comparative performance following
implantation of different types with different
costs (performance includes primarily the
longevity of implants and their effectiveness
in pain relief and functional improvement).
More detailed current issues are:
• cemented versus cementless designs
• indications for different patient groups such
as age groups
• optimal alloys for components in terms
of elasticity,2"4 biocompatibility5 and
abrasive wear3
• bearing surface materials at the interface of the
head and cup components
• pain implicated with uncemented
stem components
• the relative merits of different types of coating
on uncemented components.
Some authors have suggested that design goals for
the hip prosthesis are actually incompatible1,6 and
that this is seldom acknowledged.1 There are a
number of examples:
• strengthening of the cement—prosthesis
interface may weaken the cement-bone
interface and vice versa
• modular components must try to allow for
optimal fit and for maximum initial stability
at the same time
• stems must try to be flexible in order to avoid
'stress shielding' (leading to atrophy of the
surrounding bone) but be stiff enough for
initial stability to promote ingrowth of
bone and avoid damage at the bone-
prosthesis interface.
Aim of this review
The major focus of this review is on different
types of prosthesis technology in terms ofmethods
of fixation. Somewhat less attention is given to
related issues such as cementation technique
and the mechanics of component loosening
associated with different metal alloys or
other materials.
This report forms part of an extended systematic
review of the effectiveness and cost-effectiveness
of total hip prostheses. It includes a critical
overview of published research literature on
the performance of prosthetic technology in
THR and an economic appraisal of the impli¬
cations of different costs of prostheses in the light
of evidence about survival of different models.
This takes the form of an economic model which
can be used - by healthcare purchasers or pro¬
viders - to estimate the effects on total THR
costs of varying the cost of resource inputs to
the model, including the price of prostheses.
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Chapter 2
Indications for primary total
hip replacement
THR is undertaken for severe degenerative jointdisease, especially arthritis. The two main con¬
ditions treated by this approach are osteoarthritis
and rheumatoid arthritis. Osteoarthritis is associ¬
ated with advancing age while rheumatoid arthritis
is more likely to occur in young adults. Other
diseases treated by the procedure include avascular
necrosis, congenital dislocation, Paget's disease,
ankylosing spondylitis and traumatic arthrids.
There is uncertainty regarding both the definition
of exact criteria for hip replacement surgery and
the symptoms which might be associated with
maximal benefit from surgery. Variation in the rates
of THR surgery across regions in England7 raise
questions about the consistency of decision-making
in general practitioner (GP) referrals and in
choosing THR treatment. Orthopaedic surgeons
have been "making-do without randomised trials"8
of case selection for hip joint replacement.
Few studies have examined the question of optimal
indications for THR in detail. Trials and other
studies tend to take surgery as indicated and
randomise patients by type of prosthesis or surgical
method. Some consensus statements, aimed at
distilling opinions on good practice in this area,
have been made but the shortcomings of such
approaches should be recognised. The US National
Institutes of Health Consensus Development states
that "candidates for THR should have radiographic
evidence ofjoint damage and moderate to severe
persistent pain or disability or both that is not
substantially relieved by an extended course of non¬
surgical management".9 A recent study employing
the Delphi technique specified criteria for identify¬
ing appropriate patients for referral to a surgeon
for consideration for arthroplasty.10 Pain and
functional status were the key criteria but age,
ability to work and other important factors were
also considered. Orthopaedic surgeons in the UK
who were interviewed as part of this study also
supported the primacy of pain and function, with
pain being seen as the most important factor. An
initiative in New Zealand, which aims at ensuring
that those most in need are offered surgery, has
involved the development of a scoring system,
again using consensus methods, for determining
priority for majorjoint replacement. Pain is the
most important component of this score, with
functional activity, movement ability, deformity,
multiple joint involvement and ability to live
independently all contributing to a lesser extent.11
It may be concluded that the principal indications
for THR are pain and functional limitation; how¬
ever, this conclusion is the result of consensus
rather than primary research. Disease-specific
pain is, of course, difficult to define both clinically
and as an outcome measure in hip prosthesis
follow-up studies.
While there is a basic consensus on the primary
indications for total hip replacement per se, more
detailed indications for the procedure are less
clear. During the 1970s and 1980s, patients aged
between 60 and 75 years were considered to be
most suitable for the procedure; however, more
recently, this age range has been extending in
both directions. In younger age groups, procedures
such as osteotomy and fusion may be considered as
alternatives but there is no evidence to suggest that
these are preferable. Data on potential risk factors
such as age, weight and medication are insufficient
guides to treatment for individual patients and
there are no clear indications for different surgical
approaches and techniques. Choices of different
types of implant for different patient groups are
surrounded by uncertainty and variations in
surgical practice. The extent to which surgeons
exercise choice of type of prosthetic component
in relation to patient criteria such as age (as a
proxy for activity level), diagnosis, bone stock
quality and weight (body mass index) is unknown.
3
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Chapter 3
Evolution of different types of prosthetic
technology for total hip replacement
The periods of major development in THRtechnology fro the initial cemented
procedure to the more recent major design
innovations are shown in Table 1.
The theoretical advantages and disadvantages of
the different designs and fixation methods of hip
prostheses are not discussed in detail here. Basic
differences between the different types are
described below.
In the 1970s, high failure rates of the early
cemented THRs were found, which were
characterised by bone loss (osteolysis) and
mechanical loosening of prostheses. The cause
was considered by many to be 'cement disease',
that is, a direct reaction between the 'cement'
(i.e. polymethyl methacrylate) and the body
tissue. This beliefwas a major stimulus in the
search for alternative solutions to the problem
of long-term fixation and led to the concept of
cement-free fixation. Methods of cementation
have themselves evolved and are conventionally
classified into the three 'generations' with the
characteristics noted in Table 1.
Various cement-free methods have been developed
which can be summarised broadly as:
• press-fit methods, in which fixation is sought
by closeness of fit between prosthesis and bone,
often assisted mechanically by techniques such
as threading and augmentation by screws, nails
or pegs, and 'macro-interlock' design features
such as ribbed stems designed to improve
fixation by wedging
• porous-coated, in which cementless technology
is treated at surfaces adjacent to bone with an
inert microporous coating in the form of mesh
or beads with the aim of encouraging ingrowth
of bone into the prosthesis surface
• hydroxyapatite- (HA-) coated, which is
similar to porous coating in concept but
the surfaces adjacent to bone are coated
with HA, a form of calcium phosphate
ceramic considered to be biologically
active and capable of direct chemical
bonding to bone.
TABLE I Major developments in THR technology
| Prosthesis type 1960s 1970s 1980s 1990s
| /st generation








































| Fully modular late early
1980s/ 1990s 1
In hybrid models, a cemented stem is combined
with an uncemented cup, which retains the rela¬
tively good performance of cemented stems but
substitutes possibly superior cement-free cups; this
allows immediate weight-bearing and, hence, may
be seen clinically as suitable for older patients
unable to use crutches.
In the fullymodular type of prosthesis, the
problem of achieving close anatomical fit is
tackled by making available a range of sizes of
separate subcomponents of the total prosthesis,
including the acetabular cup, the femoral
PAPER 3
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stem, and the separate sleeve and head of the
femoral component. Manufacturers are developing
increasing modularity, and an increase in modular
connections in a prosthesis leads to increased
production costs.
Ceramic heads and cups (among
combinations ofmaterials) have t
in an attempt to lessen wear and t
production of damaging particles
surfaces of the prosthesis.
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Chapter 4
Types of outcome measure
There are, broadly, three types of outcomemeasu available for review in the ortho¬
paedic literature on total hip prostheses:
• the lifespan of the prosthesis, which is usually
referred to as its 'survival' and is typically
represented by survivorship analysis or revision
rates (i.e. rates of replacement of prostheses)
• prosthesis function in situ, which is measured
typically by one of several standardised clinical
hip scoring systems (outlined below) and which
includes symptomatic loosening
• radiographic definitions of possible failure,
including bone loss (osteolysis), subsidence
of the stem component, migration of the cup
component and wear of materials.
In practice, revision rate/survivorship is reported
differently in different studies. Many studies use
'survival analysis' to assess the longevity of implants.
This calculates, in a given cohort, the number of
implants surviving unrevised each year as a pro¬
portion of those still in situ. In terms of the per¬
formance of the prosthesis itself, the key criterion
for failure is revision for aseptic loosening, that is,
as far as possible the defined outcome is caused
by characteristics of the prosthesis rather than
by confounding factors such as infection or dislo¬
cation (which maybe due to accidental falls). In
practice, reporting of the causes of revision is
variable and sometimes just the revision rate is
given without any qualification regarding its inter¬
pretation. In such cases, it is impossible to know
whether causes of revision normally irrelevant to
the prosthesis technology, such as infection, have
been included. Other dimensions used in pros¬
thesis survival analysis, which may or may not be
included in different authors' definitions of failure,
include radiological evidence of loosening and
patient tolerance of symptoms. Some studies
include 'pending revisions', others do not.
The total mechanical failure rate is also frequently
reported. This refers (usually) to revision rates
caused by aseptic loosening combined with
radiographic evidence of loosening, fracture
or other mechanical failure of components.
The main clinical hip scoring systems are briefly
described in Table 2. Scores are allocated by a
clinician. The Harris and the Merle d'Aubigne
systems are the ones most frequently reported
in the studies reviewed here.
Pain is conventionally graded from 'mild'
through 'modest' to 'severe'. Some studies report
the proportion of patients found to be 'pain-free'.
A problem with these grades is that studies rarely
indicate whether pain is related to context; for
example, whether it is related to a particular
TABLE 2 Most frequently cited clinical hip scoring systems
Merle d'Aubigne
(also in a version revised by Charnley)
SKftWAWSSSWSS.'Sftl
Harris
3 dimensions: Hip function graded as 'good; fair;
pain, mobility, walk; each scored 0-6 medium; poor'
4 dimensions (score):
pain (0—40), function (0—47),
range of motion (0-5),
absence of deformity (0-8)
Johnston 5 dimensions
pain, activity, mp/walk, walking aid,
ambulation time
HSS (Hospital for Special Surgery) 4 dimensions:
pain, walk, range of motion,
function: each scored 10 points
Combined score = 100;
< 70 poor; 70-79 fair; 80-90 good;
90-100 excellent
(In studies,'good' and 'excellent' results |
frequently classified together, and a
'mean Harris' combined score given
for a cohort.)
Combined:
32+ excellent; 24-31 good;




level of physical activity. Grading is undertaken by
the clinician.
Thigh pain, which is fairly frequently reported in
studies of uncemented implants because it appears
to be a problem in at least some of these, has rarely
been reported for cemented implants and cannot
be inferred from the pain dimensions included in
the common hip scales. This makes comparison of
this aspect between the two broad technologies
difficult. Some studies in which this outcome is
compared for different types of prosthesis are
reviewed later in the chapters in which the key
results of clinical studies are presented.
Of the outcome measures commonly used in
the studies reviewed, reporting of radiographic
measurements is the most diverse and difficult to
interpret. It is frequently stated that radiographic
results do not correlate with clinical findings and
prosthetic survival; however, this is a controversial
subject in which the evidence from one study to
another is conflicting. The possibility of predicting
later failure from early radiographic measures is an
important issue, especially in the context of the
proliferation of unproven novel designs and tech¬
nologies. In one study it was suggested that failure
of the femoral component due to loosening can be
predicted with 86% specificity and 78% sensitivity
using standard X-ray techniques.12 Migration/
subsidence (of the stem component) of greater
than 1.2 mm per year12 or at 2 years post-implant13
have been suggested as the best threshold for
prediction of failure.
Radiographic evidence is treated as a standard
outcome measure in many studies of hip prosthesis
technology, regardless of its potentially predictive
role. The most common dimensions analysed are
loosening, migration (especially of the acetabular
component) and subsidence (of the stem). Again,
there is variation in the threshholds and criteria
used by different authors in defining these
measures. Other measures used are stability, pre¬
sence of continuous radiolucent lines (indicative
of possible loosening) around components, change
in orientation of components, signs ofwear or
abrasion of prosthetic surfaces and presence of
particulate debris associated with wear.
A number of negative outcome measures are not
included in the summaries of studies critically
appraised in this review because they do not aid
comparison of performance of the prosthetic
technology per se. These include:
• infection (for example, Ahnfelt and colleagues,14
in their analysis of 15 different implant models,
report no difference between implants when
failure leading to revision for infection is
the end-point)
• dislocation
• postoperative fracture (often associated with
accidental falls)
• mortality
• intraoperative complications (e.g. blood loss)
• deep vein thrombosis and pulmonary embolism.
Measurement of quality of life, pain, activities of
daily living and satisfaction, using patient-derived
measures, are notably absent from the literature
reviewed. Issues in the measurement of outcomes of
THR have been discussed in more detail elsewhere
(for example, by Heaton et al.15) and form the focus
of a separate report commissioned by the NHS R&D
Health Technology Assessment programme.
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Chapter 5
Review methodology: search strategies,
selection criteria and critical appraisal methods
Literature search
The reviewers had the benefit of a large
bibliographic database compiled within their
department to support a number of research
projects on epidemiology and service provision
for THR. Additional searches were conducted
employing a modified Cochrane strategy for
identifying randomised controlled trials (RCTs)
on Medline, 1980-95, and broad criteria for
THR/arthroplasty for 1995 on Medline and
Embase. As the review project progressed, ad hoc
searching identified a number of important
studies published in 1996. Separate searches
using a variety of terms (such as control*,
versus, compar*, match*) were conducted on
Embase, 1990-96, to identify studies with com¬
parison or control aspects in the study design.
The searching was limited historically because
prosthesis models change continually; hence,
collecting evidence on superseded models was
considered to be unproductive. A number of
individuals and organisations, for example,
the Medical Devices Agency, were
contacted directly.
Selection criteria
The following criteria were applied:
• identifiable type of total hip prosthesis,
including named models not currently used
in the UK
• clinical data given (excluding, for example,
laboratory-only studies)
• patient group: adult with a primary diagnosis of
hip arthropathies/congenital deterioration,
excluding hip fracture
• follow-up period specified
• outcome definition for prosthesis failure to
include survivorship and/or revision rate and/or
radiographic criteria
• type of evidence: observational or
experimental design
• stage of study (end/interim) reported
• only English language articles or
abstracts included.
In addition, a large number of bioengineering
and prosthesis retrieval studies of the mechanics
of loosening, migration, subsidence, and laboratory
studies ofwear of material components have been
collected; however, these are not reviewed in
this report.
Excluded studies
Many studies were excluded from the review
following inspection of the full text of retrieved
articles. The reasons for exclusion at this
stage included:
• unusual diagnostic profile of patient group
• lack of primary data included in the article
• rare and obsolete prosthesis design
• high proportions of revision operations in
the study group.
The exclusions included a small group of studies of
uncemented porous-coated designs with very short
(2-3 years) follow-up periods.
Critical appraisal methods
A total of 233 studies giving primary data were
included in the review.
It is difficult to isolate the outcomes associated
with the prosthetic technology and design in
THR from potentially confounding variables,
especially surgical techniques, surgeon-specific
factors and patient characteristics. Priority in
the appraisal of studies has thus been given to
studies with an element of comparison or control
of these variables. There are very few RCTs to
draw upon.
Checklists were used to control the appraisal
process. Separate checklists were used for RCTs,
non-controlled comparative studies and obser¬
vational/cohort studies without comparative
features. Each study was reviewed by one of the
research team (either AF or GK). Blinding to
author or affiliation was not employed. The
checklist criteria are presented in chapter 6.
These were adapted from the similar approach
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used by Cowley in her Medline-based review of
the same subject for the Australian Institute of
Health and Welfare.16 Studies were given a rating
A, A/B, B, B/C or C based on the extent to
which the appraisal criteria were met. In the
presentation of results, ratings A, B and C only
have been used for the sake of simplicity; A/B
ratings were deemed to be A-rated and B/C
ratings were deemed to be B-rated. Definite
failure to meet one of the key criteria resulted
in a C rating. Studies which met all key criteria
were rated A or B, depending upon performance
against the other criteria. Criteria were not given
explicit weights and were not regarded as of
equivalent weight in these decisions. They thus
have a subjective component. The ratings provide
a simple method of summarising the quality of
the studies reviewed using the checklist criteria
and, hence, should be regarded as shorthand
summaries of the detailed appraisals carried
out for each study.
The main classifications used in structuring the
presentation of studies in this report are the type
of research design and types of prosthesis. The
criterion-by-criterion appraisal of each study is
presented in the appraisal tables in the appendix
to this report. Key data were extracted for each
study and these are presented in the data tables
in the appendix. Individual written summaries
of each RCT reviewed are presented at the
beginning of the appendix.
Publication bias
The major focus of this review is on the compar¬
ative effectiveness of different prostheses rather 1
than the effect size associated with prostheses com- j
pared to another type of intervention. Formal
methods of assessment of publication bias cannot
be applied to the small number of RCTs available S
for this review. It is possible that more reports of
studies giving poor results associated with particular
models may be published in non-English language j
journals, which were not included in this review, j
but the proportion of the reviewed studies
reporting failures and 'poor' results is relatively j
high, suggesting fairly open editorial policies in j
which publication bias toward positive or 'good' j
results is not a major concern. A very small number j
of English-language abstracts of non-English
articles have been included where sufficient j
information was available. These are noted in
the appraisal tables in the appendix. Further
abstracts were scrutinised but it was judged that, j
for the limited additional information likely to be j
obtained, translation was not warranted. No RCTs j
were covered by these abstracts. A more important 1
factor affecting interpretation of results is the
institutional origin of studies, the majority coming j
from specialist and teaching centres. Also note¬
worthy is the small proportion of studies in which i
some of the authors may be seen to have a direct j
vested interest in the commercial prospects of the
particular component reported upon.
J
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used by Cowley in her Medline-based review of
the same subject for the Australian Institute of
Health and Welfare.16 Studies were given a rating
A, A/B, B, B/C or C based on the extent to
which the appraisal criteria were met. In the
presentation of results, ratings A, B and C only
have been used for the sake of simplicity; A/B
ratings were deemed to be A-rated and B/C
ratings were deemed to be B-rated. Definite
failure to meet one of the key criteria resulted
in a C rating. Studies which met all key criteria
were rated A or B, depending upon performance
against the other criteria. Criteria were not given
explicit weights and were not regarded as of
equivalent weight in these decisions. They thus
have a subjective component. The ratings provide
a simple method of summarising the quality of
the studies reviewed using the checklist criteria
and, hence, should be regarded as shorthand
summaries of the detailed appraisals carried
out for each study.
The main classifications used in structuring the
presentation of studies in this report are the type
of research design and types of prosthesis. The
criterion-by-criterion appraisal of each study is
presented in the appraisal tables in the appendix
to this report. Key data were extracted for each
study and these are presented in the data tables
in the appendix. Individual written summaries
of each RCT reviewed are presented at the
beginning of the appendix.
Publication bias
The major focus of this review is on the compar¬
ative effectiveness of different prostheses rather
than the effect size associated with prostheses com¬
pared to another type of intervention. Formal
methods of assessment of publication bias cannot
be applied to the small number of RCTs available
for this review. It is possible that more reports of
studies giving poor results associated with particula;
models may be published in non-English language
journals, which were not included in this review,
but the proportion of the reviewed studies
reporting failures and 'poor' results is relatively
high, suggesting fairly open editorial policies in
which publication bias toward positive or 'good'
results is not a major concern. A very small number
of English-language abstracts of non-English
articles have been included where sufficient
information was available. These are noted in
the appraisal tables in the appendix. Further
abstracts were scrutinised but it wasjudged that,
for the limited additional information likely to be
obtained, translation was not warranted. No RCTs
were covered by these abstracts. A more important j
factor affecting interpretation of results is the
institutional origin of studies, the majority coming
from specialist and teaching centres. Also note¬
worthy is the small proportion of studies in which
some of the authors may be seen to have a direct
vested interest in the commercial prospects of the
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Chapter 6
Summaries of effectiveness studies and results
of critical appraisal
The majority of studies of the outcomesof hip prostheses in primary THR are
observational in design. Few RCTs have been
published. This review has tried to maximise
the use of studies with an element of comparison
between prosthesis types. The most studied single
model is the cemented Charnley. The great
majority of studies have appeared in a small
number of specialist orthopaedic journals and
emanate from specialist orthopaedic centres and
departments, mainly in teaching hospitals. About
12% of the reviewed studies originate in the UK
Length of follow-up is inadequate for the full
evaluation of the longevity ofmore recently
introduced types of prosthesis. The methodo¬
logical quality of studies is, in general, low,
especially notable being the lack of sample
size calculation in any of the reviewed studies.
In most studies, the sample sizes actually
reported appear to be notably smaller than
would be ideally recommended to achieve
valid generalisable results.
Summary of study characteristics
Numbers of reviewed studies
for different comparisons and
prosthesis types
Meta-analyses
A single meta-analysis exists in the orthopaedic
literature on total hip prostheses1' and is
commented on later in this chapter.
RCTs and comparative studies
A total of 78 RCTs and comparative studies
are included in this review (17 RCTs, 61 other
comparative studies).
The prosthesis (or prosthesis type) comparisons
which these studies make possible overall are
summarised in Table 3.
It can be seen that the most numerous
comparisons in the literature are between
alternative cemented designs, followed by
TABLE 3 Numbers of trials and comparative studies included
! Type of prosthesis Cemented Other Ceramic HA- Hybrid Modular Press- Porous Re- |
I - Charnley cemented coated fit surfacing |
| Cemented - Charnley 1
| Other cemented 12 15




Press-fit 2 5 5 4
! Porous 3 10 1 4 6 2 2
| Resurfacing 2 5 1 2
NB: This table excludes six studies which did not fit into the above divisions, one being the meta-analysis referred to above. A blank cell
indicates that no study for this comparison was found in the review. I I
i
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12
cementless porous-coated versus cemented,
HA-coated and hybrid designs of prothesis.
Other RCT7comparative studies
There are 11 other studies which are not
straightforward prosthesis versus prosthesis
comparisons. These are dealt with separately
from the above studies in chapter 10. They
include comparisons of patient variables and
fixadon types and techniques, together with
reports assessing why outcomes such as
dislocation and fracture may occur.
Observational studies
A total of 145 observational studies were reviewed
(see Table 4).
TABLE 4 Numbers ofobservational studies reviewed
j-i
| Type of prosthesis











A further six observational studies of uncemented
threaded press-fit acetabular components were
reviewed for data extraction purposes but not
appraised, because this design has generally
been abandoned.
Journals of publication
The journals in which the reviewed studies of
hip prostheses mainly appear and the number of
articles are presented in Table 5 (RCTs and compar¬
ative studies) and Table 6 (observational studies).
In Table 5, two studies which were published
in separate journals (Clinical Orthopaedics and
Related Research and CanadianJournal ofSurgery)
reported on the same cohort of patients and are
jointly appraised in this report, although they
are recorded separately here. The single meta¬
analysis study was not included.
Only four of the RCTs and comparative studies
listed in Table 5 appeared in non-orthopaedic
TABLE S Journals in which RCTs and comparative
studies appear
| Journal name Number Percentage
of studies of total
1 Clinical Orthopaedics and
I Related Research
| Journal of Bone and Joint
I Surgery [American]





| Acta Orthopaedica Scandinavica
§
| Journal ofArthroplasty



















TABLE 6 Journals in which observational studies appear
| Journal name Number Percentage 1
L___ of studies of total
I Clinical Orthopedics and
I Related Research
28
| Journal of Bone and Joint Surgery
| (American + British combined)
46 32
| Journal ofArthroplasty
| Acta Orthopaedica Scandinavica
| + Acta Orthopaedica Belgica
I Others (e.g. Orthopedics, Journal
| ofOrthopaedics and Rheumatism,







journals; one each in; CanadianJournal of
Surgery, Australian and New /ZealandJournal of
Surgery, Investigative Radiology and KeioJournal
ofMedicine.
Only two of the observational studies (Table 6)
appeared in non-orthopaedic journals or other
specialist sources: CanadianJournal ofSurgery, and
Australian and New ZealandJournal ofSurgery.
Overall, it is clear that a small number of specialist
orthopaedic journals account for the vast majority
of publications of primary research studies on total
hip prostheses. Very few studies are published in
generalist medical journals.
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Country/area in which studies
are conducted
RCTs and comparative studies
The countries of origin of the RCTs and
comparative studies are shown in Table 1, both in
terms of the number of studies and as percentages
of the total. The one joint study, between the UK
and Switzerland, is recorded for both countries.
The single meta-analysis study is not included.
TABLE 7 Country of origin ofRCTs and comparative studies
| journal name Number Percentage
























NB: List includes one joint study between the UK and Switzer¬
land, which is recorded for both countries. The single meta¬
analysis study is not included.
Notably, 47% of RCTs came from Sweden and 18%
from the UK 41% of the comparative studies came
from the USA and 10% from the UK
Observational studies
The approximate percentages of reviewed obser¬
vational studies by country/area are presented in
Table 8.
Types of hospital from which published
research originates
The great majority of studies came from specialist
orthopaedic centres or teaching hospitals. A small
number of district general hospitals can be identi¬
fied, and a few studies report multicentre results in
which all types of hospital have been included. The
preponderance of specialist centres must be borne
in mind when interpreting the studies' results.
Diagnostic profiles of patient groups
The major primary diagnosis in the great majority of
published studies is osteoarthritis of the hip. In most
| Country of origin Percentage of total
1 UK 13
* a Bawaw - «a* * , ~ «»





series the proportion of patients with osteoarthritis
varies between 50% and 80%. The next most pre¬
valent condition is rheumatoid arthritis. In studies of
patients in younger age groups the proportion with
rheumatoid arthritis tends to be higher. Very few of
the cohorts studied have been confined to patients
with a single disease entity. Few studies perform
subgroup analysis by diagnostic group.
Maximum follow-up periods
The period of follow-up is obviously important
in the evaluation of prosthesis technology. Where
possible, the maximum stated follow-up period
reported in each of the studies reviewed are sum¬
marised in Table 9 (RCTs and comparative studies)
and Table 10 (observational studies). In those studies
in which mean or median follow-up period only was
stated, an informed guess of the likely maximum
period has been made, based on other studies and
publication dates. Comparison of these results gives
an indication of the typical length of follow-up
available from published studies for the different
types of prostheses. Losses to follow-up and death
mean that numbers of hips reviewed at the
maximum period are frequently low.
TABLE 9 RCTs and comparative studies: maximum
follow-up periods









1 Cemented - Charnley 12 13.5




| Uncemented press-fit 16 4.5
1 Uncemented porous-coated 23
i
5
1 Uncemented HA-coated II 3
| Hybrid 6 5
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TABLE 10 Observational studies:maximum follow-up periods




| Cemented - Charnley 45 15.5 |
| Other cemented 29 10 i
| Uncemented press-fit 13 7-8 j
| Uncemented porous-coated 33 7 i
| Uncemented HA-coated 10 4 I
1 Hybrid 6 6 ji;
14
It can be seen clearly from the tables that follow-
up periods for non-cemented types are on average
only short term. The longest follow-up period of
studies of non-cemented prostheses included in
this review was about 10 years.
Sample size
None of the reviewed studies of any type reported
a prospective calculation to estimate required
sample size.
Sample size as a criterion was not included in the
checklist of criteria because the range of different
outcome measures used in studies have different
implications for sample size. A large difference in
clinical hip scores, for example, maybe detected
with a relatively small sample but small differences
in relative survival of prostheses, when revision of
the hip is the definition of survival, requires
relatively large sample sizes.
An analysis of the reviewed studies, according to our
own sample size calculations under the assumptions
for each type of study design, is presented below.
RCTs and comparative studies
Two sample size calculations have been made, one
stringent and the other more relaxed. In the first,
in order to detect a difference of 4% in the survival
rates between two prosthesis designs, assuming an
expected survival rate of 90% at 20 years (95%
confidence interval, 80% power) would require an
achieved sample size of 1085 hips per arm. Allow¬
ing for death during follow-up, and assuming mean
age at operation of 65 years, an initial sample size
of 3600 hips per arm might be required at this level
of stringency (fewer for younger age groups). Alter¬
natively, assuming a survival rate of 80%, in order
to detect a relatively large difference of 10% in
prosthesis survival would require an achieved
sample size of some 313 hips per arm, or about
480-500 hips per arm if a total follow-up of
300 hips per arm was required for 10 years.
The numbers of reviewed RCTs and comparative
studies of prosthesis versus prosthesis meeting
these sample size criteria are as follows:
• > 3600 per arm - none
• > 1000 per arm - one (Havelin, et al., 199418)
• > 480 per arm - none except the above18
• > 300 per arm - the above18 plus two (Ebram-
zadeh, et al., 1994;19 Schreiber, et al., 199320).
In summary, only three of the RCTs and
comparative studies reviewed have sample sizes
enabling statistically valid comparisons for hip
survival between prosthesis groups over the
defined minimum of 300 hips.
Observational/cohort studies
A sample size of 600 hips is required in order to
have a 95% confidence interval with an estimated
precision of ± 0.04 (i.e. confidence interval with
width of 8%), for an assumed 60% prosthesis
survival rate at 20 years. Larger samples would be
required in order to have the same precision for
higher percentage survival assumptions. In compari¬
son to studies of the survival of cemented prostheses
with long follow-up, a 60% survival rate is a conser¬
vative assumption. This sample size estimate assumes
that total follow-up is possible which, in practice,
it is not because of the death of a proportion of
the initial recipients of a prosthesis (this is likely
to be about 70% if the mean age at operation is
65 years).21 Thus, to achieve total follow-up of about
600 patients would require an initial cohort of some
2000 patients (this figure does not take account of
the fact that most studies include a proportion of
surviving patients who are lost to follow-up).
Only three of the 145 observational studies
reviewed include cohorts fulfilling this sample size
criterion, those by Ahnfelt and colleagues,14 based
on the multicentre Swedish registry, Dall and
colleagues,22 both in cohorts given the Charnley
prosthesis, and Mohler and colleagues,23 following-
up the Iowa Hip cemented prosthesis.
The great majority of observational studies have
cohort sizes of between 100 and 500 hips.
Appraisal results
Full results of the appraisal of individual studies are
given in the appraisal tables in the appendix. The
numbers of A-rated studies and the percentages of
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studies meeting the individual appraisal criteria are
summarised below. The rating procedure used is
that described in chapter 5.
Study using meta-analysis
The single meta-analysis study17 combines the
data from observational studies internadonally
of uncemented press-fit threaded acetabular cups
and compares the results to cemented and porous-
coated control groups, also using combined data.
Extracted data from the study are included in the
data tables in the appendix but the study has not
been included in the checklist appraisal. The
practice of combining data from observational
studies is, in principle, methodologically weak
because of the effects of confounding and selection
and other biases in single, observational, non-
randomised studies. Even given the very careful
selection of studies which the authors achieved,
it is difficult to account fully for possible sources
of heterogeneity in combined studies.24 However,
it should be noted that the results of the major
comparison of relative effectiveness in this meta¬
analysis are supported by orthopaedic surgical
practice internationally, in which use of the
threaded cup design has been largely abandoned.
A-rated RCTs and comparative studies
The numbers ofA-rated RCTs and comparative
studies are presented in Tables 11 and 12.
The number ofA-rated observational studies are
presented in Table 13.
Proportions of studies meeting appraisal criteria
The overall appraisal results for each criterion
TABLE 11 RCTs and comparative studies: number ofA-rated
studies for prosthesis versus prosthesis comparisons
TABLE 13 Observational studies: numbers ofA-rated studies for
each prosthesis type
Type of study Number of Number of
studies A-rated studies
TABLE 12 Other RCTs and comparative studies: number
ofA-rated studies
| Type of study Number of Number of
f studies A-rated studies
1 RCT 2 0
| Comparative 10 22"7
I N8: Excludes the meta-analysis study.
1 Type of prostheses Number of Number of
studies A-rated studies
| Cemented - Charnley 45 7
::: ft:
| Other cemented 29 12 g
1 Uncemented press-fit 13
| Uncemented porous-coated 33 9
| Uncemented HA-coated 10 6
I Hybrid 6 I
I (See appraisal tables in appendix for details)
for each type of study design are summarised in
Tables 14-17.
In addition to the appraisal results for RCTs present¬
ed in Table 14, two other RCTs which do not make
prosthesis versus prosthesis comparisons have been
reviewed. They meet the appraisal criteria as follows:
criterion 1 - neither
criterion 2-1
criterion 3 - neither









criterion 13 - neither
criterion 14-2
criterion 15 - neither
criterion 16-1
criterion 17 - neither.
A number of general comments on the design
of studies of hip prosthesis outcomes in the ortho¬
paedic literature can be made on the basis of the
results presented in Tables 14-17.
Methodological weaknesses in the studies are
of particular concern in the description of study
group characteristics from which representative¬
ness might be assessed. Only one in three of the
RCTs identified the method of randomisation.
In the comparative studies, the major weaknesses
are in descriptions of the process of assignment of
patients to prosthesis groups, and in establishing
the comparability of patients in comparison groups
(either through matching or statistical analysis).
Fewer than half of the observational studies give an
account of the selection of patients included in the
study (in addition, there are very few descriptions
of clinical indications for prosthesis choice). Review
of the observational series suggests that prosthesis
selection practice is based largely on the prefer¬
ences of clinicians and surgical centres.
PAPER 3
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Prospective sample size calculations have not been
evident in the scientific orthopaedic literature on
the clinical results of hip prostheses.
Most studies have made neither clinical nor
radiological evaluations independendy of the
operating surgeon nor has blinding to the
intervention been employed where appropriate.
TABLE 14 Appraisal summary ofprosthesis versus prosthesis
RCTs (n= IS)
! Key criteria
I Method of randomisation identified and
appropriate
Patient groups balanced or effect of any







Patients blind to prosthesis type
Assessments of clinical/radiological outcome
blind to prosthesis type if possible 2(13)
Appropriate statistical analysis 10 (67)
Number of patients deceased or lost
to follow-up reported or included in
statistical analysis 13(87)
Xv x ■>
I 7 Follow-up period - mean and range 15 (100)
8 Prosthesis model specified 15 (100)
9 Clearly defined criteria for measuring
outcomes 14 (93)
10 Age - mean and range 14 (93)
Other criteria
-»C4«4H44M4t4Q-X«M4M-HHtWKWmit
11 Quantification of outcomes 13 (87)
12 Follow-up data compared with preoperative
data (preferably mean and range) 8 (53)
13 Independence of investigators (declared
or no vested interest) 6 (40)
14 Numbers of men and women given 11(73)
15 Weight - mean and range 9 (60)
| 16 Preoperative diagnoses with percentages/
numbers of patients given





TABLE IS Appraisal summary of prosthesis versus prosthesis





I Method of assignment of patients to




| 2 Patients matched or differences
evaluated in valid statistical analysis
| 3 Appropriate statistical analysis undertaken 32 (64)
4 Number of patients deceased or lost to
follow-up reported or included in analysis 29 (57)
I 5 Follow-up period - mean and range
6 Prosthesis models specified
| 7 Clearly defined criteria for measuring
I outcomes






If retrospective, patients selected without
knowledge of outcomes 27 (71)
10 In prospective studies, follow-up
assessments blind to prosthesis type,
if possible 2(15)
Results given for specific models
(and sizes)




Follow-up data compared to preoperative
data (mean and range) 10 (20)
14 Independence of investigators (declared
or no vested interest) 12 (24)
I 15 Numbers of men and women given 41 (80)
16 Weight - mean and range 14(27)
I 17 Preoperative diagnoses with percentages/
numbers of patients given 34 (67)
| 18 Clinical evaluation independent of
operating surgeon 4(10)
| 19 Radiological evaluation independent and
blinded to clinical results 3 (6)
is*wi-:s*:*»::x;x*x
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TABLE 16 Appraisal summary ofother comparative studies
(n= 10)
Key criteria
I Method of assignment of patients to







| 2 Patients matched or differences evaluated
in valid statistical analysis 7 (78)
I 3 Appropriate statistical analysis undertaken 8 (80)
!:! 4 Number of patients deceased or lost to
| follow-up reported or included in analysis 9 (90)
| 5 Follow-up period - mean and range
xx-x-xxx-x-x-xcx-xc-x-xxwx-x'x.x^xr.'xowx-xx-x-x'x-x^x-xx-xx'x-x-xvx




I 7 Clearly defined criteria for measuring
I outcomes
| 8 Age - mean and range
Other criteria






10 In prospective studies, follow-up assessments
blind to prosthesis type, if possible NA
I I Results given for specific models (and sizes) 6 (60)
:-x-x^x<-X'X-x-x<xrxxx'X-xwx-x<-^x-x^x-x-xwx««x-x'x/x->x«x-xwx--x-x-»:-Xv»:->x-x-:-x-xwxwx^x-x<-x«x-x-:-x«X'X-:->x-:«XvX-
12 Quantification of outcome criteria 9 (90)
| 13 Follow-up data compared to preoperative
data (mean and range) 3 (30)
| 14 Independence of investigators (declared
1 or no vested interest) 4 (40)
ji;




| 16 Weight - mean and range
8 (80)
4 (40)
17 Preoperative diagnoses with percentages/
numbers of patients given 9 (90)
0(0)
| 18 Clinical evaluation independent of
operating surgeon
| 19 Radiological evaluation independent and
blinded to clinical results 2 (22)
NA, not applicable
TABLE 17 Appraisal summary of observational studies (n = 145)





Method of selection of
patients identified
Follow-up period - mean
and range 13/135
Number of patients lost to
follow-up or deceased -
reported or included in analysis







reviewed patients stated with
percentages/numbers 83 112/135




9 Valid statistical analysis






I I Data given for deceased patients 25 23/93




| 13 Radiological evaluation independent
and blinded to clinical results 14





| 15 Weight - mean and range 23 27/115
-.'■X'XvXvXvX-X-X-X
| 16 Surgical technique/approach stated 77
:j:x'x*x-x-x:x-x-x-x-x-::x,xx-x-::x-x-xx*xx-xx.xxxvx-x-xxxxx.x*x-xx-x-x-x-xx-x-xx-x:x-x-x-xrx:x-xi
| 17 Grade/experience and number
of surgeons stated 47
89/115
54/115





| 19 Unilateral/bilateral results separate 0
>x-;'Xwxyx-x-x-;-x-x«x-x-:«vX-:-x-:->:w>xi<'X-x-:'>x<':-xwx-:->X'X-x-x-:-x-x;x-x-x-x<
20 Independence of investigators
(vested interest) stated 28 32/115
^Sx.:x>:.>:.:Xx-;-x-xx-:«.>ssx-X
O-X^XC-XX-WX^XSX-X-X-X-XWI-WX-I-XWNXVX^X-W^-xwwxwx-XWXX-X-X-X-:':
The 'number applicable' for each criterion varies for several
reasons: a number of studies which clearly failed by one or more of
the key criteria were not appraised for the remaining criteria; some
criteria (e.g. data given for deceased patients) were not applicable
in some studies; in a very small number ofstudies from which data
have been extracted, only an abstract was available. The denom¬
inator in calculating percentages has been adjusted accordingly. 17
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Chapter 7
Effectiveness of hip prostheses: a summary of
key results from clinical studies
Given the methodological quality of thereviewed studies, results for different types
of prostheses should be treated as estimates with
wide confidence intervals. The majority of studies
come from specialist centres and this is likely to
have a bearing on the generalisability of the
results. Clinical outcomes are measured by pros¬
thesis survival, radiographic measurement and
hip scoring. Clinical hip scoring is likely to under¬
estimate the qualitative significance for recipients
of hip implants of pain and function.28 Taking these
points into account, the following conclusions
can be drawn about the performance of different
types of prosthetic hip technology on the basis
of the evidence summarised in this chapter.
Cemented designs in general show good survival
results at 10-15 years plus. Models with good,
published, comparable results (at about 10 years
or more) include the Stanmore, Howse, Lubinus,
Exeter and Charnley designs. The rate of acetabu¬
lar revision in cemented implants remains proble¬
matic. There is some evidence that all-polyethylene
acetabular components are preferable to metal-
backed designs in terms of longevity of the implant.
Evidence of short-term comparisons between
non-cemented porous-coated designs and
cemented designs is equivocal. One comparative
radiographic study suggests that cemented acet¬
abular components performed better than
porous-coated designs but that porous-coated
stems performed better than cemented models.
The first 10-year survival results for porous-coated
models appear to bear comparison with the
cemented models for the same follow-up period,
especially when the relatively lower average age
of the patient groups implanted with the porous-
coated models is taken into account.
The comparative evidence strongly suggests that
thigh pain is a problem associated with porous-
coated (and other cementless) implants, to which
cemented designs are not prone. In the observa¬
tional studies of porous-coated implants, reports
of thigh pain prevalence ranged between about 2%
and about 25% at 2-7 years follow-up, with several
studies reporting prevalence values at about the
higher 25% level, including in non-loose stems.
In contrast, in the small number of studies of
HA-coated models, mild to moderate thigh pain
was found in between 0% and about 5% of patients
at 2-5 years follow-up. This is a relatively good
result in comparison to reports of porous-coated
implants and requires further substantiation.
Radiographic studies of cemented versus HA-
coated designs suggest that HA-coated models
have better early fixation and less migration than
cemented models. The lesser migration ofHA-
coated models may be associated with less early
postoperative pain, according to one comparative
study. With maximum follow-up periods of only
3-4 years for this form of fixation, longer-term
studies of survival and clinical results are required.
Hybrid prostheses appear to do well in the short
term but the available studies cannot give any indi¬
cations for their mid- or long-term results. Given
wide confidence intervals, for early (6-7 years)
survival this type of design can be regarded as
comparable with the best cemented designs. Early
survival is superior to that for uncemented porous-
coated implants, and early thigh pain in cemented
stem components in hybrid implants is minimal
or absent compared with porous-coated designs.
Longer follow-up, especially of the coated acetab¬
ular component of hybrid implants, is required to
ascertain the medium- and long-term performance
of this design.
Little evidence is available on fully modular
prostheses. Theoretically, modularity permits
greater intra-operative flexibility for the surgeon
and potentially better component fit but further
evidence, especially in comparison to cemented
implants, is required. One comparative study
suggested that a fully modular stem performed less
well than cemented stems. Laboratory analysis of
retrieved components suggests that mixed-alloy
components are more prone to corrosion than
single alloy devices.29
Evidence for the performance of ceramic hips
is equivocal. Wear rates are less than for other
materials at the articulating surface of the joint.
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Comparative studies have suggested either lower or
equivalent revision rates for ceramic versus cement¬
ed implants at medium-term follow-up. The impli¬
cations of laboratory studies of alternative bearing
surface materials require further investigation.
The uncoated press-fit and resurfacing types of hip
prosthesis generally have survival results notably
inferior to the other types of design available.
In the following three chapters the results of the
review are presented, as follows:
• results of each comparison of different types of
prosthesis taken from RCTs and comparative
studies (chapter 8)
• results from selected observational studies for
different types of prosthesis (chapter 9)
• results from comparative studies on selected key
issues, including thigh pain, bearing-surface
materials, inter-surgeon and inter-hospital
comparisons (chapter 10).
A brief summary of each RCT included in this
review is presented in the appendix (see page 83).
I!
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Chapter 8
Results of studies comparing different types
of prosthesis
Each type of prosthesis was compared, in turn,to all other types of THR where permitted
by the available studies. For some comparisons
there were more than two or three relevant studies
which could be summarised (see Table 3) and, in
this situation, only those studies with the highest
rating, longest follow-up and/or survivorship
results are included. One comparison noted in
Table 3 (i.e. ceramic versus resurfacing) is not




Only one paper compared one form of Charnley
with another. Flanges on the prosthesis may reduce
the incidence of loosening but this was a small
study with a C-rating and so no definite conclusions
can be drawn.
Hodgkinson and colleagues, 199330
The Charnley hips were implanted flanged
(n = 168) or unflanged (n = 182). The patients
were well matched statistically, with an approxi¬
mate mean age of 58-60 years, and 70% had
osteoarthritis. All the prostheses were inserted
by the same surgeons. Accurate data at 9-11 year
follow-up were available for 302 prostheses
(152 unflanged, 150 flanged). In total, there
were 15/350 (4.3%) revisions (which included
11 patients who were excluded from further
analysis because the revisions occurred before
the 10-year follow-up), nine of which had
radiological evidence of loosening. Analysis of
demarcation lines (or the extent and width of
any radiolucent lines) showed the flanged
prostheses in a better light than the unflanged.
No demarcation was seen at the 10-year follow-
up in 43% of flanged hips compared with
30% in the unflanged group. Similarly, 19%
of flanged prostheses had demarcations grades
of 2 or more (indicating radiographic loosening)
compared with 25% in the unflanged group.
(These differences were significant but the





Three papers were selected from others in the
same category on the basis of length of follow-up
and survival analyses. All of the papers making this
comparison were C-rated and so leave doubts about
the validity of the results. In the first two papers
summarised here, Charnley is the superior hip,
with Lubinus and T-28 giving closely comparable
results. However, the third paper suggests the oppo¬
site - there is still an 84% survival rate for the
Charnley at 10 years but this is neither as high as
in other reports nor as high as the Stanmore with
which it is compared (however, as no patient details
were given no comment can be made on any effect
this may have had). Overall, the Charnley prosthe¬
sis gives consistently good mid- to long-term results.
It cannot be concluded with certainty that any of
the other cemented prostheses is consistently
equal to the Charnley.
Ahnfelt and colleagues, I99014
Results from this retrospective study were taken
from a Swedish multicentre registry. The patients
had an approximate median age of 64 years for
women and 66 years for men, with a main diagnosis
of osteoarthritis. In all cases, the hips had been
implanted originally between 1979 and 1986 and
had required revision. Survival without revision
for loosening of the original THR was observed for
various prostheses. The Charnley hips had a 92%
survival at 10 years (n = ?). The observed survival
in eight out of ten other cemented prostheses
for which results were quoted ranged from 63%
(Christiansen) to 89% (Stanmore) at 10 years
and from 95% (Exeter) at 5 years to 93%
(Lubinus) at 9 years. C-rated.
Ritter, I9953'
The Charnley prosthesis (n = 260) was compared
with four other cemented hips: Muller (n = 163),
T-28 (n = 642) and 319 MOSC hips, the latter with
either an all-polyethylene cup or a metal-backed
cup. The average follow-up time ranged from
8.9 to 12.7 years. One surgeon performed all
the operations. In all, 66% of the patients had
PAPER 3
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osteoarthritis and their mean ages ranged from
59 years (Charnley) to 76 years (Muller). Over
200 patients were lost to follow-up. Of the Muller
and MOSC metal-backed, 20% failed within 1 year
of the operation, while only 9% of the MOSC all-
polyethylene failed (compared with 14% Charnley
and 10% T-28) within the same period. An analysis
of survival at 10 years showed the Charnley and
T-28 to be superior: Charnley, 93% (20 years =
76%), and T-28, 93% (17 years = 75%), MOSC
all-polyethylene, 90% (12 years = 87%), Muller,
81% (17 years = 56%), and MOSC metal-backed,
60%. C-rated.
Britton and colleagues, 199632
In this prospective study, 205 Charnley and
982 Stanmore prostheses, implanted or implant
supervised by one surgeon, were compared after
a median follow-up period of 8 years. No patient
details were given. In all, 7% of the hips were
revised, 38/81 because of loosening. When 'revision'
was the end-point, Charnley hips were reported to
have an 84% survival rate at 10 years compared with
93% for Stanmore hips and, when the end-point was
'onset of slight pain', a 44% survival rate at 10 years
compared with 48% for Stanmore. The survivorship
curves were reported to be similar for both pros¬
theses for the first 8 years. Beyond this, Charnley
hips became significantly worse irrespective of the
end-point chosen, that is, need for revision or the
onset of different levels of pain. C-rated.
Charnley versus ceramic
Comment
The number of ceramic hips was too small in this
study to draw conclusions about them or their
performance in relation to the Charnley.
Hoffman and colleagues, 1994"
This retrospective study involved a total of
1166 hips in 974 patients. Six surgeons (grade
not specified) performed the operations in either
a publicly funded hospital (66%) or at a private
clinic (34%). The patients involved had an average
age of 66 years and 89% had a diagnosis of osteo¬
arthritis; there were slightly more males (54%) than
females and 55% of operations were to the right side
of the body. This section of the report refers to only
part of the overall study. The Charnley prostheses
(n = 867) had 72 failures recorded, six caused by
loosening; with an annual failure rate of 1.78%
and a survival rate of 73% at 15 years. The ceramic
prosthesis (Autophor, n = 35) had a failure rate




The numbers involved in this study were too
small and the length of follow-up too short for
any differences between the two prostheses types
to be demonstrated unless one performed
extremely-badly. Further studies are needed
in this area as it is an important comparison
which has been neglected.
Bradley £ Lee, 199234
In this RCT, the Furlong (HA-coated prosthesis,
n = 97) was compared with the Charnley (n = 73).
The patients (with primary osteoarthritis, average
age 68 years, range 45-75 years) were randomly
allocated by year of birth. A total of 139 patients
were reported on at 1-year follow-up and 74 at
2-year follow-up. The results at 1 year and 2 years,
based on the Harris Hip Scores, were very similar
in both groups (no pain: Furlong 98%, Charnley
96%, p = }; number without a limp, walking
distance and use ofwalking aids, ability to
climb stairs and put on shoes/socks, all had
"uniformly good average results"). There




Hybrid prostheses appear to do well in the short
term but the available studies cannot give any
indications for their mid- or long-term results.
Both studies here had a C-rating. The first had
very small numbers and, although a statistical
difference regarding absolute rotation was noted,
it is not clear if this would translate into greater )
problems for the Harris-Galante prosthesis in
later years and so it is difficult to comment on
this result. :
J
Onsten and colleagues, 199435
Charnley stems were implanted in both bilateral
hips under the same anaesthesia in 29 patients
in this RCT. One hip had a Harris-Galante type 1
cup and the other a Charnley cup. At 27 month
follow-up, 21 patients (diagnosis, osteoarthritis;
age range, 41-76 years) were assessed. Five
Charnley and three Harris-Galante prostheses
did not migrate or rotate. Mean values of absolute
migration between the groups in any direction
did not differ (p = 0.06- 0.98) but the mean
values of absolute rotation did (p = 0.08-0.008)
- the Harris-Galante hips rotating the most.
C-rated.
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Callaghan and colleagues, I99536
As part of a larger study, 330 Charnley hips
(follow-up minimum 20 years) and 89 Charnley
hips in patients less than 50 years old (follow-up,
16-22 years) were compared to 130 hybrid hips
(Harris-Galante type 1 cup plus IOWA cemented
stem; follow-up, 5 years) and 61 similar hybrids
used as revisions (follow-up, minimum 5 years).
No patient details were given. In the Charnley
groups the cup revision incidence was 10.6% in
the 20-year follow-up and 13% in the younger
age group; loosening was 12.8% and 37%,
respectively. The stem revision incidences in
the two Charnley groups were 3.2% and 2.2%
for the 20-year follow-up and the young age
group, respectively, while loosening was reported
in 4.3% and 6.1%, respectively This is in contrast
to the hybrid groups where no revisions (or re-
revisions) were reported and only one migration
in the revision group occurred; however, follow-
up was only for 5 years or more. Wear rates were
also assessed in this study, with the Harris-Galante
cups (28 mm head) reported as having less wear




Even at 1-year follow-up, the Charnley showed
better results than the press-fit design. A reduced
probability of survival, higher revision rates caused
by loosening, increased risk of subsidence and
general lack of performance does not inspire con¬
fidence in this type of prosthesis in comparison
to the Charnley.
Wykman and colleagues, 199137
Charnley and Honnart Patel-Garches prostheses
were each inserted into 75 patients during an
RCT; 15 patients in each group had bilateral
arthroplasties (age range, 29-82 years; osteo¬
arthritis, 77%). The two prostheses had a similar
probability of survival at 5-6 years approximately
(Charnley, 88%; Honnart Patel-Garches, 82%;
p, not significant). More revisions were required
in the Honnart Patel-Garches group over 5 years
(18.7%, all for loosening, all but one causing
mid-thigh pain) compared with the Charnley
group (11%, five for loosening, no mid-thigh
pain). A further five in the Honnart Patel-Garches
group had a possible need for revision caused by
mid-thigh pain (increasing the revision rate to
25%). Subsidence ofmore than 4 mm occurred
in 5% (Charnley) and 33% (Honnart Patel-
Garches). C-rated.
Olsson and colleagues, 198S38
A total of 119 patients had either a cemented
(Charnley, n = 61, mean age 67 years) or non-
cemented (Honnart Patel-Garches, n = 59,
mean age 64 years) prosthesis implanted;
82% of patients had osteoarthritis. Clinical evalu¬
ation showed similar preoperative results but the
Charnley prosthesis performed better at the
1-year assessment - Harris Hip Score and Limp,
Charnley versus Honnart Patel-Garches, p < 0.001;
maximal walking speed, Charnley versus Honnart
Patel-Garches, p < 0.05 (twice as many patients
with the Honnart Patel-Garches prosthesis
required a device to assist them). A quantitative
analysis of gait showed the latter group to have
slightly better preoperative results but 1 year
after surgery the Charnley group had greater




In both of the studies summarised below relatively
few porous-coated prostheses were assessed; the
porous hips had only short- to mid-term follow-up
compared with the Charnley hips. It is therefore
very difficult to make conclusive judgements about
relative performance. However, it would appear
that porous hips have good short-term survival
and, if this were to continue in the longer term,
may be comparable to the Charnley.
Callaghan and colleagues, 199536
As part of a larger study, 330 Charnley hips
(minimum follow-up of 20 years) and 89 Charnley
hips in patients under 50 years of age (16-22 years
follow-up) were compared with 100 PCA prostheses
(minimum follow-up of 7 years). No patient details
were given. In the Charnley groups, cup revision
incidence was 10.6% in the 20-year follow-up group
and 13% in the younger age group; loosening
was 12.8% and 37%, respectively. Stem revision
incidences in the two Charnley groups were 3.2%
and 2.2%, respectively, with loosening reported in
4.3% and 6.1%, respectively. The porous-coated
group had a cup revision incidence of 4% and a
migration incidence of 5%, which included two
revised cases. C-rated.
Hoffman and colleagues, I99433
This retrospective study involved a total of
1166 hips in 974 patients. Six surgeons (grade
not specified) performed the operations in either
a publicly-funded hospital (66%) or at a private
clinic (34%). The average age of patients was
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66 years, 89% had a diagnosis of osteoarthritis,
there were slightly more men (54%) than women
and 55% of operations were to the right side of
the body. This section of the report refers to only
a part of the overall study. There were 72 failures
of the Charnley prostheses (n = 867) recorded,
six caused by loosening; with an annual failure
rate of 1.78% and a survival rate of 73% at
15 years. Neither the Harris-Galante (n = 105)
nor the PCA prostheses (n = 38) had any




The results do not encourage the use of resurfacing
hip prostheses.
Ahnfelt and colleagues, I99014
The results of this retrospective study were taken
from a Swedish multicentre registry. The patients'
median age was approximately 64 years for women
and 66 years for men; the main diagnosis was osteo¬
arthritis. In all cases the hips had been implanted
originally between 1979 and 1986 and had required
revision. Survival without revision for loosening of
the original THR was observed for various pros¬
theses. Charnley hips had a 92% survival at 10 years
(n = ?) whereas the Wagner resurfacing hip pros¬
thesis had only 28% survival at 10 years - the worst




There are a great number of cemented prostheses
available and, from the selection of studies below,
it can be seen that results can vary considerably.
There have been many design modifications over
time, some apparently beneficial and others not.
Some modifications, such as in the well-known case
of the Christiansen prosthesis (see, for example,
Ahnfelt et al., 199014), have had disastrous results.
From these studies, prostheses such as Stanmore
and T-28 appear to give good results over mid-term
follow-up as does the Spectron/ITH combination
in the short-term. The Spectron/Biofit and
Lubinus SP hips may prove to have good out¬
comes but the numbers were too small to draw
any conclusions. The Ritter study1" suggests
that cemented all-polyethylene acetabular
components perform better than cemented
metal-backed components.
Ahnfelt and colleagues, I99014
The results of this retrospective study were taken
from a Swedish multicentre registry. The patients'
approximate median age was 64 years for women
and 66 years for men; the main diagnosis was osteo¬
arthritis. In all cases the hips had been implanted
originally between 1979 and 1986 and had required
revision. Survival without revision for loosening of
the original THR was observed for various pros¬
theses. Eight out of ten cemented prostheses had
results quoted for them. The observed survival
ranged from 63% (Christiansen) to 89% (Stan-
more) at 10 years and from 95% (Exeter) at 5 years
to 93% (Lubinus) at 9 years. The Christiansen
prosthesis gave very poor results compared with
the other cemented types. (This 'trunnion-bearing
device' was popular in the late 1970s in Sweden and
in 5 years more than 5000 were implanted. By 1986,
1524 of them had been revised and survival analysis
predicted that 200 more would require revision in
the following 4 years). C-rated.
Ritter, I99531
Four cemented hips were compared - 163 Miiller,
642 T-28, and 319 MOSC hips with either an all-
polyethylene cup or a metal-backed cup. The
average follow-up time ranged from 8.9 years to
10.1 years. One surgeon performed all the oper¬
ations. The mean ages of the patients, 66% of
whom had osteoarthritis, ranged from 62 years
(T-28) to 76 years (Miiller); 13% of patients were
lost to follow-up. Within 1 year of the operation,
20% of both the Miiller and MOSC (metal-
backed cup) failed, while only 9% of the MOSC
(all-polyethylene) and 10% of the T-28 failed
within the same time. Apart from metal-backing,
the larger femoral head size of the Mtiller may
also be implicated. An analysis of survival at
10 years showed the T-28 and MOSC (all-
polyethylene) to be superior to the others: T-28
93% (75% at 17 years), MOSC (all-polyethylene)
90% (87% at 12 years), MQller 81% (56% at
17 years) and MOSC (metal-backed) 60%.
C-rated.
Espehaug et al., 199S39
In a Norwegian multicentre survey, 12,179 hips
were followed-up for a mean of 3.2 years (maxi¬
mum 6.4 years) at various hospitals. Approxi¬
mately 50% of the patients were in the age range
65-74 years (diagnosis was not given). The 5-year
failure rates for the prostheses ranged from 7.33%
for Miiller type hips (n = 116) and 4.96% for
Spectron/Lubinus combinations (n = 302) to
0.85% for Spectron/ITH combination (n = 1034)
and Spectron/Biofit (n = 152); Lubinus SP hips
(n = 129) required no revisions. C-rated.
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There were too few results (all from C-rated
studies with small numbers of patients) to make
convincing statements regarding the relative
benefits of ceramic and cemented. Ceramic
prostheses were originally designed to reduce
wear and one comparative study (Zichner &
Willert, 1992,40 in which the same surgeons
performed all operations) showed this to have
been achieved in the hips assessed, together
with a lower revision rate than for cemented
prostheses. The short-term results compared
with cemented prostheses appear to be worth
investigating further.
Zichner andWillert, 199240
A Miiller-type endoprosthesis was inserted into
354 hips in 313 patients between 1970 and 1980:
149 with a Protasul-2 ball, (average follow-up
66 months); 105 with Protasul-10 ball (average
follow-up 46 months); 100 with a ceramic ball
(average follow-up 73 months). All the prostheses
were implanted at the same clinic by the same
surgeons using the same technique. As a result
of loosening, 10% Protasul-2 and 4.8% Protasul-10
prostheses were revised compared with 2% of the
ceramic types. Displacement rates were also
assessed: 30% of the non-revised Protasul-2 ball
hips had a displacement rate of > 0.2 mm/year,
8% with a displacement rate of > 0.3 mm/year;
20% of the non-revised Protasul-10 ball hips
had a displacement rate of > 0.2 mm/year.
However, 95% of all ceramic ball prostheses
had a displacement rate of < 0.02 mm/year,
with 63% having a displacement rate of
<0.1 mm/year. C-rated.
Schuller andMarti, I99041
Weber type prostheses with metal heads were
inserted in 48 patients at a teaching hospital
and compared with 46 similar prostheses with
ceramic heads inserted at a private clinic. The
mean follow-up was 10 years (range 9-11 years)
for patients with osteoarthritis (age range
48-78 years). In each group, 33 patients were
available for subsequent analysis. Wear for the
metal-head hips was 0.96 mm and for the ceramic
hips 0.26 mm (p< 0.001). Of the cemented hips,
9% were revised because of loosening, 12% were
loose; 6% of the ceramic hips were revised
because of loosening and 9% were loose (p, not
significant). No analysis assessing the possible
influences surrounding the different types of
hospital was undertaken. C-rated.
Hoffman and colleagues, 199433
This retrospective study involved a total of
1166 hips in 974 patients. Six surgeons (grade
not specified) performed the operations either
at a publicly funded hospital (66%) or at a private
clinic (34%). The average age of the patients was
66 years, 89% had a diagnosis of osteoarthritis,
there were slightly more males (54%) than females,
and 55% of operations were to the right side of the
body. This section of the report is only part of the
overall study. Four types of cemented prostheses
were mentioned in the study but survival inform¬
ation was only given for one: Miiller (n = 92) -
26 failed (23 were loose), annual failure rate was
6.93%, and 11-year survival rate 63%. However,
this result is confounded by the poor results of
one surgeon. The ceramic prosthesis, Autophor
(n = 35), had a failure rate of 15% in 3 years





The follow-up period for both these C-rated
studies is very short; hence, the results should be
treated cautiously. The second study used specially-
designed prostheses.12 The authors of both studies
suggested that HA-coated models had more stable
early fixation than cemented models. No difference
in early pain scores can be substantiated. Freeman
and Plante-Bordeneuve12 suggest that there is an
association between pain and the extent of early
migration on radiological assessment, and that HA-
coated components perform better in this respect,
at least in the early postoperative period. This may
be in contrast to the comparison of Charnley with
HA-coated designs (see page 22) in which no
differences were demonstrated. Longer-term
assessments involving greater numbers of
patients are required.
Karrholm and colleagues, I99442
A computer program was used to randomly allocate
the 64 patients (age range 58-66 years) in this RCT.
The patients were stratified by various character¬
istics. The hips had the Ti-Fit femoral component
inserted with a press-fit acetabular component by
one of four surgeons at one of two hospitals. The
femoral stems were inserted with cither cement
(n = 20) or an HA-coating (n = 23). After 2 years
the cemented stems had subsided more than the
HA-coated stems (p = 0.002). The HA-coated
components also rotated less compared with the
cemented stems (p = 0.03). The Harris Hip and
PAPER 3
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Pain Scores did not differ significantly between the
groups, although the small sample sizes make this
result tentative. There were no revisions within the
2 years of the study. C-rated.
Freeman and Plante-Bordeneuve, I994'2
The prosthesis in this study was specially
designed to allow measurement of vertical
migration. The THRs were either cemented
(55 hips in 54 patients, 91% with osteoarthritis,
69% female, age range 57-83 years) or HA-coated
(34 hips in 34 patients, 88% with osteoarthritis,
41 % female, age range 33-76 years). The amount
ofmigration was assessed at 2 years: cemented
hips (n = 55) had a mean of 0.55 mm, while those
hips with no pain (n = 52) had migrated 0.38 mm
on average; all HA-coated hips (n = 34) had
migrated on average 0.4 mm, the same as those
hips with no pain (n = 34). At a minimum follow-
up of 5 years, 7.9% of the cemented prostheses
were loose. At 4-year follow-up no HA-coated





As with the Charnley versus hybrid comparisons,
hybrid prostheses appear to survive in the following
studies as well as, if not slighdy better than, cement¬
ed hips in the short term but it is not yet possible to
comment on longer follow-up results. There may
be the potential for hybrid prostheses to equal or
improve on the results of cemented hips such as
those reported here. As both of these studies were
C-rated, higher quality studies are also required
of this type of comparison.
Wixson and colleagues, 199143
A total of 197 hips were implanted into 176 patients
by two surgeons and, after a mean follow-up period
of 2.8 years (maximum 4 years) 144 hips were
available for analysis. The mean age of patients,
60% ofwhom were female, was 61 years; 65% had
osteoarthritis and 15% rheumatoid arthritis. Vari¬
ous types of cemented stems were used along with
either cemented cups (PCA, TiBac, Harris) or
porous-coated (PCA, Harris-Galante, APR). The
various combinations were categorised as cemented
or hybrid as appropriate. Two cemented hips
(3.8%) were revised because of loosening while one
hybrid (3.7%) was revised (but not for loosening).
Of the cemented cups, 12% had migrated or
changed position compared with 3% of porous
cups (p = ?). C-rated.
Callaghan and colleagues, 199536
As part of a larger study, IOWA prostheses, using
second generation cementing techniques (n = 187,
minimum follow-up 10 years), were compared
with 130 hybrid hips (Harris-Galante type 1 cup +
IOWA cemented stem, 5-year follow-up) and 61
similar hybrids were used as revisions (minimum
follow-up 5 years). No patient_details were given.
In the cemented group, cup loosening occurred
in 24.5% of patients (metal-backed 17%, all-
polyethylene 30%) and stem loosening in 1.2%.
This is in contrast to the hybrid groups where no
revisions (or re-revisions) were reported and only
one migration in the revision group occurred;
however, the follow-up period was only 5 years
or more compared to 10 years or more for the
cemented group. Wear rates were also assessed in
this study with the Harris-Galante cups (28 mm
head) having less wear than the other groups but,




The fact that neither clear results nor patient
details were given for the Osteonics/DuPuy model
in the study below makes commenting on it diffi¬
cult. The cemented hips gave fairly typical results
for this type of prosthesis and appear to be superior
to the modular forms but a better evaluation
is required.
Chmell and colleagues, 199544
Three surgeons performed all the operations in
this study. No details are given about the patients
involved. Three cemented prostheses were used:
Aufranc-Turner (n = 778); T-28 (n = 823) and
Osteonics non-modular stem with cemented cup
(n = 329); these were compared with three modular
prostheses (as specified by the authors): Osteonics
modular stem and cemented cup (n = 233);
DePuy Profile modular stem with ACS modular
cup (n = 203) and Osteonics modular stem with
either Osteonics or DePuy Duraloc modular cup
(n = ?). The percentages needing revision for
loosening in the cemented groups ranged from
2.1 % of the Osteonics hips after an average
follow-up of 7.5 years to 22% of the Aufranc-
Turner hips after an average follow-up of 12 years,
the majority of these being after the first 6 years.
In the modular group, 3% of the Osteonics
modular stem (with the same cemented cup
as before) were revised within 6 years and 12%
needed revision in the DePuy Profile/ACS hip
because of linear wear or fracture (all but two of
Health Technology Assessment 1998; Vol. 2: No. 6
the 15 had a polyethylene thickness of less than
6 mm). No details were given for the Osteonics/
DePuy hip, except that they "have not been asso¬
ciated with the catastrophic failure rate seen in




The results from the three studies selected
below are conflicting. Two (one of them A-rated)
showed more problems with the press-fit than with
the cemented hips. However, in the remaining
study,43,46 although the press-fit stem showed
evidence of subsidence it was the cemented cups
which were deemed to be loose, although this was
at only 4-year follow-up. Overall, cemented types of
prosthesis would appear to be superior to press-fit.
Godsiff and colleagues, 199225 .
This RCT compared 30 cemented with 28 un-
cemented femoral components (Ring prosthesis)
in patients, age range 55-74 years, with osteoarth¬
ritis of the hip. Both patients and the non-
orthopaedic clinical assessor were blinded and
surgery was by one of two surgeons. At 2 years
both groups (n = 47) reported similar pain
incidence, the press-fit group having had more
pain at 4 and 12 months. By 2 years, 96% (cement¬
ed) and 62% (uncemented) of patients did not
require walking aids (p= 0.01-0.05). Preliminary
results indicated cemented to be superior to press-
fit; however, because of unacceptable levels of
femoral breakages at 3-5 years, the authors with¬
drew the Ring prosthesis. These failures may have
been due in part to design and manufacturing
factors, as reported in a Safety Notice issued by the
Department of Health Medical Devices Agency
(MDA SN 9520) in August 1995. The design has
subsequently been modified. A-rated.
Bourne and colleagues, 199S;45 Rorabeck and
colleagues, I99646
All patients in this RCT were operated on or
supervised by two senior surgeons using the
Mallory Head prosthesis, either cemented or
press-fit. A total of 250 patients were originally
recruited from a group with an age range of
18-75 years and were stratified by age and surgeon.
Diagnosis was osteoarthritis of the hip. Clinical
results had a 5-year follow-up period (n = ?) and
radiographic analysis a 4-year follow-up (n = 147).
Patients and clinical observers were blinded. All
clinical assessments (e.g., Harris Hip Score,
d'Aubigne Score and Sickness Impact Profile,
among others) were almost identical for each
group both pre- and postoperatively. There
was no subsidence in the cemented stems but
14% of press-fit stems subsided by 3-5 mm.
No revisions were required within 4 years and
no press-fit components or cemented stems
were loose; however, 26% of the cemented
cups were described as definitely or probably
loose. C-rated.
Krismer and colleagues, 199141
Uncoated RM cups were paired with Muller
stems to form the press-fit hip and 160 from
173 (mean age of patients 57 years, average
follow-up 5.3 years) were assessed and compared
with 263 from 309 Muller prostheses (mean age
of patients 63 years, average follow-up 6.1 years).
The diagnosis in 75% of patients was primary
coxarthrosis. None of the cemented prostheses
migrated during the study period but 25% of the
press-fit migrated between 2.1 and 16 mm. After
7-8 years, 12% of the press-fit hips had been
revised and 40% were loose compared with





Ten comparisons of these types of prosthesis have
been reviewed overall. In only one of the three
papers selected below was an attempt made to
compare the two types of prosthesis at the same
time after surgery. In one study with medium-term
follow-up and a fair sample size, Callaghan and
colleagues36 suggested that the cemented acetabu¬
lar component performed better than the porous-
coated but that the porous-coated stem was better
than the cemented. As with the Charnley compari¬
sons, porous-coated types appear to have good
short-term survival results which need to be
followed further.
Callaghan and colleagues, I99S36
As part of a larger study, IOWA prostheses, using
second generation cementing techniques (n = 187,
minimum follow-up period 10 years) were com¬
pared with 100 PCA prostheses (minimum follow-
up 7 years). No patient details were given. In the
cemented group, cup loosening occurred in 24.5%
of patients (metal-backed 17%, all polyethylene
30%) and stem loosening in 1.2%. The PCA
prostheses had a cup revision incidence of 4%
and a migration incidence of 5%, which included
two revisions. C-rated.
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Hoffman and colleagues, 199433
This retrospective study involved a total of
1166 hips in 974 patients. Six surgeons (grade
not specified) performed the operations at either
a publicly funded hospital (66%) or a private clinic
(34%). The average age of patients, ofwhom 89%
had a diagnosis of osteoarthritis, was 66 years;
there were slightly more males (54%) than females,
and 55% of operations were to the right side of
the body. This section of the report forms only a
part of the overall study. Four types of cemented
prostheses are mentioned in the study but survival
information is only given for one: Muller (n = 92) -
26 failed (23 were loose), the annual failure rate
was 6.93%, and the 11-year survival rate 63%.
However, this result is confounded by the poor
results of one surgeon. Neither the Harris-Galante
(n = 105) nor the PGA. (n = 38) prostheses had
any revisions in approximately 3-4 years of
follow-up. C-rated.
Hearn and colleagues, 199543
A total of 36 consecutive patients underwent
primary cemented THR (Charnley, Dual Lock
or Pennsylvania Total Hip) followed by primary
porous-coated THR (Trilock or Taperloc) of the
contralateral hip (total number of hips, 72). Of
these, 60 were assessed after 8.1 years (cemented
hip) and 3.0 years (porous hip) ('same interval'
data for the cemented hips were also compared
with the porous data at 3.6 years). The patients'
age range was 21-82 years, 92% had diagnoses
of osteoarthritis and 8% of rheumatoid arthritis.
Preoperative pain levels differed (cemented
3.1, porous 2.5, p= 0.002), as did the range of
movement measurements at the same interval of
follow-up (cemented 5.1, porous 5.6, p = 0.002).
There was no migration or subsidence, and there
were no revisions. One cemented stem was





All three papers summarised below report
resurfacing prostheses to be inferior to. all of the
cemented hips with which they were compared.
Thus resurfacing prostheses cannot be recom¬
mended as an alternative to cemented THRs.
Reigstad and colleagues, 1986'"
A total of 155 Muller and 149 ICLH prostheses
were implanted into 231 patients (age range
60-79 years) by 13 surgeons. All patients were
diagnosed with osteoarthritis of the hip and had
a mean follow-up of 48.5 months. No Muller hips
were revised compared with 8.7% ICLH (p< 0.001)
and, in addition, one component (0.6%) was
loose compared with 12 (8%), respectively. Post¬
operatively the Muller group had consistently
higher scores than the ICLH group on all three
modified Merle d'Aubigne and Postel parameters
and total hip function. The level of significance
reached by 1 year in 3/4 parameters was
p< 0.001. C-rated.
Ritter and Gioe, 1986s"
Bilateral hips in 50 patients were replaced with
one cemented T-28 prosthesis and one Indiana
conservative resurfacing hip using the same
anaesthetic; 45 (90%) of these patients were
followed-up for a minimum of 5 years. The mean
age of the patients was 62 years (range 21-87 years)
and 79% were diagnosed with osteoarthritis.
There was no difference in the level of pain in
the non-revised hips, as recorded by the Hospital
for Special Surgery Rating System. Two (4.4%)
cemented hips were revised (none were loose)
and 15 (33%) resurfacing hips were revised
(these patients were younger, average age
55 years). C-rated.
Ahnfelt and colleagues, I990'4
Results from this retrospective study were taken
from a Swedish multicentre registiy. The patients
had an approximate median age of 64 years for
women and 66 years for men, and a main diagnosis
of osteoarthritis. In all cases the hips had originally
been implanted between 1979 and 1986 and had
required revision. Survival without revision for
loosening of the original THR was observed for
various prostheses. Eight out of ten cemented
prostheses had results quoted for them. The
observed survival ranged from 63% (Christiansen)
to 89% (Stanmore) at 10 years and from 95%
(Exeter) at 5 years to 93% (Lubinus) at 9 years.
This is in comparison to the Wagner resurfacing
hip prosthesis which had only 28% survival at




No statistical analysis was performed on the revision
figures in the paper below but, given the difference
in follow-up time, the results may be roughly equal,
suggesting no difference at short-term follow-up
between the cemented and cementless methods
of fixation of ceramic hips.
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Riska, 1993s 1
The Ceraver Osteal aluminia on aluminia
prosthesis was implanted with either a cemented
ceramic cup (n = 143, mean follow-up period
6.7 years) or an uncemented ceramic cup (n = 112,
mean follow-up period 3.6 years). One surgeon
performed the operations on the patient group
who had a mean age of 62 years and 73% of
whom had a diagnosis of osteoarthritis. Prostheses
with the cemented cup had 16 revisions (11.2%)
and 14 were loose. Seven revisions (6.3%) were




Very small numbers of ceramic prostheses were
included in the only study permitting comparison
of these two types. Strong conclusions cannot be
drawn, although the results suggest that ceramic
prostheses are unlikely to be superior to porous-
coated over the short term.
Hoffman and colleagues, 199433
Study details are given above (page 23). The
ceramic prosthesis (Autophor, n = 35) had a failure
rate of 15% in 3 years, giving an approximate
annual rate of 5%. Two different porous-coated
THRs were included in the study: Harris-Galante
(n = 105) and PCA (n = 38). Both had a follow-up
period of roughly 3-4 years (compared with
approximately 6 years for the ceramic prosthesis)




From the two studies selected from the five
available, HA-coated prostheses appear to be more
stable than press-fit in the (very) short term, being
associated with less migration/subsidence and pain
and possibly with greater mid-term survival.
Huracek and Spirig, 199452
Forty pairs of patients were retrospectively
matched for various aspects from 127 possible
cases. One surgeon inserted all the hips either with
an HA coating or without (press-lit). All patients
had primary osteoarthritis, their average age was
71 years and average length of follow-up was
4.1 years. The occurrence of pain was assessed:
59.3% ofHA hips had no pain compared with
only 22.5% of press-fit hips (p< 0.0016). No
HA-coated cups showed signs of migration and
7.5% of HA-coated stems subsided. In the press-fit
hips, 32.5% of cups migrated by 5 mm or more and
30% of stems subsided. There were no revisions or
loose components in either group. C-rated.
Moilanen and colleagues, 1996s3
The SLF cup (together with a Freeman cemented
or uncemented stem) was inserted either with
an HA-coat or without (press-fit). The mean age
of the patients given an HA-coated cup was
59.7 years (74% with osteoarthritis, 2.3 years
follow-up) while those with press-fit cups had a
mean age of 62.6 years (95% with osteoarthritis,
3.4 years follow-up). There was no difference in
mean migration rate between the two groups but
the press-fit group had more radiolucent lines
associated with them (27%) than did the HA-
coated group (6%, p < 0.05). Two revisions were
required in the HA-coated hips within 7 months
of the operation, neither being caused by loosen¬




Both of these studies have only a short follow-up
period. The porous-coated hips seemed to have
more subsidence and did not initially fix as well
as the HA-coated hips. How this would affect the
longer term clinical and survival outcomes is
unclear at the present time. One study suggests
there are no differences in hip scores, including
pain, between the two types in the early post¬
operative period. This is echoed by one obser¬
vational study.54 Further investigation of the
two types of coating is required.
Karrholm and colleagues, I99442
A computer program was used to randomly
allocate the 64 patients (aged 58-66 years) in
this RCT. The patients were stratified by various
characteristics. The hips had the Ti-Fit femoral
component inserted with a press-fit acetabular
component by one of four surgeons in one of two
hospitals. The femoral stems were inserted with
either an HA-coating (n = 23) or were porous-
coated (n = 21). After 2 years the porous-coated
stems had subsided more than the HA-coated
(p= 0.02). The Harris Hip and Pain Scores did
not differ significantly between the groups. Pain
or discomfort in the thigh was reported (HA-
coated, n = 5; porous-coated, n = 8; p = ?).
There were no revisions within the 2-year
period. C-rated.
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McPherson and colleagues, 1995s5
HA-coating was added to a prosthesis, this time
an APR-I hip, to perform this study. Data were
collected prospectively but the study groups
were selected retrospectively. From 2B0 patients,
42 pairs were matched, giving an average age of
approximately 56 years (the diagnosis of the
patients is not given but was used during the
matching process). Using a modification of the
DeLee-Charnley Fixation Score, the authors
suggest that fixation was better in the HA-coated
hips (p = 0.002) after a minimum follow-up
period of 3 years - porous-coated hips: 62%
Grade IA, 33% Grade IB; HA-coated hips: 93%
Grade IA, 7% Grade IB. The mechanical failure
rate for both groups was 5% - one revised HA-
coated hip and one HA-coated and two porous-
coated hips loose. C-rated.
Hybrid versus porous-coated
Comment
All three papers found hybrid prostheses to be
superior to porous-coated over the short term,
especially as regards the stem component. The
studies reported thigh pain to be more closely
associated with the porous-coated hips as were
movement and the need for revision.
Wixson and colleagues, 199143
Originally 197 hips were implanted into
176 patients by two surgeons, and 144 hips were
available for analysis after a mean follow-up time
of 2.8 years (maximum 4 years). The mean age
of the patients, 60% of whom were female, was
61 years; 65% were diagnosed with osteoarthritis,
15% with rheumatoid arthritis. Various types of
porous-coated cups (PCA, Harris-Galante, APR)
were used together with either cemented stems
(PCA, SixTi/28, ATS, Harris Design 2 and CHD)
or porous stems (PCA). The various combinations
were categorised into hybrid or porous, as appro¬
priate. Thigh pain was recorded at 3 years:
cemented stem 3%, porous stem 13%; p < 0.05.
There was no subsidence of the cemented stems
while 5% of the uncemented ones changed
position (as did 3% of the cups). More revisions
occurred in the porous hips (7.7%, 4/5 loose)
than the hybrid (3.7%, none loose). C-rated.
Goetz and colleagues, 1994s6
One surgeon performed 255 operations on
patients with an age range of 40-71 years,
95% ofwhom had a diagnosis of osteoarthritis.
Retrospectively 82 hips (in 74 patients) were
matched and compared, with an approximate
6-year follow-up period. All had a Harris-Galante
cup with either a Harris-Galante stem or a Harris
Precoat (cemented) stem. Osteolysis was assessed
in both groups: 29% of the porous hips showed
osteolysis (five were loose) while the hybrid hips
showed none (p< 0.0002; there was no relationship
between femoral head size and osteolysis). A total
of 12% of porous stems were revised (4/5 were
loose, eight had subsided or migrated). None
of the hybrid hips required revision (p< 0.02),
all were stable with no radiolucent lines. None
of the cups in either group had migrated or
been revised. C-rated.
Moloney and Harris, 199057
Precoated cemented stems and Harris-Galante cups
were compared to Harris-Galante prostheses in a
retrospectively matched study of 25 pairs of hips
(selected from a group of 136 hips). One surgeon
performed the operations and follow-up was for
2.5-3 years. The patients' age range was 54-69 years
(average 61-62 years) and 96% had osteoarthritis.
Postoperative Harris Hip Scores differed between
the groups (hybrid 96, porous-coated 84; p< 0.02)
as did thigh pain (hybrid 0, porous-coated 20%;
p = ?). Migration had occurred in 20% of the
porous group stems, but not the hybrid stems
(there were no radiolucent lines or migration
associated with the cups of either group). Of the
porous group, 16% required revision, 3/4 due




Comments on this one study are difficult to make
as not all the data are given for the different pros¬
theses, nor are any patient details given. The only
possible comment is that the hip which combined
a modular stem with a cemented cup (classed as
a 'modular' type by the authors) faired better than
the fully modular prosthesis on which data
were given.
Chmell and colleagues, 199544
Three surgeons performed all the operations in
this study. No details are given about the patients.
Three modular prostheses were used as a part of
this study: Osteonics modular stem and cemented
cup (n = 233); DePuy Profile modular stem with
ACS modular cup (n = 203) and Osteonics modular
stem with either Osteonics or DePuy Duraloc
modular cup (n = ?). Of the Osteonics modular
stem, 3% were revised within 6 years and the
DePuy Profile/ACS hip needed revision in 12%
ir» O T ^
caused by liner wear or fracture (all but two
of the 15 had a polyethylene thickness of less
than 6 mm). No details were given about the
Osteonics/DePuy hip, except that they "have
not been associated with the catastrophic failure
rate seen in the ACS cups". C-rated.
Press-fit versus press-fit
Comment
Both studies were C-rated and only one had the
basic minimum numbers of patients (see page 14).
It would appear that the material from which the
prostheses are made might influence the results.
Further work is needed to assess this more fully
but, given the poor results of the press-fit types
compared with other prostheses, this is probably
not worthwhile.
Schreiber and colleagues, 19932°
The Balgrist prosthesis was used in this study
with either an outer split ring of high-density
polyethylene (61 patients had a thin (6 pm)
coating of titanium on the outer surface) or of
titanium alloy. The study was retrospective. The
patients' age range was 23-76 years (average
approximately 55 years) but diagnosis and the
number of surgeons involved is unknown. From
717 hips, 606 were assessed after 4.5 years
(polyethylene) or 1.3years (titanium). During
the follow-up to this study, 13% of primary and
21% of revised polyethylene types were revised,
as were 0.7% primary and 5% revised titanium
alloy types (p = ?). C-rated.
Nashed and colleagues, 1995s8
This is included as part of a larger study in which
cemented prostheses were compared with the two
press-fit prostheses mentioned here. The retro¬
spective study involved one surgeon; the patients
had an approximate mean age of 50-51 years, with
diagnoses of osteoarthritis and rheumatoid arthritis
in 53% and 16%, respectively. The press-fit hips
were both BIAS prostheses with a metal-backed
cup, one with a titanium head (n = 15) and the
other with a cobalt-chrome head (n = 74). The
follow-up period was approximately 6 years.
Osteolysis occurred in 87% of the hips with
titanium-heads (87% stem, 40% cup) and in 24%
with cobalt-chrome heads (22% stem, 14% cup).
The incidence of osteolysis was statistically higher
in the titanium group than in any other group
(including the cemented hips). Hips with osteolysis
were found to be more likely to require revision
than those without osteolysis in the overall study
(p < 0.001). C-rated.
Press-fit versus porous-coated
Comment
In the one study in which this comparison was
included, the porous cup performed better than
the press-fit cup. This would appear to be consist¬
ent with other studies comparing either porous or
press-fit to other types where press-fit designs are
uniformly inferior to other types of prosthesis.
Pupparo and Engh, 1989s'
In this prospective study, AML stems were
combined with either an S-ROM Anderson cup
(smooth-threaded) or an S-ROM Super cup
(porous-threaded). One surgeon, of unknown
grade, performed the operations. The ages of the
patients were not stated but 86% of them had a
diagnosis of osteoarthritis. Approximately 67% of
the hips originally recruited were available for
follow-up assessment at 2-3 years. Of the hips with
an Anderson cup, 29% were classed as unstable anc
nine had migrated by a mean of 5.5 mm, whereas
the hips with a Super cup showed no migration anc
were all classed as stable (p< 0.001). No Super cup
hips were revised but six of the Anderson cups




The three prostheses used in the study summarised
below gave similar results over the short term. How¬
ever, the number of patients was small and the ratio
of disease types unusual compared with the vast
majority of comparative studies used in this report.
This being the case, further work is required involv¬
ing larger numbers to gauge if this is a true result oi
if the different prostheses do differ in any way.
Hwang and Park, I99S60
Three types of porous-coated prosthesis are
compared in this prospective study: AML (n = 90,
mean follow-up period 5.2 years); PCA (n = 117,
mean follow-up period 4.7 years); Harris-Galante
(n = 63, mean follow-up period 3.8 years). The age
range of the patients was 20-86 years (approximati
mean 48 years). The diagnosis for this group of
patients was very different from most other studies
as the main diagnosis was of avascular necrosis
(66%) with osteoarthritis in 18%. One surgeon
was involved in replacing the hips. Approximately
19% of each group had thigh pain. Stem subsi¬
dence ranged from 0-8 mm, with an approximate
average of 2.1 mm, and was similar for all groups,
as was the number with subsidence of 3 mm or
PAPER 3
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more (AML 10%, PCA 13.7%, Harris-Galante
12.7%). Cup migration did not differ between
the groups (all approximately 4.1% 0 and no
revisions were reported. C-rated.
Porous-coated versus resurfacing
Comment
The study summarised here concentrates on
heterotopic bone formation and not on the usual
outcome measures. Although this study (with few
patients and a higher number of padents with
avascular necrosis than most studies) showed no
difference between the two types of prosthesis,
resurfacing replacements are not recommended
for the usual indications for THR, because of the
results shown in the comparisons above.
Duck and Mylod, I99261
The original population from which the study
group was taken was not stated but the study con¬
centrated on 66 hips in 55 patients with a range of
diagnoses, such as 34.5% osteoarthritis and 36.4%
avascular necrosis. The average age of the group
was 60 years (range 33-76 years). As part of a
larger, retrospective study, AML porous-coated hips
were compared to resurfacing prostheses (TARA
and Indiana Conservative hip) 3 years after the
operation (number of surgeons performing surgery
unknown). The study concentrated on the occur¬
rence of heterotopic bone formation: 59% of the
uncemented total hips had heterotopic as did 56%
of the resurfacing hips. The authors concluded that
there was "no significant correlation between the
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Results of selected observational studies
The summaries presented in this chapter shouldbe read in conjunction with the more detailed
data tables for each type of prosthesis in the
appendix to this report. The best available studies
of each prosthesis type have been selected for
inclusion here, as indicated.
Cemented designs
Charnley
The studies summarised in Table 18 fulfill the
following criteria:
• A or B-rated by the reviewers
• cohort size of > 200 hips followed-up
• survival or revision rate data presented.
Non-Charnley cemented designs
The studies presented in Table 79fulfil the same
criteria as the Charnley studies presented in
Table 18.
Comment
As a group, these selected studies of cemented
prostheses show that rates of early survival (up to
10 years) are generally very good for most models;
TABLE 18 Selected studies of the Charnley cemented prosthesis
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mean 60 87% survivorship at 10-12 years (revision rate 8%)
mean 62 Re-operation 2.2% (+1.2% pending)




Revision rate for aseptic loosening: stem 0.0%, cup 0.7%





Stem revision rate for aseptic loosening: 3% at 10 years, 14% at
20 years; cup revision rate: 4.5% at 10 years, 16% at 20 years
(osteoarthritis risk revision 20% at 10 years, 49% at 20 years)
Stem revision rate 1.2% (4.9% failure); cup revision rate
7.4% (17% failure)
Revision rate for aseptic loosening I I % at 15 years
(stem 2%, cup 10%)
median 62 Probability of revision 10.7% at 20 years
mean 68 Revision rate 6%; 89% survivorship at 20 years
mean 66 92% survivorship at 13 years (7% revised)
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revision rates at a minimum of 10 years in age
groups from mid-50s to mid-60s range from about
2% to about 13%. Revision rates in the one series
of young patients (byjoshi and colleagues)67 are
moderate for such a group of young pauents with
a diagnosis of osteoarthrius. Given the unknown
part played by potenually confounding factors,
comparisons between prostheses on the basis of
these observauonal studies can be made only tenta¬
tively and by treating the reported survival rates as
estimates requiring wide confidence intervals.
Taking this into account, the Howse, Exeter and
Lubinus models appear to bear comparison with the
Charnley atmedium term (10-15 years) follow-up.
Uncemented designs
Porous-coated
Only four of the reviewed studies of cementless
porous-coated technology fulfil the same criteria as
the 17 studies of cemented prostheses summarised
in Tables 18 and 19. Three of these are by the same
group of authors, Engh and colleagues,8M2 and
present results for the same component, the AML
straight stem. The results from the most recent of
these studies82 are summarised in Table 20 together
with those from the A-rated study by Owen and
colleagues,85 in which more than 200 hips were
followed up, and from the only other study with
10-year results (Sotereanos et al, 1995).84
The study by Owen and colleagues83 records
a steep decline in survival of cups between years 6
and 9, especially in younger patients, which is
attributed to severe polyethylene wear caused by
the use of the large (32 mm) stem head size. Engh
and colleagues' results82 are good for medium-term
follow-up, especially when the relatively young
mean age of the study group is taken into account.
With the exception of these two studies and that by
Holman and Tyer,85 the numbers of hips followed
up with porous-coated prostheses are very modest,
with the majority being about 100 and many being
fewer than this.
The results at 10 years appear to bear comparison
with the cemented models for the same follow-up
period, especially when account is taken of the
relatively lower average age of the patient groups
implanted with porous-coated models compared
with those receiving cemented models.
The AML and PCA models are those for which
results have been most frequently published
(of the reviewed observational studies: PGA,
13 studies; AML, 8; Harris-Galante, 6). Sotereanos
and colleagues' results for the AML stem are
exceptionally good.84
Thigh pain is an issue for porous-coated implants.
In the studies reviewed, reports of its prevalence
range from about 2% to about 25% at 2-7 years'
follow-up. Several studies report prevalences of
about 25%, including in non-loose stems.
The amount of porous-coating on stem
components is an issue. The majority of
34
TABLE 19 Selected studies of cemented non-Charnley prostheses
| Study Prosthesis Number Age
type of hips (years)
(follow-up
period, years)
ji August, et al., 198674
Bryant, et al., 199175
Fowler, et al., I98876
Ohlin & Onsten, 199077 Lubinus
Partio, et al., 199478 Lubinus
McKee-Farrar 230 mean 60
(10-22)




91 % survivorship (revision) at 10 years, 84% at
15 years, 27.5% at 20 years
60% survivorship (revision)








Howse 265 mean 63
(10-15)
Revision rate 3% for aseptic loosening
Revision rate 11.5%; 87% survivorship at 10 years
90% survivorship (revision) at 10 years, 80.8%
at 15 years
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AML stem 223 mean 55
(minimum 10)
Results
85% stem survivorship at 12 years
| Owen, et al., 199483 PCA 241 mean 47 57% survivorship at 7 years (including
1 (2-9; mean 5) recommendation for revision)
| Sotereanos, et al., 199584 BIAS and 121 and 166 mean BIAS: revision rate 4.1 % at 10 years; survivorship
1 AML stems (10 and 8) 53-54 95.4% at 11 years; AML: revision rate 0.6%;
1 survivorship 99.3% at 9 years
porous-coated implants, where the information
was given, had the coating on the proximal part
of the stem plus the cup. In a comparative study
on animal models86 (not appraised in this review),
it is suggested that total circumferential coating is
associated with more bone loss than partial coating.
HA-coated
Three studies met the criteria of being A- or B-
rated, including more than 200 hips and having
survivorship results reported.54 87'88 These are
summarised in Table 21 together with the two
studies with the longest follow-up.89,90
Of the nine HA-coated studies summarised in the
appendix, five report on the American Osteonics
Omnifit components, thought to be the most
widely used HA-coated model internationally.91
It is clear that the numbers of patients/hips and
lengths of follow-up periods are insufficient to draw
even tentative conclusions about the performance
of this technology on the basis of survival data. The
evidence for early postoperative pain associated
with this type of technology suggests mild to moder¬
ate thigh pain in between 0% and about 5% of
patients at 2-5 years' follow-up. This is a relatively
good result in comparison to the results for
porous-coated implants.
Uncoated press-fit
Only one study in this category is A- or B-rated,
follows-up more than 200 hips and presents survival
results.92 This study of Mathys 'isoelastic' cups re¬
ports a high level of revision for aseptic loosening,
mostly occurring after at least 8 years of implant¬
ation. The component was abandoned. Two of the
other studies reviewed reported on the Mathys RM
isoelastic components.93,94 The first93 also showed
relatively poor results for the uncoated cup
(although the ages of patients were not reported)
TABLE 21 Selected studies of uncemented HA-coated prostheses
Study
Tonino, et al., 199587
iji
I Koch, et al., I99388
s
d'Antonio, et al. 1992"'
I Capello, 199489
j
| Geesink & Hoefnagels,
I 1995'°
Prosthesis Number Age






















(5.6-7.6) (31 <50 years)
No revisions
Revision rate (pain/aseptic loosening) 3.3%
100% stem survivorship, 99% cup
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Engh, et al., 199782 AML stem 223
(minimum 10)
mean 55 85% stem survivorship at 12 years
— i
1
Owen, et al., 199483 PCA 241
(2-9; mean 5)
mean 47 57% survivorship at 7 years (including
recommendation for revision)






BIAS: revision rate 4.1 % at 10 years; survivorship
95.4% at 1 1 years; AML: revision rate 0.6%;
survivorship 99.3% at 9 years
Dorous-coated implants, where the information
vas given, had the coating on the proximal part
of the stem plus the cup. In a comparative study
on animal models86 (not appraised in this review),
it is suggested that total circumferendal coating is
associated with more bone loss than partial coating.
HA-coated
Three studies met the criteria of being A- or B-
rated, including more than 200 hips and having
survivorship results reported.54,87'88 These are
summarised in Table 21 together with the two
studies with the longest follow-up.89,90
Of the nine HA-coated studies summarised in the
appendix, five report on the American Osteonics
Omnifit components, thought to be the most
widely used HA-coated model internationally.91
It is clear that the numbers of patients/hips and
lengths of follow-up periods are insufficient to draw
even tentative conclusions about the performance
of this technology on the basis of survival data. The
evidence for early postoperative pain associated
with this type of technology suggests mild to moder¬
ate thigh pain in between 0% and about 5% of
patients at 2-5 years' follow-up. This is a relatively
good result in comparison to the results for
porous-coated implants.
Uncoated press-fit
Only one study in this category is A- or B-rated,
follows-up more than 200 hips and presents survival
results.92 This study ofMathys 'isoelastic' cups re¬
ports a high level of revision for aseptic loosening,
mostly occurring after at least 8 years of implant¬
ation. The component was abandoned. Two of the
other studies reviewed reported on the Mathys RM
isoelastic components,93,94 The first93 also showed
relatively poor results for the uncoated cup
(although the ages of patients were not reported)
TABLE 21 Selected studies of uncemented HA<oated prostheses
::xwx-x-x»x-x-x-x*x'x-x'x-xx-x-x,x'x-x-x«xx-x-x-x-x-xw-x-x*x-x-x,x-x<«'x-x'x^x'x-x-x
Study
Tonino, et al., 199S87
Prosthesis Number Age
type of hips (years)
(follow-up
period, years)




I Koch, et al., 199 3 88 Furlong 190 ?
(2-5, mean 2.9)
I d'Antonio, et al., 199254 Omnifit
s
I Capello, 1994 89 Omnifit
stem only
|prrinn.orrinvrriirrrnnrnnir|lirori1101.-prinil nr-nrn.
| Geesink & Hoefnagels, Omnifit 100/118 mean 53
j 199S90
•Xx*x-:oxwXvXx*X9-xxxxxx-x-x<x-:XvX-x-xx-x-x:-xo:.x-:-x<-x-xx-XvX-x:,xxx-x-:«ox-x-x-XvX-
320 mean 50 No revisions
(minimum 2)
V % / ■.
Results
Revision rate (mechanical) 1.4%
§No revision or loosening
151 mean 50 Revision rate (pain/aseptic loosening) 3.3%
(5)
•xx-xx-x-x-x-x-x-x-:-xv:
(5.6-7.6) (31 < 50 years)
100% stem survivorship, 99% cup
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at 9 years, and the second94 recorded relatively poor
clinical and survival results for the RM stern in small
numbers of patients followed-up for 7-9 years).
Other studies of uncoated press-fit cups, mostly
with peg or screw-enhanced fixation, show gener¬
ally poor results (see press-fit data table in the
appendix). The one exception is that by Kennedy95
who, in a C-rated study (ages not specified), re¬
ported good results at 3-6 years' follow-up for the
Arthropor cup; however, this success is attributed
to the exact reaming surgical technique used,
rather than to the prosthesis design. In studies of
the Ring prosthesis, adequate numbers of patients
are followed-up but their ages are not reported.
In general, early clinical and survival results for the
press-fit stems are not encouraging in comparison
to either uncemented coated or cemented models.
Results for threaded cups have generally been
poor, and the design has been largely abandoned
(a selection of observational study results are given
in the data tables in the appendix).
Hybrid designs
In this category only one study, by Helfen and
colleagues,96 follows-up more than 200 hips and
presents survival results. The maximum follow-up
period in published studies is about 7-8 years. The
study by Helfen and colleagues is summarised in
Table 22, together with two other studies with the
longest follow-up periods. Helfen and colleagues'
study suggests good early clinical and survival
results in patients who are probably somewhat
younger than average for THR. Given wide
confidence intervals, this type of design can be
regarded as comparable with the best cemented
designs for early survival results.
TABLE 22 Selected studies ofhybrid prostheses
I Study Prosthesis Number Age Results
type of hips (years)
(follow-up
period, years)
1 Helfen, et a/., 199396 Marburg 212 mean 60 n = I, revision for loosening
! (3-6)
| Schmalzried & Harris, Two stem- 97 mean 61 n= I, revision for stem loose (in a custom
| I99397 collared, screw-fix (mean 6.5) component); n = I, cup revision
I cup models
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Summary of results in relation to key issues
The results included in this chapter are takenfrom RCTS and comparative studies only. First
clinically important issues are considered:
• thigh pain, fracture, dislocation and bearing
surface materials.
Then studies of factors that affect the performance
of prostheses are considered, together with poten¬
tially confounding factors in the interpretation of
study results:
• hospitals/surgeons, and patient ages and
body mass.
Finally, studies are considered that report aspects of
surgical (cementation) technique, fixation and one
unusual prosthetic design.
Thigh pain
While thigh pain has been identified as a problem
in users of uncemented coated femoral com¬
ponents, it is reported on less frequently as an
separate outcome from general hip scale scores
in observational studies of Charnley and other
cemented stems. However, it is possible to
comment on this issue on the basis of the
comparative studies and trials reviewed here.
In summary, each of the five studies in which the
thigh pain associated with porous-coated stems is
compared with either cemented,42,43 press-fit" or
hybrid designs,57,100 shows a higher and clinically
more significant incidence in porous-coated
models. Thigh pain has also been found to be
significantly higher in uncoated press-fit compared
with Charnley cemented prostheses.3' The one
study in which different porous-coated models are
compared shows fairly consistent levels of thigh
pain (range 17-21%) between them.60
Fracture
In the following study, the effects of fractures on
clinical outcome were investigated by comparing
uncemented hips with different types of fracture
(according to the position of the fracture on the
femoral shaft) with similar prostheses which had
not fractured.
Mallory and colleagues, 1989""
Within a 4-year period, 56 femoral fractures
occurred in various types of cementless total hip
arthroplasties. These were divided into three
groups by the authors: Type I (80%), Type II (16%)
and Type III (4%). A total of 96% of the fractures
occurred intra-operatively and 4% from post¬
operative trauma. The average age of the patients
was 50.4 years (range 21-81 years) and 55% were
female; 61% of THRs were primary replacements,
the remaining 39% being revisions (91% of these
for loosening). The control group comprised
randomly selected pa'tients with cementless THRs
without intraoperative fractures, whose prostheses
were implanted during the same period. There
were no statistically significant variations between
the groups. Types I and II were compared to the
controls for "improvement by operation" and their
modified d'Aubigne-Harris scores. No statistical
differences were found. C-rated.
Comments
The authors concluded that long-term problems
were not associated with Type I fractures (proximal
zone) and possibly not with Type II (middle zone),
although the numbers in the study were too small
to be sure. The number of Type III fractures (distal
zone) (n = 2) was too small to draw any conclu¬
sions. This subject requires further investigation
to determine more precisely the prognosis for
such fractures.
Dislocation
The reasons for dislocations occurring in some hips
were investigated in two studies which considered
the same problem but from different angles: in
one the effect of patient variables was assessed
while in the other CT scans were used to assess
the prosthesis components.
Hedlundh and Fredin, I995102
The median age in this group of patients was
70 years (range 22-94 years), approximately
68% were female and approximately 48% had
osteoarthritis and 23% rheumatoid arthritis. 37
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Out of 1838 patients who had received a Charnley
prosthesis, 60 hips had dislocated; these were
matched with 120 non-dislocated hips, which
formed the control group. Mortality was higher
in the patients in the dislocated group (53%)
compared with those in the control group (24.5%,
p< 0.001), although the median age at death was
similar. In a logistic regression none of the tested
factors proved to be related to dislocation; however,
alcohol abuse in men was more common in the
dislocation group (50%) than in the control
group (18%) (p = 0.01). C-rated.
Pierchon and colleagues, I994'03
Within a 2-year period, 38 patients with dislocations
were treated; 53% were women, the average age
was 57 years and 66% had a diagnosis of osteo¬
arthritis. Muller prostheses were used in most
cases (29 self-locking femoral types, five dysplasia
types; 12 cups were cemented and 26 uncemented).
Of the 38 patients, 11 had been operated on by the
same surgeon on the contralateral side and had
not dislocated; details of three further prostheses
were added to these to form a control group
(further details of types of prosthesis or patients
details were not given). Component alignment
analysis was by CT scan. No differences in mean
cup abduction, cup anteversion or femoral neck
anteversion was found. In seven of the dislocated
hips which underwent re-operation, the possible
reasons for dislocation, as diagnosed by CT scan,
were only confirmed in two cases. In the other five
cases, instability of the hip was caused by lack of
tension in the soft tissues. C-rated.
Comments
Hedlundh and colleagues102 reported an increased
mortality rate among those with a dislocation but
this was thought to be caused by lack ofmuscular
strength and decreased coordination rather than
by old age. Pierchon and colleagues103 also thought
that dislocation was caused by lack of tension in the
soft tissues. One interesting observation was the
association between dislocation rates and alcoholic
abuse in men.
Bearing surface materials
Some comparative studies have addressed this
aspect of hip replacement results. Those reviewed
here were given a low rating in the appraisal.
The wear of different materials is implicated in
the production of particulate debris which, in
turn, is associated with osteolysis and loosening of
the prosthesis. The results for different bearing
surface combinations are commented on below.
Ceramic on ceramic
Only one study,51 which was C-rated, considered
ceramic on ceramic bearing surfaces. The study
compared cemented cups to uncemented screw
cups in ceramic prostheses. Over a follow-up period
of 1-12 years, 9% of all the prostheses required
revision. No comments or analysis of the bearing
surfaces are made in this study. This is a rare
form of design.
Ceramic on polyethylene
Prostheses with metal femoral heads and polyethyl¬
ene cups were compared with those with ceramic
femoral heads and similar cups in two, C-rated
studies. In both studies the ceramic- polyethylene
combination gave superior results to the metal-
polyethylene combination. In Miiller-type pros¬
theses,40 95% of the ceramic head hips had a wear
rate of less than 0.2 mm/year compared with only
64—77% of the metal version (range of follow-up
period, 2.5-9 years). A mean wear value of 0.26 mm
was found in Weber-type prostheses with a ceramic
rotating head over a mean follow-up period of 10
years;41 this was less than the mean wear found in
the same type of prosthesis but with a metal rotating
head (0.96 mm; p< 0.001). However, this last result
should be viewed with caution as the two prostheses
were implanted in different hospital settings.
Metal on polyethylene
The main metal used for femoral heads now is
stainless steel, superseding the titanium alloy and
cobalt-chrome alloy to which many published
studies refer. It is difficult to comment on the
metals used as a bearing surface because ofmany
other factors being present in the published
studies. For example, in one C-rated study,58 a
cobalt-chrome BIAS stem (with an uncemented
metal-backed cup) was compared with three
titanium BIAS stems with different cups. The
titanium stem with cemented polyethylene cup
gave the best results, with the least amount of
wear and no osteolysis, but a titanium stem with
an uncemented metal-backed cup gave the worst
results. It would have been useful to compare the
results with a cobalt-chrome stem with polyethyl¬
ene cup but this was not included in the study.
However, some general comments can be made.
There appears to be less wear in those prostheses
with a complete polyethylene cup compared with
those with a polyethylene liner. Linear wear rates
for the all-polyethylene cups tend to be about 0.05-
0.1 mm/year.41-58'104'105 Details of polyethylene-liner
wear related to porous-coated prostheses were given
in two further studies: both the mean wear (0.73
mm)106 and wear rates (0.6-0.8 mm/year)60 were
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higher than the results above and so may need to be
considered when choosing this type of prosthesis.
Comments
Further analysis needs to be performed in order
to gain a better understanding of the optimal
materials for bearing surfaces, as wear and debris-
mediated osteolysis are considered to be important
reasons for loss of fixation and subsequent failure.
Inter-surgeon and intei^hospital
comparisons
In multi-surgeon and multicentre studies confound¬
ing effects might be introduced by systematic differ¬
ences between surgeons and/or between hospitals
(for example, in stocking some prosthesis designs
but not others). A number of the RCTs and
comparative studies illustrate these points.
Surgeons
Marston and colleagues, 1996107
Surgeons in training performed 15/16 primary
procedures, which subsequently required revision,
using (in 14/16 cases) the anterolateral approach.
(Difference in revision rates between experienced
and trainee surgeons, p = 0.005; relative risk of
requiring revision at 5-10 years postoperatively,
11.47 times greater for trainees, 95% confidence
interval 1.53-86.06). Surgeons in training only
performed the operation unsupervised after being
considered fully competent by the consultants who
had taught the technique. Technical errors were
identifiable in 11 cases. No significant difference
was found between the Stanmore and Charnley
prostheses. C-rated.
Ahnfelt and colleagues, I99014
Information was available on 37 surgeons
(mainly working in two hospitals), all of whom
were categorised as experienced surgeons. Two
of 33 surgeons had fewer complications of aseptic
loosening than the others and one had more
(p <.0.001) re-operations than any of the others.
However, if complications were analysed taking
into account the number of primary operations
performed per year, there were no statistical
differences. C-rated.
Hoffman and colleagues, 1994"
Nine different prostheses of various types with
different lengths of follow-up, implanted by six
surgeons, were studied in multi-variable regression
analysis. Prosthesis type was not significant. The
surgeon performing the operation was a significant
factor, particularly if the prosthesis used was stand¬
ardised to the Charnley (p< 0.001). However, the
results of a single surgeon were not as satisfactory
as the overall results and this factor masked any
difference attributable to prosthesis in the two
main groups (Charnley, Muller). Unsupervised
registrars performed no worse than other grades
of staff. C-rated.
Hospitals
Ahnfelt and colleagues, I990'4
Rates of revision for aseptic loosening and deep
infection were compared between different types
of hospitals. Statistical differences were found
between university (tertiary), regional (secondary)
and community (primary) hospitals. University
hospitals reported more infection than the others.
This could be caused by the selection of patients
with special problems, which demanded lengthy
and extensive procedures.
In a comparison of aseptic loosening in all pros¬
theses (except the Christiansen prosthesis and the
surfacing replacements), regional hospital results
were better than the others (p< 0.001). C-rated.
Hoffman and colleagues, 1994"
Nine different prostheses were used by six surgeons
at either a publicly funded hospital or a private
clinic. Prostheses implanted in the private hospital
survived only 70% as long as those performed in
the public hospital (p< 0.001). The two patient
groups were of a similar age, sex and natural life-
expectancy. Average period of attendance at follow-
up clinics was shorter in the private group than in
the public group and may be a contributing factor
but the multi-variable analysis was unable to explain
the difference in survival of prostheses between
these types of hospital. C-rated.
Schuller and Marti, I99041
The use of the same type of prosthesis was
compared in a teaching hospital environment
(with a metal head) and in a private clinic (with
a ceramic head). The amount ofwear measured
differed significantly (p< 0.001) but the possible
confounding effect of differences attributable to
the hospital setting was not addressed - patient
groups were considered clinically comparable
although the "main differences between the
groups were socio-economic". C-rated.
Comments
The evidence from these studies for the compar¬
ative effect of grade/experience of surgical staff
upon prosthesis longevity is conflicting. Multi-
variable analysis of variance was not possible in the
study by Ahnfelt and colleagues,14 so the respective 39
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contribution of surgeon, hospital and patient-
related factors could not be estimated. This study
suggests that the more specialised centres have
better results overall, measured in terms of aseptic
loosening and revision.
Body mass
It is rare that studies such as the following A-rated
study are performed even though patient variables
are important to outcomes of THR. Patient char¬
acteristics should be researched more fully in hip
prosthesis survival studies.
Lehman and colleagues, 199427
In this retrospective study, primary THRs without
cement, implanted over a 7-year period, were divided
into two groups dependent on the body-mass index of
the patient concerned. Normal weight patients had
an index of between 20 and 30 (n = 142 hips), while
obese patients had an index,of > 30 (n = 60 hips).
The obese group had a subsection within it of those
who were morbidly obese - body mass index of 40 or
more (n = 8 hips). Those with a body-mass index of
less than 20 were excluded. The patients, 30% of
whom were female, had an approximate average age
of 50 years, and 62% had a diagnosis of osteoarthritis.
Normal weight and non-morbidly obese groups had
a significant increase in each functional measure
between prostheses- and postoperative evaluations
(p< 0.001). The morbidly obese group also had
increases, although smaller, in most of the measures
(p= 0.01-0.05). In the normal weight group, 7% of
cups and 7.7% of stems were either loose or revised,
compared with 8% of cups and 1.7% of stems in the
non-morbidly obese group (p, not significant). The
morbidly obese group had no loose components
and none required revision. A-rated.
Comments
This authors of this study concluded that obese
patients (those with a body-mass index of > 30)
could benefit from primary total hip arthroplasties
without cement and that obesity did not markedly
increase the operative risk. However, they do point
out that "substantial differences might occur with
long-term follow-up". This needs to be researched
more fully.
Age groups
Neumann and colleagues, I996I0S
One surgeon performed 240 Charnley hip arthro¬
plasties in 211 patients in just over 6 years and data
on the patients were collected prospectively. A total
of 52 hips were implanted in patients aged between
34 and 55 years, 37 (71%) ofwhom were available
for follow-up after approximately 17 years. Of
patients aged over 55 years, 41 % were also available
for follow-up after a similar period (n = 77/188).
A diagnosis of osteoarthritis was made in 79% of
cases. The only difference seen in Charnley Hip
Scores was in the Function section, where the older
group had slightly reduced scores. This was
thought to be caused by a deterioration in general
health. The number of revisions and loose com¬
ponents were higher in the younger group but this
was not statistically significant. Thus the probability
of survival at 20 years did not differ between the
two groups (younger group = 88.3%, older group
= 89.3%). B-rated.
Comments
There is conflicting evidence on the performance
of different prostheses in different age groups. Age
is used as a proxy for physical activity levels but this
is not a straightforward assumption. The study
above concluded that Charnley low friction arthro¬
plasties can be used for younger patients with
"excellent long-term results" comparable to those
in an elderly age group. However, in the C-rated
study by Hoffman and colleagues,38 in which vari¬
ous types of prostheses were assessed, the hips were
reported to survive longer when implanted into
older patients. Hips in patients over the age of
66 survived longer than those in younger patients
(p < 0.05). More studies such as that by Neumann
and colleagues108 are needed, in which one type of
prosthesis is compared in different age but other¬
wise matched groups, in preference to studies
involving many types of THR from which only
generalised conclusions can be drawn.
Cement types
The following paper investigated a new bone
cement (Boneloc®) which had been developed
to reduce both the leakage of chemicals and the
curing temperature, both considered to be possible
reasons for the failure of cemented prostheses. The
new cement was compared to a conventional poly-
methyl methacrylate cement (Palacos®). The mech¬
anical and chemical properties of Boneloc were
assessed during laboratory tests and presented
with the clinical results. The study reported the new
Boneloc to have "inferior fixation" to die conven¬
tional Palacos, giving indications of increased risk
of loosening. The authors suggest that this was
probably caused by its mechanical properties and
possibly by other mechanisms such as an increased
release ofmonomers.
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Thanner and colleagues, 1995""
This was a comparison of two types of cement -
Boneloc and Palacos - involving 30 hips in 30
patients, aged 63-76 years, 27 ofwhom had primary
osteoarthritis. Full radiostereometric analysis was
possible in 24 patients only at 1 year (one Boneloc
patient had died). Palacos fixed cups had "a small"
lateral migration while cups with Boneloc migrated
medially (p = 0.03) and proximally (p = 0.04); 1/16
Palacos stems subsided 0.27 mm while 6/13 Boneloc
stems subsided 0.22-1.0 mm (p= 0.005). Increased
acetabular radiolucent lines and femoral "relative
cement- cortical bone contact" occurred in the
Boneloc group compared with Palacos (p = 0.04 and
p = 0.03, respectively). Harris Hip and Pain Scores
and a Visual Analogue Scale for pain improved
postoperatively (p= 0.0004-0.002) but did not differ
between the groups (p, not significant). C-rated.
Cementing techniques
Cementing techniques in Charnley prostheses
have been assessed most frequently, as in the first
two papers summarised below. In the third paper
cementing techniques are not compared (the
authors state that they did not differ greatly between
the two groups) but differences between Charnley
designs are assessed over the same period; thus, the
results may impinge on the other studies.
Cornell and Ranawat, 1986"°
Early cementing techniques were used to implant
four different prostheses in 62 hips between 1971
and 1978 and modern cementing techniques were
used in 16 hips (two types of prosthesis, 1979-80).
The hips were followed-up retrospectively after
5 years. The patients had a mean age of 48 years,
79% having a diagnosis of osteoarthritis, and 55%
were women. There was a lower incidence of radio-
lucent lines around the cups plus lower radiolucent
scores in the modern technique group (p < 0.025
for both). There were no revisions in either group.
The modern technique group had no loose
components by 5 years. By 10 years the early
technique group had three cups loose. C-rated.
Ranawat and colleagues, 1988'"
One surgeon performed 155 operations using
cemented prostheses and, from these, 100 were
matched for age, sex, diagnosis and body weight.
Between 1970 and 1975, 50 operations were per¬
formed using early cementing techniques; the rest
were implanted after 1979 using modified tech¬
niques. After a 5-year follow-up, 8% of the early
group had migrated compared with none of the
modified group (p = ?) and the cumulative radio¬
lucent score was found to be lower in the modified
group (p = 0.0005). Within the 5 years no early
technique hips were found to be loose or require
revision. None of the cups in the modified tech¬
nique group were loose or revised but one stem
required revision because of loosening. B-rated.
Do// and colleagues, 1993112
Between 1970 and 1986 a variety of surgeons
implanted 1309 Charnley low friction arthroplasties
in 1809 patients. From this group 666 hips were
assessed after approximately 8 years: 264 early
generation design (1970-77) and 402 second
generation design (1975-86). Approximately 77%
of the patients had osteoarthritis, their approxi¬
mate mean age was 60 years and 60% were women.
The probability of survival with respect to loosening
at 10 years was reported to be 99.35% for the early
hips and 86.8% for the second generation hips
(p < 0.0001). The revision rates for both were
similar: 8% early, 9% second generation. C-rated.
Other studies
Other prostheses have also been assessed, as
part of other studies, with respect to cementing
techniques. Stanmore hips had a 10-year survival
without revision probability of 91.6%, when first
generation techniques were used, compared with
97.4% for second generation (p= 0.005).32 In
another study, 307 T-28 and 162 TR-28 hips were
implanted using early techniques and 99 MOSC
hips were inserted using modern techniques. An
increased incidence of femoral subsidence of
> 5 mm in the T-28 and TR-28 hips compared with
the MOSC hips (p, 0.004-0.0075) was attributed by
the authors to the different methods of fixation.
Comments
The two studies which assessed cementing
techniques in Charnley both showed lower radio¬
lucent line scores and incidence to be associated
with the modern cementing techniques. Over the
5-year follow-up period in both studies, this did
not translate into higher revision or loosening
rates but this may occur later. However, the second
generation Charnley design hips in the third paper
had a lower probability of survival, compared to the
first generation and, if these hips were used
together with the modern cementing techniques,
the longer-term results might not be so clear.
Aseptic loosening
The study below was designed to assess the
possible reasons for loosening within the
Stanmore cemented prosthesis.
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Kristiansen and Steen Jensen, I98S"3
A total of 33 Stanmore hips with aseptic loosening
were compared with a matched control series
without loosening. The diagnosis for 94% of the
patients was osteoarthritis, their mean age was
64 years and the study had a mean follow-up period
of 36 months. Previous operations had been
undertaken in four of the revision group compared
with none in the control group (p< 0.05). Loosen¬
ing occurred more often when calcar bone stock
was thin prior to surgery (p < 0.001); insufficient
packing was found in 88% of the loose hips and
39% of the stable hips. A varus position of the stem
was associated with loosening as opposed to the
neutral or valgus positions. B-rated.
Comment
The factors associated with failure possibly
contributed to the loosening of prostheses. There
is scope for review of further good quality studies
on the mechanics of loosening in other patients
and in other types of prostheses.
Wire versus cable
One study compared these methods of fixation.
Kelley and Johnstone, 1992u
Either a Charnley or an IOWA stem was paired with
either a Charnley (22 mm) cup, an all-polyethylene
(28 mm) cup or a metal-backed (22 mm) cup.
Two methods of fixation were used: stainless steel
wire (n = 162) or cobalt-chrome cable (n = 160);
follow-up period was approximately 6 years. The
patients' approximate mean age was 66 years,
52% were women and 81 % had a diagnosis of
osteoarthritis. Trochanteric union rates were 75%
for the wired hips and 79% for those with cable.
Breakage of the entire trochanteric fixation con¬
struction (all three wires or cables) occurred in
43% wire and 12% cable (the cables in 56% of the
hips unravelled, 47% of these had no broken
cables). Analysis of roentgenographs (performed
independently of the surgeon and blinded where
possible) showed loosening of the cup in 12% of
wired hips and 23% of the cabled ones. The
difference in cup loosening, adjusted for cup
type, was significant (p = 0.003). A-rated.
Comments
Cable was introduced to improve trochanteric
union rates but this study did not show any
significant results in this area. Bone destruction
occurred more frequently with cable (p< 0.001)
and was associated with debris coming from the
cables themselves. Debris may be responsible for
the higher incidence of cup loosening in those
hips with cable. These results suggest that there
is no advantage of cable over wire and, as the
authors point out, caution should be used
when considering the use of cable for
trochanteric fixation.
Isoelastic hip versus porous-
coated prosthesis
This paper was not included with other prosthesis
comparisons because the Butel prosthesis is of a
different type to all the others.
Jacobsson and colleagues, 1994114
Two senior surgeons operated on 56 patients
(24 women, 32 men, mean age 52 years), of whom
75% had osteoarthritis; the rest had a variety of
reasons for the unilateral hip operation. Patients
were matched in pairs for sex, age, weight and
radiographic appearance before being randomly
selected (no details of method) to have a Butel
(stem made of four rods for flexibility) or a PCA
(rigid) stem (three different press-fit cups were
used). Each pair was operated on by the same
surgeon and was followed-up for 3 years. The PCA
stem gave better results, as assessed by Harris Hip
Scores (mean 94.4 compared with 78.5 Butel,
p-value not given) and the number of prostheses
definitely or probably loose (PCA 18%, Butel 86%).
Both groups required three hips to be revised
because of loosening (one further Butel hip was
revised for other reasons). C-rated.
Comment
The Butel was "designed to obtain flexibility
similar to the proximal femur by using four rods
(titanium alloy) connected proximally and distally"
and was supposed to "exhibit fewer signs of stress-
shielding". However, the porous-coated prosthesis
gave better Harris Hip scores and was far more
stable than the Butel system. Although the
numbers of revisions were similar in both groups
during the 3-year follow-up period, the increased
number of Butel hips which were definitely or
probably loose may indicate that more of these








The aim in this chapter is to estimate the costs
of THR using an economic model. The focus is
on the model developed to incorporate relevant
characteristics and costs which enables comparisons
to be made of different prostheses. Results are
presented by applying this model using available
data. The model can also be applied as new data
become available on the survival of exisung pros¬
theses, on new prostheses, on changes in costs or
local data. Thus the results give an assessment of
the state-of-the-art now, and the model enables
these findings to be revised as new data become
available. The model itself is therefore an equally
important product of the research as are the
results themselves.
Methods
The obvious costs of a THR are those of primary
replacement. However, the total expected costs are,
in fact, greater than this and may include the costs
of revision.
The concept of total expected costs is based on
those costs expected to be incurred over a number
of years. In the case of THR, total expected costs
are the sum of the primary replacement costs and
the expected costs of revision. These expected costs
of revision are the actual cost of revision multiplied
by the probability that a revision will be performed.
Thus a combination of a low revision rate and a low
revision cost will result in a low expected cost of
revision; likewise, a high revision rate combined
with a high revision cost will result in a high
expected cost of revision. Given a population who
have had primary THRs, a number of revisions will
be required in each future year and associated costs
will therefore be incurred in each future year. For
comparability, these expected costs are converted
into their value now (present value). This conver¬
sion is required because a given quantity ofmoney
has different values in different years in Lhe future.
The basic principle is that the present value of £1
in the future is less than the value of £1 now. The
conventional method of converting costs into their
present value is called discounting and is explained
in more detail below.
By calculating the total expected costs of THRs,
comparisons between different prostheses can be
made. Assume a choice of two prostheses: Y needs
no revisions over 20 years and X has, say, a 1 % per
annum revision rate. Prosthesis Y costs £1000 more
than prosthesis X. A purchaser, making a decision
based on expected costs only, would chose Y rather
than X if the expected costs of revisions of prosthe¬
sis X over the next 20 years were more than £1000
(and vice versa). Thus for equivalent total expected
costs over 20 years, primaiy plus expected costs of
revisions of prosthesis X must equal primary costs
of prosthesis Y.
Comparisons of different prostheses can thus be
made if details of primary and revision costs and
survival data are known for both. The method can
also be used for making comparisons for which
costs are known but survival data are not. For
example, assume that there are no survival data
for prosthesis A but the costs of a primary replace¬
ment are known, and both costs and survival data
are known for prosthesis B. If the primary replace¬
ment costs of prosthesis A are greater than the
total expected costs of prosthesis B, then it is inevit¬
able that the total expected costs for prosthesis A
will be greater than those for prosthesis B. Even if
prosthesis B had a higher revision rate than pros¬
thesis A, B would still be preferred if a decision
was based on cost alone.
This model calculates expected costs over 20 years
and assumes that the quality of life of recipients
is equal however many revisions are undertaken.
Obviously, in terms of benefits to individual
patients, any prosthesis with a lower revision rate
would be preferred, as patients would not need to
undergo repeated surgery. If long-term quality-of-
life data were available for various prostheses, it
might be possible to undertake a cost-utility
analysis lo compare properly the costs and benefits
of THR. These data are, however, not available.
Care should therefore be taken to consider the
dis-benefits of repeated revisions when making
choices between prostheses.
Empirical data are not readily available on all the
cosls which contribute to the total cost of a THR
or on survival rates. When there are empirical
data, these often indicate wide variations. Hence, 43
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using mean values may give misleading results for
the expected costs of revisions and of the choice
between prostheses for different orthopaedic
surgeons. When the data on which the calculation
depends are subject to a degree of uncertainty, it
is vital to undertake a sensitivity analysis in which
'high' and 'low' estimates are stated for each com¬
ponent that is subject to some imprecision. These
high and low estimates are substituted in place of
the original values and the effects on the final
outcome examined. The input factors that have the
greatest effect on the level of total expected costs
can then be investigated to see if they would
change the relative total expected costs.
The model
Previous articles based on similar methods have
been published by Daellenbach and colleagues
in 19902S and by Gillespie and colleagues in 1995.115
Daellenbach and colleagues developed a mathe¬
matical model based on costs and patient survival
for comparative economic appraisal of cemented'
and cementless prostheses. Their results suggested
the numbers of additional years a cementless
prosthesis needed to last, above that of a cemented
prosthesis, to justify its extra cost of NZ$1200. The
figures were given for a range of additional costs
of revision.
Gillespie and colleagues115 used Swedish and
Australian data to estimate the potential cost-
effectiveness of new prostheses with unknown
outcomes for different age groups and mortality
rates. The present value of the future costs of a
prosthesis of known cost and survivorship was
compared to the theoretical present value of a new
prosthesis with known cost but unknown outcome.
Their results indicate that possible future savings
resulting from increased survival and lower revision
costs do not justify the use of prostheses which cost
substantially more than a conventional component.
Similarly, in 1996, Pynsent and colleagues1111
suggested a model for purchasers based on a
"lifetime care package". For a given initial outlay,
a purchaser would buy a primary replacement and
any subsequent THR revisions. The initial cost
would take into account, among other factors, the
quality of prosthesis in terms of expected revision
rate. This computer-based model takes account of
prosthesis failure, death of the recipient and re-
revision rate. Its conclusion is that if this method
of pricing lifetime care according to quality of
prosthesis was adopted, then monitoring, and
thus the availability of survival data, would improve.
Additionally, there would be a disincentive to
suppliers to publish overoptimistic survival rates.
This is because the supplier charges a fixed cost
for the care package and would thus incur a loss
if the actual cost of lifetime care was higher than
that advertised.
The model developed here is based on the
equation given by Gillespie and colleagues115 and
is used to estimate the present value of expected
total costs of THR over 20 years.
The equation is of the form:
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Cj = cost of prosthesis j






Lmi = probability of an individual at age m
when receiving a hip replacement
being alive in year i
PcjTni = probability of prosthesis Cj in an
individual aged m needing to be
revised in year i
R = additional costs of a revision (i.e.
additional hospital costs)
1/(1 + r)' = a discount factor where ris the
discount rate, i = 0-19 where 0 is the
year of the primary operation.
Essentially this gives the present value of pros¬
thesis C as dependent upon initial prosthesis and
hospital costs, plus the sum of expected future
costs of revision. Future costs of revision are
themselves dependent on the age of the recipient
and the survival of the implant. All future costs
are discounted.
Primary operation costs
Data on resource use were obtained from two
collaborating hospitals in different regions of
England. Both hospitals gave details of the prices
they charged for primary unilateral THRs. These
costs were broken down into theatre, ward, physio¬
therapy and prophylaxis costs for each hospital.
One hospital also gave costs of revision surgery.
Prosthesis costs were given separately.
For both hospitals, the cost per hour in theatre
and the time spent in theatre was determined.
One hospital had supplied these details in their
prices. The other gave total theatre costs only,
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broken down into theatre medical staff and other
theatre costs. From separate data on operation and
anaesthetic time, average theatre time for primary
replacements was estimated and thus the cost per
hour of theatre time. Data were obtained for ward
costs in a similar way. Both hospitals gave total ward
costs for primary replacement. One hospital gave
details of cost per day and the average length of
stay; for the other ward, cost per day was estimated
from data on the average number of days stay and
the total ward costs supplied.
By sensitivity analyses it was possible to determine
the effect on the present value of total expected
costs of long and short theatre times and lengths
of stay.
In three studies, by Francis and colleagues,11'
Wittmann and colleagues,118 and Sharrock and
colleagues,119 it is suggested that cementless pros¬
theses reduce the risk of postoperative thrombo¬
embolic disease, while Laupacis and colleagues120
found no difference in the frequency of deep vein
thrombosis between two patient groups (cemented
and cementless). Lieberman and Geerts121 suggest
that prophylaxis against deep vein thrombosis
reduces both symptomatic thromboembolism
complications and saves lives, and saves subsequent
healthcare expenditure. Data on prophylaxis costs
provided by one of the collaborating hospitals
indicated that they were a small proportion (1.8%)
of total primary replacement costs. In summary,
prophylaxis costs make up only a small proportion
of total costs and the evidence suggests that pro¬
phylaxis against postoperative thromboembolic
disease is cost-effective.
Prophylaxis and physiotherapy costs were supplied
by one of the collaborating hospitals (Hospital A).
The second hospital was not able to separate these
costs from other costs and therefore those for
Hospital A were used as a proxy and subtracted
from theatre and ward costs as appropriate. To
allow cost per hour in theatre and on the ward to
be calculated (see above), prophylaxis and physio¬
therapy costs were included in the model indepen¬
dently from overall ward and theatre costs.
Data supplied by one of the hospitals suggested
that prices charged for a revision are 1.19 times the
price of a primary unilateral replacement; that is,
the additional costs of revision are 19% greater
than the primary replacement costs. Using this per¬
centage, the additional costs of revision were there¬
fore made proportional to the primary replace¬
ment costs for both hospitals. The additional
costs for revision are due, in part, to the longer
operation time (on average, 40 minutes extra)
and longer length of stay (approximately 3 days).
The model assumes that the impact of these extra
times remains proportional to the costs of primary
revision. This allows the sensitivity analyses to
impact on both primary and revision costs.
In 1996, Pynsent and colleagues116 suggested that
the overall costs of revision surgery were twice that
of a primary replacement because of the longer
operation time and length of stay in hospital. No
empirical evidence, however, was presented to
justify this assumption. Revision surgery can be
complicated and difficult to perform, with the
personnel undertaking the revisions requiring
higher skill levels. As such, revision costs cannot
be assumed to be equal to primary replacement
costs. This issue was examined in the sensitivity
analysis by altering the revision costs to double the
primary costs and determining the effect on the
total expected costs.
The two collaborating hospitals gave their own
prosthesis costs. Both supplied the price charged
to purchasers for 'a hip prosthesis'. This was the
average prosthesis price for all types of prostheses
used in the hospitals and was not the specific price
of a Charnley or other model. The survival data
and prosthesis cost of the Charnley are used as
the gold standard in the model for comparison
with other prostheses. We decided to model the
equation using the hospitals' prosthesis costs first
and then using the price of a Charnley prosthesis
as quoted by Murray and colleagues.91 The costs
of other prostheses were also taken from this paper
to allow comparisons to be made between different
prostheses using costs that were provided for the
same year. This paper reviewed all manufacturers
and distributors in the UK and listed prostheses
supplied by most major competitors with their
market price. Where survival data were available
for other (non-Charnley) prostheses, these were
used with associated prices to estimate total ex¬
pected costs. However, prices may vary from those
stated, dependent upon quantity purchased and
arrangements with purchasing organisations.
Local prices should be used where known. The
published prices were used to indicate a range
of market prices for the sensitivity analysis.
Prosthesis survival data
The probability of an implant needing revision
in year i was estimated from published sources.
As mentioned above, the survival data and prosthe¬
sis cost of the Charnley are used in the model as
the gold standard for comparison with other types
of prostheses. The survival data for the Charnley
Economic model
for up to 20 years have been published in various
articles.7,9,122 The data from these sources were
collated and a best esdmate of the probability of
revision in each year over 20 years was calculated.
Gaps in the data were filled assuming a straight
line relationship between two known points. The
average revision rate per year over 20 years for a
Charnley prosthesis was about 1% (ranging from
a low of 0.5% to a high of 3%).
To estimate the present value of expected total
costs for a range of competing prostheses, the same
exercise was undertaken for other types. As our
review of evidence has shown, there are few data
available on the survival rates ofmany prostheses.
Often the survival rate was known at only one or
two points in time, for example, after 4 or 5 years.
For these prostheses, a straight line was fitted
through the known point(s) and 100% survival
(at time zero). This rate was then extrapolated
over 20 years. Obviously, survival may not be linear,
and rates of revision will increase as the number of
years since replacement increases. Some implants
show a dramatic rise in revision rate after about
5 years. Care should be taken when interpreting
the results of prostheses with limited survival
data. A rise in revision rate above the linear
rate assumed in the model would result in
increased expected costs.
Much of the published survival data are reports
from 'centres of excellence' and may not therefore
reflect common practice in the UK where revision
rates may be higher. However, as long as data from
centres of excellence are used consistently for all
prosthesis types, the comparisons ought to be a
reliable guide to the relative performance of differ¬
ent prostheses. What matters is relative cost. How¬
ever, if the model is to be used at local level to
inform purchasing decisions, it is important to
model local survival rates in the equation. An
increase in the probability of revision will result
in an increase in the total expected costs.
The sensitivity analysis gives total expected costs for
straight line revision rates over 20 years of 3% and
5% per year.
Discount factor
The convenuonal way of accounting for costs
(and/or benefits) of a treatment occurring over
a number of years is to put them on the same basis
by discounting. The value of £1 in i years time is
less than the value of £1 now, even after allowing
for inflation. This is because costs incurred in the
future are less important to us than costs now. To
allow for this change in value over time, costs
incurred in the future are multiplied by a weighting
factor (the discount factor) thus enabling the
comparison of current and future costs as if they
occurred at the same time. The discount factor is
1/(1 + r)\ where ris the discount rate and i the
year in which the costs (or benefits) occur.
The total expected costs of a hip replacement
include the original replacement and the costs
of any subsequent revisions. Revisions may occur
in any year and the costs occur at the same time.
For those revisions taking place in 15 or 20 years
time, the present value of these costs will be small
because the denominator of the discount factor
becomes larger (as i increases). The discount factor
applied to a cost 20 years into the future is about
0.39; that is, the present value of a cost incurred
20 years hence is only about 40% of its nominal
value. This model estimates the total expected costs
over a maximum of 20 years. Costs due to revisions
will be incurred after 20 years; however, for the
reasons described above, these costs will be small.
The discount rate in the original calculation was
assumed to be 5%. This figure was varied in the
sensitivity analysis to 0% and 6%.
Mortality data
The probability (Lmi) of a patient who received
a primary hip replacement at age m being alive in
year i was calculated from OPCS Mortality Statistics
for 1992.123 The probabilities for males and females
were modelled separately in the equation. Median
age at primary operation (70 years) was calcu¬
lated from data supplied by one of the hospitals.
Swedish data supplied by Malchau and colleagues122
supports this by giving mean age at primary
replacement for men as 67.5 years and for women
68.2 years. An age of 70 years and the correspond¬
ing probability of being alive in year iwas used in
the calculations for both hospitals.
In the absence of any other data it is assumed that
individuals who have had a hip replacement have
a mortality rate equal to the general population for
their age group. However, the true mortality rate
for individuals with osteoarthritis and rheumatoid
arthritis is different from the general population.122
Current research by the Somerset and Avon Survey
of Health (Personal communication, 1996) suggests
that people with a THR may have a lower life-
expectancy than average. Accurate data on true
mortality rates are not known. If these data were
available and used in this model, and the mortality
rates were higher than for the general population,
then total expected costs would be lower than
suggested because of the greater number of
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individuals dying before their prosthesis needed
replacing. A youngest age of 20 years and an oldest
of 80 years was used in the sensitivity analysis. For
elderly patients, the discount factor combined
with the high mortality rate results in very small
expected costs in 20 years time. However, for young
patients, the low mortality rate and the increasing
THR revision rate over time mean that a high pro¬
portion of younger individuals will survive longer
than their implants and, despite the discount
factor, these costs are still important. Young
patients will live for more than 20 years (that is,
longer than the span of the model) and this must
be considered when comparing the results.
Assumptions
A spreadsheet model is used to estimate the total
expected costs of one prosthesis relative to another.
The results from the model are intended to further
current knowledge and to aid decision-making, not
to prescribe policy. This model is based on a
number of simplifying assumptions.
• As explained above, the model assumes prices
quoted in a 1995 paper.9 These prices may have
changed and prices of prostheses may also vary
between purchasing institutions. Any increases
in prosthesis price will obviously increase total
expected costs. More importantly, any change
in the relative prices of prostheses may change
their relative cost-effectiveness.
• A further assumption is that prosthesis revision
rates are linear when long-term survival data are
not known. These estimates are based on trends
for the years immediately following primary
replacement. The assumption that the rate is
linear throughout the 20 years of the model will
underestimate longer-term revision rates and,
thus, underestimate total expected costs.
• The model assumes that mortality rates of THR
recipients are equal to those of the general popu¬
lation. This assumption is made because of the
lack of data on actual mortality rates ofTHR recip¬
ients. If actual rates are higher than average, then
the model will overestimate total expected costs,
and this may change rankings of cost-effectiveness.
This is because, if the mortality rate of THR
patients increased, thus reducing length of life,
there would be no change in the total expected
costs of a low revision prosthesis whereas there
would be a reduction in number of revisions and,
hence, costs of a high revision rate prosthesis.
• No account is taken in the model of re-revisions.
There is, inevitably, a cumulative effect in that
a number of primary replacements will fail,
be revised and fail again. Revision THRs have
a greater chance of needing a further revision.116
This is not incorporated in the model which
assumes a maximum of only one revision over
the 20-year period. Including re-revisions would
increase the total expected costs.
Results
This section includes:
• an estimate of total expected costs, based on
survival data for the Chamley prosthesis and
on actual hospital costs
• a comparison of the total expected costs of
other prostheses
• a sensitivity analysis.
An estimate of total expected costs
(based on survival data of the Charnley
prosthesis and actual hospital costs)
The costs provided by both Hospitals A and B are
presented in Table 23. Published yearly survival
rates for the Charnley prosthesis and the estimated
revision rates used in the equation are presented
in Table 24.
TABLE 23 Primary unilateral replacement costs in Hospital A
and Hospital B
Type of cost Hospital A (£) Hospital B (£)
I Prosthesis 629
1 Theatre I 197 946





| Total for primary 3614
1 unilateral
1
| (Additional revision costs) (693)
£








° Ward costs in HospitalA include direct and indirect
overheads and exclude SIFT payments.
b NA, not available.
If the revision rates from Table 24 and the costs
from Table 23 are used in the model, with the
average age of primary implant (70 years) and a
discount rate of 5%, the present value of expected
revision costs for a selection of years will be those
shown in Table 25 (for each hospital and for men
and women separately). The primary replacement






































| * To avoid negative revision rates, when survival rates rose over
| time, the rates were assumed to be a straight line between the |
| years on either side.
In the Methods section above, a choice of two
implants was assumed, one needing no revisions
over 20 years and the other having about a 1 %
revision rate (as in the above model). A prosthesis
with an expected 100% survival rate over 20 years
has costs over 20 years equal to primary replace¬
ment costs. A purchaser making a decision based
on expected costs only would not be prepared to
pay substantially more over 20 years for one
prosthesis rather than the other.
The costs of primary replacement and expected
revision costs over a number of years for men and
women are presented in Table 25. The expected costs
of revision for women are slightly higher than for
men because of the lower mortality rate for women;
that is, fewer women die before needing a revision.
In Hospital A, for men, the difference between the
cost of a primary replacement (£3614) and the
expected total costs over 20 years is £297, the
expected costs of revisions. For Hospital B the
difference in costs is £344. The expected revision
costs over 20 years for women are £371 and £431
for Hospitals A and B, respectively.
These figures imply that, for male patients in
Hospital A, assuming equal hospital costs for
different prostheses, a purchaser would not be
prepared to pay more than £297 extra, compared
with the cost of the current prosthesis, for a new
type of prosthesis. Paying more than £297 extra
(that is, £926 in total) for the 'no revisions'
prosthesis would result in the costs over 20 years
being greater than costs using the current implant.
Using the costs supplied by Hospital B, the maxi¬
mum extra a purchaser would be prepared to pay
for a no revisions prosthesis is slightly higher at
£344 (£973 in total).
TABLE 25 Present value of expected revision costs for males and females for a selection of years (average hospital prosthesis and
Charnley prosthesis costs separately)
Present value of total expected costs (£)
Hospital A
| Prosthesis price 629a
1
| Primary replacement 3614
| costs (including prosthesis)
ijl-x-x-x-xvx-x-xivx:-::-::: :-x-x-Xvx:::-:-x-x-x-::-x-x-x-x-:-:-x-:-Xv: :'X'X-x:v:-x-:-x-x::-x-xx.x:: x-x-xx.xxvx-x-xvx-x-x-x-ixxx-x-
| Expected costs of revisions Male Female
I At end of 5th year 136 145
I At end of 10th year 244 278
| At end of 15th year 265 310


































| "Average prosthesis cost in HospitalA, including cement (£71)
1 b Cost of Charnley prosthesis9
I c Average prosthesis cost in Hospital B
¥.-.xx-x<-x->x-x-:->X';x--sxv:-x«-x«<
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Similar figures using the lower prosthesis
prices quoted by Murray and colleagues9 give
the maximum extra a purchaser would be
prepared to pay for a no revisions prosthesis
in men as £278 and £320 for Hospitals A and
B, respectively (£631 and £673 in total, respec¬
tively). For women, the corresponding figures
are £348 and £401, respectively (£701 and £754
in total, respectively).
Obviously, given a choice, the recipient of an
implant would prefer the prosthesis with the
lowest revision rate or not to have to undergo
revision surgery at all. Here only the expected
total costs of THR have been examined, without
considering any benefits.
Comparison of the total expected costs
of other prostheses
An indication is presented here of the total
expected costs of a range of competing prostheses,
for comparison with the above estimates which
used the survival rates for the Charnley prosthesis.
Published costs and estimates of survival rates were
used in the model together with the cost data from
Hospital A.
These results are based on published survival
rates from centres of excellence which may not
reflect common practice but do compare prosthe¬
ses in similar settings. The expected costs of both
prostheses will be greater in hospitals where the
prosthesis survival rate is lower.
The results are given separately for prostheses
where the longer-term survival rates are available
(i.e. more than 10 years) and for prostheses where
only short-term survival rates are known (i.e. less
than 10 years).
Prostheses evaluated over the long term
(with 10 years or more data on survival)
Survival rates of 10 years or more were used for five
types of cemented prosthesis and one cementless
prosthesis. These data are presented in Table 26,
together with the price of the prosthesis, if available.
The results were derived separately for men and
women, using the following assumptions:
• hospital cost data from Hospital A
• for cemented prostheses, the average cost (£629
including cement) from Hospital A was used if
no prosthesis specific cost was available
• for cementless prostheses, the average
price (£1150) of those listed by Murray and
colleagues9 was used if no specific prosthesis
cost was available
• a recipient aged 70 years at time of implant
(unless otherwise stated)
• a discount rate of 5%
• the cost of reoperation remained proportional
to the cost of primary operation (excluding
prosthesis cost)
• linear prosthesis revision rates (except for the
McKee-Farrar prosthesis for which the actual
rates were known).
Actual revision rates will probably rise over time
leading to greater expected costs than those indi¬
cated here. The resulting expected costs using
these linear assumptions are presented in Table 27.














I Cemented alumina-alumina (age < 50 years)i24





























TABLE 27 Expected total costs ofCharnley prosthesis and seven comparison prostheses







































3489 3506 3514 3543 3522 3560
3579 3604 3621 3667 3636 3697




















TABLE 28 Published prices of prostheses and their survival rates
| Make/type Price of 4-year 5-year 7-year 9-year
I prostheses survival rate survival rate survival rate survival rate1
i
^
(£) (%) (%) (%) (X) |
:
Cemented



























The expected total costs of the Charnley are
£3616 and £3686 per hip over 20 years for men and
women, respectively. From Table 27, prostheses with
survival data of 10 or more years, the Stanmore,
with a prosthesis and cement price of £356, has
expected total costs of £3522 (£3560 for women)
over 20 years, almost £100 (£126) less than the
Charnley. The Exeter prosthesis has similar costs
over 20 years to the Charnley at £3636 (£3697),
with an initial prosthesis and cement cost of £411.
The one cementless prosthesis (DePuy's AML) at
£799 is seemingly not a cost-effecuve option for
either men or women given the assumptions used in
this model.
Prostheses evaluated over the short term
(with less than 10 years data on survival)
Survival rates of less than 10 years were used for six
cemenied and three cementless types of prosthesis.
These data are presented in Table 28, together with
the price of prosthesis if available. The results were
derived from the model using the same assump¬
tions as above. The resulting expected costs are
given in Table 29.
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TABLE 29 Expected total costs ofCharnley and eight comparison prostheses
Expected total costs (£)
Over 5 yearsMake/type Assumed
price (£)
Over 10 years Over IS years Over 20 years
Male Female Male Female Male Female Male Female




| Muller straight stem 405 3422 3424 3535 3561 3587 3639 3606 3676
1 Lubinus IP
s
629 3727 3733 3784 3802 381 1 3842 3820 3861
I CAD 629 3731 3738 3798 3819 3829 3866 3840 3887 1
| Lubinus SP 771 3821 3825 3858 3870 3875 3895 3881 3907




1260 4276 4278 4295 4302 4305 4315 4308 4321
I Harris-Galante 1 ISO 4259 4266 4329 4352 4362 4401 4374 4424
! PCA 1 150 4270 4278 4346 4370 4381 4423 4394 4447 |
Some of the figures on which Tables 27and 29
are based use an assumed prosthesis price and
estimates of revision rates that are probably
lower than actual revision rates. The results
should therefore be treated with some caution.
However, Tables 27and 29do allow comparison
of costs over a number of years between the
gold standard of the Charnley and the
competing prostheses.
Table 29 presents the results for prostheses with
less than 10 years survival data; actual survival
rates over 20 years may be different from the linear
ones assumed. Only the Muller straight stem at
£3606 (£3676 for women) over 20 years, for an
initial prosthesis and cement cost of £405, is
similar in cost to the Charnley. All of the cement-
less prostheses have expected costs over 20 years
of about £700 more than a Charnley prosthesis
and all are more costly than any of the
cemented prostheses.
Sensitivity analysis
The purpose of a sensitivity analysis, as described
above, is to indicate how sensitive the results are
to certain key components in the model. The
most important consideration here is the effect
that changes in the key assumptions will have
on the expected costs of revisions and on the
relative cost-effectiveness of different prostheses
in terms of total expected costs. For simplicity,
the sensitivity analyses presented here model
the equation for men and for Hospital A's
costs only.
The sensitivity analyses explore three main issues.
1. What effect do changes in the different inputs
to the model have on total expected costs?
2. Does the relative cost-effectiveness of different
prostheses change as these inputs are changed?
3. In general, what are the relationships between
prosthesis price and revision rate?
The effect of changes in the different inputs
to the model on total expected costs
The purpose of this sensitivity analysis is to
determine the effect on total expected costs
over 20 years of different input data. For example,
the model assumes that the length of stay as an
inpatient after a THR is 13 days. This is the average
length of stay from local data but other data suggest
that the range may be from 9 days to 22 days.
Clearly, substituting 22 days into the model for
13 days will raise costs. The question is - by how
much over 20 years? Other data in the model are
also subject to such uncertainties and, hence, are
explored in this sensitivity analysis.
Using the Charnley prosthesis cost and survival
data plus other assumptions as explained above,
each of the main components in the model are
altered, as appropriate, to a low and high estimate.
Of the seven components in the model, three
impact predominantly on costs in the current
period, one affects future costs alone (revision
costs), two affect the expectation of future costs
(revision rate and recipient age) and one affects
the weight given to future costs (the discount rate).
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The original data and the estimates used in the
sensitivity analysis are presented in Table 30. The
effects on the total expected costs over 20 years
of varying the level ofmajor current costs (that is,
hospital and prosthesis costs) are shown in Table 31.







| Ward: length of stay 22 daysc 13.2 days








| Age at operation 40 years
Revision rate 5%
Discount rate 0%
TABLE 31 Effects on total expected costs over 20 years of
varying the level ofmajor current costs
|
s




| ° From Murray, et al., 1995,91 plus El I for cement
| bData from Hospital A (Personal communication, 1997)
| c Data from Trent Region for 1990 (Personal communication,
! '997)
1 d Rates assumed in our basic model




cost cost cost differ¬ expected
(*) (£) ence (£) cost differ- §
| (high - low ence (£)





4650 3581 1000 1069
| Theatre: 4831 3153 1500 1677
| length of stay |
| Ward: length 5160 3314 1560 1846
| of stay
fLwWOWWWHCWOWMOMMWOW 1
The range of time spent in theatre is taken from
data provided by Hospital A (1-4 hours). From an
average time of 144 minutes and total theatre costs,
the cost per hour of theatre time was calculated to
be about £500. Thus an increase in theatre time
of 3 hours results in an increase in the cost of a
primary operation of about £1500. From Table 31,
the increase in total expected costs over 20 years of a
3-hour increase in theatre time is £1677. When these
costs are compared with the increase in cost of the
primary operation, it is clear that the additional
future costs are relatively small (about £170).
The cost of an inpatient stay in Hospital A was
calculated as about £120 per day. As above, the
number of days stay as an inpatient may range from
9 days to 22 days (1990 data from Trent Region:
Personal communication, 1997). Such an increase
in stay (13 days) results in an increase in the cost of
a primary operation of about £1560. The resulting
increase in expected future costs over 20 years is
£1846. Thus, it is clear that the expected future
costs are about £285.
For each of the three analyses above, the impact
on total expected costs is between £1000 and
£2000. These are substantial increases for an
operation that costs about £3500. Most of these
costs are incurred in the current period and have
very little impact on future expected costs.
The effects on total expected costs over 20 years of
varying four factors affecting the level of expected
future costs are shown in Table 32: discount rate,
additional costs of revision, recipient age, and
revision rate. The results are modelled using the
assumptions for prostheses evaluated over the
long term (page 51).
The discount rate affects all costs incurred; the
further into the future the costs are incurred, the
greater the effect (i.e. the smaller the present value
of the discounted costs). Reducing the discount
rate from 6% to 0% results in an increase in the
current value of expected future costs of £143 when
calculated over 20 years. The discount rate used in
the model is 5%. The difference in costs between
an assumed rate of 5% and 6% is very small (£14).
The effect of a change in prosthesis price from
£250 to £1250 falls on both current and future
costs. From Table 31 it can be seen that an increase
of £1000 in prosthesis price results in increased
expected future costs of £1069 over 20 years.
Obviously £1000 of this increase occurs in the
current period; thus, the present value of expected
future costs is only about £70 over 20 years.
The effect of any additional costs of revision, that
is, revision costs in excess of the costs of a primary
replacement, occur, by definition, in the future.
These costs are thus subject to the effects of rate of
revision, survival of recipient and discount rate. Com¬
paring an extra revision cost of £3614 to no extra
cost of revision gives a small additional expected
future cost of over 20 years of £249. This means that,
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despite the higher level of skill needed for revision
surgery, the costs over 20 years are relatively low.
The probability of a recipient surviving to a time
when a revision may be needed is dependent on
age at operation. The increase in expected costs
over 20 years for a primary replacement in a
40-year-old compared with an 80-year-old man
is £378. This model incorporates a maximum
of 20 years costs. Obviously, an individual aged
40 years could incur at least two 20-year periods;
hence, the lifetime costs would be far greater.
However, the further into the future that the costs
are incurred, the lower their present value because
of the discount factor (see page 48 above) and
therefore the less 'important' they become.
It is clear from Table 32 that the revision rate has
the largest effect on the total expected costs over
20 years. A change in the revision rates of pros¬
theses from the best estimate of Charnley prosthesis
survival (approximately 1% revision.per year) to
5% per year results in additional expected costs
over 20 years of £1320. The costs over 20 years with
a 3% revision rate would be £4584 (£673 more than
a 1% revision rate (not shown)).
From Tables 31 and 32 it is apparent that the factors
affecting the total expected costs of THR by the
greatest amounts are prosthesis and hospital costs
and the revision rate.
TABLE 32 Effects on total expected costs over 20 years of









Additional costs of revision 4112 3863 249
'1
J
| Recipient age 4163 3785
x-x*x*y/«x«*x*x->»!
378 1
Revision rate 5230 391 la 1320 J
1 " Using 1 % per year revision rate 1
Does the relative cost-effectiveness of different
prostheses change as input costs are changed?
Given that, for named prostheses, prices and
revision rates are known, the variable input in
the model that will have a large impact on total
expected costs is hospital costs. In order to
establish any changes in the relative cost-
effectiveness of different prostheses, low and high
estimates of hospital costs (combined theatre and
ward costs) are modelled - that is, 60 minutes in
theatre and 9 days as an inpatient as the low cost
estimate and 246 minutes and 22 days as the high
cost estimate. The results are presented in Table 33.
From Table 33, it can be seen that there are very few
changes in the relative cost-effectiveness of prosthe¬
ses as hospital costs are changed. The prostheses
listed in the table are ranked according to the low
cost estimate. The McKee-Farrar and CAD prosthe¬
ses are the only ones to change order in the rank¬
ing when the higher hospital costs are modelled.
The McKee-Farrar prosthesis moves down the
ranking by two places and CAD by one place.
TABLE 33 Relative cost-effectiveness of different prostheses
using low and high estimates of hospital costs
x*s»x-x«x-x*x










Cemented alumina-alumina 2500 5941
| (age < 50 years)
| Howse 2613
1
§ Cemented alumina-alumina 2729







I Prostheses with less than 10 years survival data
I Cemented
| Miiller straight stem mi 5736
| Lubinus IP 2498 5938
1 CAD 251 1 5970





1 Omnifit 3040 6339
| Harris-Galante 3050 6496
| PCA 3063 6525
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The reason for the change in relative cost-
effectiveness of the McKee-Farrar is that the pros¬
thesis survival rate falls quite markedly after about
15 years (15-year survival 84%, 20-year survival
49%). As more revisions are needed, the increased
hospital costs impact to a greater extent on future
costs than for the other prostheses with lower
revision rates. The survival data for the McKee-
Farrar prosthesis were available and have been
used for each and every year up to 20 years. Such
detailed data were not available for other pros¬
theses and, hence, survival rates were assumed
to be linear. It may be that the survival rates of
other prostheses fall equally quickly as that of the
McKee-Farrar, thus increasing the high cost
estimate of other prostheses.
In the bottom half of Table 33, showing prostheses
with less than 10-years' survival data, the CAD
prosthesis moved down the ranking by one place
to below the Lubinus SP when higher hospital costs
were used. The assumed linear revision rates for
the CAD and Lubinus SP prostheses are similar
(0.007 and 0.004 per year, respectively). The reason
for the Lubinus SP being more expensive using low
hospital costs is that the prosthesis itself is more
expensive than the assumed price of the CAD
(£771 and £629, respectively, including cement).
As hospital costs increase, prosthesis price becomes
a smaller proportion of total costs and the higher
revision rate of the CAD becomes the most
influential factor on total expected costs.
Overall, the relative cost-effectiveness of different
prostheses does not appear to be altered under
assumptions of different hospital costs. The main
finding is that if revision rates increase dramatically
over time, increases in hospital costs will have a
greater impact on total expected costs than
lower revision rates.
The relationship between prosthesis price and
revision rate
For general reference, the relationship in terms of
expected total costs over 20 years between differ¬
ently priced prostheses, revision rates and discount
rates are shown in Table 34. Hospital costs in these
scenarios are assumed to be the same for all prices
of prosthesis. Prosthesis costs range from £400 to
£2000, revision rates from zero to 5% per year,
and the discount rate from zero to 6%.
Where the revision rate given in Table 34 is zero,
the total expected cost shown is the cost of primary
operation only. This is not affected by changes in
the discount rate as there are no future costs. The
important question to be answered from this
information is whether or not greater costs of
prosthesis result in lower total expected costs
because of lower expected revision rates.
Assuming an 'average' prosthesis price and revision
rate of £700 and 2%, respectively, with a 5% dis¬
count rate, Table 34 gives the total expected costs
as £4342 over 20 years. As expected, the higher the
cost of prosthesis, the lower the revision rate must
be to make the THR cost-effective in terms of total
expected costs. For a £1000 prosthesis to be com¬
parable in total expected costs with such a £700
prosthesis, revision rates must be 1% or less per
year over the 20 years. A £1500 prosthesis costs over
£100 more for just the primary operation so would
be required to have a zero revision rate even to be
considered in comparison to a £700/2% revision
rate prosthesis. Primary replacement costs for a
£2000 prosthesis are equivalent to total expected
costs over 20 years of a £700 prosthesis with a 4%
revision rate.
The cementless prostheses listed in Tables 27and 29
and the more expensive prostheses in Table 33 have
greater total expected costs under the assumptions
in this model than cemented/lower priced pros¬
theses. Cementless prostheses are generally more
expensive than cemented but may last longer in
younger patients. If this is the case then, in younger
patients, it could be expected than a £1500 prosthe¬
sis with a 0% or 1% revision rate may be more cost-
effective than a £700 prosthesis with, say, a 2% revi¬
sion rate. The relative cost-effectiveness of different
prices of prosthesis and revision rates in a 40-year-
old patient are presented in Table 35.
If the revision rate of a cemented prosthesis
(price £700) in a 40-year-old patient is 3% per
year over 20 years, the total expected costs would
be £5314. Using this as the comparison figure, it
is clear that more expensive prostheses can be
more cost-effective with a lower revision rate.
For example, assume a cementless prosthesis is
priced at £1500. With a 1% revision rate, this
prosthesis would be more cost-effective than our
£700/3% comparison (£5127 and £5314, respec¬
tively). Likewise, both a £1000/2% revision rate
and £2000/no revisions prosthesis would be more
cost-effective over 20 years (total expected costs
£5146 and £4985, respectively).
The conclusions that can be drawn from Tables 34
and 35, under the assumptions made in this model,
are that:
• for patients aged 70 years at primary THR, lower
priced prostheses with 1-2% revision rates are
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Total expected costs (£)
(0% discount rate) (5% discount rate) (6% discount rate)
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1 1 - 3803 3691 3675
I 2 4220 3997 3965
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usually more cost-effective than higher priced
prostheses even with lower revision rates
for younger patients, aged 40 years at primary
replacement, higher priced prostheses with low
revision rates can be more cost-effective than less
expensive ones with higher revision rates.
Summary and conclusions of the
economic analysis
The model presented above estimates the relative
cost-effectiveness of different prostheses in terms
of total expected costs. The results are intended
to assist decision-making, not to be a prescription
for policy.
The model is dependent upon a number of
simplifying assumptions because of limitations
in the data. These assumptions may affect both
the total expected costs and the relative cost-
effectiveness of prostheses in the following ways.
Total expected costs would increase and relative
cost-effectiveness may change if re-revisions were
included in the model. For a prosthesis with a
high revision rate, the cumulative effects of the
costs of re-revision would be greater than for
a prosthesis with a lower revision rate. For example,
in Tables 34 and 35, high cost/low revision pros¬
theses may become more cost-effective than low
cost/higher revision rate prostheses.
Data on the survival ofmany of the prostheses are
limited. Some survival data are only available for up
to 4 or 5 years. The model assumes linear extrap¬
olation of survival data to 20 years. The survival rate
ofmany prostheses may in fact fall (sometimes
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dramatically) over time. Increases in revision rates
to levels above those assumed will increase total
expected costs. Cost-effectiveness rankings will also
be changed if rates of revision of prostheses change
relative to each other.
The model also assumes that individuals who have
had a hip replacement have a mortality rate equal
to the general population for their age group. If,
however, as studies suggest, these individuals have
on average a lower life-expectancy, total expected
costs would be lower than estimated here because
of the greater number of individuals dying before
their prosthesis needs replacing.
Increases (decreases) in prosthesis costs used will
increase (decrease) total expected costs. Changes
in prosthesis prices relative to each other may also
change relative cost-effectiveness. Costs at specific
hospitals can be modelled to allow for differences
in purchaser prices.
The model does not calculate costs occurring after
20 years, although the present value of future costs
is reduced by the discount rate.
The general conclusions under the assumptions of
this model are summarised below.
• Compared with Charnley prosthesis survival data
from centres of excellence and a prosthesis cost
of £353 including cement, the model suggests
that a no revisions prosthesis should cost not
more than about £650 to have equivalent total
expected costs over 20 years (Table 25).
• Given the hip survival data used in the model,
the Stanmore prosthesis appears to be more
cost-effective over 20 years than the Charnley
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prosthesis; the Exeter Polished and Muller
straight stem are of similar cost-effectiveness
(Tables 21 and 29).
• Prosthesis cost, hospital costs and revision rate
are the components of the model that have the
biggest impact in terms of changing total
expected costs (Tables 31 and 32).
• Very high and very low estimates of hospital
costs change the total expected costs of
individual prostheses but have little effect
on their relative cost-effectiveness (Table 33).
• In 70-year-old (men), a low price prosthesis is
generally more cost-effective than a high price
prosthesis, even with a very low revision rate
{Table 34).
• In 40-year-old (men), prostheses with high
prices and low revision rates can be more
cost-effective than low priced prostheses with
higher failure rates (Table 35).
Despite data of variable quality, and limited
data on important characteristics such as long-
term'survival of prostheses, the approach based
on total expected costs enables robust conclu¬
sions to be drawn on choice of prostheses. This
approach also enables new prostheses to be
assessed against those for which good data are
available. The model allows new assessments
to be made relatively easily as new data
become available.
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Chapter 12
Conclusion
Health technology assessment deploys theperspectives and techniques of different
scientific disciplines in order to produce research-
based information of relevance to policy-making
and practice in the health service. This review has
employed health economics and systematic critical
review of clinical research to examine the issues of
costs and outcomes of hip prosthesis implantation.
Clinical decisions of surgeons as to the choice of
prosthesis for given patients take place in the con¬
text of a range of other factors beyond the evidence
regarding optimal outcomes. These include, for
example, the presumed ease of a revision operation
offered by different technologies, and a surgeons'
familiarity with certain models and the associated
surgical techniques (with regard to the latter, for
example, the newer cementation techniques are
reported to have diffused relatively slowly into
THR practice in the UK127).
The culture of the manufacture and clinical
application of hip prostheses is characterised
by a high level of innovation and experimentation.
New models are proliferating and many of the new
models are also among the most expensive. Clinical
outcomes during early postoperative follow-up are
unreliable as guides to future performance. This
means that comparative performance is difficult to
evaluate. The cost of the prosthesis is a significant
component of the total cost of the THR procedure.
A full policy analysis of the options for containing
costs and maintaining or improving quality of
hip prosthesis performance is beyond the scope
of this report. It can be noted that a surveillance
scheme for hip implants, based on the concept
of a 'recommended list', was agreed in 1981 but
not implemented. There are a number of possible
avenues, not necessarily mutually exclusive,
which might be considered in a policy appraisal.
These include:
• the concept of the lifetime care package for
healthcare commissioners, which includes a
quality incentive for the prosthesis supplier and
an insurance element for the clinical service
provider and healthcare commissioner,116
discussed in the context of the economic
model presented in this report
• nationally co-ordinated audit and the use
of registers such as those employed in the
Scandinavian countries
• the role of the national Medical Devices Agency,
providers and purchasers specifically in requir¬
ing reports of adverse incidents and generally in
the use ofmechanisms for monitoring outcomes
in terms of hip scores and prosthesis longevity
• implant standardisation programmes,128 which
can show cost savings and quality maintenance
using patient scoring systems to match prosthesis
type to expected demand placed upon
the prosthesis
• use of competitive bidding practices by hospitals
or consortia
• restriction of substantially new technologies to
high-quality multicentre controlled trials
• audit of standards of surgical training and
experience, especially with newer types of
prosthesis which require familiarity with new
instrumentation and techniques.
Improving effectiveness and cost-effectiveness of
total hip prostheses requires major commitment
from the many disciplines involved in health
technology assessment in this area, and the health
service and policy users of these assessments.
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Chapter 13
Summary and recommendations
In this summary the findings of our review ofevidence and the main results of our econ mic
model in estimadng the cost-effectiveness of alter¬
native hip prostheses are presented. It includes
recommendations for future research and sug¬
gestions regarding THR policy in the NHS. Policy
options relating to monitoring, innovation and
the diffusion of hip prosthesis technology were
suggested in the previous chapter, although a full
and detailed consideration of these awaits further
dedicated investigation.
Clinical research on hip
prosthesis technology
• Clinical outcomes of THR are measured by
prosthesis survival, radiographic measurement
and hip scoring. Clinical hip scoring performed
by clinicians is likely to underestimate the
qualitative significance of pain and functional
impairment for patients receiving hip implants.28
Incorporation of patient perspectives is inad¬
equate. Different studies define clinical outcome
measures in somewhat different ways, making
comparison of studies difficult.
• The great majority of studies appear in a small
number of specialist orthopaedic journals and
emanate from specialist orthopaedic centres and
departments, mainly in teaching hospitals. This
has a bearing on the generalisability of the results
of individual studies. The cemented Charnley
prosthesis is the most studied single model.
• About 12% of the reviewed studies originate in the
UK Length of follow-up is inadequate for the full
evaluation of the longevity ofmore recently intro¬
duced types of prosthesis. Evidence for association
between early radiographic signs of loosening and
migration and long-term prosthesis survival is
equivocal, although there is some evidence that
early radiographically defined failure predicts
later requirement for revision of the prosthesis.
• The majority of studies of the outcomes of hip
prostheses in primary THR are observational in
design. Few RCTs have been published. This
review maximises the use of studies with an
element of comparison between prosthesis types.
• Critical appraisal of relevant studies shows that,
with some exceptions, the methodological
quality of studies is generally poor. Especially
notable is the lack of reporting of a sample
size calculation in any of the reviewed studies.
Sample sizes actually reported in most studies
are notably smaller than would be recom¬
mended to achieve valid generalisable results.
• Given the generally poor methodological quality
of the reviewed studies, results for different types
of prostheses should be treated as estimates with
wide confidence intervals.
Comparative evidence for hip
prosthesis technologies
Taking the above points into account, the following
conclusions can be drawn about the performance
of different types of prosthetic hip technology on
the basis of this review. (Definitions of the different
types of prosthesis can be found in chapter 3.)
• Cemented designs in general show good survival
results at 10-15 years and beyond. Models with
good, published, comparable results (at 10 years
or more) include the Stanmore, Howse, Lubinus,
Exeter and Charnley. The rate of acetabular
revision in cemented implants remains proble¬
matical. There is some evidence that all-
polyethylene acetabular components are prefer¬
able to metal-backed designs in tenns of longevity
of the implant. Newer (second-generation)
cementation techniques in general provide
better results than traditional techniques.
• Evidence of short- to medium-term comparisons
of prosthesis longevity between non-cemented
porous-coated designs and cemented designs is
equivocal. The first 10-year survival results for
porous-coated models appear to bear comparison
with the cemented models after the same follow-
up period, especially taking into account the
relatively lower average age of the patient groups
implanted with the porous-coated models. One
comparative radiographic study suggests that ce¬
mented acetabular components performed better
than porous-coated designs but that porous-coated
stems performed better than cemented models.
• The comparative evidence suggests strongly that
thigh pain is a problem associated with cement-
less porous-coated implants, to which cemented
designs are not prone. In the observational
studies of porous-coated implants reviewed here,
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reports of its prevalence range from about 2%
to about 25% at 2-7 years follow-up, with several
studies reporung prevalences around the higher
25% level, even in non-loose stems.
• In contrast to porous-coated models, the small
number of studies of cementless HA-coated
models reportmild to moderate thigh pain
ranging from 0% to about 5% of patients at
2-5 years follow-up. This is a relatively good
result in comparison to reports of porous-coated
implants and requires further investigation.
• Radiographic studies of cemented versus
HA-coated designs suggest that HA-coating
has better early fixation and less migration than
cemented models. The lesser migration of HA-
coated models may be associated with less early
postoperative pain, according to one compar¬
ative study. However, with maximum follow-up
periods of only 3-4 years for this form of
fixation, longer-term study of survival and
clinical results is required.
• Hybrid prostheses appear to do well in the short
term but the available studies cannot give any
indications for their mid- or long-term perform¬
ance. Given wide confidence intervals, this type
of design can be regarded as comparable with the
best cemented designs for early (6-7 years) sur¬
vival. Their early survival is superior to uncement-
ed porous-coated implants, and early thigh pain
in cemented stem components in hybrid implants
is minimal or absent compared with porous-
coated designs. Longer follow-up, especially of
the coated acetabular component of hybrid
implants, is required to ascertain the medium
and long-term performance of this design.
• Little evidence is available about fully modular
prostheses. Theoretically, modularity permits
greater intraoperative flexibility for the surgeon
and potentially better component fit but further
evidence, especially comparison with cemented
implants, is required. One comparative study
suggests that a fully modular stem has performed
less well than cemented stems. Laboratory analy¬
sis of retrieved components suggests that mixed-
alloy components are more prone to corrosion
than single alloy devices.29
• The implications of laboratory studies of altern¬
ative bearing surface materials require further
assessment. The small amount of evidence for
the performance of hips with ceramic bearing
surfaces is equivocal. Wear rates are less than for
other materials at the articulating surface of the
joint. Comparative studies have suggested either
lower or equivalent revision rates for ceramic
versus cemented implants at medium-term
follow-up. Ceramic heads are common, but
major manufacturers are currently developing
metal-metal versions of common designs,
for which published evidence is lacking.
• The uncoated press-fit and resurfacing types of
hip prosthesis generally have survival results not¬
ably inferior to the other types of design available.
Economic modelling
• The economic model developed in this study
and presented in the report can be used to
model the cost-effectiveness of different hip
prostheses under any different resource and
clinical outcome assumptions which healthcare
practitioners and decision-makers might foresee.
The general conclusions under our assumptions
used in this model are summarised below.
• Prosthesis cost, hospital costs and the revision
rate are the components of the model that have
the biggest impact in terms of changing total
expected costs for THR procedures.
• Very high and very low estimates of hospital
costs change individual prostheses' total
expected costs but have little effect on their
cost-effectiveness relative to each other.
• Compared with survival data for the Charnley
cemented prosthesis from centres of excellence,
and assuming a prosthesis cost of £353 including
cement, the model suggests that even a no
revisions prosthesis should cost no more than
about £650 currently (1997 prices) to have
equivalent total expected costs over 20 years.
Only cemented prostheses are currently
available at this price.
• In 70-year-olds (men), a low price prosthesis is
generally more cost-effective than a high price
prosthesis, even with a very low revision rate.
• In 40-year-olds (men), prostheses with high,
prices and low revision rates can be more cost-
effective than low-priced prostheses with higher
failure rates.
Policy/service implications
The authors suggest that:
• mechanisms for improving support for the use
of appropriate prostheses could be examined in
a wide-ranging policy analysis, to include combi¬
nations of local contracting, coordinated audit
or monitoring, central UK registers, and regu¬
lation of new technologies via coordinated trials
• healthcare commissioners could consider model¬
ling costs of alternative prosthesis designs and
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models using their own local input resource
assumptions and outcome data, along the lines
of the model demonstrated in this report.
Given the variation in effectiveness of prosthesis
types, the authors suggest that commissioners and
providers could consider the following monitoring
issues when developing policy.
• The range and extent of use of prostheses known
to have results poorer than the best cemented
designs, such as the Stanmore, Howse, Lubinus,
Exeter and Charnley prostheses.
• In the case of substantively new designs, appro¬
priate monitoring and evaluation (including
cost dimensions) prior to diffusion into
routine practice.
• The extent of implantation of different design
types (such as cemented, hybrid, porous) in
relation to age-groups of patients, seeking audit
of clinical and patient outcomes.
• Routine rates for different types of prosthesis -
including revision (and re-revision) rates - as
proportions of total THR rates for the provider/
NHS Trust, taking into account status as general




• Improvements should be sought in the design
and reporting of the generality of research
studies in this area. Notable aspects are sample
sizes, reporting of data on characteristics of
the study group or groups, use of blinding
or independent evaluation as appropriate,
and reporting of patient selection criteria
and procedures.
• Further inclusion of patient-derived quality-
of-life measures in studies of hip prosthesis
performance is essential. Clinical hip scoring
systems do not take account of the patient's
point of view in assessing outcomes.
• Further review from existing studies of short-
term hip score outcomes could yield valuable
information about pain and everyday activity
during the early 'settling down' postoperative
period, which appears to vary between different
types of prosthesis.
s The existing clinical research on THR assumes
that given tolerable pain and physical function,
longevity of the implant is the primary goal.
This may be the case from the patients' perspec¬
tive also but this has not been demonstrated.
If ease of revision were an important criterion
from the patient's perspecdve as well as from the
surgeon's then the choice of implant would be
affected. Patients' values and choices regarding
quality of life in relation to the perceived risk
of undergoing a revision operation should be
investigated. This applies especially to younger
and/or more active patients for whom revision
is more likely.
• There is scope for review of further good
quality studies, not included in this review, on
the mechanics of loosening in different types
of prostheses.
• New primary studies of the mechanics of
loosening could employ radiographic techniques
and/or autopsy limb retrieval approaches.
Prosthesis types
• Reporting of longer follow-up studies especially
of the hybrid and cementless HA-coated models
is required in order to assess further the early
promising outcomes of these technologies.
Longer follow-up of the cOated acetabular com¬
ponent of hybrid implants is required to ascer¬
tain the medium and long-term performance
of this design.
• Results for thigh pain in HA-coated models
appear relatively good in comparison to
reports of porous-coated implants, and this
requires further examination for longer follow-
up periods. The extent and significance to
patients of thigh pain associated with porous-
and HA-coated implants should be assessed.
• The implications of laboratory studies of
alternative bearing surface materials require
further review and investigation.
• Porous-coated cementless designs should be
monitored further where already implanted
to assess longevity.
• Fully modular designs may offer advantages
in surgical procedure but the lengths of
follow-up are currently insufficient to establish
patient benefits or problems of this type
of design.
• In the past there has appeared to be reluc¬
tance, inertia or lack of resources in many
orthopaedic departments in the UK to adopt
new cementation techniques for cemented
prostheses.127 More recent information is
required on the use of these methods so
that, given the better outcomes generally
associated with them, their use can
be encouraged.
• Further exploration is required of associations
between radiographic signs of loosening/
migration and later mechanical failure of differ¬
ent designs. Insufficient data exist on the pre¬
dictive power of radiographic measurements. 6.
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Appendix I
Data tables and appraisal tables
The Data Tables, which include data extractedfrom all the studies include in this review, and
the Appraisal Tables, the detailed checklist-based
appraisals of these studies, form the major part of
this appendix.
However, given the high value placed upon -
and the relative scarcity of- RCTs in the scientific
orthopaedic literature on hip prostheses, a brief
summary of each of the RCTs included in this
review is presented first. Details of the critical
appraisal of each are in the appraisal tables.
Studies with reference numbers are mentioned
in the main text.
Individual summaries of RCTs
Bourne and colleagues, I995;45
Rorabeck and colleagues, I99646
There have been a number of reports of this
patient population. These two papers present
the most recent results.
All patients were operated on or supervised by two
senior surgeons using the Mallory Head prosthesis,
either cemented or press-fit. Originally 250 patients
were recruited from a group with an age range of
18-75 years, and were stratified by age and surgeon.
Diagnosis was primary or secondary osteoarthrids
of the hip without additional life threatening
illnesses. Results of clinical aspects were reported
with a 5-year follow-up (number of patients not
stated) and for radiographic analysis with a 4-year
follow-up (147 patients). Patients and clinical
observers were blinded. All clinical assessments
(for example, Harris Score, d'Aubigne Score and
Sickness Impact Profile) were almost identical for
each group both pre- and postoperatively. There
was no subsidence in the cemented stems but
14% of press-fit stems subsided by 3-5 mm. No
revisions were required within the 4 years and
no press-fit components or cemented stems
were loose; however, 26% of the cemented
cups were termed definitely or probably
loose. C-rated.
Bradley and Ledd, I99234
In this study the Furlong (HA-coated prosthesis,
n = 97) was compared with the Charnley (n = 73).
The patients (with primary osteoarthritis and of
average age 68 years, range 45-75 years) were
randomly allocated by year of birth, even num¬
bered years to the Furlong, odd numbers to the
Charnley (any patient technically unsuitable for
the HA-coated prosthesis were excluded irrespec¬
tive of their year of birth). This paper reported
on 139 patients with follow-up of 1 year and
74 patients with 2 years. Patients were seen pre-
and postoperatively at their homes by a nurse
practitioner, radiographic assessment took place
at hospital at similar time intervals. The results
at 1 year and 2 years were very similar in both
groups (that is, numbers with no pain or limp,
walking distance and use 'ofwalking aids, ability
to climb stairs and put on shoes/socks). No
patients were lost to follow-up but two in each
group died of unrelated causes. There were no
revisions or evidence of loosening. C-rated.
Carlsson and colleagues, 1995
Originally 352 patients were included in this
study from five Swedish orthopaedic departments
(separate randomisation was performed at each
centre, where surgical approach and prosthesis
type differed). Those with radiographic loosening
and diagnoses other than primary arthrosis were
excluded (among others) leaving 190 hips. Three
of the prostheses studied had a large collar
(Lubinus, Harris Design 2 and Scanhip) while
the Exeter and Charnley were collarless. Resorp¬
tion of the resected femoral neck was more often
observed in prostheses with a true collar (odds
ratio at 5 years postoperatively 4.1, p< 0.001) and
to a greater extent (p < 0.001). No details were
given either of the patients or if the assessments
were performed blindly and/or independently
of the operating surgeon. C-rated.
Ciccotti and colleagues, 1994
Primary cementless THRs were inserted
into 60 patients with osteoarthritis (mean age
63-66 years). They were matched for age and
weight prior to randomisation (no details) to
HA- or porous-coated Taperloc prostheses and
to postoperative weight-bearing status (at 6 or
12 weeks), thus giving four groups. Eight 0.8 mm
tantalum markers were also positioned in the bone
during the operation. All patients were assessed
after 2 years. No differences were found between
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the groups either relating to the coating on the
prostheses or to the timing of weight-bearing
status as measured by Charnley scores (pre- or
postoperatively) or by Visual Analogue Scales for
thigh pain. Migration was less than 1.40 mm in
all groups and no revisions were reported to
be necessary within the 2 years. C-rated.
Godsiff and colleagues, I99225
In this study 30 cemented were compared with
28 cementless femoral components (Ring pros¬
thesis) in patients with an age range of 55-74 years
and a diagnosis of primary osteoarthritis of the hip
only. Patients were assigned to a group by choosing
one out of two envelopes themselves and were
blinded to the result. Surgery was by one of two
surgeons and the clinical assessment was by an
independent, non-orthopaedic medical practi¬
tioner. At 2 years the two groups (n = 47) reported
a similar pain incidence, the cementless group
having had more pain at 4 and 12 months. By
2 years 96% cemented and 62% cementless did
not require walking aids (p, 0.01-0.05). Prelim¬
inary results seemed to indicate cemented to
be superior to cementless; however, because
of unacceptable levels of femoral breakages at
3-5 years, the authors withdrew the prosthesis.
A-rated.
Jacobsson and colleagues, 1994'14
Two senior surgeons operated on 56 patients
(24 women, 32 men, mean age 52 years) ofwhom
75% had a diagnosis of osteoarthritis, the remain¬
der having various reasons for the unilateral hip
operation. Patients were matched in pairs for sex,
age, weight and radiographic appearance before
being randomly selected (no details ofmethod) to
have a Butel (stem made of four rods for flexibility)
or a PCA (rigid) stem (three different press-fit cups
were used). Each pair was operated on by the same
surgeon and were followed-up for 3 years. The PCA
stem gave better results as assessed by Harris Hip
Scores (mean 94.4 compared with 78.5 for Butel,
/►value not given) and the number of prostheses
definitely or probably loose (PCA 18%, Butel 86%).
Both groups required three hip revisions because
of loosening (one further Butel hip was revised
for other reasons). C-rated.
Karrholm and colleagues, 1994b42
A computer program was used to randomly allocate
the 64 patients (age range 58-66 years) to three
study groups. The patients were stratified by age,
sex, weight, bone quality and diagnosis (primary
or non-inflammatory secondary osteoarthritis).
The hips had the Ti-Fit femoral component
inserted with a press-fit acetabular component
by one of four surgeons in one of two hospitals.
The femoral stems were inserted with either
cement (n = 20), an HA-coating (n = 23) or were
porous-coated (n = 21). Six 0.8 mm tantalum
markers were inserted into the femoral com¬
ponent. After 2 years the cemented and porous-
coated stems had subsided more than the HA-
coated (p= 0.002 and 0.02, respectively). The
HA-coated components also rotated less than the
cemented stems (p = 0.03). The Harris Hip and
Pain Scores did not differ significantly between
the groups. Pain or discomfort in the thigh was
reported in two cemented, five HA-coated and
eight porous-coated prostheses (/>=?). There
were no revisions within the 2 years. C-rated.
Kelley and colleagues, 1993
A total of 84 hips in 84 patients were randomly
assigned a Harris Design 2 prosthesis either with
(n = 44) orwithout (n = 40) a collar (method of
randomisation not described). The operations
were performed by two surgeons. After an average
follow-up period of 4.6 years (range 2-7 years)
32 patients with collarless (mean age 70 years) and
38 with collared prostheses (mean age 68 years)
were available for study (six patients died from
unrelated causes). Patient diagnosis was mainly
degenerative joint disease (79%). Postoperative
pain and mobility levels were similar in the two
groups as were the Harris Hip Scores. The amount
ofmigration or radiolucency at the bone-cement
interface did not differ significantly between them
but the collar seemed to alter subsidence in the
hips (mean 0.5 mm, as opposed to a mean of
2 mm for the collarless prostheses, p< 0.05). In
all, 5% of collared and 9% of collarless prostheses
required revision because of aseptic loosening
of the femoral component (p=?). C-rated.
Krismer and colleagues, 1994
In this study, migration was compared in two
acetabular components - RM cup (HA-coated with
a CLS stem) and PCA cup (porous-coated with a
PCA stem). The patients (age range 50-65 years)
were stratified by age and the two surgeons prior
to randomisation and were followed for 5.2 years
(mean). Diagnosis was primary or secondaiy osteo¬
arthritis only. Almost one-third of the patients were
lost or excluded from radiological assessment and
almost halfwere not clinically evaluated. The
Standard System of Terminology for Reporting Results
(SSTRR) was used to compare clinical findings
such as Pain (no/mild pain: RM 94%, PCA 97%;
p= 0.05) and Limp Without Support (no/slight
limp: RM 90%, PCA 55%; p = 0.02). Migration
assessment found greater longitudinal movement
in the PCA cup. As loosening was defined as
Health Technology Assessment 1998; Vol. 2: No. 6
> 1 mm longitudinal migration, 12% RM and 27%
PCA cups were termed loose (p = 0.08). C-rated.
Marston and colleagues, 1996107
Random number tables were used to assign
213 patients to a Stanmore prosthesis and 200 to a
Charnley hip. For the 53 bilateral operations the
second hip was also randomised giving 14 patients
with two different prostheses. The mean age of the
360 patients (126 men, 234 women) was 67 years
and >85% had primary osteoarthritis. Various
surgeons at various grades performed the oper¬
ations using three different approaches. The mean
follow-up period was 6.5 years (range 5-10 years;
76 patients died and two were lost to follow-up)
and the hips were reviewed by an independent
observer. There were no differences in Harris
scores between the groups either pre- or post¬
operatively. Three Stanmore and four Charnley
stems were asymptomatically loose (the Stanmore
had radiolucent lines > 2 mm around the compo¬
nent). Revision rates did not vary greatly between
the prostheses (4.2% Stanmore, 3.5% Charnley).
However, the relative risk of requiring revision
was found to be 11.47 times greater for trainee
compared with qualified surgeons. C-rated.
Olsson and colleagues, I98538
A total of 119 padents had either a cemented
(Charnley, n = 61) or uncemented (Honnart
Patel-Garches, n = 59) prosthesis implanted.
The mean ages of the patients were 67 years and
64 years, respectively; 82% had a diagnosis of
osteoarthritis and 10% of rheumatoid arthritis
(with the remainder miscellaneous). The number
and grade of surgeons was not specified. Clinical
evaluation showed similar preoperation results but
the Charnley prosthesis performed better at the
1 year assessment - Harris Hip Score and Limp
(Charnley vs. Honnart Patel-Garches) p< 0.001;
maximal walking speed (Charnley vs. Honnart
Patel-Garches) p < 0.05 (twice as many patients
fitted with the latter device required an ambulator)'
device). A quantitative analysis of gait showed the
Honnart Patel-Garches group to have slightly better
preoperative results but 1 year after surgery the
Charnley group showed greater improvement.
No revisions were reported. C-rated.
Onsten and Carlsson, 1994
As a result of primary arthrosis, 60 patients
(age range 40-70 years) had a unilateral hip
replaced. A computer program randomised them
to either a cemented, all polyethylene Charnley
socket (n = 30) or a cementless, porous-coated
Harris-Galante type 1 socket (n = 30). Any unstable
screws were removed from the Harris-Galante
prosthesis during the original operation (this did
not affect subsequent results) and between five and
ten 0.18 mm tantalum markers were inserted into
the pelvis and socket of both types to aid movement
analysis during the 2-year follow-up period. There
were no revisions reported. Harris Hip and Pain
Scores did not differ between the groups. There
were no overall differences in either migration or
rotation in any axis by 2 years but 15/27 (55.5%)
Charnley and 28/30 (93.3%) Harris Galante
sockets displayed "significant" movement at
2 years (p = 0.001). C-rated.
Onsten and colleagues, 1994"
Charnley femoral components were inserted
bilaterally, under the same anaesthesia, into
29 patients with primary osteoarthritis by one of
three surgeons. A Harris-Galante type 1 acetabular
component was randomly implanted in one hip
and a Charnley acetabular cemented component
into the other. Tantalum balls (0.8 mm diameter)
were inserted into the pelvis and acetabular cup
during the operation. In all, 21 patients (42 hips)
were studied (age range 41-76 years) for an
average of 27 months. Five Charnley and three
Harris-Galante cups did not move at all. The
maximum migration (in any direction) was 1.7
and 2.1 mm, and maximum rotation was 2.2 and
2.0 degrees for the Harris-Galante and Charnley
prostheses, respectively. There were no differences
in the mean values of absolute migration between
the groups in any direction (p = 0.06-0.98) but
there were in the mean values of absolute rotation
(p = 0.08-0.008) - Harris-Galante hips rotating
the most. C-rated.
Reigstad and colleagues, 19864'
In all, 155 Muller and 149 ICLH prostheses
were implanted into 231 patients (age range
60-79 years) by 13 surgeons. All patients in this
study were diagnosed with osteoarthritis of the
hip (excluding those with heavy bone loss in the
femoral head or earlier fracture of the femoral
neck) and had a mean follow-up of 48.5 months.
No Muller hips were revised as opposed to 8.7%
ICLH (p< 0.001), and, in addition, one component
(0.6%) was loose compared to 12 (8%), respec¬
tively. Postoperatively, the Muller group had con¬
sistently higher scores than the ICLH group on
all three modified Merle d'Aubigne and Postel
parameters and total hip function. This reached
a level of significance (p< 0.001) by 1 year in
3/4 parameters. C-rated.
Soballe and colleagues, 1993
Migration of titanium-coated femoral components
and HA-coated stems in a Riometric prosthesis 8
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were compared in this RCT. The same surgeon
performed the surgery on all the patients (aged
48-68 years). The diagnosis was primary osteo-
arthrius (one patient had secondary osteoarthritis).
Radiographic analysis was blinded. All components
had migrated by B months but by 12 months the
titanium-coated stems had migrated further than
the HA-coated (p = 0.02), possibly indicating an
increased risk of subsequent loosening and revision
of the prosthesis. The HA-coated THR was also
associated with higher Harris Hip Scores and less
pain (measured by Visual Analogue Scale) at
12 months. A problem with the study was that
small numbers of patients were involved -
12 titanium-coated and 14 HA-coated prostheses
were available for clinical and conventional
radiographic assessment, and eight and seven,
respectively, for roentgen stereophoto-
grammetric analysis. C-rated.
Thanner and colleagues, 1995108
This comparison of two cement types - Boneloc
and Palacos - involved 30 hips in 30 patients, age
range 63—76 years, 27 ofwhom had primary osteo¬
arthritis. Tantalum markers (0.8 mm) were inserted
into the cup of the Spectrum EF prosthesis and the
pelvis. Full radiostereometric analysis was possible
in only 24 patients at 1 year (one Boneloc patient
had died). Palacos fixed cups had 'a small' lateral
migration while cups with Boneloc migrated
medially (p= 0.03) and proximally (p= 0.04);
1/16 Palacos stems subsided 0.27 mm whilst 6/13
Boneloc stems subsided 0.22-1.0 mm (p= 0.005).
Increased acetabular radiolucent lines and femoral
'relative cement-cortical bone contact' occurred
in the Boneloc group compared with the Palacos
group (p = 0.04 and p = 0.03, respectively). Harris
Hip and Pain Scores and a Visual Analogue Scale
for pain improved postoperatively (p = 0.0004—
0.002) but did not differ between the groups
(p, not significant). C-rated.
Wykman and colleagues, 1991"
A comparison of cemented (Charnley) and
cementless press-fit (Honnart Patel-Garches)
fixation in 150 patients; 15 in each group had
bilateral arthroplasties (age range 29-82 years;
diagnosis 77% osteoarthritis, 10% rheumatoid
arthritis, 13% miscellaneous). The two prostheses
had a similar probability of survival by 5-6 years
approximately (Charnley 88%, Honnart Patel-
Garches 82%; p, not significant). More revisions
were required in the Honnart Patel-Garches
group over 5 years (18.7%, all for loosening, all
but one causing mid-thigh pain) compared to
the Charnley group (11%, five for loosening, no
mid-thigh pain). A further five Honnart Patel-
Garches prostheses had possible need for revision
due to midthigh pain (increasing the revision rate
to 25%). Subsidence ofmore than 4 mm occurred
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(i) 124 in 124 patients
(ii) 126 in 124 patients
Radiographic data:
4.8 years (range 4-6);




















Outcome measures and results
Harris Hip Score (mean):
(i) Preoperative, 43; 5 years, 96
(ii) Preoperative, 42; 5 years, 97.
d'Aubigne Score:
(i) Preoperative, 9; 5 years, 17.4
(ii) Preoperative, 9; 5 years, 17.5.
WOMAC:
(i) and (ii) Preoperative pain score, 6;
5 years, I (similar findings for other
WOMAC dimensions).
MACTAR Index:
(i) Preoperative, 7.8; 5 years, I
(ii) Preoperative, 7.7; 5 years, 0.67.
Sickness Impact Profile -
Global Physical Score:
(i) Preoperative, 25.2; 5 years, 5.2
(ii) Preoperative, 23.3; 5 years, 5.0
(individual components gave similar results).
Time trade-off:
(i) Preoperative, 0.26; 5 years, 0.76
(ii) Preoperative, 0.30; 5 years, 0.61.
6-minute walk:
(i) Preoperative, 227 m;5 years, 392 m
(ii) Preoperative, 229 m; 5 years, 409 m;
p, not significant.
Migration/subsidence:
(i) I cup migrated, no subsidence
(ii) I cup migrated; 10 (14%) stems subsided
by 3-5 mm.
Revisions/loosening:
(i) 20 cups definitely/probably loose (26.3%);
no stems loose; no revisions
(ii) no revisions; no components loose.
Rating
p Bradley & Lee,
I 1992
| (UK)























Based on Harris Hip Scores:
No pain:(i) 98% (ii) 96%;p = ?
Absence of limp, walking aids used, walking
distance, stairs, movement: uniformly good
average results (p = ?).
No revisions or radiographic evidence of
loosening.
I Carlsson, et al.,
| 1995
i (Sweden)




















Not specified Resorption of the resected femoral neck:
patients: (i) 19% (ii) 19% (iii) 42% (iv) 56%
(v) 54%).
(Odds ratio, 4.1; p < 0.001; more often seen in
those with true collar. Amount of resorption is
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Outcome measures and results
Charnley scores:
Preoperative - no significant differences
between groups for pain, function or motion:
Postoperative - no significant difference in
pain, function and motion at 2 years.
Visual Analogue Scales for thigh pain:
No significant difference between groups
(2 years).
Migration:
No significant difference between groups -























































58 in 54 patients: Age range
(i) 30 55-74 years;
(ii) 28 . mean
Followed-up for (i) 64.4






(i) 28 (28 patients) Mean age
(ii) 28 (28 patients) 52 ± 8 years

























Authors' own 5-point scale:
Pain and mobility (at 2 years) -
(i) 15 pain free with no restriction
(ii) 15 pain free with no restriction.
Use of walking aids:
(i) 22 (96%) did not use any aids
(ii) 15 (62%) did not use any aids (p, 0.01 -0.05).
NB: At 3-5 years there were an unacceptable
number of stem breakages: discontinued
prosthesis use. (seeWilson, et al., 1992 in
RCT reference list).
Harris Hip Score:
(i) +3 years, mean 78.5 (42-100)
(ii) +3 years, mean 94.4 (59-100)
P = ?
Loosening:
(i) 24/28 (86%) loose or possibly loose
(ii) 5/28 (18%) loose or possibly loose
P = ?
Revisions:
(i) 4 (14.3%), 3 due to loosening
(ii) 3 (10.7%),all due to loosening.
Harris Hip Score (medians): C
(i) Preoperative, 43 (21-58):+2 years, 96 (64-100)
(ii) Preoperative,48 (14-67);+2 years,95 (63-100)
(iii) Preoperative, 39 (18-62); +2years, 94 (66-100)
p, not significant.
Harris Pain Score:
(i) Preoperative, 10 (0-20);+2 years, 44 (30-44)
(ii) Preoperative, 10 (0-30);+2 years, 40 (20-44)
(iii) Preoperative, 10 (0-30); +2 years, 40 (20-44)
p, not significant.
33 hips (31 patients), no or slight pain
Thigh pain (pain or discomfort in the thigh):
(i) 2; (ii) 5; (iii) 8; p, ?
Migration of centre of stem (minima/maxima):
(i) -0.8; -0.3 mm
(ii) -1.2;-0.8 mm
(iii) -2.7; -0.3 mm
(i) & (iii) subsided more than (ii);
(i) vs. (ii) p, 0.002; (ii) vs. (iii) p, 0.02.
Rotation (median absolute value of anterior-
posterior tilt about the transverse axis):
(i) 0.4; (ii) 0.2; (iii) 0.4 degrees
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Outcome measures and results Rating






















84 in 84 patients
Mean follow-up
4.6 years (range 2-7)
70
0) 38, (ii) 32
(0 61 (ii) 59
Follow-up: maximum

































(53 patients bilateral -




413 hips (59 by
questionnaire/interview,











(i) No/slight pain, 33/38 (87%)
(ii) No/slight pain, 27/32 (84%)
p, not significant.
Activity patterns:
(i) Able to ambulate unlimited distances,
17/38 (45%)
(ii) Able to ambulate unlimited distances,
14/32 (44%)
p, not significant.
Harris Hip Score (mean):
(i) 89.5; (ii) 86.7; (p > 0.05).
Migration: no significant differences in
movement or bone-cement interface
radiolucency between groups.
Subsidence: (i) Mean 0.5 mm (± 1.5);
(ii) Mean 2 mm (± 4); (p < 0.05).
Revisions/loosening:
(i) 2 (5.3%) revisions due to loose stems
(ii) 3 (9.4%) revisions due to loose stems
P.?
Mean age (SD):
(i) 58 years (4)





SSTRR system - Pain:
(i) No/mild pain, 29 patients (94%)
(ii) No/mild pain, 32 patients (97%)
p, 0.05.
SSTRR system - Limp without support:
(i) No/slight limp, 28 patients (90%)
(ii) No/slight limp, 18 patients (55%)
p, 0.02.
Migration:
(i) Longitudinal: mean 0.05 mm; maximum
mediolateral 0.10 mm; medial > 2 mm - 2 cups
(ii) Longitudinal: mean 0.34 mm; maximum
mediolateral 0.04 mm; medial > 2 mm - 2 cups.
Revision/loosening:
3 revisions: I septic loosening, 2 CLS stems
revised
(i) 5 (12%) cups loose
(ii) 12 (27%) cups loose
p, 0.08.
Harris score:
(i) Preoperative, 46.0; postoperative, 91.4
(ii) Preoperative, 46.0; postoperative, 91.2
p, not significant.
Asymptomatic loosening (radiolucent lines
> 2 mm):
(i) 3 stems and corresponding cups (average
subsidence for 57 stems at 7 years, 2.8 mm)
(ii) 4 stems and corresponding cups (average
subsidence for 51 stems at 7 years, 2.6 mm)
p, not significant
Revisions (all for suspected loosening):
(i) 9 (4.2%; I cup, 2 both, 5 stems, I
exploration)
(ii) 7 (3.5%; 5 stems, I both, I no details);
relative risk of requiring revision 11.47 times
greater for trainees (95% CI, 1.53-86.06);













Olsson, et al., 1985
(Sweden)
RCT; cemented




Grade of surgeon, Number of THRs, Patient age;
type of hospital, length of follow-up other patient
and surgical and number of variables
technique patients followed-up reported
Not specified (i) 61 in 61 patients Mean age:
General hospital




with trochanteric (i) 60-61
osteotomy (ii) 55-58 (depends Weight
(ii) posterior on assessment)
Heightwithout trochanteric
osteotomy Diagnosis

























(i) 30 in 30 patients




58 in 29 patients
Follow-up 27 months
(range, 23-49 months)
42 in 21 patients
| Reigstad, et al.,
| 1986
| (Norway)
RCT; cemented 13 surgeons, grades







135 ICLH and all
Miiller -
anterolateral








304 (231 patients) -
(i) 155; (ii) 149
+ 2 years, 296














Harris Hip Score: C
(i) Preoperative, 40; at I year, 89
(ii) Preoperative, 40; at I year, 78
Preoperative, p, not significant; at I year p < 0.001.
Limp (moderate/severe):
Preoperative: (i) 92%; (ii) 93%; p, not significant
Postoperative: (i) 20%; (ii) 45%; p < 0.001.
Maximal walking speed:
(i) Preoperative, 94 cm/s;at I year, 124 cm/s
(ii) Preoperative, 94 cm/s; at I year, 109 cm/s
Preoperative, p, not significant; at I year,p < 0.05;
twice as many in (ii) required ambulatory devices
compared with (i).
Quantitative Gait Analysis:
Preoperative, no significant differences between
groups, but (ii) consistently better results; at
+ I year, (i) had better results in all variables.
No revisions reported.
Harris Pain Score: C
(i) mean 42; (ii) mean 42.
Harris Hip Score:
(i) mean 91; (ii) mean 93.
Migration/rotation:
No overall differences between groups at 2 years.
Number of sockets displaying significant
movement at 2 years: (i) 15/27 (55.5%);
(ii) 28/30 (93%);p,0.001.
No revisions necessary by 2 years.
Charnley Score for both cup types:
pain: mean 6 (4-6); walking: mean 6 (3-6);
range of motion: mean 5 (2-6).
Maximum migration: (i) 1.7 mm;(ii) 2.1 mm.
Maximum rotation: (i) 2.2 degrees; (ii) 2.0
degrees; p = ? (5 Charnley and 3 Harris-Galante
cups did not move).
Mean values of absolute migration did not differ
between groups (p, 0.06-0.98).
Mean values of absolute rotation for the
cups around:
transverse axis: (i) 0.7; (ii) 0.4; p, 0.008
sagittal axis: (i) 0.6; (ii) 0.4; p, 0.03
longitudinal axis: (i) 0.7; (ii) 0.4; p, 0.08.
(i) Charnley modified d'Aubigne & Postel:
Pain: (i) preoperative, 1.65; +2 years, 5.93;
+5 years, 5.81
(ii) preoperative, 1.61; +2 years, 5.73 ;
+5 years, 5.53.
Walking: (i) preoperative, 1.70; +2 years, 5.82;
+5 years, 5.80
(ii) preoperative, 1.74;+2 years, 5.60**;
+5 years, 5.50.
Function: (i) preoperative, 6.82; +2 years, 16.41;
+5 years, 16.41
(ii) preoperative, 6.74; +2 years, 15.85 ;
+5 years, 14.97s;
*(i) vs. (ii): p, 0.001; ~(i) vs. (ii): p < 0.001; #(i) vs.
(ii): p, 0.014.
Migration/subsidence:
(i) cup: no migration; stem: I subsided 8 mm
(ii) cup: no migration (except in 3 revised);
stem: no subsidence in those not revised.
Revision/loosening:
(i) no revisions, I stem asymptomatically loose
(ii) 13 (8.7%) revised [(i) vs. (ii): p < 0.001],
12 loose (12 stem, 8 cup).
continued jij
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28 in 27 patients














Preoperative, (i) mean 48 (SEM 2.1); (ii) mean 56 (SEM 3.7);
At I year, (i) 87 (SEM 3.9); (ii) 98 (SEM 0.8)
P.?
Pain (Visual Analogue Scores):
At rest: (mean (SEM))
(i) Preoperative, 5.9 (0.8); at I year, 2.0 (0.9)
(ii) Preoperative, 5 (0.7); at I year, 0.42 (0.35)
p, not significant.
In function: (mean (SEM))
(i) Preoperative, 7.5 (0.67); at I year, 2.11 (0.8)
(ii) Preoperative, 7.0 (0.5); at I year, 0.64 (0.35)
p, not significant.
Maximal total point motion (mm) or migration:
(i) Mean 3.9 (SEM 0.8) (n = 8)
(ii) Mean 1.7 (SEM 0.4) (n = 7)
p < 0.05.
Maximum subsidence in both groups - 0.2 mm.
Calcar resorption - present equally in both.
! Thanner, RCT:













30 in 30 patients
Follow-up at I year






Harris Hip Score - median (range): C
(i) Preoperative, 51 (24-70); at I year, 90 (56-97)
(ii) Preoperative, 45 (22-61); at I year, 93 (65-99);
p, not significant.
Harris Pain Score - median (range):
(i) Preoperative, 20 (10-30);at I year,40 (20-44)
(ii) Preoperative,20 (10-20);at I year,40 (30-44)
p, not significant.
Pain Visual Analogue Scale (mm) - median (range):
(i) Preoperative, 67 (50-99); at I year, 6 (0-50)
(ii) Preoperative, 66 (25—100); at I year, 3 (0-37)
p, not significant
Harris scores and Visual Analogue Scale pre- vs. postoperative:
p. 0.0004-0.002.
Migration/subsidence:
(i) Cup: small lateral migration (no value); stem: 1/16 (6.25%)
subsided by 0.18 mm
(ii) Cup: migrated medially and proximally (no values); stem: 6/13
(46%) subsided by 0.22-1.0 mm;
Stem: (i) vs. (ii) for all observations 6 weeks-12 months: p, 0.005.
Radiolucent lines:
Cup:(i) average 11% (0-47); (ii) average 30% (0-50) of
acetabular cup circumference involved (p,0.04);
Stem (increased relative cement-cortical bone contact):
(i) median 41% (9-59); (ii) median 50% (33-65); p, 0.03.
































(i) 90 hips in
75 patients(?)














Harris Hip Score (medians): C
(i) Preoperative, 37.3; 3-5 years, 95.3; 54 patients (79%)
good/excellent; (ii) Preoperative, 38.1; 3-5 years, 88.7;
48 patients (70%) good/excellent; p, not significant.
Harris Pain Score (mean):
(i) Preoperative, 13.5; 3-5 years, 96% patients slight or no pain
(ii) Preoperative, 14.7; 3-5 years, 86% patients slight or no pain;
p, not significant.
Mid-thigh pain:
(i) none;(ii) 6 months, 46/72 (64%) had pain;> 3 years, 18/46 still
in pain, all have been/will be revised.
Calcar resorption > 2 mm:
(i) 38%; (ii) 58%; p,?
Migration/subsidence:
(i) cup: 59% had radiolucent zone > 2 mm between bone and
cement; stem: 16% subsided > I mm, 5% > 4 mm (radiolucent
zone > 2 mm = 16% between bone and cement); (ii) cup: 67%
had non-continuous radiolucent zone between implant and bone,
9% > 2 mm; stem: 66% subsided > I mm, 33% > 4 mm (all had
non-continuous radiolucent zone between stem and bone).
"Failure events", 22 patients (15%):
(i) 8 (11%),5 due to loosening;(ii) 14 (19%),all due to loosening.
Survival analysis (at 5-6 years approximately):
(i) 88%; (ii) 82%.
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Grade of surgeon, Number of THRs, Patient age; Outcome measures and results
type of hospital, length of follow-up other patient
and surgical and number of variables


































iii (xiii) Richards II
i (xiv) McKee-
i'i Arden
I (xv) Lubinus SP
plus more (not
ii stated)
s Cemented: i, ii, iii,













98 in 89 patients
Follow-up I year
(i) 35 in 31 patients







































(i) More frequent proximal line formation:
(i) 20-25.7% vs. (ii) 3.2%; p < 0.02
(ii) More frequent distal line formation:
(ii) 74.3—82.9% vs. (i) 40-42.9%; p <0.001.
Heterotopic bone formation:
(i) No formation 39.4%; (ii) No formation, 58.%;
p, not significant.
Calcar resorption (% of cases):
(i) 58.8%; (ii) 5.7%; p, not significant.
Stem subsidence (% of cases):
(i) 14.3%; (ii) 0%; p, not significant-
Revisions: none reported.
C
Aseptic loosening main cause of both reoperation
(54%) and revision (74%).
Observed survival without revision for loosening:
(i) 63% at 10 years
(ii) 9^% at 10 years
(iii) not specified
(iv) 93% at 9 years
(v) 85% at 10 years
(vi) not specified
(vii) 84% at 10 years
(viii) 28% at 10 years
(ix) 89% at 10 years
(x) 95% at 6 years
(xi) 95% at 8 years





Significant increase in cup loosening in rheumatoid
arthritis patients > 65 years compared with osteo¬
arthritis (p = ?)•Osteoarthritis: men had more
loosening than women in all age groups, with the
55-64 years group having the highest risk for revision
for men; women have decreasing risk of loosening
with increasing age (p < 0.001). Rheumatoid arthritis:
younger, more active patients have an increased risk
of revision due to loosening.
Hospitals: regional (secondary) hospitals had better
results than university (tertiary) or community
(primary) hospitals with respect to loosening
rates (p < 0.001).
ij: Bankston, Retrospective -






































(i) 0.06 mm/y; (ii) 0.05 mm/y; (iii) 0.08 mm/y;
p, not significant
Volumetric wear rates:
(i) 34.76 mm3/y;(ii) 33.72 mm3/y;(iii) 46.14 mm3/y;
p, not significant.
Acetabular progressive radiolucencies in at least one
zone: (i) 24.7%; (ii) 11.7%; (iii) 26.0%; (ii) < (i).p, 0.04;
(ii) < (iii), p, 0.005.
Incidence of complete: (i) 11.7%; (ii) 6.5%; (iii) 3.9%;
between groups, p, not significant
Femoral osteolysis/subsidence (> 5 mm):
(i) Osteolysis: 3.9%; subsid: 19.5%
(ii) Osteolysis: 5.2%; subsidence: 20.8%
(iii) Osteolysis: 5.2%; subsidence: 5.2%.
Osteolysis: p, not significant
Subsidence: (iii) < (i), p, 0.008; (iii) < (ii), p, -0.004.
88
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Outcome measures and results Rating








































(i) 208; (ii) 982
Follow-up:
Median 8 years






















- complete progressive radiolucencies:
(i) 13.0%; (ii) 5.4%; p, 0.75;





No differences between results from each centre so C
combined results reported.
Pain:82.3% (1431),none; 14.3% (248),mild;2.7% (47),
moderate; 0.7% (15), severe.
Activity level: 86.4% (1503), normal; 10.9% (190), good;
2.1% (37), fair; 0.5% (9), poor.
Range of movement 90.8% (1579), > 90° flexion; 7.9%
(139), 60-89°; 1.2% (20), 30-59°; 0.1 % (I), 0-29°.
Migration: no cup migrated more than 5 mm.
Revisions/loosening: 18 (1.03%) revised; 10 due to
stem loosening (2 cups revised at same time), I due
to traumatic cup loosening.
Revisions/loosening: 81 /1190 (7%) revised, 38 due to C
aseptic loosening. No significant difference in cause
of failure for different implants (p > 0.5).
Survival rate at 10 years:
(i) 84% ± 6.3 for a 'revision' end-point (n = 107);
44% ± 8.7 for 'onset of slight pain' end-point
(ii) 93% ± 2.6 for a revision end-point (n = 332.5);
48% ± 4.9 for onset of slight pain end-point
Survivorship curves: similar for both (i) and (ii) up
to 8 years; after this (i) significantly worse for 4/5 end-
points (revision or onset of different levels of pain),
p, 0.026-0.004.
Cementing techniques:
(ii) I st generation, 1973-79 (n = 560) - 10-year survival
without revision 91.6%; 2nd generation, 1979-86 (n = 422)
- 10-year survival without revision 97.4%; p, 0.005.
(i) All hips (88% pre-1977) vs. (ii) n = 280 (1973-77) -
10-year survival (no revision), (i) 79.1 %, (ii) 86.3%;
p, 0.07.
Thigh pain: (
(i) 3% - 3 (patients (2 mild, I moderate); none
required analgesic, none had pain at I year;
(ii) 23%: 3 with severe pain (no further details,
previously reported).
Average Harris scores:
(i) Thigh pain group: hip 88, pain 38; no thigh pain
group: hip 96, pain 43;
(ii) No details, previously reported.
Radiographic analysis:
(i) Positioning - neutral 63%,mildly valgus 10%, mildly
varus 28%; fit - no patient had good metaphyseal fit,
27% had good isthmal fit; subsidence: 10 patients (11 %);
8 patients, 0-6 months (6 patients 3-5 mm, 2 patients
6-8 mm); I patient, 6-12 months by 6-8 mm; I with
thigh pain, 3-5 mm by 6 months; calcar changes:
common in those with thigh pain (100%) and without
(84%); cortical hypertrophy and cancellous hypertrophy
uncommon in both subgroups.
(ii) Positive correlations between thigh pain and fol¬
lowing features made (reported in more detail previ¬
ously): (a) tight diaphyseal fit through the isthmus; (b)
subsidence > 2 mm; (c) periosteal cortical hypertrophy
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type technique patients followed-up reported
;ij Callaghan,


























(a) n = 897 Not specified (a) Effect of cup design: C
(i) 330 (> 20 years) (i) cup revision incidence 10.6% - definitely/probably
(ii) 89 (16-22 years) loose 12.8%; stem revision incidence 3.2% -
(iii) 187 (> 10 years) definitely/probably loose 4.3%;
(iv) 130 (5 years) (ii) cup revision incidence 13% - definitely/probably
(v) 100 (> 7 years) loose 37%; stem revision incidence 2.2% -
(vi) 61 (> 5 years) definitely/probably loose 6.1 %;
(iii) cup loosening 24.5% (metal-backed 17%,
(b) n - 210 all-polyethylene 30%); stem loosening 1.2%;
(I)! (20 years) no revjsjons or loosening;
(Ii) I (15 years) (v) CUp revision incidence 4% (migration incidence
(iii) ? (10 years) 5% _ jnc|U(jes 2 revised cases);
(iv) ? (7 years) (vj) no revisions (I migration);
(v) ? (5 years)
(b)Wear rates:
Less wear in Harris-Galante I component









































(i) 45; (ii) 38; (iii) 6; (iv)
3; (vi) 8
Not specified 100 revisions performed, 87 due to suspected
loosening (7 had no radiolucent lines around the
socket and were stable at surgery).
Charnley radiographic classification (modified by
author):
Grade I - total number sockets 7; number of loose
sockets 0 (0%);
Grade 2 - total 31; loose 4 (13%);
Grade 3 - total 28; loose 4 (14%);
Grade 4 - total 34; loose 22 (65%);
(or Grade 4 - total 7, loose 4 (57%); and Grade 5 -
total 27, loose 18 (67%)).
12/34 (35%) sockets had obvious migration or
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(i) Aufranc-Turner General hospital
(ii) T-28

























„ _ _ „ Specialist hospital
CAD, Muller, K



































(i) Average 12 years
(ii) ? (58 patients,
10-14 years)
(iii) average 7.5 years?
(range 5-8)
(iv) 6 years
(v) minimum 5 years
(vi)!
(0 336





Not specified (i) 22% rate of revision for aseptic loosening, most C
after 6 years; loosening due to progressive bone-
cement radiolucencies. In absence of loosening, bone
loss or osteolysis not seen.
(ii) Stem loosening greater with I st generation
cementing techniques than 2nd but osteolysis not seen
in either group unless loosening occurred. In
58 patients (follow-up 10-14 years), 3.4% cups revised
for loosening, 21% had continous radiolucencies but
no osteolysis apparent.
(iii) 28 mm head group: revision for loosening
2.8%, radiographic loosening 22%, osteolysis 0%
after 5-8 years. For all: revision for loosening 2.1%;
average time to revision 91 months.
(iv) Revision for loosening 3.0%; average time to
revision 71 months.
(v) 75/125 had polyethylene thickness < 6 mm; 13
revised for liner wear or fracture (average 41 months),
19 with eccentric wear, 15 with osteolysis. Remaining
50/125 had liner > 6 mm; 2 revised for liner fracture,
5 for eccentric wear, 4 were osteolytic.
(vi) "Have not been associated with the catastrophic
failure rate seen in the ACS cups" - no further
details given.
101 in 85 patients
Follow-up:
(i) vs. (ii) = 5 years
(i) subgroup analysis 5
years vs. 10.7 years
78 (62 patients)




























Modified d'Aubigne-Postel scores: C
All patients (both groups) - excellent/good results.
Cups with radiolucent lines at 5 years:
(i) 71%, mean cup radiolucent score 1.15 ± 1.73;
(ii) 60%, mean cup radiolucent score 0.19 ± 0.25;
p < 0.025.
Radiolucency, 10 years vs. 5 years:
(i) mean 1.6:1.15 mm.
Revisions/loosening:
(i) no revisions, 3 cups (2 patients) loose by 10 years;
(ii) no revisions, no loosening by 5 years.
Modified d'Aubigne-Postel (grades 5-6): C
(i) pain 82.7%; function 73.4%; motion 75.0%;
(ii) pain 83.6%; function 77.1%; motion 81.8%.
p, I (unrevised hips only; function: Charnley class
C excluded).
Wear (cup):
(i) 1-2 mm, 15.7%; 3-4 mm, 4.2%;
(ii) 1-2 mm, 11.7%; 3-4 mm, 2.5%. p,!
Resorption (stem):
(i) 1-2 mm, 3.8%; 3-4 mm, 13.3%; 5 mm+, 9.4%;
(ii) 1-2 mm, 4.1%; 3-4 mm, 6.2%; 5mm+, 7.4%. p, ?
Radiolucency (stem):
(i) 13.2%; maximum width: 2 mm, 2.9%; 3 mm+, 3.4%.
(ii) 20.4%; maximum width: 2 mm, 8.1 %; 3 mm+, 5.0%;
P,}-
Radiolucency (cup):
(i) 49.4%; maximum width: 2 mm, 8.2%; 3 mm+, 2.5%.
(ii) 50.7%; maximum width: 2 mm, 5.8%; 3 mm+, 3.6%;
P>!
Migration/subsidence:
stem: (i) 2 mm, 5.0%; 3 mm+, 7.1%;
(ii) 2 mm, 2.3%; 3 mm+, 6.8%;
cup: (i) 1-2 mm, 2.5%, 3 mm+, 2.0%;
(ii) I-2 mm, 2.0%; 3 mm+, 2.1%./>,?
Probable loosening (no revisions):
(i) 9/264 (3.4%): cup 1.9%,stem 1.6%, both 0%;
(ii) 27/402 (6.7%): cup 2%, stem 3.7%, both 1%.
10-year survival probability related to loosening:
(i) 99.35%; (ii) 86.8%; (95% CI, 80.9-92.8; p < 0.0001).
Revisions:
(i) 21 (8%). Loosening: cup only I; stem only 2; both 2;
(ii) 38 (9%). Loosening: cup only 2; stem only 18; both 9.
continued
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| (USA) Various types ofprosthesis used
| but a 'significant
I percentage' were:
1 (i) AML Porcoat
| (ii) Dual-Lock





Grade of surgeon, Number of THRs, Patient age;
type of hospital, length of follow-up other patient
and surgical and number of variables
technique patients followed-up reported





posterolateral 38%; (i) 39 Diagnosis
anterior 14%; trans¬ (ii) 18
trochanteric 7% (iii) 9 Side of body
Rating
Occurrence of heterotopic bone formation (HBF):
Total hip: cemented, 15/22 (68%); noncemented,
10/17(59%).
Hemi-arthroplasty: cemented, 9/13 (69%);
noncemented, 2/5 (40%).
Resurfacing:5/9 (56%); (11/17 (65%) revision cases
had HBF).
No significant correlation between type of
procedure and % bone formation.
Pain and HBF, no correlation; range of movement
























(i) n = 67
(ii) n = 61
> 50 years
(i) n = 346





















1 (ix) Lubinus SP/
Lubinus SP






































Best results if: C
(a) > 2 mm and < 5 mm proximal medial thickness
of cement mantle; (b) < 2 mm proximal medial
thickness of cancellous bone; (c) stem filled more
than half of distal part of medullary canal; (d) stem
in neutral orientation.
Worst results if: •
(a) cement mantle > 10 mm thick; (b) > 2 mm of
proximal medial thickness of cancellous bone; (c)
stem filled half or less of medullary canal; (d) varus
orientation.






(vi) Spectron/Lubinus SP, 4.96%
(vii) Biomet/Biomet, 1.25%
(viii) Spectron/Biofit, no revisions
(ix) Lubinus SP/Lubinus SP, no revisions
(x) Muller type/Muller type, 7.33%.
Revisions/loosening:
(i) 115 revised (1.7%), 63% due to loosening
(ii) 23 revised (1.4%), 48% due to loosening
(iii) 12 revised (0.9%), 83% due to loosening
(iv) 4 revised (0.4%), 25% due to loosening
(v) 12 revised (2.4), 25% due to loosening.
Other combinations, 18 revised (1.9%), 100% loose.









(i) 125 in 117 patients (i) 54 years












(i) & (ii), > 5 years
(iii) & (iv), 2 years
(i) Ac 2 years, 100 in
93 patients; at
> 5 years, 89 in
81 patients
(ii) At 2 years, 55 in
54 patients; at > 5
years, 38 in 37 patients
(iii) (\c 2 years, 41 in
38 patients;





Loosening (thigh pain needing analgesic or revision): C
(i) 22/89 (24.7%); (ii) 3/38 (7.9%); p. ?
Migration:
Rate of migration at > 5 year follow-up -
(i) 0.78 mm/y; (ii) 0.27 mm/y; p < 0.0001;
(i) loose hips 1.5 mm/y; stable hips 0.6 mm/y;
p< 0.0001;
(ii) loose hips 3.4 mm/y; stable hips 0.2 mm/y;p, ?
Amount of migration at 2-year follow-up -
(i) all (n = 100) 1.85 mm; no pain (n = 80) 1.45 mm;
(ii) all (n = 55) 0.55 mm; no pain (n = 52) 0.38 mm;
(iii) all (n = 41) 1.7 mm; no pain (n = 36) 1.3 mm;
(iv) all (n = 34) 0.4 mm; no pain (n = 34) 0.4 mm;
P.'
'Migration test':
Migration rate of 1.2 mm/y had 78% sensitivity and 86%
specificity for distinguishing hips which would fail.
(Group 4 at 4 years: no hips termed loose or revised;
techniques used in groups I and 3 were discontinued.)
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32 mm (2), 28
mm (9), 26 mm
















(i) 74 months (43-100)




Preoperative: (i) 49 (33-66); (ii) 53 (32-70);
P'-'
Latest follow-up: (i) 89 (40-100); (ii)97 (84-100);
p < 0.002.
Osteolysis:
(i) stem: 12/41 (29%) (5 loose); (ii) stem: 0;
p < 0.0002. No relationship between size of
femoral head and osteolysis.
Revisions/loosening:
(i) stem: 5 (12%) revised (4 due to loosening);
8 subsided/migrated; cup: no migration/revisions.
(ii) stem: no revisions (p < 0.02), all radiographically
stable, no radiolucent lines; cup: no migration/
revisions.
iji Hamada, et al., Retrospective
I 1993
1 (Japan) (i) Model Y





71 in 71 patients
Average follow-up
(maximum):
(i) 4 years 7 months
(6 years 9 months)
(ii) I year 8 months









Extent of press-fit (contact ratio) I year
postoperatively:
(i) Excellent 7; Good 8; Fair 11;
(ii) Excellent 23; Good 2; Fair 0;
P.!
Thigh pain:
(i) 11 /26 (42%) patients with pain for I -6 months
and 6-24 months postoperatively;
(ii) 2/25 (8%) patients with pain for I -3 months and



































< 65 years 31%
> 65 years 3%
Sex
Aseptic loosening (cumulative survival until revision C
due to loosening) caused 68% of 263 failures.
(i) Cup 99.4%, stem 98.3%, after 4.5 years
(ii) Cup 98.4%, stem 96.1% after 4.5 years; 2.3 times
more likely than (i) to need revision because of
loosening.
Revisions after 4.5 years:
(i)AII hips 2.7%; < 65 years 3.3%; women 1.9%;
men 4.5%;
(ii) All hips 6.5%; < 65 years 7.9%; women 6.3%;
men 6.8%.
Risk of revision: Uncemented hips at 2.0 times
higher risk than cemented when adjusted for sex and
age; increase in risk for patients aged < 60 years with
uncemented hips is 2.9 compared with 2.4 and 1.2 in
those aged 60-64 and > 65 years, respectively.
Havelin, et al., Retrospective Not specified -
1995
; (Norway)























Revision rates for aseptic loosening (overall 4.5%)
and cumulative survival after 4.5 years:
(i) 18.6% & 81.4%; (ii) < 1% & 99.5%;
(iii) 13.6% & 86.4%; (iv) 3.6% & 96.2%;
(v) < 1% & 99.5%; (vi) 5.6% & 94.4%;
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72 in 36 patients
Most recent visit:
(i) 8.1 years (2.7-18.2)




60 in 30 patients



































Retrospective Not specified 231 in 203 patients Age not
specified
Cup: Universal Specialist hospital Follow-up:
cup design
Posterior without
Minimum 3 years; Sex matched
maximum 5 years but not
Stem: Bimetric trochanteric specified
(i) cemented osteotomy (i) 97
(ii) uncemented (ii) 134 Weight
matched but
(i) Hybrid Also matched: not specified
(ii) Porous- (i) 66 in 58 patients




























(i) Preoperative - pain 3.1; motion 3.0;function 2.5;
most recent - pain 5.6; motion 5.5; function 5.3;
same interval - pain 5.7;motion 5.1; function 5.3.
(ii) Preoperative - pain 2.5; motion 3.6; function 2.5;
most recent/same interval: pain 5.6; motion 5.6;
function 5.3.
Preoperative pain (i) vs. (ii), p, 0.002.
Range of movement: same interval (i) vs. (ii), p, 0.002.
Harris Hip Scores (most recent visit, 19 patients
only): (i) 91.6 (75.5-99.7); (ii) 91.3 (55.7-99.7);
p, not significant.
Patient preference: cementless 39%; cemented 22%;
no preference 39%.
No migration or subsidence noted.
Loosening: (i) one stem probably loose; (ii) none.
Revisions: none reported.
Mortality: C
(i) 32/60 (53%); (ii) 29/118 (24.5%); p < 0.001; death
risk same for single and recurrent dislocations. .
Median age at death (range): (i) 77 years (56-90);
(ii) 77 years (59-91); p, not significant.
Logistic regression: gender, length, weight, obesity,
previous contralateral hip surgery and previous
arthrotomy of ipsilateral knee had no influence on
dislocation rate.
Alcoholism (in men only):
(i) 10/20 (50%); (ii) 7/38 (18%); p, 0.01.
Mean linear wear (range): C
(i) all cups: 0.42 mm (0-2.75); matched 0.47 mm
(0-2.75);
(ii) all cups: 0.73 mm (0-4.21); matched 0.72 mm
(0-4.21);
p < 0.04 for both.
Mean linear wear rate (range):
(i) all: 0.14 mm/y (0-0.92); matched: 0.15 mm/y
(0-0.92);
(ii) all and matched: 0.22 mm/y (0-1.41);
(p < 0.05).
Radiolucent lines:
(i) 7 cup side; I stem side (I stem subsided);
(ii) 6 cup side; 5 stem side (no subsidence).
Mean pain score: (i) 3.11; (ii) 3.13; p, not significant
Mean function score: (i) 2.81; (ii) 2.76; p,
not significant.
Mean movement score: (i) 2.58; (ii) 2.65;
p, not significant
Radiolucency:
Grade 0 (none): (i) 43%; (ii) 30%;
Grade l:(i) 39%; (ii) 45%;
Grade 2 and above: (i) 19%; (ii) 25%\p < 0.05;
Grade 2 and above, radiographic loosening;
progression of radiolucency almost identical
for both groups.
Revisions:
15/350 (4.3%) revised (I I within 10 years,4 at or
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Number of THRs, Patient age;
length of follow-up other patient
and number of variables
patients followed-up reported






1166 in 974 patients
(i) 867; (ii) 105: (iii) 92;
(iv) 38: (v) 35; (vi) 14;








(i) 4.9 years (1-16)

















four significant factors for survival: sex, age,
surgeon, hospital.
Revisions/loosening:
(i) 72 failures (6 loose); (annual failure rate 1.78%;
15-year survival rate 73%);
(ii) no failures;
(iii) 26 failures (23 loose); (annual failure rate 6.93%;
11-year survival rate 63%);
(iv) no failures
(v) failure rate in first 3 years 15%.
(Remainder not given as numbers too small)
Radiolucency:
(i) complete radiolucent line > 2 mm, 5/18 (28%);
partial radiolucency, 12 (66%); I migrating prosthesis
(6%);
(ii) complete radiolucent line > 2 mm, 12/18 (67%);




all components loose; all surrounded by fibrous



















(i) 71 in 66 patients
(ii) 70 in 61 patients
Follow-up (range):
(i) 4.3 years (2-6.5)












pain - (i) 3.1; (ii) 3.0; p, not significant;
function - (i) 2.6; (ii) 2.6; p, not significant;
motion - (i) 3.1; (ii) 3.1; p, not significant.
Charnley Scores (postoperative):
pain - (i) 5.6; (ii) 5.7; p, not significant;
function - (i) 5.1 (ii) 5.6; p < 0.001;
motion - (i) 5.4; (ii) 5.6; p, not significant.
Cup migration > 5 mm (all cemented):
(i) 2 (7.3%); (ii) 4 (6%);p, not significant
Definite/probable loosening of stem:
(i) 3 (4%); (ii) 3 (4%).
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Number of THRs, Patient age; Outcome measures and results
length of follow-up other patient






(i) 3.8 years (2-6)
(ii)(a) 3.8 years (2-6)













(i) Charnley Scores, pre- vs. postoperative (range):
pain, 3.0 (2-5) vs. 5.5 (2-6); function, 2.8 (2-6) vs. 5.4
(2-6); range of motion, 3.1 vs. 5.6; p, ?
(i) Limp: 89% no limp; 11% mild/moderate limp.
(i) Revisions/loosening: no revisions, all stems stable.
(ii) Charnley Scores (pre- vs. post-operative):
pain, (a) 3.0 (b) 3.0, vs. (a) 5.6 (b) 5.7; function, (a) 2.7
(b) 2.9, vs. (a) 5.5, (b) 5.5; motion, (a) 3.1, (b) 3.2, vs.
(a) 5.5, (b) 5.6; (for all (a) vs. (b) comparisons,
p, not significant).
(ii) Limp: (a) no limp 88%; mild/moderate limp 12%;
(b) no limp 90%; mild/moderate limp 10%.
















































(i) 5.2 years (2.1-8.5)
(ii) 4.7 years (3.1-8.0)
(iii) 3.8 years (2.0-6.9)
270 in 214 patients
(i) 90 (+5 years,71)
(ii) 117 (+5 years, 90)









Harris Hip Scores (modified):
(i) Pre- vs. postoperative, 48 vs. 78;
(ii) Pre- vs. postoperative, 45 vs. 74;
p, not significant.
Pain: no pain - (i) 59.3%; (ii) 22.5%; p < 0.0016.
Migration/subsidence:
(i) cup, no migration; stem, 3 (7.5%)
subsided/migrated;
(ii) cup, 13 (32.5%) migrated by 5 mm or more; stem,
12 (30%) subsided/migrated.
Revisions or loosening: 0/80.
Harris Hip Scores: C
(i) preoperative, 45; latest follow-up, 93; excellent, 71 %;
(ii) preoperative, 41; latest follow-up, 91; excellent,
76%;
(iii) preoperative, 44; latest follow-up, 91; excellent,
69%;
P.!
Thigh pain (at 5 years):
(i) 17%; (ii) 21%; (iii) 19%; p, ?
Stem orientation:
(i) neutral 90%; varus 4%; valgus 6%;
(ii) neutral 87%; varus 9%; valgus 4%;
(iii) neutral 94%; varus 5%; valgus I %;
P.'
Osteolysis of the neck:
(i) 8%; (ii) 15%; (iii) 10%; p, ?
Loss of proximal bone density:
(i) 7%; (ii) 20%; (iii) I3%;p,?
Heterotopic bone formation (mild or moderate):
(i) 15.6%; (ii) 15.4%; (iii) 9.5%; p, I
Stem subsidence/migration, average (range):
(i) subsidence - 2.1 mm (0-8), > 3 mm 10%;
migration - present at 3 years 10%, progressive 3.3%;
(ii) subsidence - 2.2 mm (0-7), > 3 mm 13.7%;
migration - present at 3 years 13.7%, progressive
5.1%;
(iii) subsidence - 1.9 mm (0-6), > 3 mm 12.7%;
migration - present at 3 years 12.7%, progressive 4.8%.
Cup migration (present at I year):
(i) 3.3%; (ii) 4.3%; (iii) 4.8%; no progressive migration.
Average wear rate (range) of polyethylene liner:
(i) 0.7 mm/y (0.5-3.1); (ii) 0.6 mm/y (0.4-2.8);
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| Krismer, et al.,
| 1991
j? (Austria)





















































(55 died, 22 revised,










(i) 6 years I month












503 in 452 patients
Follow-up:
5.8 years (± 1.24)








(i) 207; (ii) 892
After criteria applied:
(i) 173 in 160 patients
(ii) 309 in 292 patients
Follow-up:
(i) 5.3 ± I.I years
(ii) 6.1 ± 1.3 years
(i) 160 in 147 patients







Outcome measures and results Rating
Walking ability (data given for total group only):
Distance: preoperative average 200 m, +2 years
2000 m (stayed constant at subsequent follow-ups).
Speed: preoperative average 0.5 m/s, +1 year 1.0 m/s,
+11.5 years 0.7 m/s.
No requirement for aids: preoperative 3%; +5 years
45%: + 11.5 years 23.3% and 50% did not use them
regularly.
Harris Hip Score:
(i) mean 74.8 ± 17.3 (44% good/excellent);
(ii) mean 72.9 ± 19.6 (51% good/excellent);
p.'-
Pain score - no or occasional pain: (i) 76%; (ii) 69%;
P. •
Revisions: 22/118(18.6%) - (i) 16; (ii) 6; (number
caused by loosening not given).
Loosening: 30/93 (32.2%) radiographic loosening,
(i) 14-8 stems, 2 cups, 4 both;
(ii) 16-10 stems, 2 cups, 4 both.
Survivorship analysis:
Mean annual rate of re-operation - (i) 1.61 %;
(ii) 0.91 %; p, not significant.
Cumulative numbers of survivors - (i) 82.2%;
(ii) 89.5%; p, not significant.
Wire vs. cable: A
Trochanteric union rates: wire 75%; cable 79%.
Non-union rates: wire 13%; cable 8%; p, 0.36.
Breakage (all three wires/cables): wire 43%;
cable 12%;p< 0.001.
Migration of wire/cable debris or fragments:
Wire: to cup notch area 8%, < 2 cm 26%;
Cable: to cup notch area 16%, < 2 cm 26%.
Bone destruction: (i) 9%; (ii) 29%; p < 0.001.
Rates of loosening (according to prosthesis type):
Chamley: total 3/70 (4.3%); wire 2/42 (4.7%);
cable 1/28 (3.6%).
28 polyethylene: total 24/68 (35.3%);wire 9/30 (30%);
cable 15/38 (39.5%).
28 metal-backed:total 30/184 (16.3%);wire 9/90 (10%);
cable 21/94 (22.3%).
Differences in cup loosening, adjusted for type: p, 0.003.
Revisions/loosening of total group (n = 643):
(i) 4 revisions (2.4%), 2 for cup loosening,
(ii) 10 revision (6.25%), 5 for cup loosening;
(further surgery required: (i) 5; (ii) 5.)
Hip pain in groups 5 and 6, d'Aubigne classification: C
(i) 87% patients; (ii) 80% patients; p, not significant.
Subsidence:
(i) 32/260 (12%) migrated > 2 mm;
(ii) 17/159(10.6%) migrated.
Loosening (maximum follow-up 7-8 years):
(i) 21/260 (8%) (RM cup, 12/156,7.7%; cemented cup,
9/104,8.7%);
(ii) 19/159 (11.9%) (cemented cup).
Revisions due to loosening:
stems (i) 5 (1.9%); (ii) 6 (3.7%).
Subjective results: C
Satisfied (i) 94.6%;(ii) 91.7%;p,not significant
Range of motion:
Flexion: (i) 102 ± 16.9; (ii) 93 ± 15.3; p < 0.001.
Gain in flexion:(i) 27 ± 24;(ii) 20 ± 26;p,0.011.
Migration:
(i) 35/140 (25%) migrated between 2.1 and 16 mm;
(ii) no migration values recorded.
Revisions/loosening (after 7-8 years):






DATA TABLE 2 contd Non-controlled comparative studies included in the review
| Study Study Grade of surgeon, Number of THRs, Patient age; Outcome measures and results Rating
| (country) design and type of hospital, length of follow-up other patient
| prosthesis and surgical and number of variables
type technique patients followed-up reported
| Kristiansen & Retrospective, Not specified 320 in 308 patients 64 years Cortical index (range) at the calcar femoral:
| Steen Jensen, matched (48-79) at (i) 0.15 (0.12-0.21); (ii) 0.18 (0.13-0.27); < 0.01
§ 1985 Teaching hospital Follow-up (range): primary (i.e. calcar bone stock thin prior to surgery).
1 (Denmark) Stanmore 36 months (4-68) surgery
(standard type, *^ot sPeci"e<J Cementation technique:
I Unusual 29 mm head, (i) 33 revisions $ex Insufficient packing, (i) 29/33 (88%); (ii) 13/33 (39%);small collar, (due t0 loosening) Pf 0 0005.142 mm stem) (")33 controls Weight Positioning of the prosthesis:Ce ented Diagnosis valgus, (i) 8/33 (24%); (II) 10/33 (30%);
1 neutral, (i) 7/33 (21%); (ii) 16/33 (48%);
varus, (i) 18/33 (55%); (ii) 7/33 (21 %); p < 0.0005;
varus position is related to loosening in stem.
Lehman, et al., Retrospective By, or supervised by, 324 in 284 patients; (i) 48 years Clinical parameters:
I 1994 one senior surgeon divided by body-mass (19-73) Pain (no/mild pain pre- vs. postoperative) -
1 (USA) Stem: HS2P, index. (ii) 50 years (i) 3 (2%) vs. 129 (91%); p < 0.001;
Omnifit, Teaching hospital (i) 20-29 normal (17-67) (ii) 0 (0%) vs. 48 (92%); p < 0.001;
j Unusual °mn|"e>< Not SD„ified (II) 30-39 obese (ill) 52 years (iii) 0 (0%) vs. 7 (88%); p, 0.02;Cup. Dual- 4o+ wjthin group (37-72) p, not significant - (i) vs. (ii), (ii) vs (iii).
geometry, (ij) morbidly obese
Peripheral Self- (< 20 excluded) Sex Mobility (not needing support to walk, pre-vs.
Locking, Mecron postoperative):
ring, Harris- Follow-up (range): Diagnosis (i) 73 (51 %) vs. 130 (92%); p < 0.001;
Galante cup (i) 49 months (24—92) Wpiphf 00 23 (44%) vs. 44 (85%); p < 0.001;
(ii) 20-49 months
VI.; u rn»j II. -1-1 vu-i/o;, y - v.w .,
^ (iii) 3 (38%) vs. 5 (63%); p, not significant;
Various (24-89) Body Mass (postoperative (ii) vs. (iii) p < 0.05; all others,uncemented (iii) 45 months (25-81) Index p, not significant).
(i) 142 in 127 patients LimP (no/sl'ght limP> Pre" "• postoperative:
i) 60 in 55 patients 0> 46 <32X> «• '31 <97^ P < 0 0011 •inn O o ii 7 (13% vs. 44 85% ; p < 0.001;(iii) 8 in 8 patients <"> 7 <'3%> «•44 (8S%>'P < 00011
part of (ii)) (iii) 2 (25%) vs. 6 (75%); p, 0.043
nnr cianifirant — m \/« /ift fii\ vc(p, not significant - (i) vs. (ii), (ii) vs. (iii)).
Trendelenburg sign present (pre- vs. postoperative):
| (i) 63 (44%) vs. 126 (89%); p < 0.001;
(ii) 20 (38%) vs. 47 (90%); p < 0.001;
(iii) 2 (25%) vs. 7 (88%); p,!
| (p, not significant - (i) vs. (ii), (ii) vs. (iii)).
Heterotopic ossification:
Class III: (i) 15%; (ii) 13%; (iii) 2/8 (25%); p, not
significant. Class IV: no patient in any group.
Osteolysis of femur:
| (i) 13%; (ii) 13%; p, not significant ((iii) 0%).
Wear of polyethylene acetabular liner:




(i) cup, 7 (4.9%) revised (all loose) + 3 loose;
I — stem, 9 (6.3%) revised (6 loose) + 2 loose;
| (ii) cup, 3 (5%) revised (all loose) + 2 loose;
stem, I (1.6%) revised (loose) + 0 loose;
(iii) no revisions or loosening;
((i) vs. (ii), p, not significant for revision or
mechanical failure rates).
Failure rates of components - stem:
HS2P,5/33 (15%) (average follow-up 69 months);
Omnifit, 2/83 (2%) (average follow-up 54 months);
Omniflex, 5/86 (6%) (average follow-up 36 months).
Failure rates of components - cup:
dual-geometry, 2/165 (I %) (average follow-up
46 months);
Mecron ring, 13/34 (38%) (average follow-up
69 months);
Harris-Galante, 0/2 (0%) (average follow-up
| 44 months);
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Grade of surgeon, Number of THRs, Patient age; Outcome measures and results
type of hospital, length of follow-up other patient
and surgical and number of variables

















Type I (n = 45) -AML 33%, MHP 31%, PCA, 24%,
ceramic 7%, SRN-REV 5%;
Type II (n = 9) -AML 33%, MHP 33%, ceramic 22%,
SRN-REV 12%;
Type III (n = 2) - PCA 100%.
Improvement by operation (includes fracture
types I and II):
(i) Great/very great, 51/54 (94.4%);
(ii) Great/very great, 47/53 (88.7%);
p, not significant.
Modified d'Aubigne-Harris Score,Types I and II only
(p, not significant):
Pain (a) preoperative, (b) postoperative:
(i) (a) score 112,27; 3/4,27; (b) 3/4,13; 5/6,40;
(ii) (a) 1/2,22; 3/4,32; (b) 3/4,10; 5/6,44.
Function (a) preoperative, (b) postoperative:
(i) (a) 1/2,18; 3/4,35; (b) 3/4,23; 5/6,30;
(ii) (a) 1/2,11; 3/4,43; (b) 3/4,17; 5/6,37.
Range of motion (a) preoperative, (b) postoperative:
(i) (a) 112,4; 3/4,49; (b) 3/4,16; 5/6,37;




































(i) 32 months (24-46)
(ii) 37 months (24-57)
(i) 25
(ii) 25















115 in 97 patients
CO 55
(ii) 60 (21 Charnley,
39TiBac)
Matched pairs - pre- vs. postoperative mean (range):
(i) 52 (38-67) vs. 96 (80-100); (ii) 48 (33-67) vs. 84
(35-100); postoperative comparison, p < 0.02.
Overall group - pre- vs. postoperative mean (range):
(i) 55 (28-70) vs. 97 (74-100); (ii) 57 (20-76) vs. 87
(35-100); (matched pair scores preoperatively did
not differ significantly from equivalent original
group scores).
Pain:
(i) 24/25 (96%) no or slight pain; (ii) 19/25 (76%)
no or slight pain; p, ?
Thigh pain:
(i) None; (ii) 5/25 (20%);
p.i
Limp:
(i) 19/25 (78%) no limp, 5/25 (20%) mild limp:
(ii) 11/25 (44%) no limp, 9/25 (36%) mild limp;
p.!
Migration - cups:
None or complete radiolucency in both groups.
Migration - stems:
(i) all radiologically stable, no migration;
(ii) 5/25 (20%) radiologically migrated;
p.!
Revisions:











Hospital for Special Surgery hip rating system
(n = 115):
(i) Good/excellent 55 (100%);
(ii) Good/excellent 60 (100%).
Rate of linear polyethylene wear:
(i) 0.08 mm/y, (ii) 0.078 mm/y; p, not significant
Volumetric polyethylene wear rate:
(i) 32.9 mm /y; (ii) 30.3 mm3/y;p, not significant
Revisions/loosening (n = 108):
No revisions, (i) 32% (16) probably loose; (ii) 16% (9)












































Outcome measures and results Rating
(i) 55 years Harris Hip Score - average (range):
(23-73) (i) 95.1 (65-100); 39 (93%) excellent/good;
(ii) 56.5 years (ii) 95.8 (59-100); 41 (98%) excellent/good;
(22-71) p, not significant.
Sex Harris Pain and Limb Scores - no significant
Weight difference (no data given).
(Also matched Modified Engh Radiographic Fixation Score:
for Diagnosis Grade IA, B or C at 3 years: (i) 38 (90%);
Charnley (") 35 (83%); fc not significant.
activity and Modified DeLee-Charnley Fixation Score (3 years):
class; bone (i) Grade IA, 39 (93%); IB, 3 (7%);
quality and (ii) Grade IA, 26 (62%); IB, 14 (33%); IC, 2 (5%);
type, and (i) vs. (ii), p, 0.002; HA has better fixation.
surgical tech- Revisions/loosening:
nique but Mechanical failure rate, (i) 5% - I revised (due to
details not loosening) plus I unstable (loose?);































































(i) 71 (two revised by
7 months and excluded
from further analysis)
(ii) 40






Total average 6.9 years
(2.3-12.5)
(i) 9.4 years (4.3-12.5)
(ii) 7.8 years (3.3-10.5)
(iii) 6.6 years (4.3-8.0)
























Number with pain requiring analgesics: C
(i) Preoperative, 66/69 (96%); +3 years, 0/30 (0%);
(ii) Preoperative, 36/40 (90%); +3 years, 2/33 (6%);
p, not significant.
Number able to walk continuously for 30 minutes:
(i) Preoperative 5/69 (7%); +3 years 22/30 (73%);
(ii) Preoperative 5/40 (13%);+ 3 years, 26/33 (79%);
p, not significant
Vertical linear wear at 3 years:
(i) 0.07 mm ± 0.19 (n = 15); (ii) 0.10 mm ± 0.17
(n = 28); p, 0.61.
Migration (mean):
(i) rate 0.06 mm/y (ii) rate 0.20 mm/y; p, 0.22.
Length of follow-up or migration level by 6 months
neither affected the results nor predicted subsequent
rate. Ceramic ((i) 40%, (ii) 23%) vs. metal femoral heads
did not affect rate.
Radiolucent lines: (i) 3/52 (6%); (ii) 8/30 (27%); p < 0.05.
Revisions: (i) 2 revisions, none due to loosening;
(ii) no revisions.
Harris Hip Score, preoperative vs. +3 years: '
(i) 43 (I-87) vs. 89 (51-100);
(ii) 41 (I -100) vs. 86 (61-91); p, not significant
Harrris Pain Score, preoperative vs. +3 years:
(i) 15 (0-44) vs. 41 (30-44);
(ii) 15 (0-44), vs. 42 (40-44); p, not significant
Thigh pain: (i) +3 years, 5% incidence; (ii) no thigh pain.
Limp incidence: (i) 18%;(ii) 22%; p, not significant.
Radiolucency: 6% hips had lines in each stem zone;
7/134 (5%) cups had lines in 2/3 zones; no revisions
or loosening.
Average wear rates:
(i) 0.10 mm/y; (ii) 0.13 mm/y; (iii) 0.25 mm/y;
(iv) 0.17 mm/y; p, ?
Osteolysis (%) (stem lysis (%), cup lysis (%)):
(i) 0 (0,00); (ii) 31 (24,7);
(iii) 87 (87,40); (iv) 24 (22, 14).
Incidence of osteolysis statistically higher in (in) than
any other group (p < 0.001) and statistically lower in
(i) than in any other group (p < 0.005).
Revisions:
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Number of THRs, Patient age;
length of follow-up other patient
and number of variables
patients followed-up reported































Pain - identical for both groups preoperatively and
at each follow-up;
Function:(i) median 5; (ii) median 44 at latest
follow-up;
(ii) probably due to deterioration in health
Motion: no substantial differences between groups.
Revis ions/loosening:
Revisions: (i) 5/52 (10%); (ii) 15/188 (8%);
Loosening: (i) 3 (6%); (ii) 5 (3%); p, 0.37.
Probability of survival at 20 years:
(i) 88.3% (95% CI ± 9.8%);
(ii) 89.3% (95% CI ± 5.8%);
p. 0.82.


























(i) 39 (1st dislocation,
22; recurrent, 16 +
I exclusion)
(ii) 14(11 contra¬













(i) 44.5° (30-68°); (ii) 43.6°; p, not significant.
Mean cup anteversion:
(i) 24.2° (-5-45°); (ii) 22.3°; p, not significant.
Mean femoral neck anteversion:
(i) 16.5° (-30-37°); (ii) 14°; p, not significant.




































Measured bone density loss compared with
contralateral ('normal') hip:
(i) -57% (-42,-85); (ii) -8% (+5,-30);
(iv) 58-69 years (iii) -34% (-30, -60); (iv) -14 (+15. -30);
(v) -43% (-36,-70).
(i) vs. (iii) vs. (v), p, not significant; (ii) vs. (iv) p, not






Sex Those with collar associated with less bone density
loss in proximal femur. Bone mineral density in
contralateral hips similar in all groups (72% hips




















(i) 82 (? patients) Age not
(ii) 62 (> patients) specified
Follow-up (range): Weight
(i) 33.3 months (24-49)




(i) pain 5.59 ;walking 5.54;
(ii) pain 5.68; walking 5.50.
Migration:
(i) 16 (29%) unstable, nine had migrated by mean
5.5 mm (3-11 mm);
(ii) all stable, no migration;
p <0.001.
Revisions/loosening:





DATA TABLE 2 contd Non-controlled comparative studies included in the review
| Study Study Grade of surgeon, Number of THRs,
| (country) design and type of hospital, length of follow-up
|:j prosthesis and surgical and number of
1
H——
type technique patients followed-up
ji; Ranawat, Retrospective, One senior surgeon 100 in 87 patients
1 etal., 1988 matched
| (USA) - Specialist hospital Follow-up (range):Charnley:
Not specified
(i) 5 years, average
| Unusual (i) 23; (ii) 35 10 years (8-12)
| T-28: (i) 17; (ii) 9 (ii) 5 years
| CAD Miiller:
s
(i) 6; (ii) 0 5 years, 100 hips
| Charnley Muller: (50 pairs)
(i) 3; (ii) 2 (i) 10 years, 37 hips
















































(i) 2388 in (i) 64.7 ±
2388 patients 7.2 years
(ii) 459 in 459 patients (ii) 64.0 ±
Follow-up:
8.1 years
(i) 5.7 years (± 0.7) Sex











290 in 55 patients 62 years
(i) 143 patients (25-86)
(ii) 112 patients (three
already excluded) Sex
Follow-up (range): Diagnosis
(i) 6.7 years (1-12)




(i) 5 years, 4 (8%); 10 years, 5/37 (2-5 mm) (14%);
(ii) 5 years, 0 (0%).
Radiolucency:
Cumulative score lower in (ii) than (i), p, 0.0005;
(i) 7 (14%) with score of 4 or more;
(ii) I (2%) with score of 4 or more.
Revisions/loosening:
(i) no cup/stem revision required 5 years (I revision
due to socket migration at 8 years);





(i) 38/40 (95%), no/slight pain;
(ii) 37/40 (92.5%), no/slight pain.
Use of ambulatory aids:
(i) 37/40 (92.5%), no aids; (ii) 38/40 (95%), no aids.
Migration/subsidence:
(i) 13 (32.5%) cup migrated > I mm; 8 (20%) stem
subsided > I mm;
(ii) 9 (22.5%) cup migrated > I mm; 8 (20%) stem
subsided > I mm.
Radiolucent lines (> I mm):
stem - (i) 3; (ii) 5; p, not significant cup: (i) 8; (ii) 17;
p, not significant.
Revisions/loosening: I hip in each group revised due
to aseptic loosening.
Charnley Scores: C
All without revision had excellent/good scores;
scores averaged 4-6 for all sections.
Revision/loosening:
(i) revision, 16 (11.2%); loosening, 12 cups, I stem,















(n = 85); anterior
(n- 15)









Pain: Hospital for Special Surgery hip rating system
(excluding revised hips):
(i) Preoperative mean, 3.1; +5 years, 5.5;
(ii) Preoperative mean 3.1;+5 years,5.6;
p, not significant
Revisions/loosening:
(i) 2 revised (none loose);
(ii) 15 revised (6 acetebular, I femoral,4, both loose);
patients with resurfaced hips requiring revisions were
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DATA TABLE 2 contd Non-controlled comparative studies included in the review
Study Study Grade of surgeon, Number of THRs, Patient age; Outcome measures and results
(country) design and type of hospital, length of follow-up other patient
prosthesis and surgical and number of variables







Muller (n = 163)
T-28 (n = 642)




























Retrospective One senior surgeon
Weber type Teaching/private
(i) metal rotating hospital
head















717 in 644 patients
(i) 346 in 309 patients
(318 primary;
28 revision)




(i) 55.4 months (I-116)





















Number feiled I-year post-surgery:
Charnley, 32 (14%); Muller, 29 (20%);
T-28,57 (10%); all-polyethylene MOSCr9 (9%);
metal-backed MOSC, 28 (20%).
Survival analysis - % survival < 90% by:
Charnley: 10 years, 93%; 20 years, 76%;
Muller: 10 years, 81%; 17 years, 56%;
T-28: 10 years, 93%; 17 years, 75%;
all-polyethylene MOSC: 10 years, 90%; 12 years,
87%; metal-backed MOSC: 10 years, 60%.
Revisions:
(i) primary: 42/317(13%); revisions: 6/29 (21%);
(ii) primary: 2/280 (0.7%); revisions: 5/91 (5%);
M
Wear of polyethylene:
(i) mean 0.96 mm; (ii) mean 0.26 mm; p < 0.001.
Revisions/loosening:
(i) revision, I cup, 2 stems (9%) due to loosening;
loose: 2 cups, 2 stems (12%);
(ii) revision: I cup, I stem (6%) due to loosening;
loose: 2 cups, I stem (9%).






























































Anterolateral, 0/53, posterolateral, 25/508 (4.9%),
Primary operation: 19/477 (4%); revision, 6/84 (7%).
Men: 6/215 (2.8%); women: 19/346 (5.5%);
p, not significant.




DATA TABLE 2 contd Non-controlled comparative studies included in the review
| Study Study Grade of surgeon, Number of THRs, Patient age; Outcome measures and results Rating
| (country)
1
design and type of hospital, length of follow-up other patient |
prosthesis and surgical and number of variables 1
L_ type technique patients followed-up reported

























10-year survivorship of patient (not hip):
(i) 85% alive (95% CI: 79-89) (n = 202/237);
(ii) 82% alive (95% CI: 78-85) (n = 367/449);
(iii) 82% alive (95% CI: 77-86) (n = 133/332
estimated).
10-year survivorship (sex): men 77%;
women 86%.
10-year survivorship after 65th birthday:
















(a): (i) 51, (ii) 57
(b): stable (i) 23, (ii) 23;
revised (i) 17, (ii) 29;
Total (i) 40, (ii) 52
Follow-up (range):




(a): (i) 49; (ii) 55
(b): (i) 40 (23 stable,
17 revised)
(ii) 52 (23 stable,
29 revised)
(a) not Stem subsidence (a):
specified Identical, mean against time, p, not significant
(b) 63 years (mean migration: 0-6 months 1.39 mm; 0-1 year
1.93 mm; 0-5 years 2.68 mm; 0-9 years 3.42 mm).
Sex Data given as a combined group (migration rate:
0-6 months 1.82 mm/y;6-l2 months 0.96 mm/y;
Diagnosis 1-2 years 0.54 mm/y; 2-9 years 0.21 mm/y).
Stem subsidence (b):
stable: +2 years 35/46 (76%), migrated < 2 mm;
revised: +2 years 7/46 (15%), migrated < 2 mm;
p< 0.001.
Radiolucent zone (around entire cement-bone
interface): stable: 2%; revised: 89%;
p.'.
Migration at interfaces:
stable - 7% stem-cement; 77% cement-bone;
17% both;


























545 in 518 patients
(i) 76 (14%)















(i) + (ii) 8%; (iii) 11 %; p, 0.02.
Subsidence > 5 mm:
(i) + (ii) 2.85%; (iii) 4.5%; p, not significant;
subsidence > 2 mm without radiological evidence.
(ii) 10.8%, 32 hips.
Radiographic loosening of RM cup:
(i) + (ii) 35%; (iii) 7%; p, 0.03;
(i) vs. (ii) p, 0.002.
Revisions/loosening (including deceased patients):
41 revised in total, 20 stems revised;
(i) revised, 5/76 (6.57%), 3 loose (3.94%);
(ii) revised, 10/381 (2.62%), 6 loose (1.57%);
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Outcome measures and results Rating
Harris Hip Score:
cemented - preoperative 100% fair/poor;
most recent 77% excellent/good; mean at
4 years, 91;
uncemented - preoperative 99% fair/poor;
most recent 89% excellent/good; mean at
4 years, 90;
hybrid - preoperative 100% fair/poor; most
recent 89% excellent/good; mean at 4 years, 95;
p, not significant.
Harris Pain Score (preoperative vs. most recent
follow-up - mean):
cemented: 16 vs. 42,84% no/slight pain;
uncemented: 16 vs. 43,98% no/slight pain;
hybrid: 14 vs. 43 100% no/slight pain;
P. ■
Thigh pain at 3 years:
cemented stem, 3%; uncemented stem, 13%;
p < 0.05.
Need for walking aids: cemented -
preoperative 80%; most recent 23%;
uncemented - preoperative 57%;most recent, 11%;
hybrid - preoperative 70%; most recent 29%;
p
Migration/subsidence:
cemented - cup, 6 (12%) migrated or changed
position; stem, no subsidence,
uncemented - cup, 3 (3%) changed position;
stem 3 (5%) subsided.
Revisions/loosening:
cemented - 2 (3.8%) revisions (due to loosening);
uncemented - 5 (7.7%) revisions (4 loosening);





























(i) 2.2 years (0.5-6.3)
(ii) 3.6 years (0.2-9)










Diagnoses of revisions of failed previous
operations:
(i) 30.7%; (ii) 8.4%; (iii) 13.5%; ('significantly
more in (i)';p, ?)•
Incidence of cup failures (clinical):
revision rate - (i) mean 3.58%, (ii) mean 1.44%*,
(iii) mean 1.61%*;
migration - (i) mean 8.85%, (ii) mean 0.64%*,
(iii) mean 1.48%*;
pain score - (i) mean 15.10%, (ii) mean 3.01%*;
(iii) mean 4.53%*;
(* all significantly different from (i) a < 0.05).
Incidence of cup failures for revision subgroup:
revision rate - (i) mean 14.59%; (ii) 3.68%;
(iii) 3.35%; (i) vs.(ii),and (i) vs. (iii) a < 0.5.
migration: (i) mean 17.56%; (ii) 12.50%;
(iii) 8.18%;
(i) vs. (iii) a < 0.5.
Incidence of cup failures (radiolucencies):
progressive - (i) mean 7.64%; (ii) 1.97%;
(iii) 6.08%.
(i) vs. (ii), (i) vs. (iii) a < 0.5.
> I mm:(i) mean 55.15%; (ii) 12.49%;
(iii) 19.07%;
(i) vs. (iii) a < 0.5.
complete: (i) mean 3.31 %; (ii) 3.58%;
(iii) 2.33%.
incomplete: (i) mean 52.45%; (ii) 60.70%;






DATA TABLE 2 contd Non-controlled comparative studies included in the review
Study
(country)





























(i) 63 in 63 patients





















Outcome measures and results Rating
Radiolucent lines: C
(i) 47/51 cups in unrevised hips (92%) had line in one
zone or more: highest prevalence 86%, zone I:
(ii) 14/71 cups in unrevised hips (20%) had line in
one zone or more; highest prevalence 16%, zone 3;
p ~ ■
Osteolysis:
(i) 19/51 (37%) cups had linear or expansile
osteolysis;6/51 (12%) stems with osteolysis
(all in medial region).
(ii) 13/71 (18%) cups had expansile osteolysis
(no linear): 23/71 (32%) stems with osteolysis
(21 in medial region).
% hips with osteoloysis similar for both groups.
Stability:
(i) 19/51 (37%) unrevised cups termed unstable;
(ii) 2/71 (3%) unrevised cups termed unstable.
Revisions:
(i) cups: 12/63 (19%) - all due to loosening; stem:
1/63 (1.6%), due to dislocation;
(ii) cups: 3/74 (4%) - I due to loosening; stem: 1/74






































Displacement rates (wear rates):
(i) in those requiring revision, all > 0.2 mm/y, 40%
> 0.3 mm/y; in non-revision group, 40 (29.9%)
> 0.2 mm/y, 11 (8.2%) > 0.3 mm/y;
(ii) in those requiring revision, all > 0.2 mm,
4 > 0.4 mm/y; in non-revision group, 20 (20%)
> 0.2 mm;




(i) 15(10.0%) revised due to loosening;
(ii) 5 (4.8%) revised due to loosening;
(i) + (ii), 20 (7.9%);
(iii) 2 (2%) revised due to loosening;
P.!
"■ % S (% s--
Data tables of observational
studies
Studies are grouped in the following order: Charn¬
ley studies, other cemented models, cemendess
porous-coated, cementless HA-coated, cementless
uncoated press-fit, hybrid, cementless mixed,
threaded cups.
The results presented in the tables are for the latest
follow-up unless otherwise stated. Scores given for
clinical rating systems (e.g. Harris) are means for
the patient groups unless otherwise stated. Where
numbers of hips followed-up are given in paren¬
theses (e.g. (222)), this refers to the number in the
total series, the actual number reviewed for the
published study then being given separately, and
not in parentheses.
The 'total mechanical failure' rate is the number
of revisions plus failures as defined by radiological
criteria; these vary from study to study but generally
include definitions of loosening, migration,
stability, and fracture of components.
mm
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DATA TABLE 3 Observational studies: Charnley
| Study, country, rating Number followed-up
(duration of follow-up)













Brady & McCutchen, 1986 (170)
USA 155 followed-up
C (10 years)
Carlsson, et al., 1986
Sweden
B/C









(5-12 years 5 months (osteoarthritis))















Not specified 3.3% revision
3 revisions in heavy patients at
9 years; I st generation cementation
- precise technique
Survival 91% at 10 years;
survival 82% at 20 years
Dal I, et al., 1988
South Africa
B




(mean 12 years, range 10-14)
2059
(mean 10 years 5 months,
range 3-17 years)
Mean 61 years n = 4 (4%) stems loose; Osteoarthritis 76%
87% > 50 years 14% revised - 4 loose cups,
1 stem loose, 7 stem fracture,
2 recurrent dislocations,
hence, 5% revisions for loose
+ 6% radiography failures
Not specified 9.1 % total revision rate
(loose cup 2.1%, loose
stem 4.9%); + 6% possible
radiography failure
I st generation stems fractured
more frequently but more loosening






















499 primaries + 197 revisions
(696)
(5-15 years; just over 25% followed-up
at > 10 years; mean not specified)
| Gudmundsson,




| Hamilton & Joyce, 1986
ii Canada
1 B
| (same patients as
| Hamilton & Gorczyca,
I 1995)
680
60% at 10 years
(18 years)
186
67.2% (n = 125)
(10-14 years)
Mean 62.4 years; 4.5% total mechanical +
range 22-67 years infection failure rate
2.2% re-operation of
primaries, + 1.2% (n = 6)
pending failure
48% osteoarthritis; single surgeon
Mean 56 years; Survival 81 % at 18 years;
range 18-79 years survival 91.6% at 10 years;
pain 4.6 at 17 years
(d'Aubigne-Postel and
Charnley);
walking 4.6 at 17 years;
range of motion, 4.4 at
17 years
Median 71 years; 29% loosening; 86%





230 followed up for 3-1 I years
about 100 at 6 years
86% > 50 years Revision rate as loose:
cup 0.7%, stem 0.0%;
n = 14 stem subsidence;
n = 6/230 cup migration
(2.6%)
Community hospital; large
percentages of death and loss to
follow-up not accounted for; 61 %
patients dislocation/childhood
conditions, etc.; single surgeon;




DATA TABLE 3 contd Observational studies: Charnley
| Study, country, rating Number followed-up Age Outcome measures; Notes/comments £
L (duration of follow-up) results
| Hamilton & Gorczyca, 224 Mean 58 years Mean d'Aubigne score Shows strong association between |
| 1995 83% at 10 years between 5 and 6 every wear and migration/revision; single £
! Canada (minimum 10 years year except 19th. surgeon ;
1 B (maximum 20 years) 12.5% cup migration; :
| (same patients as mean not specified) 6.7% cup revision; 2.6%
£ Hamilton & Joyce, (n = 5/188) stem migration/ i;i
I 1986) subsidence/ fracture, 6.3% £
I stem revision I
■s
:*x*x*x*:*x*x<«*k***x*x*«*x*k*>xvx*x*x*x*x**x*x*x*J
| Hartofilakidis, et ai, 104 Mean 57 years; 78.5% asymptomatic 20% total revisions (7% for £
| 1989 89% range 24-82 years 5.5 pain aseptic loosening) £
;!; Greece (10-14 years) 5.1 function |
1 B 4.9 motion 1
x**xxx*x*xvx*xxx«*xx-x*x**xx*:-sxxvxx*x****x«*x*".i
1 Hodgkinson, et al., 1993 Cup; unflanged Not specified 30.3% no radiological ££
! c 152 demarcation at 10 years £
i 83.5% 1
| (1—10 years) |
:::-x-xwx-x-x-xv%x-x-x-x.xxx-:-x-xx-:-x-x-x-x-x-x-x-x-xo wx******x**x****x*^^^ s*****s*«*w*a*«^^
| Hodgkinson, et al., 1993 Cup; flanged Not specified 42.7% no radiological
| (same study as above) ISO demarcation at 10 years;
| (see Comparative studies) 89.3% flanged compared with £
1 (1 -10 years) randomly selected unflanged. I
£ Flanged socket better than £
t unflanged by radiography £
criteria at 10 years, statistically £
£ significant. Previously revised £
| hips excluded £
rmswsiswftwmfejssmsmc'mwmiwowiiswsafrxjsmss ;*xx**v.. •.
| Johnsson, et al., 1988 204 Males: median 65 years, Revisions 14.7% £
£ Sweden 100% range 36-87 years;




range 47-84 years 1
| Johnston & 326 Not specified 9% femoral loosening; 1




8 x , .... - x ***** x -- ****** x ♦> > V.. 8W MWWWSM8WWs***x***s*«***x**b**k*:*x*s**x*xx*x*s:*x*x*h*x**m*k**x**x****>x*x**x*x********xV'X*S*:*x*:*x***X*x**:***x*x*:»X**:*x*SX***x***x*"J
1 Joshi. etai, 1993 (218) Mean 32 years, At 20 years: Wrightington; survival analysis and 1
1 UK 166 range 16-40 years total survey 75%; stem SEMs; significantly greater failure risk £
1 A (mean 16 years, surgery 86%; cup in years 10-20, and in osteoarthritis 1
I range 10-24 years) surgery 84%; compared with rheumaoid arthritis;
i: Aseptic loosening: (osteoarthritis risk of revision 20% |
£ stem: 3% at 10 years; at 10 years, nearly 49% at 20 years); £
£ 14% at 20 years; cup, small head, tapered stem £
£ 4.5% at 10 years, £
£ 16% at 20 years; £*
| 4% stem subsided > 5 mm !
$
£ Karachalios, et al., 1993 95 Charnley Not specified 27.4% cups migrated; 15.8% 1
i§ Greece 57.9% stems subsided; survival — I
! c (12-18 years; average related to centre of rotation £
1 13 years 5 months) of prosthesis and body weight J
1 Kavanagh, et al., 1989 333 Males: mean 65 years, Probability of failure: at 1 year, "!
I USA 49.8% range 38-85 years; 0.9%; 5 years, 4.1 %; 10 years, £
1 C (15 years) females: mean 64 years, 8.9%; 15 years, 12.7%
| range 39-84 years 1
*x*x*x*x*x*x*x*x*^^^^ X*X*X**XvX*X*XvX*X*X*XXXXXXX*X*X*XXX*X*X*X*XX*vX4
1 Kobayashi, et al., (703) Mean 58 years, Charnley mean 16.1 Factors in mechanical loosening
| 1994a; 1994b 326 stems followed-up for range 18-79 years (max. 18) 1.2% (4) stems study, e.g. canal width; about £
£ USA/Japan mean 13 years 3 months revised; 4.9% (16) radio- 113 congenital dysplasia, about £
£ (2 studies) 328 cups followed-up for logically stem fix failure. 1/3 osteoarthritis; includes table of £
1 A/B mean 13 years 2 months 7.4% (24) sockets revised; 12 previous > 10-year follow-up £
£ (10-20 years) 17% (56) radiological failure; studies of radiographically diagnosed 1
£ n = 9/703 revisions for stem Charnley cup failures for aseptic £
I fail excluded from the loosening (this study is the largest)
follow-up series |
- .v * _ **x-x***x***x«*.:.x*^^ ;*x*x*x*x*x*x*x*x*xxxx**x**x*x*x*x**x*x*x*x*x*x*:
| Langlais, et al., 1995 (446) 11% trochanteric non-union 48 followed-up for mechanism of
§
| France 48 1.3% (6) re-operations for loosening, osteolysis; stems only
$ Not rated (mean 6 years 5 months) instability followed-up |
| continued
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DATA TABLE 3 contd Observational studies: Charnley
s Study, country, rating Number followed-up Age Outcome measures; Notes/comments
| (duration of follow-up) results 1
| Madey, et ai, 1997 356 Mean 69 years, Total revision rate 9%, 5% for
KM.MMMMMMMaMHttKeMMMMMWMMKMMHwMMMMMMKMMOM
Patient satisfaction measured;
I USA 142 followed-up range 24-88; for aseptic loosening. survival analysis; relatively high
| a/b (minimum 15 years) > 15-year follow-up, At minimum 15 years: total revision dislocation rate attributed to small
| mean 62 years rate for aseptic loosening, 11% head; 2nd generation cement §
f (stem 2%, cup 10%) technique; single surgeon
1 McCoy, eta/., 1988 100 Mean 60 years, 87.5% excellent/good, 7.5% fair, |
| USA 40% range 25-84 years 5.0% poor; 90.8% survival at |
1 a/b (15-17 years) 16 years; 96% survival at 15 years,
1 _|,,[|||n-[r__,r|,_r_r,,rcri_i|o|,,||]o,[j|,|ci,o cup only |
| Neumann, et al., 1996 240 Young compared with 20 year revision rate for 1 1.7% Near-complete follow-up
| Denmark (15-21 years) older groups (see younger patients; 10.7% for |
1 B Comparative studies) older; no significant difference |
| (see Comparative studies) between groups
•X-X-XMXMIMX-XMX-XMXMWMX-X-X-XMXMX-X-XMIXMX-W-IMX-X-Xiii:
| Neumann, et al., 1994 241 Median 62 years, Probability of revision 10.7% at |
:j; Denmark 96% survivors (n = 103) range 34-79 years 20 years; 7% < 3 for pain |
! B (15-20 years) movement (Charnley score) 1
| (superseded by 30% loosening I
| Neumann, et al., 1996)
| Nicholson, 1992 185 Not specified Revision > 13%; j|
1 New Zealand 100% cup loosening 17.7%, survival 1
i c (15-22 years) 90.9%; stem loosening 21.9%, |
survival 88.1 % |
ill Older & Butorac, 1992 388 Mean 68 years, Revision 6%; District General Hospital
1 UK 34% range 42-85 years loosening 17% cups, survival I
B (17-21 years) 89% at 20 years (cup and stem) I
iji Older, 1986 217 Median 64 years, 88% satisfactory; 6% revision;
1 UK 70.5% (n = 153) range 42-55 years 92% patients satisfied J
1 C (10-12 years) 1
| Picault& Michel, 1995 786 for 10-15 years Not specified d'Aubigne (15-20 years): !I France 290 for 15-19 years pain 5.8; mobility 5.7; walk 5.4; i|
1 c? 107 for 15-23 years 84% pain-free at 15 years; 7.7%§
I (15-23 years) stem subsidence; survival 85%
:•!
<-X-:M:-X<-X-X-XXX-X<-X-XMXMMX'X^M:-:-X->XX-X-X-X<'XM:X-:::V:V:V::-::;:-
ij Ranawat, et al., 1989 152 Not specified 72% survival (revision) I
| USA (17+ years) 1
| Not rated
_____ I
| Rasmussen, et al., 1991 95 Not specified Survival 85%; 14/15 revisions for
;i; Denmark (10 years) aseptic loosening; 71 % pain free |
| B? (82% of non-revised); stem 1subsidence (> 5 mm) in 9% 1
__ _J
ij Schulte.et al., 1993 322 Charnley Mean 65 years, 90% survival (retained implant);
| USA 98.5% range 29-86 years 85% pain free; 53% no walking aids;
f c (20+ years) 10% revised I
ij Skeie, et al., 1991 629 Charnley Mean 66 years, 92% survival at 13 years; 86% patients District General Hospital
ji Norway 89.7% range 23-88 years good result; 7% revised |
\ A (10-15 years) j:
\ Solomon, et al., 1992 (156) Mean 38 years; Mechanical failure survival 88% at Contains table (9) reviewing
| USA 130 all < 50 years, 10 years; radiological loosening in published cemented results in young f
1: b/C Mean 10 53% 41-50 years 12%; d'Aubigne mean score 14.8 patients; follow-up range 2 years
£ (3-16 years) 8 months-12 years; revisions for
mechanical failure in follow-up
1 >5 years, 2.6-21.2%
> Stauffer, 1982 207 Mean 64 years, Revisions 10.8%; cup loosening |
I USA 90% range 39-84 years 1 1.3%, stem loosening 29.9% i
f b (10 years) i
i Sullivan, et al., 1994 (89) Mean 42 years, Cups 13% (11) revised for aseptic Survival + CIs; good follow-up rate; f
I USA 84 range 18-49 years loosening; stems 2% (2) for mechanical polished stem; old cementation; |
1 A/B (mean 18 years, range failure; survival for aseptic loosening: single surgeon
1 16-22 years) cup 76% ± 12; stem 92% ± 12; |
I total mechanical failure including 1
\







DATA TABLE 3 contd Observational studies: Charnley
Age
Not specified







Thomas & McMinn, 1991 1069 Charnley
UK (10+years)
Wejkner & Stenport, 1988 325
Sweden
B















| Wroblewski & Siney, 1993 1324 Charnley Mean 47 years,
| UK (Wrightington) 193 reviewed range 24-68 years




At 5 years: n = I revision for
loosening + I pending: loose cup
in +2, stem subsidence in +2,
2 conversions (8/107 failures, 7.5%)
92% survival at 10 years; no
improvement following change of
cement techniques
Mean 64 years, range





56% excellent, 28% good, 8% fair,
8% failure (Charnley scores)
16% revised: mean time to revision,
10.8 years
85.3% pain free; 78% full range of
movements: subsidence 29%; socket
migration 22.5%
Notes/comments




Dislocation 0.63%; revisions not
specified, estimated as about 13-14%
from survival graph (dislocation + stem
fracture + loosenings) 16 years (from 1324);
infection 0.3-1.5%; pain free 85% (from 193);
normal function 60%
no
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DATA TABLE 4 Observational studies: cemented - non-Charnley
Study, country,
rating


















Mean 41 years, About 25% (n = 10) revisions
range 18-49 years (10 cups aseptic loosening, 2 stems)
Notes/comments
Severe disease, some failures in two
young patients; three patients
receiving renal dialysis.
Bosco, et o/., 1993
USA
A/B
Dorr, et al., 1994
USA
C
















86 (48 + 38) Mean 55 years, Hospital for Special Surgery rating:
(mean 6 years range 20-80 years 71% satisfactory; 5.8% (n = 5) revised
7 months or 6 years for aseptic loosening (3 for both
4 months, range components, I stem, I cup); 10-year
2-14 years) survival rate: age > 60 years, 57%
(67 followed-up for ± 20; age < 60 years, 50% ± 22;
minimum 5 years) difference not significant;
radiographically: 22% definite








241 at 5-10 years





67% revised for aseptic loosening.
All patients aged < 30 years revised
or pending; 13/16 cups and 3/25
stems pending revision.
No significant difference reported
between designs but no data given;









Reviews other studies with high
cup failure in very young patients;
recommends non-arthroplasty
treatment.
Mean 66 years Total mechanical failure 11 %
8 months, (revision rate, not specified); 1.64%
range 30-84 years stem loose; 3.9% cup loose; 5.4%
fractures (attributed to early struc¬
tural defect); cups revised, n = 6; 74%
stems no sign of loosening.
73% osteoarthritis; includes 5-year
















Mean 44 years, Mean Harris score, unrevised 92;
range 34-76 years no revisions for loosening; 13.8%
(n = 4) radiographic loosening.
12.5% (48) revised for loosening;
revisions age-related.
Hirose, et al., 1995 Variety of designs; (192) Mean 65 years, Johnston: pain none/mild 95%;
USA all stems cobalt- 131 range 22-85 years walk satisfactory 84%; (other
B chrome, most (mean 7 years, factors not specified).
with collars; cups range 5-12 years) Cup mechanical failure rate 18.4%,
mixed - metal-/ including 9.6% revised (minimum
non-metal-backed; 5-year follow-up).
2nd generation Stem mechanical failure rate 3.1%,
cement technique including 2.3% revised.
60% primary osteoarthritis.
Karrholm, et al., 1994 Stem only -
Sweden Lubinus SP I, plus
A/B cemented poly¬
ethylene cups






(median 5 years -
10 months, range
4 years 9 months-
7 years 10 months)







Median 68 years, Stem revisions, n = 9, (10.7%) - 7 for
range 41-83 years thigh pain + radiographic loosening
(but 6 were re-revisions) + I primary
for osteolysis at 8 years.
RSA of migration: logistic regression
found migration at 2 years best predictor
of failure (probable revisions > 50% if
subsidence > 1.2 mm at 2 years).
Discusses other studies on failure
prediction; percentages of revisions
may mean results not applicable to
primary THR.
(Mean 59 years - 1.5% (29) loose at mean of 5 years,
failed hips only) 1.1% revised.
Study of loosening/osteolysis.
This type of failure not found in
polished Charnley stems in study
by same authors.
Ohlin, 1990 Christiansen 265 Not specified Radiographic survival at 10 years:
Sweden (median 6 years) stem 67%, cup 0%; 1/3 revised for
B aseptic loosening.
Abandoned design.
Ohlin & Onsten, Lubinus 202 for survival; Median 68 years, 3% revised for aseptic loosening
1990 151 for clinical range 29-94 years (n = 3 cups, 2 stems, 2 both); 13%
Sweden follow-up cups loose at 5 years; 10% stems
B (mean not specified, loose at 5 years; clinical function
range 3-6 years) not specified.
Hip dysplasia only factor associated
with loosening; age < 65 years














Age Outcome measures; results Notes/comments













Mean 71 years, Harris score 91; 97% excellent/
range 41-92 years good; thigh pain 3%.
1% (I) stem revision for loosening;
no other loosening (0/81).



















Mean 64 years Total revision rate 11.5%
(loosening plus technical error);
estimated survival rate 87% at
10 years.
Aseptic loosening: cup + stem 6.5%;
stem only 2.5%; cup only 2.1%.
No hip score reported.
(506) Mean 63 years, 90% survival at 10 years;
265 at 10 years range 19-89 years 80.8% survival at 15 years.
34 at 15 years 8.3% revised at 10 years; total
(mean not specified, revisions 54,42 at < 10 years,
range 10-15 years) 29 for aseptic loosening.
Total failed including clinical/
radiographic 11.8%; revisions for
aseptic loosening 4.35% at
10 years; revision for stem



























Mean 63 years, Harris score 97; 98% excellent,
range 22-90 years Stem loose (definite/probable/















d'Aubigne total 16.6 (pain 5.7,
walk 5.2, range of motion 5.7);
93% excellent/good.
I revision at 6 years for stem
loosening; no cup revisions, no
ceramic head breaks; 7% (4) cups






























Mean 63 years, Hospital for Special Surgery rating:
range 18-88 years mean 32.7; 92% excellent/good.
Survival (loosening) 89% ± 3% at
4 years; 4.3% revision (done/pending).













Mean 66 years Harris score: 86.
6 year survival (revision) 97%
(89.7-100%); 6 year survival
(revised or loose) 79%
(62.3-95.8%); (failures: 7 cups,
2 stems, I both).
Good results attributed to
cementing technique and precoating
of prosthesis with cement to
decrease risk of de-bonding;
osteoarthritis 74%.
Mean 71 years, Charnley score: pain none/mild 78%.
range 39-83 years 5.6% revision rate (8/143 - 6 stems
+ 2 cups loose); radiographically,
21% definite/probable stem loosening,
3.6% cup loosening.
Most frequently used cemented
prosthesis in Finland; 71 % osteo¬
arthritis; no significant differences
for cup/stem survival, osteo- and
rheumatoid arthritis, cup size, stem
design, weight or gender groups;
lower survival for age < 65 years.
Osteoarthritis 60%; senior +
junior surgeons.
Osteoarthritis 78%; no association
between loosening and age; poor
stem results attributed to poor
cementing and too large stem com¬
ponent; matt surface may prevent
distal movement of stem within
cement mantle.
All osteoarthritis secondary to
congenital dysplasia - high risk for
cup failure. Wear not correlated
with loosening but with calcar
resorption. Authors suggest same
bearing surface suitable for
cementless implant in younger
patients. Includes table comparing
with three other prostheses..
Mean 57 years, 9% (7) revisions, at 6-10 years (loose);
range 20-77 years survival 77% at 9 years (revisions)
or 73.7% (revision + radiographic
criteria).
87% unrevised excellent/good.
Authors abandoned this design,
quoting Russotti, 1988. Advise
roughening or precoating of stem
for cemented implant or choice of
cobalt-chrome material; poor canal
fill achieved in this series.
Osteoarthritis 60%.
All grades of staff undertook
operations. Significant association
between Harris scores and
radiographic evaluations.
PAPFQ .1
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Mean 61 years Harris score 90; thigh pain in 27% No association between















Mean 51 years 9 cup revisions; radiological:
(range 24-71 years) 40/75 neutral cups stable,
7/27 vertical cups. Fixation improved
in 2 years in 12, worsened in 26.
Harris score excellent/good in 85%
(good in 61/64 stable cups, and 28/40
unstable cups).
Bead loosening was progressive.
AML; stem (+ cups) 343:204 for
5 years (mean






4 years 2 months;
(ii) 143 without,
mean follow-up
























X-ray: 7% stems unstable at
minimum 2 years postoperatively.
Stable fix survival 94% at 5 years,
88% at 8 years.
d'Aubigne-Postehat 5 years: pain
5.7, walk 5.7, some thigh pain/limp
in 9.4% patients.
(i) mild pain 7.8%, moderate 0%;
(ii) mild pain 20%, moderate 14.7%.
Revision rate 4.4% (15, including
11 cemented cups for aseptic
loosening, 3 stems, none for
aseptic loosening).
**
For subset < 55 years + no
rheumatoid arthritis (n = 107),
survival rate for stem fixation,
92% at 9 years (i.e. no difference
from overall series).
Combined mechanical failure
rate, 6.4% at 5 years.
Revision rate 4.4%; revision rate
porous-coated stems 1.5%; stem
revision rate for loosening 0.7%
(3/393); 5/227 porous-coated cups
revised (2.2%); revision rate for
cemented cups 7.5% (I 1/166),
survival 81.2% at 10 years; I I-year
stem survival 91.8%.
Overall failure rate include radio¬
graphic failures 10.8% (18/166).
Revision rate later group: stems
0.5%, 9 year survival 99.3% (1/227);
overall failure rate including radio¬
graphic 1.8%.











(223) Mean 55 years Re-operation rate 11.5% (20/174) -




locating cups; 4 cups loose/sympto¬
matic; 10 impending cup liner wear-
through - + X-ray, 2 loose stems.
At 12 years:
total survival 85%; stem survival
97% (SE 0.02); cup survival 92%
(SE 0.03),
Clinical (n = 147,10 years):
pain - 87% none or slight, 10% with
limiting pain; walk - 82% without
aids; thigh pain - 8.5%, 4% limiting.
Uses Kaplan-Meier; teaching
hospital; Hardinge's direct lateral.
Attempts to control for suboptimal
cup fixation in subgroup analysis.
Statistically significant difference in
survival canal-filling vs. under-sized
stems. X-ray fixation and clinical
results positively correlated.
Author is originator of the AML
system; reports on 2 models; hybrid
subset reported. No clinical function f
results.
Includes autopsy retrieval stuc
Osteo-integration stated in 96
press-fit method correct.
Authors claim stem revision rate
comparable to Charnley at 10 years
(mean age 57 years) and 16 years
(mean age 42 years) (cf. Sullivan,
et al., 1994). Patients with
re-operation and/or osteolysis
significantly younger than others.
All loose stems were 'undersized'.
Appendix I
DATA TABLE 5 contd Observational studies: cementless - porous-coated (some hybrid with porous-coated acetabular components)
Study, country,
rating










Age Outcome measures; results Notes/comments


















5 years 4 months-
10 years 5 months)
(range 19-71 years)
Harris score 92 (5 years):




end-point; revision rate 2%; stem
subsidence 5%; pain - none/slight
75%; thigh pain increasing 18-26%
in years I—4, decreasing to 16% in
year 7.
5.1% (4) stem revisions - 2.5% (2)
for aseptic loosening.
Pain: 96% none or slight, 4%
moderate; limp: none or slight,
97.3%.
Radiographic (n = 72): 70 stable
(97.2%) with signs of bone ingrowth;
osteolysis 12% (9) treated by bone
grafting (thus total mechanical failure
rate, 3.8% (3)).
Survival free of aseptic loosening at





PCA; stem + cup 318
(1-6 years; mean
not specified)

















Revisions: 1% (3) - 2 undersized
stems, I cup loosening at 3 years
in rheumatoid arthritis patient.
Harrington ARS 100-point (pain/
function/gait/motion/deformity):
good/excellent 80%; 13% some
thigh pain.
2 Harris-Galante cups revised,
I migration, I dislocation; no other
loosening.
(No function measures)








Kim & Kim, 1992
South Korea
B/C








I year 2 months-
3 years 4 months)
BIAS; stem, modular 40
(cup Harris-Galante) (2 years 6 months)
Mean 56 years
Mean 50 years
I revision; d'Aubigne score
mean 13.6.
Mean Harris score 90.7% at 2 years
(good/excellent 91.6%).







5-5 years 6 months)
Mean 52 years
(range 24-86 years)
PCA; stem + cup 116 Mean 48 years Harris score 91 (latest); 88%
(6 years I month- (range 19-85 years) excellent/good at 6 years.
7 years 5 months) 3 cups loose (+ 20 excessively
worn liners); 7 stems loose;
osteolysis in 33%.
17% with good stem fit had thigh
pain (17/98), 9% persistent thigh
pain (7/9 stems - loose-fit).
Detailed radiographic results;
multivariable analysis of clinical vs.
radiographio-results.
Osteolysis possibly related to
polyethylene thickness; discusses
other prostheses evidence for
osteolysis.
J
No statistical correlation with
migration/radiolucency of: age,
sex, cup coverage, component
inclination, number of fixing screws.
Includes patient satisfaction
(7 not satisfied); X-ray results
counter theory of osseo-
integration.
Small sample, short follow-up; no
statistically significant differences in
clinical results between stable/
unstable groups; various surgical
approaches.
Harris score, 83; 62% excellent/good.
10% stems loose (revised or to be
revised); 28% (20) thigh pain in non-
loose stems.
Radiolucency > 2 mm in 33%.
Wear related to young age but not















< 60 years; mean
41 years (range
18-59 years)
Harris score, mean 91;
81% good/excellent.
No revisions for aseptic loosening.
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Mean 43.4 years d'Aubigne score, 94% clinically
(range 16—67 years) excellent; thigh pain 23%










cup - beaded, (mean 4 years
screw-fix (+ 7 months)
cemented stems),
i.e. hybrid
Not specified 19.6% bead loosening (increasing
over time), I associated with migration,
I with broken screw.




PCA; stems (+ 100
uncemented peg-fix (2-4 years)
PCA cups)
Negre & Henry, TA6V (authors' 101
1995 model); stem + (6 years)
France cup, blasted titaniuiyi
B with press-fit cup
Mean 68 years d'Aubigne clinical: 94% 'perfect',
(range 30-88 years) 4% mild pain; 2 revisions for
ceramic head fracture; 2 stem
migrations, 3 stems loose due




1994 PCA (Howmedica) 241 Mean 47 years Overall survival (for recom-
(mean 5 years, (range 18-65 years) mendation for revision) 91 % at
range 2-9 years) 6 years (± 6%); 73% at 7 years
(± 11%); 57% at 9 years (± 20%).
6 cup failures due to loosening in
6 years; 6 stem failures in total
(one intraoperative fracture) at
mean of 4 years (all had poor
original intramedullary fit).
Osteolysis in 36% cups (n = 99)
surviving > 5 years, 13% in stems.


















Mean 49 years Harris score 84%, good/excellent;
Mayo 70% good/excellent; excluding
hips with previous major procedures;
Harris score, 88% good/excellent.
I revision for aseptic loosening,
I for persistent pain; subsidence
in 2 stems, I > 5 mm.
Mean 63 years Harris score at 2 years, 90; thigh pain Conducted in community hospital;
(range 27-95 years) 5% at 3 years; limp in 18% (believed compared porous-coated to hybrid
(no previous unrelated to prosthesis or surgical (n = 34): no statistically significant
arthroplasty in approach); 99% stable. differences (in spite of mean age
followed-up group) in hybrid group being 12 years
greater). Stem head larger than used
conventionally - attributed with
good early results by authors.
Theory of the design is to allow
bone-ingrowth without fibrous layer |
between bone-metal.
Analysis with CIs.
Mean age at revision 39 years; cup
failure at mean of 6 years; 20/26
have widespread osteolysis; all had
loose beads + excessive poly¬
ethylene wear; 12 had migrated.
Low overall survival caused by huge
decline in survival of cups in years
6-9:30% (n = 95) attributed to
severe polyethylene wear (large
head size, 32 mm was used),
osteolysis and migration. Mixed
surgeons; specialist centre; lateral
without trochanteric osteotomy.
Small sample size; cobalt-chrome;
long follow-up for beaded; patients
selected for high-risk early failure
cemented implant. Poorest results in






Mean 59 years Harris score: mean 93 (73—100).
(range 23-79 years) No cup" loosening, 4 cup revisions -
2 liners detached, I metallosis, I lysis.
No continuous radiolucent line
around whole cup.
Comparison of cemented (n = 40)
vs. non-cemented (43), porous-
coated stems: Harris scores 95 vs.
92 - caused by pain scores 43
cemented vs. 40 non-cemented; i.e.
hybrid marginally better than non-
cemented/non-cemented.
Senior surgeon.

















92.3% stable; 9% postoperative
groin pain. Harris score: 84.
Patient satisfaction; no relationship
age/Harris score; ho relationship
sex/type of stabilisation.
Two series: (i) 121; (ii) 166
(supplied separately) ((i) mean 10 years
(i) BIAS; 2 months, range
(ii) AML; stems 7-15 years
(i) + cemented cup (ii) mean 8 years
(ii) + porous-coated 3 months, range
(i) mean 53 years
(ii) mean 53 years
8 months
cup 7-12 years)
(i) 5 (4.1 %) revisions at mean of
10 years 2 months (2 for late
loosening); survival 95.4% at
11 years (13 cup revisions), (ii) I
(0.6%) stem revised for loosening,
99.3% survival at 9 years. 94.6%
pain-free at last follow-up; 3 stems
X-rayed unstable, 2 significant osteolysis.































Harris score: 95; 92.4 excellent/




100 Mean 58 years Harris score: 92.4.
(minimum 7 years) (range 22- 5% total revision - 2% stem, 3%
81 months) cup; osteolysis around stem in 11 %,
cup in 2%, both in 2%. Most patients
with osteolysis asymptomatic.
Osteolysis study: osteolysis occurred
frequently around components with
no evidence of migration/subsidence;
mean age of osteolytic group
younger by 10 years than others.























Osteonics; stem 320 (minimum
and cup 2 years);
142 (minimum
3 years)
Age Outcome measures; results
Mean 50 years Harris score, 95: pain, 93% none/
slight; thigh pain, 1.3% mild/moderate.
Subsidence > 3 mm, n = 2; revisions,
n = 10 (5 for pain, aseptic loosening);
none loose.
Total mechanical failure, 0.46% (excl. pain).
Notes/comments
Mean 48 years Harris score, 95 at 2 years; pain,
5% mild to moderate.
Revisions, 2/238 (0.8% within
2 years).
Mean 50 years Harris score, 95 at 3 years; pain,
4.2% mild to moderate, thigh pain, 1.4%.
No revisions; stems - aseptic loosening
2, X-ray unstable 0, total 0.46%; cups -
1% migration at 2 years.
Multicentre
Presumably earlier set from same series
as previous study. Patients stated to be
more active and heavier than in most
comparable studies.
Similar cup comparison results as for
study above (23 HA-, 69 porous-coated).
5 centres
Comparison of HA- (132) vs. porous-
coated ingrowth (285) cups showed no
statistically significant difference in clinical







No model name, 58
authors' experi- (6 months-2 years,
mental design; mean 10 months)
stem and cup
| Geesink, 1990 Omnifit
| The Netherlands (Osteonics);









Koch, et al., 1993 Furlong
Germany
B?
Rossi, et al., 1995 ABG
Italy Howmedica;
A/B stem and cup
100 (85 primary
reviewed)
(I year 5 months-












Mean 53 years, Not specified
range 22-
73 years
Mean 54 years, Harris score, 97; persisting pain 4%.
range 21- No loosening.
74 years Harris score by cup type: HA-coated
98 vs. non-coated 94 (but at 3 months
90 vs. 71; at 6 months 95 vs. 79).
I 18 stems; 100 cups,
threaded design only
(5 years 6 months-
7 years 6 months)
233 (190 primary)
(2-5 years, mean








Survival: stem 100%, cup 99%.
Harris score: at 3 months 90, at 6 years S
d'Aubigne: at 6 years - pain 5.8; motion
5.9; walk 5.9 (total 17.6).
Persisting pain 4%; no osteolysis.
No aseptic loosening; no thigh pain.
d'Aubigne: 15.76.
Harris cup score comparisons. HA-coated
vs. non-coated contradicts d'Antonio,
et al., 1992b study.
222 Mean 62 years
(minimum 2 years, 7 months
mean 2 years
4 months)
No association of age, gender, surgeon or
weight with Harris scores at any period.
Harris scores compare with < 90 for most
porous and press-fit series, author claims.
Notable early pain relief.
In German.
d'Aubigne: 100% excellent/good.
0% mechanical failure (I dislocation
due to cup malpositioning).
No cup migration; postoperative bone-
cup gaps disappeared in 3-12 months.
3.6% thigh pain.
4 early + 3 late dislocations (total, 3%;
2-year mechanical revision rate, 1.4%).
Activity: preoperative 14.9%, at 2 years
87.3%.
d'Aubigne: mean 17.4 (max. 18).
Minor stem migration in 6 (2.7%); normal
bone adjacent to cup in 95%.
More details of radiographic findings given.
International study; 10 surgeons; all
dislocations from same single centre.
No influence on clinical scores of age,
weight, gender, disease, Charnley
classification.
No statistical correlation between
radiographic results and clinical scores.
Very detailed radiographic analysis.
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Age Outcome measures; results Notes/comments



















Not specified Revision rate for mechanical
loosening; 1.7% (5-2 cup/
2 stem, I fractured ceramic head)
+ radiographic loosening of
2 stems (total mechanical loosening
rate for stem, 1.6%).
Pain: 89% none/slight; Harris
score > 85 (89%); thigh pain
1.3% (4).
Author claims results as good as for
porous-coated stems.






(46 for 4 years,
maximum
6 years)
Mean 57 years 32 revised; survival 77% at 6 years Indications: use of this design now
(range 18-85 years) (revision end-point). restricted to patients in whom
d'Aubigne: at 2 years 89% excellent/ cement is contraindicated by history












Harper, et al., 1995 Ring UPM cup;
UK wedge press-fit plus


















Serai, et al., 1992
Spain
B/C
I Stockley, et al., Miiller straight






















6 months; 59 for
mean 6 years
5 months)
Mean 63 years Migration-free survival 74.5% at





(Total revisions 22%); 17% revised
for loosening.
Survival 83% (76.8-89.2) at 8 years.




Mean time to granulomatous
loosening 5 years 3 months; failure
attributed to polyethylene wear.
Results compared with other





No revisions for loosening.

















Mean Harris score: 87.5.
I cup revised for aseptic
loosening; no stem revisions;
I stem subsidence of 4 mm.
Press-fit interface of 1.5 mm, reamed





Singh: 67% very good/good.
Cup migration, 17.6%; sterrr




24 Mean 61 years Harris score: mean 79.
(mean 7 years (range 46-77 years) 5 revised for aseptic loosening,
3 months, range I failed clinically.
6 years 2 months- Survival 80% at 8 years.
8 years 3 months)
Very small sample.
Pre-dates porous coating (1982-84).







Revisions for aseptic loosening,
n = 32, most > 8 years; about
28% radiologically loose at
9 years.
Abandoned.
Good results up to 6 years.
Smaller cups and use of screws
associated with more loosening;
















cup/Precoat, n = 74,
(Zimmer) stem
Helfen, et al., 1993 Marburg porous-
Germany





















Age Outcome measures; results





























Mean 63 years Harris score: 93.
(range 23-83 years) No revisions for loosening.
Notes/comments
Harris Galante/Precoat better than
ARC HD-2 clinically.
Single senior surgeon.
Mean 60 years 96% very good/good,






















2 years 6 months-














Pain: 16% mild to moderate
(most post hard activity); limp
slight to moderate in 24%.
I cup possibly unstable;
no revisions.
Harris score: 86 (90 after
excluding patients with
unrelated problems).
Pain: none, slight, mild in 97%.
No revisions; 2% (2) definite
stem loosening; 2% (2) definite
cup loosening, others stable.
Survival 95% (95-100) at
7 years I month




Authors support hybrid for
older patients.
4 senior surgeons plus assistants.
Harris score: 91; 91 % excellent/
good.
I stem revision for loosening
(in patient with previous
cemented THRs).
No stem migration; I cup
progressive radiolucency,
no cup migration.
Harris score: 93; 91 % good/
excellent.
90% no or slight pain; Pain less
for Harris-Galante group
(statistically significant).
1 revision for stem loosening -
in a custom component; no
stems loose; no Harris-Galante
cup loose or revised for
loosening; I Harris-Galante cup
revised for liner failure.
2 ARC cups migrated; no
cup revisions for loosening.
Osteolysis in 2 ARC cups,
none in Harris-Galantes.
Harris score slightly better for
Harris-Galante/Precoat group.
Bead loosening, etc., reported.
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DATA TABLE 9 Observational studies: cementless - mixed types
| Study, country, Prosthesis Number
. , i . , . ,r ■. .
Age Outcome measures; results Notes/comments




;i; Lautiainen, Two macro- (1)49 Mean 58 years Mayo: 86.7; 78% good. No correlation between radiographic
| eta/., 1994 interlock designs (II) 20 (range 36-76 years) Total revision rate 6.3%. and clinical ratings.
| B/C (i) Lord Madreporic (mean 5 years I
| (ii) Link 4 months, range i;
1 4 years 9 months- i;
!•:
if 7 years 7 months) 1
|
!;•
iji Niinimaki, RM; stem only; (114) Mean 64 years Harris score: 43% excellent/good;
|
Osteoarthritis only.
| eta/., 1994 macro-interlock 85 (range 48-79 years) Johnston: 67% pain none/slight. |
|| Finland 71 SSTRR Revisions for loosening, n = 8,
1 B questionnaire/ plus 1 fracture; total mechanical
1 radiographic failure rate, 10.6%. Ij
I (7-9 years) Radiographic failure 25%; 1
jj: subsidence > 5 mm in 12%; 1
i osteolysis in 12%.
1 Riska, 1993 Ceraver Osteal 112 Mean 62 years Revision rate, 7% for uncemented
1 Not rated hybrid/ceramic (mean 3 years cup; 1.7% revisions for aseptic ;i;:
1 2 series, cemented 6 months, range loosening. t
I
and uncemented 1-7 years) |
| cups |
1
il; Roffman & RM (Mathys, 185 Not specified No hip scores. Good ingrowth in groups (ii) and (iii). |
| Juhn, 1993 Switzerland): (i) 60 Total revisions, 2.7% (n = 5), all 1
1 Israel cup only; (ii) 96 in (i) (8.3% of group); none in
! c (isoelastic) (iii) 29 (ii) and (iii). ;i
; (i) HMHDPE (9 years) Migration, de-alignment or pain ;;5
(ii) ditto HA-coated in same, 2.7%. 1
L (iii) ditto titanium- jl
j coated f
! Stern, et al., 1992 LD; some HA-coated, 112 Mean 62 years d'Aubigne: 86% excellent/good;
1
Complex radiographic analysis.
1 c some roughened (6 months- pain 5.6%; limp 12%. %
i;i 2 years; 60 for Number loose not specified. \ii;
ii
up to 2 years) 'Low' stress shielding.
:::
SS4XWS4:'V ^ , s.
DATA TABLE 10 Observational studies: cementless - threaded cups (A sample of studies, not critically appraised; this design is now
largely abandoned.)
| Study, country Number followed-up
(duration of follow-up)
Outcome measures, results
| Bruijn, et ai, 1995
1 The Netherlands
411
(mean 4 years 6 months, range 3-7 years)
I Fox, et a/., 1994
I Canada
68
(mean 6 years, range 5-9 years)





Migration 25%: 6% revised for aseptic loosening.
Abandoned.
ioworaowwwra8raraww«ttMW«-:-xwx-x-x«*Kwxw-x*:.x*x-xwx^x-x-x-x<*x-x-x-x-^^
38% failure: 17 revisions at mean of 5 years.
Abandoned. |
x->x-:»xwx-:-x-:-x-x-x-x-:->Xv-»x<-:-:-x->»X'X-x-»:'X«-x«<-x-x-x-:-x-x«-x-x-jx«x-:.x-:-:-x-x-»:-x-y^x«-:
Survival 75% at 5 years: revision rate I 1.6%.
d'Aubigne: excellent/very good/good, 62%.
Abandoned.
| Gut, et a/., 1990
I Switzerland





(mean 2 years 4 months)
Krugluger & Eyb, 1993 103
Austria (minimum 10 years)
33% sockets loose.
8% re-operation, 10% failures including loosening.
Revision rate 24% for loosening: loosening 33%: extensive osteolysis 31%.
5-year results had been good.
II
D k BCD *2
Appendix I
Appraisal Table I -RCTs
Key criteria
1. Method of randomisation identified and appro¬
priate. 2. Patient groups balanced or effect of any
difference evaluated in valid statistical analysis. 3.
Patients blind to prosthesis type. 4. Assessments of
clinical/radiological outcome blind to prosthesis
type if possible. 5. Appropriate statistical analysis.
6. Number of patients deceased or lost to follow-up
reported or included in statistical analysis. 7.
Follow-up period - mean and range. 8. Prosthesis
model specified. 9. Clearly defined criteria for
measuring outcomes. 10. Age - mean and range.
Other criteria
11. Quantification of outcomes. 12. Follow-up
data compared with preoperative data (preferably
mean and range). 13. Independence of investi¬
gators (declared or no vested interest). 14.
Numbers ofmen and women given. 15. Weight -
mean and range. 16. Preoperative diagnoses with
percentages/numbers of patients given. 17. Clinical
evaluation independent of operating surgeon.
20
1 Key criteria Other criteria "1
| Study 1 2 3 4 5 6 7 8 9 10 " 12 13 14 15 16 17 Rating |
1 Bourne, et a/.,
} 1995®
| Rorabeck, et al.,
j 1996®
n y y y/y NS y y y y y y1 y y y n y y c
|
1 Bradley & Lee,
| 1992
y NS NS NS NS y y y n y n n NS n n y y c I
I
1 Carlsson, et al.,
1 1995
n NS NS NS y n y y y n y n NS n n n NS c j
:0C030:0MDMJ0OM»i
I Ciccotti, et al.,
| 1994
n y NS NS y y y y y y n y NS n y y NS c I
;> Godsiff, et al.,
1 1992
y y y y/NA y y y y y y y n NS y n y y _™j
| Jacobsson,
| et al., 1994*




y y NS NS y n y y y y y y y y y y n c
g
.
1 Kelley, et al.,
1 1993
n y NS NS y y y y y y y n NS y y y NS
I Krismer, et al.,
| 1994
n y NS NS y y y y y y y n NS y n y NS c
1
jii Marston, et al.,
| 1996
y NS NS NS NS y y y y y y y y y n y y c
*
|!i Olsson, et al.,
| 1986





n y NS NS y y y y y y y n y y y y NS c
| Onsten, et al.,
| 1994
y y NS NS y y y y y y y n NS y y y NS c s
i
I Reigstad, et al.,
| 1986
n y NS NS n y y y y y y y NS y y n NS c !
1 Soballe, et al.,
| 1993
n NS NS NS/y y y y y y y y y y n y y NS C I
•: Thanner, et al.,
1 1995*
n NS NS NS n y y y y y y y NS y n y NS c 1
ij Wykman, et al.,
; 1991
n y NS NS NS y y y y y y y y y y y NS c
| Studies not comparing typical prostheses.
0 Same study group. Bourne, et al., / 995: clinical data 5-year follow-up; Rorabeck, et al., 996; radiographic data 4-year follow-up.
::
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Appraisal Table 2 - Non-controlled
comparative studies
Key criteria
1. Method of assignment of patients to different
prostheses described and appropriate. 2. Patients
matched or differences evaluated in valid statistical
analysis. 3. Appropriate statistical analysis under¬
taken. 4. Number of padents deceased or lost
to follow-up reported or included in analysis.
5. Follow-up period, range and mean specified.
6. Prosthesis models specified. 7. Clearly defined
criteria for measuring outcomes. 8. Age - mean
and range.
Other criteria
9. If retrospecdve, patients selected without know¬
ledge of outcomes. 10. In prospective studies, follow-
up assessments blind to prosthesis type, if possible.
11. Results given for specific models (and sizes).
12. Quantification of outcome criteria. 13. Follow-up
data compared with preoperative data (mean and
range). 14. Independence of investigators (declared
or no vested interest). 15. Numbers ofmen and
women given. 16. Weight - mean and range. 17.
Preoperative diagnoses with percentages/numbers
of patients given. 18. Clinical evaluation indepen¬
dent of operating surgeon. 19. Radiological evalu¬
ation independent and blinded to clinical results.
Key criteria Other criteria
| Study 1 2 3 4 5 6 7 8 9 10 II 12
XttWtfMESK
13 14 15 16
■XWXSXWH
17 18 19 Rating |
M9M4WMK WMMMMM x«x*x*x.: :**X-X%N*X mmomw :*x*:*x*:*: 1
| Abrahams &
1 Crothers, 1992
n n y n y n y y NS ya y n NS y n y NS NS c !
1
| Ahnfelt, et al., 1990 n n y n n n n n n n' n n NS y n y NA NA C
*m*9m ******* ngwwwnt mm*** xmssem ******* W0KRHK svmesm SSSXSSSSSK ■wmmw
c I1 Bankston, et al.,| 1993
y y y n y y y y y y y n NS y y n NA NS
I;::-:-:-:-:-:-:-::-:-:-:-:-:-:-;-::-:::-:-:-:-:-::::::-::::::-::::-
i; Bankston, et al.,
1 1995
y y NS n y y y y y y y n NS y y n NA NS c
JLM»». === ===■ MMMWMK WWMCWe w - WMmamc :«x«x*x. MWMWM :-x«»x-x-:- MI
jj Bertin, et al., 1985 n n NS y y yb n n NA n y n NS y n y NS NS c 1
I:-:-:-:-:-:-:.:-:-:.:.:.:::::-:-:.:-:.:::.:.:-:.:::-:.:-:-:.:.:-:-:-:::-:.:-:-:-:.:-- mmm* ssmmm w *msmm Osama
s Britton, et al., 1996 n NS y y y y y n n y n n y n n n n n C |
ij Burkart, et al.,
: I993c
y n y y y y y y y y y n NS y n y NS y C |
i; Callaghan.et al.,
i 1995
n n n n n y y n NS y/n y/n n y n n n NS NS C I
i Carlsson &
; Gentz, 1982
n n NA y y y y n n n y n NS n n n NS y C 1
Laiiwaii^^ waww mmsm ammam X-XSXXW.- X.WXvXX- uwnnriuiiiminii
1 Chmell, et al., 1995 y n NS n n y n n NS y n n NS n n n NS NS C 1
bxWXWWMMMMMMMMMMMWM4w: WWSCWto ««««« «*x-»x*x- mMetww MMWKMOM HMWMW SWMMCMM :«x.x«x«
■ Cornell &
i Ranawat, 1986*
y y NS y y y y y y n y n NS y y y NS y c 1
: Dall.et al., 1993*
=:
y n n y y y y y y y y n y y n y NS NS c 1
i Duck & Mylod,
1992
n n NS n y n y y NS n n n NS y n y NS NS c I
i Ebramzadeh, et al.,
i 1994
y NA y y y y y n y n y n y y n y NA y c
/ ' ^ . ,• v • ******* >ss*ts#m :-WWSXWX ffM** io#msm wswmm mmm
! Espehaug, et al.,
1995
rr n y y y y y n y y y n NS y n n NA NA c
; Freeman & Plante-
: Bordeneuve, 1994
n n y n n n y y NS y3 y n y y n y y NS c §
: Goetz, et al., 1994 y y NS n y y y y y y y y y n y y NS NS c I
Studies not comparing typical prostheses.
| 0 Results given for type of prosthesis, not specific model.
| b Unclear if the prostheses used in this study were/are now in widespread use or designed for this study only.





Key criteria Other criteria
„„„„„„ p:,:.xw. MHMHMO pMPMMOW JX-X-XX-X-X. mi MMHHHW COM IQflPP •:x:xxxxxx xxxxxxxx xxxxxxxx xxxxxxx-xxx. •xxxxxxxxxxx: xxxxxxxxx-xxx xxxxxxxxxxxxxxxxx
| Study 1 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 Rating i;
wmW' xxxxxxxxxxx: •XXXXXXXXXXX wmw xxw-xxxxxx: xxxxxxxxxxxx ■xxxxxxxxxxx: XXXXXXXXXXXX xxxxxxxxxxxx •XXXXXXXXXXXX XXXXXXXXXXXX sxwvw; xxxxxxxxxxxx •XXXXXXXX. xxxxxxxx. msrnm XXXX«*XK- SiXXXKSS&X- ■:xx:::-x:-x::«v:.xx-
I Hamada, et al.,
| 1993
y n n n y y y y y y y n NS y n y NS NS c i:
;ij Havelin, et al., n n y y y n y y y n y n NS y n n NA NA c i
| 1994 j
•X-X-XvXvX :x,,,,,,,,, NMONMMO KNHMMM ■xxxxxxxxxxx: ,,,,,,,-xxxx: x«c««*x ONNMHOM «XXX««« xx-xxxxxxxxx •xxx-x-xxxx,- xxxxxxxxxxxx: xxxxxxxx:,,■:,,,,■:■
! Havelin, et al.,
| 1995
n n y y y y y y y y y n NS y n y NA NA c |
WWMMM ■xxxxxxxxxxx: XXXXXXXXXXXX »M«S««x xxxxxxxxxxxx; >xxxxxx:«>x: ;XXXXXXXXXXXX xx-xx-xw •xxxxxxxxxx:* • ■xxxxxxxx xxxxxxxxxxx .xxxxxxxxxxx ■xxx:«xxxxxx xwi-ixxxixxs-x;-:-A
!;! Hearn, et al.,
| 1995
y nd y y y y y y y n y y NS y n y y NS C i;
•XXXXX-XXXXX: MNMMMM BOPPP wwww«« •XXXXXXXXXXX: xxxxxxxxxxxx -x-x-x-x-x-x xxxxxxxxxxxx: MHmmwm .xxxxxxxxxxx: xx-xxxxxx •:x:x:x:x>xx xxxxxxxxxx: •xx:xxxxxxx:x x-xxxxxxxxxx: ■■■***»>:«:<■ ■xxxxwxxxxxxxxx
| Hedlundh & n y y y n y y y n y n n NS y n y NS NA c
| Fredin, 1995*
gxxxxxxxxxxxxxxw POOOPBQBOOOOI xxxxxxx-xxxx MHOOmM Ulllllllllll ■XXXXXXXXXXX:. •xxxxxxxxxxxx ■xxxxxxxxxxx: MHHOMM xxxxxxxxxxx: xxxxxxxxxxx: xxxxx-xxxxxx: xxxxxxxxxxxx xxxxxxxxxxx:,,,,.
1 Hernandez, n y y n n y y n y y y n y n n y NS NS c jI et al., 1994
....
— _ ..................... ■■•XXXXXXXXXXX •xx:-x::.-x.v.-.v xxxxxxxxxxxx. ■■XXXXXXXXXXX ftWSSftWfS ■xxxxxxxxxxxx
|i; Hodgkinson,
| et al., 1993
n y y y y y n y y y y n NS y y y NS NS c ]
HMMMMO *«,««*<■ xxxxxxxxxxxx: X-XWX-X-X: ■xxxxxxxxxxxx iOPPPPOPPPPBC OPPPCPPCPPOP. '"WW"' ■X-XXXXXXXX: xxxxxxxxxix: MMMMMK •X»W«««. 1
1 Hoffman, et al., n n y y n y y y y ye n n NS y n y NS NA c !
1994
.vx:,„yx....... ; •xxxxxxxxxxxx xxxxxxxxxxxx: xxxxxxxxxxxx: xxxxxxxxxxxx: xxxxxxxxx-xxx •xxxxxwxxxxxxxxx j
I Hohikoshi, et al., n n NS n y y y y n n y n NS y n y NS NS C
I 1994
xxxXxXXXxXXX: •......... XXvXXXWX xXXXxXXxxX: .xxxxxxxxxxxx xxxxxxxxxxxx: WSWSSSSS: ,:Xx:,:xSxxs,
■
1 Hozack, et al., n n y n y y y y NS y y y NS y y y NS NS c {
| 1993
................ ......................... ......................... ......................... ..................... ......................... xxxxxxxxxxxx •XXXXXXXXXXX: ■XXXXXXXXXXXX xxxxx:-xx:,-x:< xxxxxxxx xxxxxxxx x, s xxxxxxxxxxxx xxxxx:xxxxxx: ■xxxxxxxxxxxx xxxxxxxxxxxx: j
| Hozack, et al., n y y y/nf y y/nf y y NS NS n y y NS y y y/nf NS NS c
1 1994 j
| Huracek & y y y y y y n y y y y n8 NS y n y y NS c 1
| Spirig, 1994
I;:,,,,,,,,,,,,,x:,,,, _■ ......................... ...................... ........................ XXXXXXXXXXXX *xxx:*xxxxx: xxxxxxxxxxxx xxxxxxxx ,,xx: xxxxxxxxxxx xxxxxxxxxxxx: .xxxxxxxxxxx
|
| Hwang & Park,
| 1995
n n n y y y y y NS y y y NS y n y NS NS c
j
% warns*® x:,,,,,,,,,. iiiriiif.n-f-f- NMMUM8 x-x-xx-x-:. xxxxxxxxxxxx: xxxxxxxxxxx: rXXXXXXXXXXX: XXXXXXXXXXXX x-wv::::v. xxxxxxxxxxxx ■xxxxxxxxxxx: xxxxxxxx x-vx«x:« x«xxxx«« s ,.,xxx,xxx:,. nnnjuinnnnnnnnnnnnn ■x|
|I Jacobsson, et al.,
| 1990
n n y y y y y y NS n y n NS y y n NS NS c
kxxWSrxx-:-:-:-: : :-:-: : ■ KWftWxS* • « tmmm ***** -ssxwxw: xxxxxxxxxxx:. XSXXWHWX :WSSS*X:*S XXXxWXXXXXX :wx::sf:w::::: XXXS,«WXX:.X5ft4.4
| Kelley &
| Johnstone, 1992*
y y y y y y y y y yh y n NS y n y NA y A 1
I Krismer, et al., n n y y y y y y y y y n NS y n y NS NS C
i
1 1991a
| KflWMMM s:xxxxxxx::xx. aM«W»K asssss&tti XXXSxSXXXXX •ssawftw ftMMSMtt XXXXXXXXXXXX xwxssss xsawsxs: xxxsssaws xxx.xx:xx:x: .xxxxxxxxxxxx xxxx:x::x::x:xx viMsexss, HUSHmstmnsf -|
1 Krismer, et al., n n y y y y y y y y y n NS y n y NS NS c
| 1991b - |
| Kristiansen & NA y y n y y y y n y y n NS y y y NA NS B "I
i Steen Jensen,
| 1985* i
t Lehman, et al.,
| 1994*
y y y y y y y y y n' y y y y y y NS NS A
| Mallory, et al.,
| 1989*
y y y y n y y y n n y y NS y n y NS NS c
;i Maloney &
: Harris. 1990
y y NS n y y y y y y y y y y y y NS NS c |
*
Studies not comparing typical prostheses.
dAlthough the same patients were evaluated for two types of prostheses, operations were, on average, 4 years apart, so there were differences in many variables.
e Detailed results given for five out of nine prosthesis models,
f First part of study prospective observation, second part retrospective comparison.
8 Harris Hip Score only section to have pre- and post-operative scores compared, even though many other sections could have been assessed in this way.
h
Only loosening rates given for specific models.
' Only failure rate results for specific models.
continued
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1 Key criteria Other criteria |
1 Study 1 2 3 4 5 6 7 8 9 10 1 1 12 13 14 15 16 17 18 19 Rating §
1 Markel, et al., 1995 y n n y y y y y Y y n n NS n n n n NS C J
I McPherson,
! etal., 1995
n y y n n y y y y y n n NS y y n NS NS c j
§ Moilanen, et al.,
| 1996
n n y n y y y y y y y y y y n y y n c 1
i; Moskal, et al.,
| 1994
y n NS y n y y y n y y y NS y y n n NS c }
I Nashed, et al.,
| 1995
n y n y y y y y y n n n NS y y y NA NS c
;i Neumann, et al.,
| 1996*
NA NA y y y y y y NA y y y y n n y NS NS B
Pierchon, et al.,
1994*
n n y y n n n n n n y n y n n n NS NS C
| Pritchett, 1995 n n y n n y y n n y y n NS y n y NA NS C
Pupparo & Engh,
1989
n n NS y y y y n NS y y n NS n y y NS NS C |
Ranawat, et al.,
1988*
y y y y/n y y y y y n y n NS y y y NS NS B S
Rand & llstrup,
| 1983
n y y n y y y y y y y n NS y n y NS NS C
[ Riska. 1993 y n n y y y y y NS y n n NS y n y NS NS C
I Ritter & Gioe,
! 1986
y y NS y y y y y NS y y y y y n y NS NS C
I Ritter. 1995 n n y y y y y y y y y n NS y n y n NA C
Schreiber, et al.,
1993
y n y y y y y y y y y n NS y n n NS NS c
: Schuller &
: Marti. 1990
n n y y y y y y y y y n NS y y n NS NS c I
: Turner. 1994 n n y n n y y n n y y n NS y n n NS NS c
; Visuri, et al.,
| 1994
n y y y y y y y y y y n NS y n n NA NA c
i; Walker, et al.,
| 1995




n n y y n y y y y y n n NS n n y NS NS c
\ Wixson. et al.,
1 1991
y n y y y y y y NS n y y y y n y NS NS c I
1 Yahiro, et al., 1995 Me ta-anal esis
1 Zicat,et al., 1995 y y y n y y y y y y y n y y y y NA NS c
: Zichner &
| Willert, 1992
n n n n y y y n y y y n NS n n n NS NS c
I * Studies not comparing typical prostheses.






1. Method of selection of patients identified. 2.
Prosthesis models specified. 3. Results given for
specific models. 4. Follow-up period, range/mean
specified. 5. Number of patients deceased or lost to
follow-up reported or included in analysis. 6. Ages -
mean/range. 7. Preoperative diagnoses of reviewed
patients specified with percentages/numbers. 8.
Clearly defined criteria for measuring outcomes/
quantification of outcomes.
Other criteria
9. Valid statistical analysis. 10. Outcome data
compared with preoperative data. 11. Data given
for deceased patients. 12. Clinical evaluation
independent of operating surgeon. 13. Radio¬
logical evaluation independent and blinded to
clinical results. 14. Numbers ofmen/women
specified. 15. Weight range/mean specified. 16.
Surgical technique/approach specified. 17. Grade/
experience & number of surgeons specified. 18.
Type of hospital/centre (general/specialist/
teaching) specified. 19. Unilateral/bilateral
results separate. 20. Independence of
investigators (vested interest) specified.
An abbreviated form of these criteria is given in a
footnote to Appraisal Tables 3-9.





1 Study r 2 3 4 5 6 7 8 9 10 11
X-XXXvX
12 13 14 15 16 17 18 19 20 Rating
| Ahnfelt, et al., 1990 y y y n n n y y n n NA NA y n n n y NA C §
SSWXWS -XXx-X-X-: #miSSSiS> .:XXxxX ■•xxxXX:- SXXXX-:- :Xx-:-:xX- XXXXX-: SWoWWMS ■XXXXX- :-:-:XxXx -x-x-rx-:^ XSWStMW ■xX-:-x-:-:-x-:-:-X-:-x-x-::::
| Brady & ; y y y/n NA y y y n n NA n n y n y y n n n C 1
jjl McCutchen, 1986 |
1 Carlsson, et al., 1986 t y y y y y y y ? NA n n y/na n n y y y n n B/C !
| Carter, et al., 1991 n y y y y n n
'
c
| Collis, 1988 y y y/n y y n n n n n n n n n y y y n c 1
xxxxxx- «S«xx« XXXXXX HMMoaw xx-xxx-:- wxsxxx kxx*»»: xxxxx* 'XvXvXvX ':-:-x:vX-x-xx-:-x:-x-:|
j Dall, eta/, 1988 y y y y y y y y ? n n n n y n n n y n n B
■WW*::*: X-x-xx-:-:-:-: xxxxx-:- xxxxxx xxxxxx xxxxxx- xxxxxx- x-x-x-x-x-x xxxxxx XXXXXX xx-wxx- xxxxx* kxxxkx :-xxx«-:x- -X-X-XWXi- X-X*X«^X«-X-X:X-X-:
1 Dall, etal., 1988 n? y y y n? n? n? n? Abstract of conference paper ! 1
I x-x-x-x-x-x -x-x-xxxx XXXXXX- xxxxxx xxxxxx XXXXX-:- :xxxxx- kxxxxx :-x-:-x-x-x-x '.xxxxx- ^ ' x-x-x-x-x-x :-:x-:-:-x-x-x-x-xx-x-|:
| Dall.etal., 1993 y y y y y y y y n n NS NS y n n n n n B j•x-x-x-x-x-:- :-x-x-x-x-:-x- I:-:-::-:::-:-::-: xxxxxx :x-:xx-xx- x-xxxxx X-X-XXXX xxxxxx- XXXXXv xx-x-xx-x xxxxxx xxxxx-:- MMMMM • • X-X-X-X-Xv
| Eftekhar & y y y y/n y y y y ? NA y n n y n y y y n n B
i Tzitzikalakis, 1986
I x-x-x-x-x-x x-x-x-x-x-x- I-:-:-::::-:-:::-: .x-x-xxxx x-xxxx* xxx-xxx- I:::-:-:-:-::-::-: xxxxxx xxxxx-:- XXXXX-:- x-xx-x-x-x- x-x-x-x-x-x x-x-x-x-x-x -X-X-X-X-Xv x-x-x-x-x-x •■:-x-:-:-:-:-:-:-x-:-:-:-:-:-:-:-:-:::-
| Eftekhar, 1987® n y y y n n n c
w xx-xx-xx xxxxxx MMmMK XXXXXX :««•: XXXXXC- XvXXXX- :x-:xxx-:-:- :-x-x-x-x-:-x x-x-x-x-x-x xxxxxx ■x-x-x-x-x-:- x-x-x-x-x-x- x-x-x-:x-x-:
| Garcia-Cimbrelo & y y y y y y y y y n NS NS y y y y/n y y A 1
| Munera, 1992 I
I Gudmundsson y y y y y y y NS n n NS NS y n y n y n B
1 etal., 1985 |
I CM. mtw MMMMMOI xxxxx-:- xxxwx xxxxxx xxxxx-:-: HMOMMM HXXXXX- HMHMMW xxx-xxx MMMMM x-x-x-x-x-:- »m«4MN«W WMJ
iji Hamilton & Joyce, y y y y y y/n y y ) y n n n y n y y y n n B 1
| 1986 1
(WMMW -xx-x-xx-: XXXXX-:- XXXXXX- XXXXX-: xxxxx-: xxxxx-:- ' xxxx-xx- •:xxxxx x-x-x-x-x-x x-x-x-x-x-x xxw •x-:-x-xvx-: x-x-xx-jx-xx-xx-I
| Hamilton & ) y y y y y y y y n n n n y n y y y n n B
I Gorczyca, 1995 |
•x-xxxx-: ❖www*: xx-xx-x-:- xxxxx-:- xxxxx-: xxxxx-: xxxxxx :«:-xx-Xv xxxxx-:- •xxxxx-: XXXXX-: :xxxxx- x-x-x-x-x-:- x-.-x-xxx- xxxxx-: xxxxx.: xxxxxx x-x-x-x-x-:- -X-X-XvX-X- •x-:-x-x-x-x |
| Hartofilakidis, y y y y y y y NS n n n n y n y y y n B 1
! etal., 1989
jij Hodgkinson, et al., see Comparativ studi es C
| 1993
| Johnsson, et al., 1988 □ 1 .1 y/n ,n. 17171 n n T] NS NS XI,,1,3 n/y y 3 n C
i; 0 New data only assessed. ? Doubtful that criterion met; not clear from paper.
J Key: 1. Selection of patients. 2. Prosthesis models. 3. Results for models. 4. Follow-up period. 5. Loss to follow-up/deceased. 6.Ages. 7. Preoperative diagnoses. 8 Outcomes
j: clear/quantified. 9. Statistical analysis. 10. Comparison with preoperative data. 11. Data on deceased. 12. Clinical evaluation independent 13. Radiological evaluation |




ItwewsmMwssmmmuimium XXXXXX XX-X-XX-X- •xxxxxx xxxxxx XXXXXX- xxxxxx X-X-XsXsX-XvXvX-x-xw:- wx-xx-:-x-:-:-:-x-xx-i;:
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APPRAISAL TABLE 3 contd Observational: cemented - Charnley
yWMWMMIIGIOIIIllMIIMUMIUIMMIM) : •:•:•:•:•:•:•:•:•:• x:xx<xx:xx■xx-x-xxxs-x XXX-X-XXXLXXSXXXXjXix XXXiXXXXXXXX XXXXXXXXKX-i. / / S V i-x.vxxxxxxxx frXXSXWXKiv ~i
Key criteria Other criteria
: xxxxXXSxx: •xxxxxxxxx • ■xxxxxxxxX XjX>XXHX:X. •XXXSXXXSxA-Xxxxxsxxx xxxsxxxxxx •V»XX.-WK«XXC ■ixxxXXXSXxX •XxxxxxxxX:: •jkxxkwxxx SSSMMX •:-xxxxxxxXXxx:-xxx:x-:::$
Study 1 2 3 4 5 6 7 8 9 10 II 12 13 14 15 16 17 18 19 20 Rating |
j
XSXxHWx xxxxsxxsxk xxxxxxx xxxxxxwx ■xxxxxsxxx: tMmm •xxxxxxxxxxxxxxxxxxxx:;
| Johnston & y y y y y n n n n n NS n n n y y n n C I
| Crowninshield, 1983
| Joshi.et al., 1993 y
■ xxxxxxxxxx
y y y y y y y y y y n n y y/n n y/n y n y A s
xxxxxxxxxx xxxxxxx xxxx:xx- XXXXXXX •xxxxxxxxx. xxxxxxxxx: xxxxxxxxxx: XXXX-xxxx-. •xxxxxxxxxx •xxxxxxxxx: xxxxxxxxxx ■xxxxxxxxxx •xxxxxxxxx: •xxxxxxxxx: xxxxxxxxxx: ■xxxxxxxxxxxxxxxxxxxxS;
| Karachalios, et al., y y y y y n y y n n NS NS y n y y y n c 1
| 1993 J
I Kavanagh, et al., y
xxxxxxxxx;
y y y y y n y n n NS NS y n y n y y c j
| 1989 i
1 Koba/ashi, et al., y y y y y y y y y y n n? y y n y y y n n A/B
| 1994a 1
•xxxxxxxxx: ::::::::::: unww ■xxxxxxxxxx. xxxxxxxxxxx hm4w000w xxxxxxxxxx: xx-xxxxx-x •xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx: •xxxxxxxxxxx
I Kobayashi, et al., y y y y y y y y y y n n? y y n y y y n n A/B
I 1994b 1emmmmmmmhowmmmmmohmmmom •xxxxxxxxxx xxxxxxx. XXXNXXX xxxxx-xx xxxxxxxxxxx •xxxxxxxxxx: xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx: •xxxxxxxxxx •xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx: •xxxxxxxxxx: -xxxxw-k-x: |
| Langlais, et al., 1995 Mechanics of loosening study - not appraised ? 1
| Madey, et al., 1997 y y y y y y y y y y n n y NS y y y n y A/B
f •xxxxxxxxxx xxx-xx-x xxxxxxx: xxxxxxx: xxxxxxx xxxxxxxxxxx xxxxxxxxxx w-xk-wx: .xxxxxxxxxx: xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx: •xxxxxxxxxx: •xxxxxxxxxx: xxxxxxxxxxx xxxxxxxxxx: •xxxxxxxxx: xxxxxxxxxx: 8|
| McCoy, et al., 1988 y y y y y y y y/n n y NS NS y y n n y n A/B
•xxxxxxxxxx: ■XvXvX-X- xxxxxxx ■xxxxxxxxx: »XX»M®X •xxxxxx-xxx: xxxxxxxxxxx xxxxxxxxxx:: XMrXxxXXK- ■xxxxxxxxxx: •xxxxxxxxxx: xxxxxxxxxxx xxkwxxxxx ■xxxxxxxxxxx •xxxxxxxxxx: xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxxx:!:.
| Neumann, et al., y y y y y y y y n n NS NS y n y n y y B i| 1994 •
xxxxxxSSSXS: X-XX-NX-WS xxxx-xw XXXXXXX: XXWXXXX xxxxxxsxxxx: sxwswssx x^::w:::xx:. •xxxxxxxxxx: ■xXxxxXXXxX: xxxsxxxsx:-:.: •:WXxxXXS:: xxxxxxxxxxx: SXSWKWx. •xxXv-XXXXX: xxxxxxxxxxxxxxxxxxxxx:;:
1 Neumann, et al., see Comparative studies B
| 1996 I|
| Nicholson, 1992 n y y y n n n n n/y y n c 1
xxxxxxxxxxx: xxxxx-x-x-x vXX-X-X-X- xxxxxxx-: xxxxxxx: ■xxxxxxxxx: •xxxxxxxxxxx .xxxxxxxxxxx xxxxxxxxxxx: xxxxxxxxxxx: •xxxxxxxxxxx •xxxxxxxxx-x ■xxxxxxxxxxx xxxxxxxxxxx: xxxxxxxxxxx: yxxxxxxxxxx •xxxxxxxxxxx xxxxxxxxxxx: xxxxxxxxxxx: xxxxxxxxxxx:
1 Older, 1986 y y y y y n y n n n y NS n n n y y n C
|-xxxx:«:^^ ■xxxxxxxxxxx xxxxxxx:- xxxxxxx:. xxxxxxxxx xxxxxxxxxxx: xxxxxxxxxxx: •xxxxxxxxxxx •xxxxxxxxxxx xxxxxxxxxxx: xxxxxxxxxxx: xxxxxxxxxxx: •xxxxxxxxxxx •xxxxxxxxxxx xxxxxxxxxxx: xxxxxxxxxx: xxxxxxxxxxx: •xxxxxxxxxxx .xxxxxxxxxxx i»»aoia;iiiii088im|
§ Older & Butorac, y y y y y y y y n n NS NS y n n n?y n n B
L1992 X-X-X-X-X-X sxxxxxxx :x:xxx:x:x xxxxxxx:- xxxxxxxxx x-xxxxxxxxx: xxxxxxxxxx: xxxxxxxxxxx •xxxxxxxxxxx •xxxxxxxxxxx xxxxxxxxxxx: xxxxxxxxxxx: •xxxx:-xxx-xx .xxxxxxxxxxx ::vxxxxx:vx: .xxxxxxxxxx: xxxxxxxxxxx: xx-xk-xxxx ■xxxxxxxxxx: •xxxxxxxxxxxxxxxxxxx:J
| Picault & Michel, y y y/n n n n n Abstract only c?
| 1995 1
si Ranawat, et al., 1989
*
Conference abstract ? 1
S Rasmussen, et al.. ; y y y/n } y/n y ? Abstract only published B'
| 1991 I
xxxxxxxxxxx MMMMOM xxxxxxx: :x:x:xxx:x xxxxxxx xxxxxxxxx: •xxxxxxxxx-: ■xx:-x:«.xxx: -xxk-xxxxxx x'xxxxxxxxx xxxxxxxxxx: •xxxxxxxxxx: -xx-xxxxxxx: xxx:xxxxxxx xxxxxxxx-xx ■xx«"xx»x: xxxxxxxxxx: •■xxxxxxxxxx: xxxxxxxxxxx xxxxxxxxxxx MWWWMIWM8
| Schulte, etal., 1993 y y y n y y y n n y NS NS y n y y y y c i
| Skeie, et al., 1991 y y y y y y y y n y NA NA y n y n/y y n A j
t ' t MMMMt ' xxxxxxxxxxx X-XXXXX xxxxxxx: xxxxxxx xxxxxxx xxxxxxxxxxx •xxxxxxxxxx: -xxxxxxxxxx: •xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx •xxxxxxxxxx: •xxxxxxxxxx: xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxx: xxxxxxxxxx: •xxxxxxxxxx: xxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxi;.
;? Solomon, et al., y y y NA? y y y y n NA? n n y n n n n n n B/C
I 1992 1
S V « V v'% V xxxxxxxxxxx xxxxxxx: xxxxxxx xxxxxxx- XXXXXXX. xxxxxxxxxx: .xxxxxxxxxx: •xxxxxxxxxx xxxx-xxxxxx xxxxxxxxxx: xxxxxxxxxx: •xxxxxxxxxx: •:•:•:•:•:•:■:•:•:■:• xxxxxxxxxxx xxxxxxxxxx: xxxxxxxxxx: •xxxxxxxxxx: xxxxxwxxxx xxxxxxxxxxx xxxk w--x----x S--X :
1 Stauffer, 1982 y y y y y y y n n n NS NS y n y n y n B
| Sullivan, eta/., 1994 ? y y y y y y y y n y n n y n y y y n y A/B
1 Terayama, 1986 y y y/n y y y ) c >•:
•xxxx-xxxXx xWxxxx xxXxXXx: xxXXXXX xxxxxxx XXXXXxXXXX: •xxxxxxxxxx .xxxxxxxxxx xxxxxSSSSxx xxxxxxxxxx: , •xxxxxxxxxx xxXXXXxxXx: X-xXSXXXXXx •xxxxxxxxXx •XXXxXXXXXX X:«-xXk-:-xxxXxXxxXx:§
§ Thomas & McMinn, n y y n n n n C I
| 1991 1
..
| Wejkner & y y y y y y y y n n NS NS y n y y y/n n B
;l Stenport, 1988




y y y y y y y y y n NS NS y n n n y n B
i; Wroblewski & n y y y n y y n n n NS NS y n n n y n C
:i Siney, 1993 1
New data only assessed. ? Doubtful that criterion met; not clear from paper.
| Key: I. Selection of patients. 2. Prosthesis models. 3. Results for models. 4. Follow-up period. 5. Loss to follow-up/deceased. 6. Ages. 7. Preoperative diagnoses. 8. Outcomes
| clear/quantified. 9. Statistical analysis. 10. Comparison with preoperative data. 11. Data on deceased. 12. Clinical evaluation independent 13. Radiological evaluation




APPRAISALTABLE 4 Observational:cemented - non-Charnley
Key criteria Other criteria |
| Study ' 2 3 4 5 6 7 8 9 10 1 1 12 13 14 15 16 17 18 19 20 Rating |
I Alsema, et al., 1994 i y y y y y/n y y y n y n n y n y y ? n y A/B
:: August, et al., 1986 ? y y ~y y y y y y n n n n y n y n y n n A/B
S Ballard, et al., 1994 ) y y y y y y y y n y n n y n y y y n y A/B
| Bohler, et al., 1994 y y y y y y y y y y n n n y n y n y n n B
Bosco, et al., 1993 ? y y y y y y y y n n y y y y y y y n n A/B
| Bryant, et al., 1991 ; y y y y y y y y NA y n n y n n y n n B
| Dorr, et al., 1994 ? y y y ; y y > 7 7 NA n n y n n n y n n C 1
| Fowler, et al., 1988 ) y y y y y y y 7 y n n n y n 7 y y n n B
| Harris &
| Penenberg, 1987
7 y y y y y/n y 7 n n n n y n n y y n y B/C
| Helfen, et al., 1993 y y y y y y y y ; |
| Hi rose, et al., 1995 7 y y
*
y y y y y Abstract only B
| Jantsch, et al., 1991 7 y y y y y y y 7 n y n n n n n n 7 n n B
| Karrholm, et al.,
| 1994
7 y y y y y y y y NA n NA n y n y n y n y A/B
| Lachiewicz &
| Rosenstein, 1986
7 y y y y y y 7 n NA n n y y y n y n n B/C |
| Mohler, et al., 1995a y 7 |
| Nizard, et al., 1992 Mechanics of loosening study n A/B
| Ohlin & Onsten,
| 1990 7 y y y y y y y n y n n y y y n y n n B |
1 Ohlin, 1990 y y y y y y y y y n n n n y y y y y n n B
ij: Oishi, et al., 1994 7 y y y y y y y 7 n y/n n n y y y y n n y B |
| Papenfus, et al., 1992 7 y y y y y y y 7 y n n n y n 7 7 y n n B/C §
| Partio, et al., 1994 7 y y y y y y y y n y y y y y y y y n n A |
| Pearse, et al., 1992 Y y y y y y y y n n y n n n n y y y n n B/C |
I Roberts, et al., 1987 y y y y y y y y y n y NA NA y n y y y n n A |
Rockborn &
| Olsson, 1993
7 y y 7 y y y y > n n? n n y n y n y n y B j
| Russotti, et al., 1988 y y y y y y y y y y NA n n/y y n y n y n n A
I Thomas, et al., 1986 y y y y y y y y y NA n n n y y y y y n n A/B
1 Tompkins, et al.,
| 1994
7 y y y y y y y y y n n n y y y y y n n A/B
>; Warren, et al., 1993 Y y y y y y y y y n y n n y n y y y n n A/B |
1 ? Doubtful that criterion met; not clear from paper.
Key: 1. Selection of patients. 2. Prosthesis models. 3. Results for models. A. Follow-up period. 5. Loss to follow-up/deceased. 6. Ages. 7. Preoperative diagnoses. 8. Outcomes
i: clear/quantified. 9. Statistical analysis. 10. Comparison with preoperative data. 11. Data on deceased. 12. Clinical evaluation independent 13. Radiological evaluation
independent 14. MIF numbers. 15.Weight. 16. Surgical technique. 17. Surgeons'grade, etc. 18. Type of hospital. 19. Bilateral results separate. 20. Independence of
| investigators.
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APPRAISAL TABLE 5 Observational: cementless - porous-coated
Key criteria Other criteria
\ Study 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Rating
\ Bhamra, et al., 1992 n y y y n n y y C 1
i; Bourne, et al., 1994 y y y y y y y y y n n n y y n y n y n y A/B
Callaghan, et al.,
1 1992
y y y y y y y y y y n n n y n y y y n n " B
Cordero-Ampuero.
j! et al., 1994
) y y y y y y y y y n n n y y y y y n n A/B
i Cracchiolo. et al.,
1992
y y n? y y y y y ; y y n n y y y n y n n B/C
Engh & Massin, 1989 n y y y n y y y t n y n n y n n n y n n B
• Engh. et al., 1990 ) y f y y y y y y y n n n y y y n y n n B
Engh. 1993 n y Y i n n n ) C
: Engh. 1994 yr y y yc yIn n n y C
Engh. et al., I997d y y y min y y y y y y y n n y y y n y n n A/B |
Haddad, et al., 1990 y y y y ) y y y y y NA n y y n y y y n n A/B
Heekin, et al., 1993 ; y Y y y y y y y y y n n y n y n n n y A/B j
Hellman, et al., 1997 ) y Y y y y y y ) n NA n n y n y y n n n B
Holman & Tyer. 1992 y y y ? NA? y y y t y NA? n n n n y n y n n B/C j
| Incavo. et al., 1993 ) y y Y NA y y y y n NA n n y n n n y n n B
Jansson & Refior.
1992
t y y y y y y y n n NA n n n n n n y n n B/C
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Abstract
Human implant technologies are subject to continual innovation and proliferation, raising important issues for
technology testing, healthcare sciences, clinical performance and risk assessment, and regulation. The regulatory
environment of medical devices is being shaped by harmonisation of standards in the European Union. The aim of this
paper is to compare the histories and current regulatory environment of two technologies, breast implants and artificial
hips, and to consider the implications of this comparison for a sociological healthcare research agenda to investigate the
issues raised. The main focus is upon developments in the United Kingdom. Major points of contrast between the two
technologies include the institutional contexts in which clinical evidence has been marshalled for government attention;
the relative importance of strategic alliances between clinicians and manufacturers in the innovation process; the degree
of public controversy evident; the varying definitions of an 'adverse incident' within medical device vigilance systems;
and in the UK the presence of a national register for breast implants but not for hip implants. Inter-national contrasts
in these dimensions are noted. The analysis suggests that improved understanding is required of the institutional,
organisational and professional processes involved in implant technology innovation and regulation. A comparative
research agenda is proposed, focusing upon: innovativeness and proliferation; safety and technological standards;
clinical and social outcomes; and consumer/user information and choice. It is concluded that research in these areas will
enhance the 'evidence-base' for the evaluation of human implant technologies in the context of their innovatory and
regulatory environments. © 2001 Elsevier Science Ltd. All rights reserved.
Keywords: Implants; Innovation; Regulation; Medical device; Comparative study
1. Introduction — health technology and policy
There is a constant proliferation of health technolo¬
gies that offer benefits to public health in maintaining or
enhancing the quality of life. Continual innovation in
health technologies is increasingly being seen as a
double-edged sword, raising a multitude of policy issues
concerned with industrial competitiveness, public risk
and safety, health service effectiveness, and consumer
information and choice. The advent of an era of
'evidence-based' medicine increasingly challenges the
'Corresponding author. Tel: +44-2920-874739; fax: + 44-
2920-874759.
E-mail addresses: faulknerac@cf.ac.uk (A. Faulkner), ju-
lie.kent@uwe.ac.uk (J. Kent).
relationships between scientific and technological
knowledge, and health technology policy.
The intention of this paper is to introduce the policy
issues surrounding human implant technologies. Our
aim is to compare the histories and current regulatory
environment of two technologies, breast implants and
artificial hips; and to consider the implications of this
comparison for a social research agenda to investigate
the issues raised. The first section of the paper outlines
the policy context in which these technologies may be
understood. The second section describes the history of
innovation and current regulation of each group of
implants in order to develop a comparative research
agenda in the final section. The main focus is upon
developments in the United Kingdom, set within a
European and wider international context.
0277-9536/01/$-see front matter © 2001 Elsevier Science Ltd. All rights reserved.
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Within the healthcare policy arena internationally
there has been a growing concern about the proliferation
and cost of new technologies (Stocking, 1992;
Altenstetter, 1996). The explicit drive toward a 'know¬
ledge-based' health service (DoH, 1993) increasingly
problematises issues of the performance and ongoing eva¬
luation of innovative health technologies. Increased
concern with cost and efficiency is characteristic of the
'new public management' (Hoggett, 1991). These devel¬
opments place a premium upon the production of
knowledge about health technologies, control over
diffusion and 'quality assessment' in terms of standards
of performance. In the health arena this has led to new
inter-disciplinary alliances between public health, clin¬
ical specialties, epidemiology and the academic disci¬
plines participating in 'outcome measurement'. The
Health Technology Assessment (HTA) research pro¬
gramme in the United Kingdom arose amidst growing
concerns about cost containment and clinical effective¬
ness of healthcare interventions, reflecting developments
internationally (Banta & Luce, 1993). Part of the agenda
of the national HTA programme is directed towards
controlling the diffusion of new health technologies,
especially where a threat to health or healthcare budgets
is identified (Advisory Group on Health Technology
Assessment, 1992; Faulkner, 1997). Regulatory mea¬
sures are being extended from pharmaceuticals to
medical devices and even surgical procedures (Gelijns,
1990; Sheldon & Faulkner, 1996; Mowatt et al., 1997).
At the same time, moves toward the harmonisation of
European trading standards is further increasing atten¬
tion to the regulatory environment of new devices being
brought to the healthcare market.
The public image of technological medicine is
generally very positive, but the invention and adoption
of new medical devices present perennial dilemmas of
healthcare policy. New technologies may offer potential
benefits in terms of health gain or the relief of suffering,
but on the other hand there may be risks to health, social
or economic costs may be incurred, or ethical issues
raised. From a public health perspective, therefore,
innovation should, in principle, be promoted and not
stifled, but adequate safeguards must exist in order to
prevent potentially harmful technologies being adopted.
Different countries have evolved collections of mechan¬
isms which deal with these dilemmas in different ways,
with diverse levels of explicit regulatory control
(Altenstetter, 1996; Faro & Huiskes, 1992). Occasionally
the emergence of a particular technology heightens the
level of policy concern about these matters. Perhaps the
most outstanding example is the computed tomography
(CT) scanner, which was associated with a major debate
in the 1970s and 1980s framed in terms of a concern with
expensive 'new medical technologies' (Jennett, 1986;
Stocking, 1988), a debate which certainly paved the way
for the emergence of HTA.
Currently, this type of debate is being given renewed
impetus, especially in the context of the development
of new genetic technologies and capital-intensive
technologies such as 'telemedicine' and positron-emis¬
sion tomography (PET) scanning. This coincides with
awareness that in late modern societies subjective
experience is increasingly articulated through preoccu¬
pations with issues of risk and uncertainty, as
traditional forms of expertise and authority,
including medical authority, are being challenged
(Giddens, 1991; Beck, 1992; Gabe, 1995). However, a
corollary of the challenge to traditional medical
authority may be a re-positioning and re-defining of
the medical and allied sciences in relation to the
production of new knowledge focused around care
delivery. This may be seen, for example, in the 'evidence-
based medicine' movement, and also illustrated by
current concerns with regulation of the practices of
medical and other professions allied to medicine. While
the technologies of genetic and diagnostic information
clearly raise major ethical and social uncertainties, so
too do medical devices — though perhaps in less
obvious and less often publicised ways.
Much of the preoccupation with risk and uncertainty
has focused upon the human body as a 'project' of
modernity (Turner, 1992; Shilling, 1993; Williams,
1997). Medical devices may offer a variety of benefits
to individuals especially in terms of increased longevity
and enhanced or maintained quality of life, with
consequent collective benefits for society. What we have
termed 'human implant technologies' are an important
group of medical devices treatment with which in
principle offers benefits in maintaining or repairing the
functionality and quality of many different body parts
and systems, with implications for body image, self-
esteem and social participation. Implanted technologies
raise special questions of performance in the body and
ofmethods of assessing that performance. Evaluation of
long-term performance may require regular clinical
follow-up of implantees, attempts to develop techniques
to predict future performance, biocompatibility testing
or material analysis of devices following explantation or
death of the implantee (Fielder & Black, 1995).These
technologies have been increasing rapidly in their
numbers and variety in the last 20 years, and a vast
array of organs, vessels, tissues and bones can now be
replaced by 'artificial' or salvaged parts. While the
public and mass media imaginations appear especially
fascinated with organ transplantation, the numbers of
people directly affected by this are small compared to
those receiving surgical implants such as arterial stents,
heart valves, breast implants, joint replacements, defi¬
brillation devices, or spinal implants. Science fiction-like
images of the bionic person and the cyborg are
increasingly seen within the medical profession itself as
becoming reality (Marinker & Peckham, 1998), and
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developments in tissue engineering technologies offer the
possibility of 'living' implants.
It has been strongly argued, in investigating relation¬
ships between science and policy in healthcare, that
medical sociology should concern itself more with the
production of medical knowledge by pharmaceutical
industries and governments, in addition to its other
concerns (Abraham, 1997). Alongside this, there is an
important opportunity for medical sociology to broaden
its focus, in concert with the social study of science and
technology, to include exploration of the newly emer¬
gent healthcare sciences, epitomised by the health
technology assessment movement. We suggest that the
uses of science and technology tests in the construction
and regulation ofmedical devices in general, and human
implant technologies in particular, are an equally if not
even more neglected topic. As with pharmaceutical
products, there are significant implications for both the
protection and advancement of public health and for
healthcare budgets, as well as broader social and
economic implications. We take it that human implant
technologies are 'sociotechnical' constructs (Law &
Bijker, 1992) embodying scientific and technological
knowledge and social processes. And in parallel with
Abraham's analyses of the operation of science in
pharmaceutical regulation (e.g. Abraham, 1997), broad
political and economic factors influence this knowledge
and shape the devices upon which we might rely, either
as implantees or as consumers of other types of medical
device.
Implantable medical devices — regulatory environment
The Medical Devices Agency (MDA) is the
'competent authority' with responsibility for 'ensuring
the safety and quality' of all medical devices used in the
UK. Human implant technologies are a category of
medical device which fall within the scope of the
European Medical Devices Directives (EMDD) (93/42/
EEC). "Products as diverse as CT scanners, cardiac
pacemakers, syringes, bandages and hospital laboratory
equipment all come under the scrutiny ofMDA's highly
knowledgeable medical devices experts" (MDA,
undated). The EMDD distinguish between active and
non-active implantable medical devices. Active implants
are powered devices left in the body (e.g. heart
pacemakers). In these terms both breast and hip
implants are non-active (though bio-active coatings
and materials may be used, in which case they may be
classified at a higher level of risk). However, as our
discussion will suggest there are both similarities and
differences in the ways in which these two groups of non-
active implants have been developed and regulated.
The move from voluntary control of medical devices
in the UK to a Europe-wide statutory system raises
questions about the effects of harmonising standards
(Altenstetter, 1996; Levidow, Carr, von Schomberg, &
Wield, 1996). Since 1993 a process of harmonisation of
European standards in medical devices has begun and
the UK MDA has played a part in this process. The
award of the 'CE' (Conformite Europeen) mark now
denotes a European conformity standard and eventually
all medical devices will be required to carry this mark
(MDA, 1993a,b). Under the CE marking system medical
devices are classified according to the degree of risk
assigned to them. CE marking does not guarantee safety
but it does mean that the product may be freely
marketed anywhere in the EC without further control
(MDA, 1993a,b, 1995). Operation of a post-marketing
'vigilance system' is the responsibility of Member States
of the European Union.
Under the vigilance system in the UK, the MDA
operates an 'Adverse Incident Centre' (AIC) to which
users (for example nurses, clinicians, patients) and
manufacturers are able to report cases where a medical
device has failed or produced unwanted side effects. This
remains a voluntary system, though in certain circum¬
stances manufacturers are required by law to report
incidents (MDA, 1998a). Following investigation by the
MDA, a number of actions may follow: either a hazard
notice may be issued alerting others to potential danger;
a safety notice may be issued advising users in less urgent
situations; or a device bulletin with guidance and
information for users may be produced. Finally there
may be "an improvement in product design, labelling or
instructions for use. In some cases the manufacturer will
withdraw the products from the market" (MDA,
undated). The guidelines produced by the European
Commission on the vigilance system "are not enforce¬
able by law" (MDA, 1995, p. 5; MDA, 1998b).
However, within the UK the MDA has a duty under
the Consumer Protection Act 1987 to enforce the
essential requirements of the EMDD regulations
(MDA, 1995). Nevertheless, the efficacy of reporting
systems may be open to question: analysis of the post¬
marketing surveillance system operated in the USA by
the Food and Drug Administration shows a high degree
of under-reporting of adverse incidents to the regulatory
agency even when users have reported problems to
manufacturers (Bowsher, 1991).
There are a small number of MDA-funded implant-
specific national registries — the National Pacemaker
Database; the UK Heart Valve Registry; the Hydro¬
cephalus Shunt Registry and the National Breast
Implant Registry. According to the MDA "they are
used to provide an early warning of device related
problems and a general indication of implant usage"
(MDA, 1999a). In the arena of the new healthcare
sciences addressed to issues of health service effective¬
ness and cost effectiveness, the Health Technology
Assessment programme in the UK has given priority
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to a small number of implant technologies in its research
programme in healthcare technologies. These include
cochlear implants, intrathecal opioid pump systems,
oesophageal and aortic stents, and hip and knee
prostheses (National Coordinating Centre for Health
Technology Assessment, 1998).
Total hip joint implants
Innovation
Artificial hips have been implanted in the UK
routinely since the mid-1960s. Currently, there are over
60 different named models available in the UK. Most of
these do not have published scientific evidence to
support their use, and about half have been introduced
within the last 7-8 years. The proliferation of different
design features and materials is spectacular. The most
common design uses 'cement' to fix the prosthesis, but
non-cemented designs are increasingly being developed.
These are more expensive, and their performance is
controversial within the orthopaedic profession inter¬
nationally. A recent trend is the production of modular
designs, which introduce more mechanical components,
with the (cl)aim of achieving better anatomical fit. This
has led certain leading orthopaedic researcher-surgeons
to warn against a trend toward 'designer hips'
(Bulstrode, Murray, Carr, Pynsent, & Carter, 1993),
and the recent attempts to improve upon the standard
cemented design have been strongly criticised (Huiskes,
1993).
About 40,000 first-time implantations are carried out
annually in the UK, one-fifth of these outside the NHS.
Increasing numbers of younger and older (over 80 years)
people generally are receiving hip implants. Total hip
replacement is generally recognised to be of great benefit
in the relief of arthritic pain and improvements in
locomotor mobility. There is some evidence that
implantees' quality of life is improved. The most
common prosthesis (the 'Charnley' cemented model) is
used in between 40% and 50% of primary hip
replacements in the UK. However, some 70% of
hospitals have reported using both cemented and
uncemented models to some extent (Newman, 1993).
There appears to be a regional preference for different
types of hip implant, with uncemented models being
more common in the south of England. In Newman's
survey 30% of hospitals in England and Wales stocked
at least two uncemented models (Newman, 1993).
Unlike breast implants, no breakdown of numbers of
people registered as receiving different types of implant
is available in the UK, even on the basis of voluntary
data. Prices per unit vary widely, from about £250 to
£2000 (1996 prices) for the most expensive modular hip
systems (Murray, Carr, & Bulstrode, 1995). The pattern
of types of implant used varies widely between countries.
For example in the early 1990s more than 50% of
implants in Finland were non-cemented, while these
models accounted for only 4% of those in Sweden and
15% in Norway (Havelin, Espehaug, & Vollset, 1993).
The main materials used in hip implants are metals,
plastics and ceramics. The 'same' model is often
produced by manufacturers in different metals (tita¬
nium, cobalt-chrome) and coatings (porous mesh or
beading, pre-roughened, hydroxyapatite (a biologically
active ceramic, usually referred to as 'HA'), and others).
The bearing surface materials of the femoral head (ball)
and acetabular component (socket) also vary widely:
metal, ceramic and high-density plastics being used in
different combinations. The arrival of superalloys and
composite materials has almost eliminated mechanical
breakage in normal usage of the artificial hip. However,
there is continual innovation in materials and design
features, with more advanced production processes
being applied and rare materials being used, such as
zirconium. The Norwegian national register of artificial
hip implants (see below) yielded a count of over 400
different designs and sizes of socket component, and
nearly 400 stem components, which was felt by the
orthopaedic surgeon reporting this to be, "from a
medical point of view unreasonable" (Havelin et al.,
1993, p. 251). The stronger, new materials appear to
have brought with them their own problems, and these
may appear only two or three years after implantation.
Small changes may have large consequences (e.g. the
matt finish on the 'Exeter' femoral component, which
proved ineffective). One surgical commentator has
described the effects of the new materials thus: "We
have unleashed a torrent of particles into our joints,
producing a devastation far exceeding simple prosthetic
failure or fragmentation of parts" (Booth, 1994). This
may be a somewhat exaggerated account, but the issue
has also been recognised by a National Institute of
Health conference in the United States, and in the
United Kingdom: "The main problems of concern
related to implant design are... osteolysis due to
particulate materials, biologic responses to particles of
implant materials..." (Murray et al., 1995, p. 1952);
"new designs and material combinations... may intro¬
duce fatigue problems which as yet have not been
considered" (Styles, Evans, & Gregson, 1998). Thus
there is little doubt that the clinical effects of the new
combinations of materials do raise fundamental con¬
cerns about the safety implications of the technologies
being employed, and possible means of evaluating them.
It is certain that most implantees do not have detailed
information about the design and material composition
of their artificial hips.
The world annual market value for the orthopaedic
implant business is estimated at around $9 billions, of
which about 20% is accounted for by hips (DePuy,
1997). Six companies or groups now dominate the
international market in terms of sales. There are at least
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19 separate distributors or manufacturers of hip
implants in the UK (Murray et ah, 1995). These are
mostly multinational (mainly American) companies
specialising in orthopaedic and surgical products (e.g.
DePuy, Zimmer, Howmedica), but also include multi¬
national multi-sector companies (e.g. 3 M) and smaller
British-based firms (e.g. Corin Medical). There are
strong financial incentives to produce modified versions
of designs or even entirely new models (Bulstrode et ah,
1993). A typical company produces a range of different
implants using different materials and design concepts.
Biomet, for example (about 8% market share in
orthopaedic implants generally), in March 1999 listed
17 different trademarked femoral components, and 11
socket components in its information for surgeons
(Biomet, 1999). These cover different base materials
such as titanium or cobalt-chrome, options for bolt or
plate attachments, different sizes and stem lengths,
different coatings — porous or hydroxyapatite, cemen¬
ted or cementless, for primary or revision implantation,
modular or 'monobloc' designs, with most being
marketed for use in 'skeletally mature patients under¬
going (primary) hip replacement surgery as a result of
noninflammatory degenerative joint disease'.
Innovating orthopaedic surgeons, bio-engineering
research laboratories and manufacturers often form
strategic alliances to bring new designs to the stage of
clinical experimentation. Orthopaedic surgeons may act
as design advisers to an implant manufacturing com¬
pany. A number of analysts of technological change
have pointed to the importance of networks of interac¬
tion between different actors (included in, for example,
Bijker & Law, 1992; Star, 1995; Gaudilliere & Lowy,
1998). However, while sociological historical analysis
has been conducted on the innovation process in
cochlear implants (Blume, 1995) and heart pacemakers
(Jeffrey, 1995), little information about the interaction
of social, organisational and technological processes in
orthopaedic implant innovation can be found in
published sources. Review of clinical research about
the performance of hip implants suggests that a small
proportion of orthopaedic surgeons worldwide has a
financial as well as clinical interest in new designs
(Faulkner et ah, 1998). Anecdotal evidence suggests that
provision of conference support, training courses or
equipment by manufacturers may play a part in
influencing some surgeons' choice of implant providers.
As with pharmaceuticals, orthopaedic manufacturers
employ sales representatives to promote the sale of their
products.
Artificial hips became a matter of increased public
concern in the early 1990s in the UK. Media coverage
such as the 'High Price of Hips' (BBC2, February 26,
1993) and well-publicised scares such as the 3 M Capital
Hip failures announced by the MDA in February 1998
(MDA. 1998c) caused concern focused both at the
healthcare cost and at performance safety issues. The
'untested' status of many models was highlighted, and
advice from consumer health organisations encouraged
patients to ascertain what prosthesis is being recom¬
mended to them (e.g. Consumers'Association, 1997). The
apparent successes of operations on elderly people such
as the Queen Mother also highlighted this type of device.
An indication of governmental concern is the launch in
1999 of an investigation into total hip replacement by the
UK's National Audit Office, and in 2000 the publication
of what can be regarded as quasi-regulatory guidance for
the NHS by the National Institute of Clinical Excellence
(NICE, 2000).
Regulation
The regulatory environment of hip prostheses in the
UK has been relatively unrestrictive. A surveillance
scheme based on a 'recommended list', a limited number
of models agreed to be acceptable, was agreed between
the government and the orthopaedic profession in 1981
(Sweetnam, 1981), but it was not implemented. Unlike
some other implants there is no national registry of
clinical implant information, voluntary or otherwise,
although one regional health authority area (Trent) does
have a monitoring system of this type, established in
1990 with support from the government Department of
Health. This collects data on the brand of implant,
prophylaxis, cement, theatre environment and grade of
operating surgeon, plus age, sex and diagnosis details for
the patient. Although orthopaedic departments and
centres can be taken to record the prostheses implanted
in their own patients, there is no co-ordination of these
data between centres and the extent to which systematic
local post-implantation monitoring occurs is unknown.
This situation can be contrasted with several Scandina¬
vian countries which have national hip implant registers
which collect detailed information about the implant
model, surgical staff, operating theatre environment,
antibiotics and other items. These were established in
Sweden in 1979, Finland in 1980 and in Norway in 1987.
Until recently, in the UK in the case of hip prostheses,
only pre-clinical technological product testing has been
mandatory, under 'good manufacturing practice' reg¬
ulations. This called for technological bench tests and
biocompatibility assessments. The manufacture of
orthopaedic implants is in principle governed by a large
number of national and international technical stan¬
dards, produced by the British Standards Institute (BSI)
and the International Standards Organisation (ISO).
These cover orthopaedic implant materials in general,
and some particular features of hip prosthesis implants.
In recent years, under the impetus of the Medical
Devices Directive, European Standards have sought
convergence between national and international stan¬
dards (see above). However, it is interesting to note that
standards for material properties generally apply to the
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material as used in the production process rather than
the finished product (Paul, 1997). Furthermore, some
features of hip prostheses have to date proved impos¬
sible to subject to specific standards because of the great
proliferation of different sizes and design features. This
applies, for example, to the modular head (ball) of
femoral components (Paul, 1997). From July 1998,
following the EU directives, clinical investigations are
required under certain conditions by the MDA, in order
for a 'CE' mark (see above) to be given, enabling the
device to be placed on the market. These investigations
will be required for various reasons including: where
there is a 'completely new concept of device...where
components, features and/or methods of action are
previously unknown'; in the case of 'modification of an
existing device in such a way that it contains a novel
feature'; or where existing materials are used in a new
location in the human body (personal communication,
1997). This system thus appears to draw a distinction
between devices that are in some sense new and those
which can be shown to have an equivalent already on
the market. This parallels closely the system based
around the notion of 'substantial equivalence' used by
the Food and Drug Administration in the USA, where
the great majority of applications for 'new' products do
not require de novo clinical investigations but rely
instead upon the production of evidence that the
product is technically similar to an existing device on
the market, and on adequate 'clinical evidence' for that
type of product (Gelijns, 1990).' The MDA has
produced guidance for manufacturers carrying out
clinical investigations in the UK, including stipulations
regarding study design, sample size calculation and
statistical analysis (MDA, 1998d).
However, the MDA has not produced any general
reports on hip prosthesis or orthopaedic implant
technology as a family of devices. Under its post¬
marketing surveillance responsibility, it has produced a
small number of 'hazard notices' or 'safety notices' in
response to notifications of failures of specific prosthesis
components from hospitals. It has also, for example,
issued a notice to clarify the legal responsibility for an
implant in cases where an orthopaedic surgeon re¬
quested the addition of a new coating by a specialist
implant coating service (MDA, 1997).2 Total hip
1 The amount of documentation and production of evidence
required for an 'equivalent' device is considerably less than for a
new device, so there is clear incentive for competing manu¬
facturers to demonstrate equivalence. As Gelijns noted in the
USA, even where clinical trials have been conducted by the
device developer, there may be large variations in, for example,
the sample size of the population of implantees studied (Gelijns,
1990, p. 164).
2 In such cases responsibility passes from the device
manufacturer to the NHS Trust employing the surgeon.
implants are a Class lib (or Class III if bioactively
coated) device under the MDD system which attempts
to match the degree of regulation to the degree of risk
(Class III being the highest risk).
As part of the EU MDD 'vigilance system', CE-
marked joint replacement implants will be subject to an
enhanced requirement for reporting of adverse incidents
by manufacturers to the MDA. In essence, any failure of
an implant attributable to premature deterioration or
malfunction of the device itself will be reportable. This
will include the most common cause of implant failure
and need for a revision operation, known as 'aseptic
loosening'. In the absence of a predicted lifespan for the
device, revision within 10 years for aseptic loosening will
be reportable (MDA, 1998e). Revision within this
timespan will be regarded as an adverse incident and
will be reportable to the MDA within a suggested
elapsed time of 10 days. The MDD requires the report to
be made to the MDA Adverse Incident Centre by the
manufacturer. Users should thus report incidents to the
manufacturer, although the facility exists also for direct
reporting. However, review of the clinical research
reporting the performance of hip implants shows that
the attribution of responsibility for failure is often
contentious. The cause of failure of hip implants in
younger, more active people is especially likely to be
contested (Faulkner et al., 1998). This implies that
individual clinical assessment and local circumstances
will be paramount in determining whether a report is
actually made when revision due to possible device
failure has been performed.
In the arena of healthcare science, the national Health
Technology Assessment movement in the UK, inaugu¬
rated in 1993, made the investigation of hip prostheses
one of its top 20 priorities, arrived at following a process
of selection applying clinical, economic, epidemiological
and other criteria to over 1000 candidate technologies. It
was the subject of an 'Effective Health Care Bulletin' in
1996, which provided a review of the evidence of
published clinical research studies about hip implant
performance, including the comparative effectiveness of
different models (NHS Centre for Reviews and Dis¬
semination, 1996). This document advised that
'purchasers and providers should promote the use of
those prostheses that have been shown to perform best
in long-term follow-up', and stated that 'new prostheses
should only be used after they have been thoroughly
evaluated or as part of a nationally co-ordinated study'.
The HTA research programme has subsequently pub¬
lished two 'systematic reviews' of evidence of the
effectiveness and cost effectiveness of different hip
prostheses (Faulkner et al., 1998; Fitzpatrick et al.,
1998). These show that there is a large amount of clinical
research on the clinical outcomes of hip implants
published in specialist orthopaedic journals, that there
are few randomised trials and that most of the studies
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are of relatively small numbers of prostheses. Most
studies are authored by orthopaedic surgeons and
studies considering the issue of the benefit of hip
replacement versus non-intervention are rare. The
HTA reports conclude that policy consideration should
be given to different approaches to monitoring and
controlling hip implants, including the use of registries
along the lines of the Scandinavian models. These
reports have been drawn upon in the recent guidance
to the NHS issued by the National Institute of Clinical
Excellence (NICE, 2000), mentioned above. The HTA
reports focus almost exclusively upon clinical research
results. The extent of correlation between laboratory
performance or predictive studies of hip implant failure,
and clinical performance once implanted, is widely
debated and disputed in the orthopaedic research
literature.
The professional clinical body with concern for hip
implants in the UK is the British Orthopaedic Associa¬
tion (BOA). Affiliated to this is a specialist British Hip
Society with the purpose of providing a professional
forum for debating research and clinical practice. The
BOA and Society have been involved in a number of
activities which can be regarded as part of the self-
regulatory work of the profession and as part of the
'interorganisational field' (Blume, 1992) in which the
development of orthopaedic implants is embedded.
Representatives of the BOA have been involved in
discussion with the MDA about the implications of the
EU MDD, and these have resulted in the MDA's
guidance on joint replacement implants referred to
above (MDA, 1998e). Currently, the BOA in principle
approves of the introduction of a national register,
although there is dispute about its organisation (BOA,
1998).
This brief survey of the recent science and regulation
of hip implants indicates that even where a medical
device is widely regarded as highly successful, there are a
number of issues of uncertainty. Healthcare risk and the
implications of these devices for public health are
matters of negotiation amongst competing groups. Yet
inter-relationships between professions, manufacturers,
regulators and scientists are poorly understood. Con¬
tinual technological innovation and proliferation of
models, allied with an occasional controversial failure
have put regulatory issues high on the policy agenda. In
the European context the regulatory environment is
becoming more complex and, in principle, more
stringent especially with regard to vigilance systems.
However, the effectiveness of vigilance systems for the
timely identification of under-performing devices is in
question. Areas of uncertainty, such as the definition of
'novelty' have been identified, where it is important to
examine the operation of inter-organisational and
disciplinary forces. The roles of professional and mass
media in problematising the technology in the policy
arena have been suggested. Public policy-related aca¬
demic science has focused upon the issues of clinical and
cost effectiveness on the basis primarily of comparative
clinical research on the longevity of implants and
economic analysis. A viewpoint of implantees is
conspicuously absent in this science. The clinical and
other evidence used in regulatory technology adoption
decisions is not currently in the public arena. Tensions
between innovation and regulation, and between the




The first breast implants were a type of 'sponge' used
up until the late 1950 s. Other early experiments in breast
enlargement included the use of injected silicone and
parafin wax (Guthrie, 1994). The late 1960s marked the
beginning of commercial manufacture of silicone breast
implants by Dow Corning following the work of plastic
surgeons Cronin and Gerow. These 'first generation'
silicone implants had a thick smooth silicone shell and
were filled with silicone gel. In the mid-1970s, in an
attempt to reduce the amount of capsular contracture
(shrinkage and hardening of tissue around the implant)
modifications in design and materials produced 'second
generation' implants with thin silicone smooth shells. "It
is now accepted that these are more susceptible to
rupture" (IRG, 1998, p. 12, Malata, Varma, Scoot,
Liston & Sharpe, 1994). Saline-filled implants have also
been in use since that time and have been preferred by
some plastic surgeons because they are thought to be less
harmful if rupture occurs.
From the 1970s polyurethane foam coverings on
implants were used but were withdrawn by manufac¬
turers in the early 1990s after a ban on their use in the
US in 1991 (Guthrie, 1994). However, the use of one
polyurethane breast implant was reported in the UK
during 1995/96 (NBIR, Third Annual Report, 1997;
MDA, Safety Notice SN9620, 1996). A third-generation
of silicone implants with a thick textured shell were
developed in the mid-1980s to reduce the incidence of
capsular contracture and to minimise the rate of 'gel
bleed' (silicone gel leakage). Since 1995 a new type of
triglyceride-filled (soya bean oil) implant with silicone
shell has been available in the UK (Collagen Ltd). In the
US and Canada these have not been licensed though a
small clinical trial of these implants is being conducted
(Studin, 1998; FDA, 1998). In addition to the variations
in materials used to construct the shell (or envelope) and
filling of breast implants there are other variations
including size, shape, and some are expandable with
valves, or have a single, double or triple lumen. Two
hundred and forty two different types of named implant
brands are cited in the Foreign Settlement Program
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discussed below (Federal Judiciary Center, 1998). While
these are not all currently available as new, this indicates
the range and diversity of breast implants still in use,
that is implanted in women worldwide.
As with hip prostheses, manufacturers of breast
implants are US-based multinational companies. Sili¬
cone gel and saline implants are produced by McGhan
of the Inamed group and Mentor Corp. Hutchinson
International and Poly Implants also produce saline-
filled implants. Collagen Ltd are the manufacturers of
Trilucent ™ soya bean oil filled implants. An estimated
11 manufacturers import breast implants to the UK.
In the UK the exact number of Implants used each
year is not known, despite the setting up of a National
Breast Implant Registry in 1993. However, in 1996-97
12,829 implants were registered (see Table 1) used by
7136 patients. Although not identified by brand name
these implants have been grouped into types according
to their filling.
According to the available statistics, recipients of
breast implants are usually women who range in age
from 10 years old to 77 years. They may be identified as
belonging to two main groups — those seeking
reconstruction following mastectomy (for benign or
malignant disease) and those seeking augmentation for
cosmetic reasons. Two other groups may be identified —
those women (or girls) seeking surgery to correct
congenital deformity or developmental problems and
those women who have had previous surgery but need a
replacement implant (presumably due to product failure
or post-operative complications) (Table 2). In addition,
breast implants may be used in cases of gender
reassignment (from man to woman). The types of
benefit to be derived from breast implants are seen
primarily to concern body image, 'looking normal', self-
esteem and consequent impacts on social roles and
participation. The average age for those seeking
reconstruction is older than for those seeking augmenta¬
tion (NBIR, 1998). By far the majority of breast
implants are used for augmentation or cosmetic surgery
and of those patients and implants registered between
1993 and 1997 the proportion of those seeking cosmetic
surgery has increased.
The use of breast implants differs between the private
and public health sectors. In 1996/97 87% of total breast
implant procedures registered and carried out in the
private sector were for cosmetic reasons compared to
34% of the total breast implant procedures carried out
in the public sector. A greater proportion of public
sector operations are for reconstruction following
malignant breast disease (30%) compared with 3% in
the private sector. A greater proportion of public sector
operations are to replace breast implants (23%) whereas
these make up a smaller proportion of the total
procedures in the private sector (8%). An estimated
33% of all breast implant procedures are carried out in
the public sector (NBIR, 1998, p. 10). The cost of breast
augmentation in the private sector is approximately
£3500.
Regulation
In order to understand the regulatory context of
breast implants it is necessary to outline events in the
United States that have formed a background to UK
policies and practice. During the 1990s the use of
silicone breast implants has been controversial. In 1991,
in the US, the Food and Drug Administration (FDA)
launched an inquiry into the use of silicone gel breast
implants. Safety issues were raised since claims had been
made that there may be a link between these implants,
connective tissue disease and other adverse side effects.
Since 1992, in the US, these implants can only be used as
Table 1
Implant types of those breast implants registered, 1996-97"
Silicone gel Saline Double lumen Expandable prosthesis Lipid or polymer Other and not known Total
10,220 303 8 689 1513 96 12,829
"Source: Adapted from data in Fourth Annual Report of National Breast Implant Registry (1998). (Note: Figures may be broken
down to indicate the type of envelope which may be smooth or textured. Statistics show that the majority of implants used have a
textured envelope.)
Table 2
Numbers of patients registered during 1996/97 and reasons for implantation"
Cosmetic Mastectomy (malignant) Mastectomy (benign) Developmental Replacement Other Not known Total
4915 877 66 313 916 34 15 7136
"Source: Fourth Annual Report of National Breast Implant Registry (1998). (Note: The number of patients and implants registered
differs significantly in any year since in some cases one implant may be used, in others two.)
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part of a clinical trial (Kessler, 1992; FDA, 1998). The
FDA decision was criticised and a dispute about the
policy ruling ensued (Council of Scientific Affairs, 1993;
Brody et al., 1992; Angell, 1997; Kessler et al., 1994). At
the heart of this dispute were a number of issues about
the scientific evidence and the responsibilities of the
regulatory authority, manufacturers of implants and
clinicians. The FDA accepted "that thousands of
women had reported problems with breast implants"
(Gott & Tinkler, 1994, p. 12) and concluded that it was
not possible to give adequate information about the
risks to women of having these implants.3 In the US
today while saline-filled implants are available to every¬
one only those 'women with special medical needs', that
is 'those who have had breast cancer, a severe injury to
the breast, a birth defect that affects the breast, or a
medical condition causing severe breast abnormality'
and who are seeking reconstruction may have a silicone-
gel-filled implant as part of a trial or adjunct study
(FDA, 1998). However, it is worth noting that prior to
the controversy over evidence and the introduction of
the restrictive 1992 policy, breast implants had been
assigned a Class 1 level of risk, in other words very low
risk not requiring further research and not requiring pre-
market clearance, within the FDA medical device
framework introduced in 1976 (Palley, 1995). Although
there are many possible reasons for this, it can perhaps
be taken to reflect the general perception at the time that
the predominant use of the implant was for cosmetic
purposes and thus did not warrant the level of scrutiny
that a device provided for the treatment of illness might
require.
A growing number of litigations against breast
implant manufacturers in the US led in 1993 to a setting
up of a compensation fund for women with breast
implants (Angell, 1997). There has ensued a lengthy,
complex legal case against the manufacturers of breast
implants including Dow Corning (which was the biggest
exporter of breast implants to the UK), Baxter
3From 1985 to September 1998, 127,500 adverse reaction
reports for silicone-gel-filled implants were received by the FDA
and 49,661 adverse reactions to saline-filled implants (FDA,
1998). In the US ruling, a distinction was made between those
women seeking reconstruction following mastectomy and those
seeking cosmetic augmentation. Women in the former group
are allowed access to silicone gel implants because it was
assumed that the benefits of implants to them outweighed the
risks. However, this distinction was criticised for the different
treatment of each group and for 'federal paternalism'. It was
argued that both groups of women had rights and needs that
should be met and that if implants were safe then they were safe
for all (Parker, 1993). On the one hand, commentators argued
for greater regulation while others argued for individual
freedom to choose whether breast implants were beneficial to
them (Haiken, 1997).
Healthcare Co, McGhan and Medical Engineering (a
3M company). Together with other breast implant
manufacturers, a Global Settlement Program was set up
which included women outside the US. Some five years
later the case continues, Dow Corning has declared
bankruptcy but a number of other companies remain in
the settlement programme. More than 2000 women in
the UK have registered claims for compensation since
1994 but they have yet to receive any payments from
these funds. The outcome of these proceedings remains
uncertain. Other estimates of the number of women
adversely affected by breast implants in the UK are as
many as 60,000 (Boseley, 1998a). Rupture of these
implants is now recognised as a common occurrence,
though precise data on this are unavailable (Clwyd,
1996; IRG, 1998). In the UK estimates based on the
number of implants replaced which are registered, even
for one year, suggest that there are significant complica¬
tions which lead to repeat surgery (1422 implants were
replaced in 1996/97, NBIR, 1998).
In the context of this controversy, in the UK in 1992
the MDA set up an Independent Expert Advisory
Group to review information on allegations that there
was a link between connective tissue disease and silicone
gel bleed from breast implants (Tinkler, Campbell,
Senior, & Ludgate, 1992). There was growing concern
amongst some commentators about the safety of silicone
implants in the light of the US reports. This review was
updated two years later (Gott & Tinkler, 1994). The
conclusions and recommendations of both these reports
were that there was no evidence to support the
allegations but a National Breast Implant Registry
(NBIR) was set up in 1993 to record the use of all types
of breast implants on a prospective register. In contrast
to the situation in the US, the use of silicone-gel- and
saline-filled breast implants in the UK has continued
unrestricted.
A primary task for the NBIR was to encourage
participation in the registration process from hospitals
and practitioners. However, registration is voluntary. By
1997 280 hospital units were participating, though the
extent to which the number of registrations reflected
actual procedures carried out is still a matter for
conjecture. It was suggested that one way of measuring
compliance would be "by matching manufacturers sales
figures and registrations...." but "it would be difficult
because of the commercially sensitive nature of the
information held and the variable stock control methods
(using sale or return) of many active centres" (NBIR,
1998, p. 8). There have been criticisms of the registration
process for failing to promote retrospective registration
of those women who had received implants prior to 1993
and the voluntary nature of the process (Clwyd, 1996;
telephone interview Survivors of Silicone, 1997).
Despite the MDA's insistence in their earlier reports
that there were no safety issues relating to the continued
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use of silicone gel breast implants, a further review was
called for in 1997. The focus of the Independent Review
Group, published in 1998 was the use of silicone gel
implants (IRG, 1998). No mention was made of other
types of breast implants (such as triglyceride ones), not
even as alternative options for women. Following an
extended period of consultation the group recommended
changes to the information made available to women
considering implant surgery and suggested that a
designated body provide such information. Changes in
the consultation and decision-making process by women
and doctors were also proposed and a recommendation
made for a new consent form for implant surgery.
Importantly, the group proposed that measures be
introduced to ensure standards of care in the private
sector and that prospective registration should be made
compulsory. It was emphasised that clinicians should
report adverse incidents and the MDA should advise on
which incidents were to be reported. A new steering
group to plan and monitor a programme of research was
proposed and recommendations made that the possibi¬
lity of screening to detect implant rupture should be kept
under review. So far no change in the law to introduce
compulsory registration is planned and a programme of
further research has not yet been developed. A new
Health Select Committee of Inquiry into the regulation
of private and other independent health care was set up
in December 1998 and is currently taking evidence
(Health Committee Press Notice, HinslifF, 1998). It
seems then that the target for tighter regulation
currently is those cosmetic surgeons working in the
private sector (see also Boseley, 1998b; Collis & Sharpe,
1998).
Elsewhere in Europe opinion has been divided,
though efforts were made to reach a consensus. The
French Ministry of Health restricted use of breast
implants and also commissioned an inquiry in 1996
and a further report to the European Commission in
1997 (see regulatory requirements for breast implants
IRG 1998 website). In Finland there is a continuing
dispute about the safety issues and arguments have been
put forward for a national registry (Hovi, personal
communication, 1998) while in the Netherlands the
controversy is seen as an 'American thing' (Davis,
personal communication, 1998). However, in 1998 there
were reports of a campaign to ban silicone implants in
Europe (Watson, 1998). The European Medical Devices
Directives do relate to all types of breast implants.
Breast implants are class lib. Standards for breast
implants have now been agreed though not yet
published (EN 12180). For some time in the EU there
was no agreement about "what measures are adequate
to ensure the safety and performance of breast
implants" (DoH, 1998). Standards relate to material
and implant strength, design attributes and mechanical
tests. The safety questions remain contentious. Indeed
the IRG themselves point out that "safety is not a simple
concept. It is widely accepted by lawyers, ethicists,
doctors and regulators to mean freedom from an undue
risk of harm. The word 'undue' is critical ... safety is not
an absolute concept" and must be considered "in the
context of individual circumstances" (IRG, 1998, p. 14).
According to them risks and benefits are both to be
taken into account.
For many women who have had breast implants the
risks have been unknown and it is precisely this lack of
information that was highlighted by the IRG. In 1998, in
Britain, a woman successfully obtained legal aid to
pursue a claim against the manufacturers of her breast
implant which she believes has caused adverse effects to
her child whom she breast-fed after having the
implantation (Boseley, 1998b). Legal aid has also been
granted to some women who have had implants rupture
to enable them to pursue compensation claims against
manufacturers in this country under the Consumer
Protection Act. British lawyers have advised clients of
how the product liability legislation may be applied to
breast implants (Balen, personal communication, 1998;
APIL, 1998). Both lawyers and members of pressure
groups such as Survivors of Silicone and the Silicone
Support Group have argued that the regulatory frame¬
work has failed to prevent harm and that safety issues
around breast implants remain (Comber, personal
communication, 1998; Watson, 1998; Boseley, 1998b,
1999). In contrast clinicians in the UK have consistently
stated that "at present there is no evidence to suggest
that silicone breast implants are associated with an
increased incidence of breast cancer. There is also no
evidence to suggest that these implants cause auto¬
immune diseases such as rheumatoid arthritis" (British
Association of Aesthetic Plastic Surgeons, 1998; Coope
& Dennison, 1998). In recent years there has been
recognition that leakage of silicone can occur either as a
gradual process or due to rupture but BAAPS say this
has not been shown to be harmful. Other complications
such as capsular contracture have also been recognised
for some time (Iwuagwu & Frame, 1997). Breast
implants are now seen by some clinicians in the UK as
having a limited life expectancy of approximately 10
years (BAAPS Information leaflet on Breast Augmenta¬
tion). However, many women have received implants
unaware of these limitations.
Less than a year after the IRG report, the MDA
announced that the new soya bean oil filled breast
implants (Trilucent) are to be withdrawn and that no
more should be implanted (MDA, 1999c). An estimated
5000 women have received these implants since they
were introduced in 1995, many of whom chose these in
the context of anxieties about the safety of the silicone
gel implants. While the MDA announcement referred to
some reports of local complications which had led to
this decision 'as a precautionary measure'. They said
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"there is no evidence of permanent injury or harm to
general health. However, not enough is known about the
long-term safety and rate of breakdown of soyabean oil
in the filling and its possible effects on the body" (MDA,
1999b, 1999c; see also Iwuagwu & Frame, 1997). Media
coverage of this development says that there have been
74 adverse incident reports to the MDA since the
implants were introduced (Hall, 1999; Boseley, 1999;
Laurance, 1999; Wilson, 1999; Ellis, 1999). Women with
these implants have been advised to contact their
surgeon or GP for advice, a helpline was set up for
three days and further investigations into the safety and
risks associated with these newest implants are now
being carried out.
This discussion of breast implants outlines the
changes in their design and manufacture from the
earliest types of 'sponges' to the most recent soya bean
oil filled, silicone gel and saline implants. The use of
silicone gel implants has been especially controversial
and subject to UK government funded review and
inquiry. Policy regarding these has remained consistent
despite continuing litigation in the US and the
introduction of the EU MDD. However, after only four
years on the market the newest soya bean oil filled
implants have been withdrawn. There is currently no
clinical data publicly available on their use. Regulation
of breast implants has had a relatively high political
profile and this may help to explain why a national
registry was set up in 1993. However, despite the
recommendations of the Independent Review Group
(IRG, 1998) to introduce compulsory registration of
breast implants, this remains voluntary and as yet no
further research has been developed to look at implant
use. The effects of harmonisation in Europe are unclear
and getting agreement amongst member states about the
safety and standards relating to breast implants has been
a problem. No other European country has a breast
implant registry. There has been organised consumer
protest in the UK against the continuing availability of
silicone breast implants and increasing attention focused
on the activities of private cosmetic surgery clinics in a
current Health Select Committee Inquiry.
Conclusion: comparative research in human implants
We conclude that our analysis raises important
issues about the relationships between science, technol¬
ogy testing, and healthcare evaluation in relation to
innovation and diffusion in these human implant
technologies. The tensions between potentially beneficial
innovations and state concerns with supporting this,
whilst protecting the public health, are evident. Also the
interaction of commercial, scientific, professional and
consumer constituencies may be identified as important.
Our purpose in this section is to reflect briefly upon the
major contrasts in innovation and regulation evident in
the two implant technologies which we have described,
and to point toward the key topics for a research agenda
which our analysis suggests it is now important to
pursue.
The comparison of two technologies shows a number
of interesting points of similarity and contrast. Im¬
planted technologies present special problems of evalua¬
tion because long-term effects can generally not be
predicted with certainty and the performance of the
device is not directly observable. Perhaps most
obviously, breast implants have evoked more contro¬
versy and more legal action than hip implants (e.g.
Nyren et al., 1998; Shanklin & Smalley, 1998; Angell,
1997). Technological standards cover the production
of both, and failures of some models of each have
been reported in the UK to the governmental
surveillance agency, the MDA. The definition of a
'failure' (under MDD) differs in striking ways. Safety
issues arise in both cases, and are contentious. The
organisation of recent policy-related clinical science
for each technology has been constituted quite
differently, in the one case by quasi-autonomous
dedicated independent inquiries, in the other within
the national health service research programme (HTA).
A government-sponsored voluntary surveillance register
exists for the one but not the other. International
comparisons add a further dimension here: Finland, for
example, currently has a national register for hip
implants but not for breast implants, the opposite of
the situation in the UK. Implantees in general lack
information about the implanted device in both cases,
but this has been much more of a public issue in the case
of breast implants. Organisations of breast implantees
have been formed but not hip implantees. In both cases
members of the main specialty professions participate in
the production of clinical evidence of long-term perfor¬
mance (e.g. Benediktsson, Perbeck, Geigant, & Solders,
1997; Iwuagwu & Frame, 1997; Heitmann, Schreck-
enberger, & Olbrisch, 1998; Coope & Dennison, 1998;
Collis et al., 1998a,b, Malata, Feldberg, Coleman, Foo,
& Sharpe, 1997; Coleman, Foo, & Sharpe, 1993, Nyren
et al., 1998; Malchau, Herberts, & Ahnfelt, 1993). It
appears that the changing meanings and dominant
understandings of the different types of benefit to be
derived from these implants, cosmetic or functional,
may be salient in corresponding risk assessment
processes and regulatory decision-making. Our limited
information suggests that strategic alliances between
surgeons and manufacturers may be common in the case
of hips but less so for breast implant development.
Design proliferation and cost issues are much more
prominent as healthcare policy concerns in the case of
hip implants. Both technologies have examples of
anomalies in the availability of different implant designs,
intra- and inter-nationally.
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This brief descriptive summary based on the histories
of innovation in hip and breast prostheses and their
regulatory contexts raises many questions for a research
agenda. In general our account shows, firstly, that there
has been little study of the actors involved in innovation
and the development of these technologies. Secondly,
the organisational and inter-organisational processes
which shape human implants and their deployment in
the marketplace require investigation. There are im¬
portant issues that may be raised at different points in
the development of a technology. Drawing a parallel
with medicines testing, the possible key stages might be
identified as: pre-clinical testing, clinical testing/trial,
approval/adoption and diffusion/post-marketing sur¬
veillance (though development should not be regarded
as a unilinear process). We identify four related main
areas for further research: (i) innovativeness and
proliferation; (ii) safety and technological standards;
(iii) clinical and social outcomes; (iv) consumer/user
information and choice.
Innovativeness and proliferation
Professional knowledge and skills influence innova¬
tion through definition of the 'technical' issues and
defining what the problem is — 'problematisation'. By
examining the activity of the 'experts' — material
scientists, designers and others working in both
academic and commercial manufacturing settings —
explanations of the diversity within product ranges
will be developed. This might show, for example,
the different processes affecting the development
of variations in the coatings and finishes of hip
prostheses. Clinicians are co-producers of knowledge
about how implants work in use, so their relationships
to the scientific and commercial communities are of
particular importance (Blume, 1992). Their involvement
in clinical trials or in state-sponsored inquiries can be
expected to contribute to innovation through evaluation
of clinical outcomes and clinical audit. But also they
may have a key role in creating a demand for a range of
prostheses and contributing to product design. Thus
alliances between surgeons and manufacturers are
crucial to the feasibility and forms of possible regula¬
tion.
Institutional structures and relationships also are
important for understanding how certain brands or
types of products become more widely available than
others, or in explaining anomalies in implant availability
(licensing) between countries (Altenstetter, 1996). The
uneven pattern of use of hip prosthesis designs for
example within the UK also has direct implications for
implantees. This is of direct importance for implantees
because there may be structural influences inhibiting
access to 'the best' designs internationally. It has been
shown in the case of pharmaceuticals, for example, that
while the mass media may play a part in influencing
regulatory decisions (Gabe & Bury, 1996), the structure
of the regulatory process itself may be crucial in
accounting for such anomalies (Abraham & Sheppard,
1998). This may apply, for example, to the non-licensing
of some models of bio-actively coated implant in the
USA even though they are available in Europe.
Complex relationships between national politics, busi¬
ness, legal decisions and regulators may underlie the
development of distinct national policy for breast
implants in the USA (Palley, 1995).
It is important to examine the relationships between
the demand for certain designs or brand of implant and
clinical policy, practice or supplier/purchaser decisions
at the level — in the UK — of the NHS trust or private
clinic (Altenstetter, 1996). For example, what organisa¬
tional (and economic) factors determined the adoption
and use of the new triglyceride — oil-filled implants
rather than silicone-gel-filled models? Why, if they were
being promoted by manufacturers as the safer option
(especially given the controversy surrounding silicone
gel) were they not more widely used, at least up until the
recent withdrawal of them from the UK market? The
role of professional organisations in advising members
on policy and practice with regard to 'innovative'
products must also be taken into account in explaining
different patterns of adoption and diffusion of different
implants.
Safety and technological standards
Technological standards, laboratory testing and
biocompatibility assessment are designed to ensure the
safety of medical devices placed on the market.
However, our comparison of two technologies has
highlighted important contrasts. Until very recently a
ruptured breast implant did not constitute an adverse
incident in terms of the EC guidance on the types of
incidents to be reported, neither did other commonly
perceived 'complications' of breast implant surgery such
as capsular contracture (EC, 1998). A serious deteriora¬
tion in health or permanent impairment are criteria
defining adverse incidents and in the case of breast
implants the MDA had not accepted any evidence of
this, even though some argue it had been provided. So
while a ruptured breast implant did not previously
appear to constitute a 'failure', aseptic loosening of a hip
implant did. Now (since 1999) the predicted lifespan for
breast implants is approximately 10 years (BAAPS), and
revision within 10 years for both hip and breast implants
is now seen as a reportable adverse incident in the UK.
Soya bean oil filled implants were recalled after 74
adverse incidents were reported which raises questions
about the number and type of reports which are received
before certain policy decisions to be made. These
contrasts again raise the question of whether the
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different types of benefit and social meanings of
different implant technologies are implicated in
the different approaches to defining and assessing
risk which are evident. Thus, it is important to
investigate the social and organisational structures and
processes that shape the definition of the key aspects of
implant device regulation. This includes the processes
involved in negotiating at a local level what counts as a
reportable adverse incident, pointing towards the need
for an examination of the ways in which competing
accounts of what is acceptable practice are worked out.
This applies also at the level of the manufacturer in
deciding to report incidents to the MDA. Such an
analysis would need to draw on existing sociological
research which examines the relationships between
science and policy making (for example, in relation to
medicines (Abraham 1993, 1995) and in relation to non¬
medical technologies (Jasanoff, 1994; Cozzens & Wood-
house, 1995; Irwin, Rothstein, Yearley, & McCarthy,
1997)).
Involved in the negotiable definition of an adverse
incident, is the question of how clinical and scientific
evidence is collected and interpreted, and the institu¬
tional and professional processes in this. These processes
are crucial because they may affect both the decision
to report and its timing — of great importance if
there is a safety issue and other implantees may
be at risk if there is delay. It follows that also of
importance are the issues of the construction of
technological standards for implanted devices, and
their operation in particular instances. Could, for
example, the apparent — though contested — failure
of the 'Capital Hip' (a me-too design based upon the
standard 'Charnley' prosthesis) have been avoided had
different biocompatibility or other test data been
available to the manufacturers or the regulatory
authority? The study of the practices of technological
testing and the contestability of judgments made in
projecting from test to 'real world' performance have
been identified as important areas of concern in the
study of the development of new technologies (Pinch,
Ashmore, & Mulkay, 1992; Pinch, 1993). In this instance
this applies to standards and test procedures for
biocompatibility and other material and design proper¬
ties. Although highly technical, technological standards
are themselves the outcome of processes of negotiation,
and are open to question and further development (e.g.
Styles et al., 1998). Of interest then are both institutional
politics and the cultural production of knowledge in
issues of device safety. Controversies such as those
surrounding the use of silicone gel, and now soya bean
oil breast implants, may be approached in a number of
ways and the case for an integration of a sociology of
scientific knowledge approach (SSK) and a structural
analysis would be fruitful here (Abraham, 1994; Martin
& Richards, 1995).
Clinical and social outcomes
Surgical implants may convey a variety of individual
and collective benefits affecting longevity, quality of life
and social participation. The clinical and social sciences
are increasingly involved in assessing these benefits
and associated risks. Quality of life might be measured
in relation to specific clinical interventions such
as medicines or implants, and may also be assessed
in terms of 'social' outcomes such as participation
in social networks or employment. It has been
noted especially in the case of hip implants that there
has been a large amount of research knowledge
examining the comparative efficacy of different models
of artificial hip, whereas comparisons with alternative
interventions for arthritic pain and locomotor problems,
such as medicines or rehabilitative therapies, are
relatively rare. This suggests that there may be
systematic skewing in the setting of research agendas,
possibly associated with the institutional and profes¬
sional disciplinary interests which are able to establish
their claims to knowledge and expertise in relation to
implant technologies, as opposed to disciplines or
perspectives with an interest in comparing technological
to other forms of treatment.
A striking feature of our comparison of breast and
hip implant technologies is the different ways in which
'clinical evidence' has been marshalled for the attention
of the government and statutory authority. While
there have been inquiries into silicone breast implants
and a national registry set up, the process of gathering
evidence about hip implants has been quite different
and no registry has been set up yet (though the principle
has been much debated in government and the
orthopaedic profession since the 'Capital' incident).
Is there a common cross-technology process at work
here, reflecting distinctions between structures where
safety (inherently more difficult to assure) is the prime
issue rather than efficacy, as has been suggested?
(Bodewitz, Buurma, & de Vries, 1987). Alternatively, it
may be that the types of benefits potentially derived and
the social meaning associated with different types of
implant may be related to different institutional
approaches to evidence-related regulation of risk. Thus
the lack of attention paid to breast implants by the
National Health Service HTA in the UK may be related
to the fact that a large proportion of 'cosmetic' surgery
is carried out in the private sector. It is also notable that
while hip implants have been the object of a high level of
political concern about cost effectiveness in the context
of the NHS budget, this is not the case for breast
implants.
Our analysis raises questions about the institutional
form taken by perceived needs for surveillance of clinical
outcomes. What are the institutional and professional
prerequisites which predispose toward the establishment
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of a national registry rather than (or in addition to)
other forms of regulatory structure? Are the implants
regulated with registries in the UK special cases or
distinctive from hip and other implants in certain
respects? A comparative approach looking across the
underlying processes behind several implant technolo¬
gies may be especially valuable here. Of course, the
existence of a registry does not guarantee or presuppose
a curb on the proliferation of models (as the Norwegian
hip registry noted above demonstrates). It is thus
important to examine not only the causes of the creation
of this type of surveillance system but also its
consequences for innovation, health gain, health service
policies and implantees' safety.
Under the new EU directives 'novelty' is a pre¬
requisite for initiating clinical investigation but how this
is deiined, and the circumstances under which trials are
required, is of crucial importance. This will influence the
processes of innovation and diversification of devices. A
focus here will permit examination of the relationships
between clinical trials organised under different auspices
(e.g. commercial, government-funded) and diffusion of
the technology. For example, it is useful to know what
trials have been carried out on the 'new' triglyceride
breast implants in the UK or Europe, and the relation of
these to other forms of evidence, and to regulatory
action. The requirements and practices in the provision
of clinical evidence for 'me-too' technologies, in different
national bodies, where full new clinical investigations
are not required, should also be investigated, using case
study approaches.
User/consumer information and choice
Our comparative approach raises a number of
different issues for consumers in relation to implant
technologies. These relate to the role of implants in
issues of personal identity, access to 'expert' informa¬
tion, and the question of active participation in
innovatory and regulatory scientific processes.
Who are the users of implant technologies? Con¬
sumers, or those who are implanted with the prosthesis,
can be taken to have only an indirect relationship to
manufacturers or suppliers. The direct user is usually the
surgeon. Patients are unlikely to specify or choose the
type or brand of implant in other than the broadest
terms. However, there may be indirect ways in which
consumers shape innovation or may influence it in the
future. Implant technologies can be seen as
'constructing' or 'configuring' consumers and/or users
(Woolgar, 1991). The example of cochlear implants
provides a striking example of a technology where the
early clinical and commercial 'construction' of the end-
user proved to be strongly challenged by the user
community itself (Blume, 1997). Although recipients of
hip prostheses are generally older and the average life
expectancy of a woman with a breast implant, especially
in cosmetic augmentation, is likely to be longer, both
may be faced with difficult decisions when an implant
fails or simply reaches the end of its lifespan. Hip
implants are increasingly offered to younger people, and,
given the limited lifespan of prostheses, it is important to
examine the clinical and commercial construction of
younger implantees in interaction with consumers' own
beliefs, knowledge and values. The IRG (1998) recom¬
mends that women should have more detailed informa¬
tion about breast implants but what would be the
consequences of providing it for this or other implanted
devices? What is an acceptable lifespan for an implanted
device from the implantee's point of view? Provision of
more detailed information for consumers may thus have
indirect implications for the processes both of innova¬
tion and of regulation.
However, the issue of provision of information raises
the question of the current degree of transparency in the
activities of experts involved in risk and benefit
assessments. It remains the case that a culture of secrecy
surrounds medical regulation in the UK, although
government initiatives are beginning to address them¬
selves to the issue. Empirical documentation of this
culture has been provided in the case of medicines by
Abraham and Sheppard (1997), and in the case of
implant technologies it is not confined to the UK,
having been discussed in the case of Finland in relation
to contraceptive implants (Ollila & Hemminki, 1996).
The accessibility of information may be influenced not
only by trends in public governance, but also by the
institutional structures through which scientific risk/
benefit expertise is expressed. With the exception cited
above, this appears to be an unexamined issue in the
case of implant technologies. The issue of transparency
is associated in turn with the related issue of consumer
activism and the possible role of consumers in regulatory
science.
Consumer activism and the development of social
movements around health-related issues are growing
phenomena, documented most fully perhaps in relation
to issues of the environment and ecology (e.g. Irwin,
1995). In the case of medical science and regulation, the
foremost example is certainly the case of 'AIDS
activism' associated with the development of expertise
and direct participation in regulatory processes by gay
citizens in the USA (for a sociological view: Epstein
(1996); for a Food and Drug Administration view:
Edgar and Rothman, (1990)). The extent to which this
may be a special case involving a controversial medical
condition, high group consciousness and sense of
community, and lack of effective treatment is unclear,
but it does draw attention to questions of the social and
institutional conditions under which active consumer
participation in regulatory science might emerge. It is
notable from Epstein's study that the area where active
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contribution has most been accomplished is that of the
science related to treatment rather than to diagnosis.
Implant technologies may be seen as a technological
solution offering one form of benefit, where alternative
medical approaches might be envisaged in individual
cases. It may be the case, also, that the different
institutional relations in which the social meanings of
implants are embedded have differing implications for
consumer activity. Thus in our comparison it may be
that the apparent relative lack of institutional affiliation
between surgeons and breast implant manufacturers is
associated with the relatively higher profile of breast
implantee groups as a form of social movement, while in
the case of hip implants the mediating position of
orthopaedic surgeons contributes to a lack of a
development of active consumerisation amongst these
implantees.
In summary, comparative approaches to human
implant technologies will assist in understanding the
ways in which regulatory processes are created and
applied to different groups of technologies. This in turn
can contribute to policy appraisal in this complex area.
While there have been sociological studies of the
regulation of the pharmaceutical industry, our study of
the regulation and forms of evidence applied to human
implant technologies raises comparable but unexplored
issues. The advent of HTA is associated with a broad¬
ening of evidence-related regulatory guidance. The
contrasting histories of hip and breast implants and
their geographical variations point to significant differ¬
ences in the basis of regulatory decisions. A part played
by healthcare science in such decisions is suggested by
the HTA research programme's influence on advice
disseminated in the National Health Service to restrict
the range of hip prostheses used and for the government
to consider the case for a national registry. However, its
role in shaping national policy and regulation is less
clear. In contrast, government-funded inquiry has been
central to policy decisions relating to breast implants.
While hip implant research has focused upon longevity
and cost, the scientific discourse on breast implants has
focused upon possible causal links with disease. There
does not appear to be a consistent or widespread
commitment to the use of registries. The operation of
the 'vigilance system' also varies in each case. The
regulatory definition of device failure is open to
negotiation and is currently defined differently for our
two exemplar technologies, resulting in different thresh¬
olds of reportability. Our analysis therefore raises
important questions about post-implantation evaluation
of performance for different types of devices and the
processes by which evaluative standards are specified
and applied to them. The necessity of revision surgery in
the event of failure suggests some practical similarities,
despite the different regulatory standards in place.
Explanation of such variation in the UK system, we
argue, needs to take into account analysis of similarities
and differences between the regulatory policies, mechan¬
isms and routines across EU member states. As in the
case of pharmaceutical regulation in the European
Union (Abraham & Lewis, 1999), the national imple¬
mentation of EU-wide directives on safety and stan¬
dards raises questions of possible competitive
relationships between national regulatory bodies, and
the implications of this for public health. This in turn
leads to the question of the voluntary mutual recogni¬
tion of standards between EU countries and between
EU and other countries (Global Harmonisation Task-
force, 2000), and the extent to which such harmonisation
may be in the interests of regulators, manufacturers and
the public.
Finally, further study of innovation and regulation of
medical devices will contribute to a critical analysis of
'evidence-based medicine'. While healthcare sciences are
directed towards improving the efficacy of services, we
have shown that the ways in which this expertise is
enrolled, and the kinds of evidence produced, are of
concern in shaping regulatory decisions. Both collabora¬
tion and conflicts between different disciplines shape the
HTA agenda and healthcare knowledge (Faulkner,
1997). By comparing breast and hip implants we have
begun to look at the sources and nature of the 'evidence'
about such technologies and by whom it is produced.
Consequently, in relation to the development of new
products, we have identified a need to map out and
examine the connections between clinicians, designers,
manufacturers and patients stemming from this focus on
the social and political processes which produce
'evidence' and healthcare knowledge. We take the view
that strategic alliances between clinicians and manufac¬
turers will impact on the diffusion of products. In
addition, standard-setting and CE marking are primar¬
ily concerned with product standards and the movement
of goods in the EU market. The extent to which this
supports high-quality health services for patients is
relatively unexplored. This is the fundamental tension
between the innovative and regulatory pressures embo¬
died in these technologies. So although it has been
suggested elsewhere that commercial interests are not
included in the HTA agenda (Faulkner, 1997) it is clear
that they are important in shaping the proliferation,
availability and use of medical devices such as hip and
breast implants. These issues deserve further empirical
exploration, further analysis and wider public debate.
This may require a broadening of the definition of what
constitutes medicine's evidence-base.
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The use of prostate-specific antigen testing
in the detection of localized prostate cancer
Current opinion and urological practice in the United Kingdom
ALEX FAULKNER, SARA T. BROOKES, JENNY DONOVAN, SARA SELLEY, DAVID GILLATT, FREDDIE HAMDY *
Background: The prostate-specific antigen (PSA) test and its interpretation plays a crucial role in the detection of
early localized prostate cancer. However, inaccuracy of the test, inability to predict the aggressiveness of the disease
and the lack of evidence about the comparative effectiveness of treatments have led to major dilemmas in considering
whether to employ the PSA test and which cut-off points to use in interpreting its results. The aim of this study was
to evaluate current urological practice in the UK regarding the use of PSA testing. Methods: A postal questionnaire
survey of all consultant urologist members of the British Association of Urological Surgeons was conducted. Statistical
analysis included proportional odds regression models to examine factors associated with urologists' preferences
for different definitions of 'normal' PSA cut-off levels. Results: The survey response rate was 60%. The majority of
consultant urologists applied the PSA test routinely. There was a high level of agreement amongst UK urologists on
normal PSA cut-off points (<4.0 ng/ml) for asymptomatic men under 60 years of age. There was very wide variation
in the definition of normal PSA cut-offs for older (>60 years) asymptomatic men. A preference for lower cut-off
points, leading to investigation with ultrasound and biopsy, was significantly associated with larger urology
department size, the presence of a prostate cancer subspecialist in the department and relatively short length of
specialization in urology. Conclusions: Prostate cancer screening and early detection practices and reported incidence
rates of the disease are likely to be influenced by variation in urologists' interpretations of PSA. Despite increasing
evidence in favour of lower PSA cut-off levels, particularly for younger men (<60 years), urologists in the UK are
divided over their interpretation. Men, particularly over age 60 years, have varying chances of further investigation
following PSA testing. Any trial of prostate cancer screening or treatment should take this potential variation into
account. Standard protocols for PSA interpretation should be implemented.
Keywords: practice variations, prostate cancer, prostate-specific antigen testing, UK, urology
T,he last 10 years have seen a considerable escalation
internationally in the clinical use of the prostate-specific
antigen (PSA) serum test, paralleled by increases in
reported incidences of prostate cancer. A substantial
proportion of the increase in diagnosis is attributable to
the use of this test.1 While the test has an indisputable
role in the monitoring of the disease once diagnosed, its
use in early detection or screening programmes remains
controversial because of the uncertainty in predicting the
potential aggressiveness of the early-stage disease and
benefits of radical treatment.^ Identification of early
prostate cancer in increasing numbers of men leads to
persistent management dilemmas for patients and urolo¬
gists alike.
Prostate cancer is a major burden. Approximately one in
ten deaths from cancer in England and Wales amongst
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men are due to prostate cancer. It is the third most
common cause of cancer death following lung and colo¬
rectal cancer. The registered number of newly diagnosed
prostate cancers increased in England and Wales from
10,180 in 1986 to 13,490 in 1991, an increase of37% over
5 years.-1 The most recently available figures show an
age-standardized incidence in England and Wales of 28
per 100,000 and rates in other European countries ranging
from 15 to over 60 per 100,000, the highest rates being
reported in Iceland and Zurich, Switzerland.'1
PSA is a serine protease produced almost exclusively by
prostatic epithelium. It is present in blood, normally in
small concentrations. The serum test is quick and easy to
perform. It is used by urologists, other specialists and
general practitioners. Many different assays have been
developed, although there are a small number of market
leaders.
While it is clear that PSA measures are able to indicate
the presence of prostate cancer in many cases, there is
wide variation in reported performance. Ranges from 57
to 99% were reported for sensitivity and from 59 to 97%
for specificity in the authors' recent systematic review.-1
The US Congress Office of Technology Assessment6 in
the USA found positive predictive values for the test
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(normal 0—4 ng/ml) ranging between 11 and 50% in 16
studies in a variety of settings with different patient
selection criteria. Parkes7 pooled published data to show
a detection rate of 79% for PSA in symptomaticmenwith
a histological diagnosis, associated with an 8% false-
positive rate in asymptomatic men. Adding the PSA test
to positive digital rectal examination (DRE) results in¬
creases positive predictive value by factors of between 0.5
(20—37%)8 and 3.9 (19-75%) in asymptomatic men.9
These performance characteristics, particularly the
relatively poor specificity, together with treatment un¬
certainties, make PSA currently unacceptable as a popu¬
lation screening test.5 New methods of measuring or
indexing PSA are continually being sought. These in¬
clude age-specific reference ranges, density (ratio of PSA
to prostate volume), velocity (rate of change in the level)
and the ratio of'free' to 'complexed' PSA, which currently
is receiving the most attention.10,11
The cut-off level in PSA interpretation is critical, since
this is the main factor informing the decision to invest¬
igate further with transrectal ultrasound (TRUS) and
biopsy. Although 4.0 ng/ml is the most common cut-off
point used for defining a 'normal' PSA, lower levels are
sometimes used. There is some reason to consider lower¬
ing the cut-off level regarded as critical.12 Catalona et
al.15 reported cancers found in a screening population of
men with PSA in a range of 2.6-4-0 ng/ml: there was a
22% prevalence ofprostate cancer, the 'majority' ofwhich
appeared 'medically important'.15 Other studies reported
for volunteers with PSA in the 0—4 ng/ml range percent¬
ages of 21 '4 and 29 15 confirming prostate cancer.
Consensus about the existence and nature of the disease
is partly conditional upon changing detection techniques
and their interpretation. The adoption of new diagnostic
technologies into clinical practice is potentially influ¬
enced by many forces.16 The extent of diffusion of PSA
technology for population screening in the USA and
some European countries and its use in clinical detection
of the disease suggest that there are complex international
variations in the detection of prostate cancer in the male
population. The social and psychological effects of the use
of such diagnostic technologies, particularly in popula¬
tion screening programmes involving the asymptomatic
public, are a major concern.17
Given the acknowledged role of the PSA test in the
increasing incidence of prostate cancer and the ethical
dilemmas surrounding early detection of the disease, it is
important to know how this detection technique and its
different measurement methods are being used and inter¬
preted in everyday clinical practice. This article analyses
data from a postal questionnaire survey of consultant
urologists conducted in 1995 to examine urological
practice and opinion in the UK regarding the use of the
PSA test. This is set in the context of a review of current
knowledge regarding the performance characteristics of
PSA technologies. In particular, we investigated whether
the detection of early prostate cancer with the aid of the
PSA test is consistent between urologists and the degree
to which variations in specialist opinion and practice
might reflect evidence and uncertainties about the test or
be associated with different characteristics of individual
urologists or hospital urology departments.
METHODS
The 1995 register of members of the British Association
ofUrological Associations (BAUS) was used as the basis
for the survey. All consultant members were sent a letter
and postal questionnaire. The sampling frame was such
that the exact number of active consultant urologists
cannot be stated. Of the consultant members 15% are
estimated to have been general surgeons18 and approx¬
imately 400 (±10) urologists. -Non-responders to the
initial mailing were sent a reminder and then contacted
by telephone or facsimile and sent a further questionnaire
if required. The survey questions sought information
about urologists' practices and opinions regarding dia¬
gnosis, management and screening for prostate cancer,
using case vignettes and a mixture of closed multiple-
choice and open-ended questions (full copy available
from the authors). This article reports the results relevant
to the use of PSA testing for detection purposes.
Statistical analyses were performed - using the STATA
statistical package19 - and included an examination of
frequency distributions and the calculation ofdescriptive
statistics. The distribution of the five-category outcome,
the urologist's assessment of normal PSA cut-off points,
was examined across the different levels of possible ex¬
planatory variables using the proportional odds model.20
This considers the outcome as an ordered categorical
variable and assumes that the odds ratios are the same
across all of the possible binary representations of the
outcome, that is <4.0 versus 4.1+, ^6.0 versus 6.1+, <8.0
versus 8.1+ and <10.0 versus 10.1+ ng/ml. The explana¬
tory variables considered in these models were depart¬
ment size, the presence of a prostate cancer subspecialist
in the department, the length of time the urologist had
specialized in urology, the percentage size of the urolo¬
gist's case load ofmen having prostate cancer and the size
of the local district population. These variables were first
considered separately in univariable models and second,
after allowing for relationships between them, in multi-
variable models. The analysis was carried out for each of
four age groups separately (40-49, 50-59, 60-69 and
70-79 years).
Verbatim responses to open-ended questions were classi¬
fied into broad categories according to the theme ex¬
pressed.
RESULTS
Two hundred and forty-four practising consultant urolo¬
gists responded to the survey, a response rate of approx¬
imately 60% (see Methods). The urologists varied in their
level of specialist experience from 2 to 30 years (mean
14.1 years). Fifteen percent (36) of the urologists held
special clinics for patients with prostate cancer, 53%
(130) managed 100 or more patients and 28% (68)
managed 200 or more. Two-thirds (67%,164) estimated
that they had seen 20 or more new patients suspected of
PSA testing for prostate cancer
having prostate cancer in the previous 3 month period,
with a mean of 15.7 (median 12) newly confirmed cases
per consultant over that period.
Sevety-nine percent (193) of the urologists estimated that
at least 50% of patients referred to them had had a PSA
test performed already by theirGP and 37% reported that
at least 80% of men referred had already been tested.
Sixty-eight percent (207) of the urologists reported that
all of their patients had received a PSA test in the process
ofconfirming a diagnosis ofprostate cancer; 84% reported
that at least 50% had done so. A majority ofmen will thus
have been PSA tested again following referral by a GP,
with two-thirds of urologists testing all their patients
regardless of any tests carried out in general practice.
The assay used most commonly was the Hybritech
Tandem-R (50%), followed by the Abott IMx (11%) and
Hybritech Tandem-E (8%). Seventeen percent used
other assays and 15% reported not knowing which assay
was used for their PSA tests.
Approximately one-third of the sample had the more
recently introduced indexing methods available to them
in addition to standard PSA measurement (table 1), the
ratio of free to complex PSA being least widely available
(9%). The urologists' opinions ofwhich method of PSA
test indexing is the most useful clinically was divided
amongst the available methods, broadly reflecting their
availability, though age range was believed to be the most
useful by the smallest proportion. Twenty-eight percent
(68) were not able to give a clear opinion and a slightly
higher percentage than had it available believed the ratio
of free to complex PSA to be the most useful (table 1).
The urologists were explicitly asked whether they
believed age-specific cut-off points were useful in
principle in the diagnosis of prostate cancer and gave
open-ended comments on this issue. Opinion was greatly
divided, 38% feeling this approach was useful, 33% not
useful and 29% being undecided. The greatest number of
those who commented (45/111) referred to clinical issues
as being at least or more important than age/PSA,
defining these as the size and density of the prostate (32
responses) and the totality of the clinical decision (13
responses). Further positive comments noted that age-
specific ranges should not be interpreted too rigidly, but
that they were valuable in averting unnecessary
investigations and referrals in the older age groups,
though low cut-off points might be used defensively in
testing younger men.
The urologists varied widely in their interpretations of
appropriate cut-off levels for PSA in asymptomatic men
(figure I). Results formen over age 60 years elicited a high
degree ofambivalence amongst urologists. The greater the
age of the patient, the greater was the disagreement as to
appropriate PSA cut-off level. While 88% believed the
4.0 ng/ml cut-off point to be appropriate for men aged
40-49 years, only 10% of urologists believed this level to
be appropriate for men aged 70-79 years.
Univariable analysis (table 2) found that the presence of
a prostate cancer subspecialist in the department was
statistically significantly associated with a preference for
Percentage of urologists
'Normal' PSA level, judged by urologists
„ Sg B<4.0 D4.1-6.0 □6.1-8.0 B8.1-10.0 ■>10.0
40-49 50-59 60-69 70-79
Age-groups of 'asymptomatic men'
Figure 1 Variation in UK urologists' assessments of normal PSA
limits for asymptomatic men in different age groups
lower cut-off points for PSA in asymptomatic men over
60 years. Formen over 60 years of age or less than 50 years,
a similar association was found for larger department size
(defined as three or more consultants). The length of time
the urologist had specialized also had a significant associ¬
ation with cut-off points, urologists with more than 20
years of experience being more likely to prefer a higher
PSA level for asymptomatic men in the age groups less
than 70 years. Neither the percentage size of the urolo¬
gist's case-load ofmen having prostate cancer nor the size
of the local district population showed any association
with urologists' preferences for PSA cut-off points in any
age group.
For men aged 40-49 years, multivariable modelling
(table 3) found that the length of specialization and the
presence of a subspecialist remained statistically signi¬
ficant after adjusting for each other. Urologists with a
subspecialist in the department were five times less likely
to choose a higher cut-off point than if no subspecialist
were present. Independently of this, if the urologist had
specialized for more than 20 years, they were three and a
half times more likely to use a higher cut-off point than
if specialization were less than 10 years.
For men aged 50-59 years, size of department and length
of specialization remained independently associated with
cut-off point preference. A larger department size ap¬
peared to halve the likelihood of a higher cut-off point
level and specialization of over 20 years more than
Table 1 Availability and perceived value of different PSA
measurement techniques
Percentage (number) Percentage (number)
having method stating method
available 'most useful'
Method N==236 N=244
Simple PSA 95 (225) 29 (71)
Density 34 (81) 11 (27)
Velocity 43 (102) 17 (42)
Age range 32 (75) 5 (11)
Ratio free/
complex 9 (21) 10 (25)
Do not know - 7 (18)
Missing - 21 (50)
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Size ofdepartment 0.98 0.11 0.018 0.01
<3 consultants 1.00 1.00 1.00 1.00
S3 consultants 0.99 0.64 0.56 0.56
Subspecialist 0.0037 0.51 0.0020 0.01
Absent 1.00 1.00 1.00 1.00
Present 0.21 0.83 0.45 0.54
Length of specialization 0.0095 0.0012 0.037 0.59
<10 years 1.00 1.00 1.00 1.00
10-19 years 0.86 1.60 1.49 1.21
>20 years 3.46 3.87 2.35 1.39
Population 0.56 0.59 0.47 0.49
<250,000 1.00 1.00 1.00 1.00
250,000-350,000 1.12 1.12 0.86 1.01
>350,000 0.65 0.80 0.68 0.74
Case-load U.34 0.52 0.63 0.58
<10% 1.00 1.00 1.00 1.00
>10% 0.66 1.20 0.89 1.15
P-values (p) given to the first two significant figures and odds ratios (OR) expressed in terms of likelihood of preference for higher PSA cut-off points
Table 3 Factors associated with urologists' preferences for PSA cut-off levels in asymptomatic men of
different ages [odds ratios and confidence intervals (CI) from final multivariable regression models]




















































P-values (p) given to the first two significant figures and odds ratios (OR) expressed in terms of likelihood of
preference for higher PSA cut-off points
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quadrupled the likelihood of a higher cut-off point level
for these men.
For men aged 60-69 years, size of department, the
presence ofa subspecialist and the length ofspecialization
in urology all remained significant after adjusting for each
other. A larger department size appears to halve the
likelihood of a higher cut-oif point and urologists with a
subspecialist in the department were half as likely to
choose a higher cut-offpoint than ifno subspecialist were
present. Specialization for more than 20 years nearly
tripled the likelihood of preferring a higher cut-off point,
compared to specialization of less than 10 years.
For patients aged 70-79 years, only the presence of a
subspecialist remained significant, halving the likelihood
of preference for a higher PSA cut-off point level.
CONCLUSIONS
The results presented here are likely to be more widely
applicable to consultant urologists in the UK. However,
it has not been possible to compare the characteristics of
the responding urologists to the total BAUS consultant
membership because BAUS do not have such data. It can
be stated that the range of lengths of specialization in
urology, the range of sizes ofdepartment and the numbers
of patients with prostate cancer seen amongst the
respondents suggest that a full range is adequately repres¬
ented (see Results). Other surveys of urologists in the UK
with adequate response rates were sought for comparison.
Only one study, a surveyofurologists and general surgeons
with a special interest in urology18 conducted about the
same time as the present study, was found. This survey
investigated urological malignancies in general rather
than prostate cancer and the two surveys collected differ¬
ent demographic data on the urologists, so direct compar¬
ison between the two sets of respondents was not possible.
However, both surveys included a number ofsimilar ques¬
tions about treatment preferences for prostate cancer. For
example, where Savage et al.18 reported active treatment
being favoured by 91 % for poorly differentiated T1 disease
in patients less than age 70 years, 96% ofour respondents
favoured this and radiotherapy was favoured by 50% in
both surveys; in well-differentiated T1 disease in patients
. over age 70 years, Savage et al. reported 69% in favour of
observation alone, comparable to 66% favouring this
approach in our survey (in the case of a man aged 75 years,
PSAof20andGleasonscore3). Itseems unlikely, there¬
fore, that major response bias was occurring amongst our
'sample' of urologists, although it is possible that some of
the same urologists failed to respond to either survey.
With the reservations outlined above, we believe that our
findings are more widely applicable to consultant urolo¬
gists in the UK.
The PSA test is used as an aid in the detection of prostate
cancer in the great majority of cases in the UK. Urologists
tend to perform a PSA test irrespective of previous meas¬
urement by the GP. This may reflect 'blind' routine
testing, awareness that different assays yield different
results, knowledge that PSA values can fluctuate or a
combination of these.
Persuasive clinical arguments are frequently advanced in
support of formal screening systems using PSA for early
detection of prostate cancer. However, there is acute
conflict between this viewpoint and recent 'evidence-
based' recommendations regarding screening. This is
illustrated in the USA, where the American Cancer
Society and the American Urological Association both
recommend annual screening ofasymptomatic men start¬
ing at age 50 years, while the US Preventive Task Force
and the National Cancer Institute recommend neither
PSA nor DRE as screening tools for prostate cancer
detection. Despite these recommendations, use of the
PSA test in screening asymptomatic men in the USA
appears to be increasing.21 Recent systematic reviews of
evidence in the UK-1,22 have contributed to a policy
decision by the NHS Executive not to introduce formal
screening.28However, PSA testing iswidely available and
rising public awareness is likely to increase demand for
the test.
The number of commercially available PSA assays is
escalating. Standardization has become a major issue
internationally. Differences between the sixty-plus assays
currently available on the European market may create
difficulties in interpretation and comparability of.
incidence data.2<1 Three of the most common assays
have been shown to detect cancer at a reasonable level of
equivalence by one independent evaluation,28 although
there is conflicting evidence suggesting that one of them,
the Abott IMx assay, departs significantly from the other
(Hybritech Tandem-R).26 For the best possible interpre¬
tation of results, clinicians need to know which assay is
being used and to use information about the reference
range for the assay in question. However, the results of
the survey discussed here suggest that a notable propor¬
tion are unaware of the assay used and that standardized
technology and instructions for use are not sufficient to
secure standardized inteipretation of PSA results across
the range of clinical presentations in different specialist
service settings.
There is also some suggestion of broad ethnic and/or
geographic differences in average PSA levels in the male
population and a cut-off level lower than 3.0 has been
justified on these grounds as the level for recom¬
mendation of biopsy in an Asian (Japanese) group.10
Oesterling et al.22 also reported lower levels of PSA
amongst Japanese men than in age-matched Whites,
which was attributed to smaller gland size.
There is evidence that PSA concentration is directly
related to age.28-80 The PSA normal range of 0^1 ng/ml
does not take account of either age differences or
variations in prostate volume associated with age. Age-
specific normal reference ranges have been suggested by
Oesterling et al.29 and Dalkin et al.,81 with upper limits
as follows: age 40-49 years 2.5/- (Dalkin et al. did not give
a figure), 50-59 years 3.5/3.5, 60-69 years 4.5/5.4, and
70-79 years 6.5/6.3.
These variations in the detection of prostate cancer in
relation to different cut-off levels ofPSA suggest that the
search for a single absolute cut-offpointmay be misguided E
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and that, as Gillatt and Reynard32 concluded from their
case-control studies of four groups of men, the 'normal
range' should be adjusted depending upon the population
being assessed. While this is a sensible conclusion from
the available scientific evidence about PSA, we have
shown in this survey how consultant urologists in the UK
vary in their assessment of appropriate 'normal' cut-off
points for PSA in relation to men's age group. One-third
of the UK urologists assessed the normal range for men
aged 60-69 years as having a higher cut-off level than
Oesterling et al.28 or Dalkin et al.3' suggested and prob¬
ably more than half did so for the 70-79 years age group.
It appears that the majority of UK consultant urologists
would use a higher point, with therefore lower "sensitivity
but higher specificity and positive predictive value, before
investigating further in the case of older asymptomatic
men. These judgements may be informed by beliefs re¬
garding the value of treatment in relation to patients' age
and life expectancy and knowledge of the evidence that
PSA concentration is related to age. In the case ofyounger
men, perceived detection thresholds could be subject to
influence by defensive medical attitudes. These findings
may reflect a more cautious attitude in the UK compared
with a more aggressive surgical culture or wider diffusion
of a 'screening culture' in the USA. Greater ethnic diver¬
sity in the USA may also be an underlying factor.
The implications of our results for patient care are not
straightforward. Age-specific reference ranges in
principle should help to prevent overinvestigation of
mildly raised PSA, particularly in oldermen who may not
benefit from aggressive treatment. Published evidence
about the presence of cancer in men with PSA values less
than 4.0 ng/ml, the generally accepted 'normal' level
which the urologists in our sample appear to accept un¬
critically, suggests that for younger men this cut-off point
may be too high for the purpose ofdetection. On the other
hand, men of any age who attend larger referral centres
or centres with a subspecialist are more likely to have PSA
tests interpreted with reference to lower cut-off points
than in other centres and, thus, proceed to further
investigation by TRUS and biopsy. However, if they are
managed by a consultant at an advanced stage of their
urology career (>20 years' experience), a higher PSA level
is more likely to be used, thus reducing the likelihood of
further investigation. The generally conservative ap¬
proach to PSA interpretation in the sample as a whole
appears less pronounced amongst urologists in the early
stages of their consultant careers. While this may benefit
detection levels in men under age 70 years, it may also
imply a preference for radical treatments.33
These results imply that incidence rates of identification
of the disease are partly dependent upon service-related,
supply-induced differentials in patterns ofdetection based
on PSA testing. While it has been known that the
diffusion of PSA testing has contributed in part to the
international increases in the incidence of prostate
cancer, this study suggests that the overall increase masks
likely interregional and intraregional variation in the
stages of ascertainment of the disease. In addition, a
consequence of this variation is that in any trial c
screening or treatment for early prostate cancer, it i
crucial to implement tightly controlled and monitore
protocols for PSA interpretation in addition to stand
ardized assay technology.
Urologists' interpretations of PSA results in the UK ar
complex and conflicting, reflecting a mixture of servic
and individual consultant variations and uncertaint
about the performance of PSA technology and availabl
treatments. The results of this survey support the need 6
control the use of PSA testing. Guidelines to reduce th
scale of the routine use ofPSA testing in urology referrs
centres have been published in the UK since the surve
was conducted.3'' The effects of these guidelines shouL
be evaluated by monitoring of PSA testing rates an<
assessment of variation as in the study reported here.
This study formed part of a project funded by the NHS R&D Healt.
Technology Assessment Programme.
The views expressed in this paper are those of the authors and nc
necessarily those of the Standing Group on Health Technology, th
HTA Commissioning Board, the HTA Panel members or the De
partment of Health.
The Department of Social Medicine at the University of Bristol i
part of the Medical Research Council Health Services Researcl
Collaboration.
The authors are grateful to Dr Tim Peters for additional statistics
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Objectives—To describe the variation in
outpatient new to old ratios between con¬
sultants and between providers for seven
high volume specialties (four surgical,
three medical).
Design—This was a descriptive study at
consultant and provider unit level based
upon patient administration system data
from the South and West Regional Health
Authority for the financial year 1992-93.
Additional components of variance ana¬
lysis was used to distinguish individual
consultant effects from host institution
effects.
Setting—The former South Western
Regional Health Authority area from
Gloucestershire to Cornwall.
Subjects—Altogether 345 consultant firms
in seven specialties grouped into 13 pro¬
vider unit groups.
Main measures—New to old ratio, omit¬
ting elective inpatients followed up as out¬
patients.
Results—Variation between consultants is
greater in surgical than in medical spe¬
cialties, while absolute levels of new to
old ratios tend to be higher in surgical
specialties than in medical. Variation be¬
tween provider unit groups is also greater
in surgical specialties. Analysis ofvariance
shows that more total variance is at¬
tributable to provider unit group in gyn¬
aecology than in other specialties.
Conclusions—Within individual spe¬
cialties there is evidence of substantial
variation that is not attributable to under¬
lying differences in morbidity patterns.
There is evidence of marked variation in
terms of both individual consultants and
institutions, a finding that provides the
springboard for further analytical work.
Published routine outpatient activity stat¬
istics should distinguish between new re¬
ferrals, inpatient follow up, and clinic re¬
bookings.
(J Epidemiol Community Health 1997;51:310-314)
The importance of outpatient services in health
services policy is signalled by the UK Patient's
Charter waiting time targets. Service rate vari¬
ations are evident in many aspects of outpatient
services.1 A recent study has drawn attention
to historical trends in total outpatient workload
and in workload per consultant in the UK,2
suggesting that while the total number of hos¬
pital consultants has increased over the last 40
years, numbers of both follow up and new
patients seen per consultant have declined,
leading overall to relatively little change in the
total number of outpatients seen. The nature
of the historical "outpatient problem" is chang¬
ing as more flexible and complexmodels ofcare
delivery are being introduced at the primary/
secondary care interface.3 Further examination
of the processes of outpatient care delivery in
the National Health Service is therefore timely.
Routine workload activity data now available
can be disaggregated to examine separately
the different reasons for outpatient attendance
within specialties and within provider unit
groups.45
One approach to the problems of outpatient
workloads and waiting lists is to examine the
extent to which patients are recycled in out¬
patient clinics.267 It can be assumed that a
reduction in re-attendances within outpatient
clinics frees time in which, in principle, ad¬
ditional new patients may be seen. This is
indeed one reason for calls to increase the
proportions of consultations conducted by con¬
sultants, who are widely assumed to be less
inclined to recycle patients than are junior
staff.8 It is also part of the rationale for the
Patients' Charter requirement that all newly
referred patients be seen by a consultant. Also,
the value of routine outpatient surveillance for
a widening range of conditions is under scru¬
tiny—for example, asthma, hypertension,
rheumatoid arthritis, routine surgical follow up
for non-complicated cases, and follow up of
treated malignant conditions such as breast
cancer.9
The ratio of new to established ("old")
patients provides a measure of recycling. Vari¬
ation in this ratio has not previously been docu¬
mented at a hospital, specialty or consultant
level. Demonstration of substantial variation
beyond that expected from casemix differences,
provides prima facie evidence of variation in
clinical judgement and practices between in¬
dividuals and institutions. This can be a spring¬
board for further analytical work ultimately of
benefit to patients.10 For example, studies of
inpatient practice variations in the surgical man¬
agement of benign prostatic hypertrophy," led
to the identification of a critical level of vari¬
ation, stimulating trials of the effectiveness of
alternative therapies.
The aims of the present study are to describe
the variation in the ratio of new referrals to
re-attendances in the outpatient workload at
various levels of aggregation, to estimate the
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Specialty (no of consultant firms)
Variation in new to old referral ratios for outpatients in relation to consultant
respective contributions of organisational and
individual differences to the total variation ob¬
served, and to suggest plausible explanations




Summary data were analysed from the Patient
Administration System (PAS) Outpatientmod¬
ule implemented by South and West Regional
Health Authority. This is the routine data file
used for summarising information for Korner
returns (KH09) to the Department of Health.
Using the unique consultant code, data were
linked for the field: "Source of referral (this
attendance)". The figures for total new referrals
seen were generated from combining the
following referral categories: "GP referral",
"A & E referral", "Referral by other consult¬
ant", "Self referral", "Private patient (same
consultant)", "Domiciliary visit (same con¬
sultant)", "Outpatient attendance, other pur¬
chaser" and "Outpatient attendance, after
emergency admission". Old (established)
patient numbers were obtained from a single
code, "Outpatient attendance, this provider"
(defined as attendances initiated in the con¬
sultant clinic in which the patient is again
being seen). Inpatients admitted electively and
subsequendy followed up in outpatients were
excluded from the calculation of the ratio, since
_ their attendance represents a distinct element
of outpatient workload, separate both from re-
booked attendances and from new referrals.
Our new to old ratio differs therefore from the
new to follow up ratio which can be calculated
from the KH09 returns. Except for inpatient
follow up, these classifications to new or follow
up adopt the conventions used to derive the
Korner new and total follow up figures sub¬
mitted by regional health authorities to the
Department of Health.
Data were collected for all consultants within
the former south western region from the spe¬
cialties of general surgery, general medicine,
trauma and orthopaedics (T&O), paediatrics,
gynaecology, ear nose and throat (ENT), and
dermatology for the financial year 1992-93,
'
the most recent complete year available. These
specialties were selected because they are high
volume specialties spanning all ages and rep¬
resenting both surgical and non-surgical dis¬
ciplines . Consultant codes forwhich fewer than
200 consultations were recorded for the whole
year were excluded to avoid random variation
due to small numbers.
Hospitals have been grouped together into
"provider unit groups" to reflect the locations
in which individual consultants predominantly
or exclusively work. In cases where consultants
worked in more than one provider unit group,
the unit where most cases were seen was
deemed to be the consultant's base for the
purposes of analysis.
KEY POINTS
• Variation in the ratio of new referrals to
clinic re-bookings between consultants and
between provider units is greater among
surgical than medical specialties.
• Patients' likelihood ofbeing re-booked for
an outpatient consultation depends partly
on their place of residence within a (regional
health authority) catchment area.
• Evaluation of specialty-specific outpatient
service patterns should take account of in¬
stitutional effects as well as practice vari¬
ations between clinicians.
• Published routine outpatient activity in¬
formation should allow inpatient follow up,
clinic re-bookings, and new referrals to be
distinguished.
STATISTICAL METHODS
Interpretation of the new to old ratio may be
aided by recognising that it can be defined as:
l/mean no of re-attendances for each new patient
Any given ratio may therefore be alternatively
expressed as the number of re-attendances as¬
sociated on average with each new referral
attendance (in other words, the mean re-at¬
tendance). For example, a new to old ratio of
2.00 is equivalent to a mean re-attendance of
0.50.
Following descriptive analyses, the pro¬
portion of the variance in either the ratio or the
mean re-attendance attributable respectively
to the individual consultant/firm and to the
provider unit group was assessed using a com¬
ponents of variance analysis12 in Minitab for
Windows. Prior to undertaking these analyses
of variance, the validity of the assumption of a
PAPER 8














Figure 2 Variation in new.old ratios for outpatients between 13 provider groups within
seven specialties.
Table 1 Ratios of new referrals seen to re-attendances initiated in the consultant clinic,






General surgery (65) 0.33-2.15 0.65 0.81 1.04 0.20
Trauma and orthopaedics (60) 0.23-1.87 0.47 0.57 0.67 0.10
Gynaecology (51) 0.20-3.21 0.78 1.06 1.27 0.25
ENT (26) 0.32-1.78 0.67 0.84 1.19 0.26
General medicine (85) 0.07-1.12 0.23 0.30 0.44 0.11
Paediatrics (42) 0.03-0.64 0.20 0.32 0.45 0.13
Dermatology (16) 0.25-1.11 0.40 0.58 0.60 0.10
* Q (quartile deviation) = quartile 3 — quartile 114
2
Table 2 Magnitudes of absolute and inter-consultant firm variance in new.old ratios
Specialty No of Absolute inter- Absolute inter- Total
consultants/ consultant provider unit variance
firms variance group variance
General surgery (65) 0.110 - 0.024 0.134
Trauma and orthopaedics (60) 0.066 0.014 0.080
Gynaecology (49)* 0.143 0.113 0.256
ENT (26) 0.078 0.071 0.149
General medicine (85) 0.033 0.012 0.045
Paediatrics (42) 0.022 0.003 0.025
Dermatology (15)t 0.013 0.005 0.018
* Excluding two outliers; f excluding one outlier.
Gaussian distribution was assessed by the use
of normal plots and the Shapiro-Wilk test.13
For all specialties other than general surgery
and T&O, the new to old ratio was a closer fit
to a Gaussian distribution than was the mean
re-attendance, although for dermatology and
gynaecology it was necessary to exclude one
and two (very high) outliers respectively. For
general surgery and T&O, the results of the
analysis of variance for the new to old ratio
were nevertheless very similar to those for the
mean re-attendance and hence for simplicity
the results for all specialties are presented for
the new to old ratio.
Given the different numbers of consultations
involved for each consultant firm within a given
specialty, any such components of variance
models should account for the resultant differ¬
ential random variation. To achieve this, as
well as the unweighted analysis of new to old
ratios, two further approaches were adopted.
The first was an analysis of the new to old
ratios using weights in proportion to the total
numbers of new plus old consultations (these
were heuristic weights given that no simple
equation exists for the variance of such ratios).
The second analysis was of the number of new
consultations as a proportion (p) of the total
new plus old consultations (N), using weights
proportional to the inverse ofthe variance of the
proportion p (assuming a binomial distribution
these variances werep(l-p)IN). These analyses
are presented in table 3.
Results
VARIATION BY CONSULTANT FIRM
The main finding is the existence of marked
variation between consultant firms within spe¬
cialties in the ratio of new referrals to re-at¬
tendances (fig 1 and table 1). The greatest
variation is seen in gynaecology, ENT, and
general surgery, and the greatest overall range
in gynaecology and general surgery. Relatively
less variation was observed in T&O, general
medicine, paediatrics, and dermatology. These
findings were not altered by exclusion of con¬
sultants based in the Bristol teaching hospitals
whose outpatient practice might reflect the con¬
sequences of providing a tertiary referral ser¬
vice.
There was also notable variation between
specialties in terms of the absolute level of new
to old ratios as indicated by the medians in
figure 1. General surgery, gynaecology, and
ENT have relatively high ratios (lower mean
re-attendances), and general medicine and pae¬
diatrics have relatively low ratios (higher mean
re-attendances).
VARIATION BY PROVIDER UNIT GROUP
Since each of the provider unit groups in this
study is providing a general service to a local
population, casemix differences that may exist
between consultants can be reduced by ex¬
amining data relating to units rather than to
individual consultants. A degree of variation
clearly persists between provider units (fig 2),
although as anticipated this is less than the
variation between consultants. Absolute inter-
unit variation varies across specialties with the
non-surgical specialties exhibiting lower vari¬
ation.
It is useful in addition to examine what
proportion of the variation between consultants
is attributable to the effect of the unit in which
they work. The results of the components of
variance models are presented in table 2. Total
variance is highest in gynaecology, ENT, and
general surgery, consistent with the picture in
figure 1. Both the absolute inter-provider unit
PAPER 6
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Table 3 Percentages of variance attributable to provider unit group, calculated by three
different methods
Specialty
Percentage of variance attributable to provider unit group
Nezv:old ratio* New:old ratiof Proportion new%
General surgery 18.0 23.2 30.7
Trauma and orthopaedics 17.2 21.3 29.8
Gynaecology 44.1 46.2 55.4
General medicine 26.4 25.3 33.3
Paediatrics 13.6 21.9 25.5
■ Excluding ENT and dermatology because ofrelatively small numbers ofconsultants/consultations.
♦Unweighted analysis; f weighted by total numbers of new and old outpatient consultations;

























Figure 3 Variations in outpatient new:old ratios between seven specialties in 13 provider
unit groups.
group variance (3rd column table 2) and the
proportion of total variance attributable to pro¬
vider unit group are greatest in gynaecology
(table 3). This is the case regardless ofwhether
weighted or unweighted analysis of variance is
performed.
The total numbers of consultations in ENT
and dermatology are too small for reliable es¬
timates to be made of the relative size of inter-
provider and intra-provider group variance.
These specialties have been excluded from
table 3.
Figure 3 displays the new to old ratios for
all specialties in each provider unit group in
the region. There is variation in the likelihood of
re-attendance between the geographical areas
represented by different provider unit groups,
as shown for example by comparison of groups
K and L.
To assess the effect of the omission ofelective
inpatient follow up cases from the new to old
ratios, these attendances were analysed as a
proportion of total consultations for the three
consultant data points at each extreme of the
range in each specialty. This showed that for
all but one specialty there was no clear differ¬
ence in the proportion of total workload con¬
stituted by elective inpatient follow up between
the two extremes. The exception was ENT,
where consultant firms with the highest new to
old ratios also had relatively high proportions
of inpatient follow up in the workload (8.1%,
10.6%, 17.6%), compared with those with the
lowest new to old ratios, who conversely had
consistently low proportions of inpatient follow
up in their workloads (0.7%, 4.1%, 0.3%).
Discussion
The new to old ratio investigated in this paper
represents the balance between the two ele¬
ments of outpatient workload which account
for most patients seen. The variation in the
profiles of inter-consultant and inter-provider
ratios across specialties suggests strongly that
a specialty-specific approach is essential in ex¬
amining outpatient performance data. Of the
seven specialties examined here, the four with
the highest inter-consultant variance are sur¬
gical, and the three with the lowest variance
are broadly medical. This pattern of variation
seems specific to the outpatient setting. When,
for example, standardised inpatient discharge
ratios (defined as observed to -expected num¬
bers of discharges multiplied by 100) were
examined, wider range and variation were seen
in general medicine than in general surgery,15
the reverse of the pattern shown here for out¬
patients. This suggests that patients seen in the
outpatient setting present distinctive problems
of clinical management and organisation.
There are a number of possible reasons for
this variation. One potential explanation is arte¬
fact due to data inaccuracy. However, the data
demonstrate a reasonable and plausible level
of consistency. This was seen, for example, in
the relative magnitudes of new to old ratios in
the surgical compared with non-surgical spe¬
cialties—differences which make sense in¬
tuitively in terms of the higher proportions of
chronic illness seen in the medical specialties.
Hence in our view errors in data are unlikely
to have had a substantial effect upon the overall
profiles of variation found.
Some variation in the new to old ratio might
be attributable to the classification of sub-spe¬
cialisations. In gynaecology, for example, the
consultants/firms with the higher ratios (seeing
lower proportions of re-attendances) tended to
be classified as "gynaecology only", rather than
obstetrics and gynaecology combined. On the
other hand, the general medicine data excluded
recognised subspecialties such as cardiology,
neurology, respiratory medicine, and gastro¬
enterology. The persisting variation at provider
unit group level shows that classification of
subspecialties is not the full explanation of the
variation, even in gynaecology.
Variation in the ratio might theoretically also
be accounted for by different practice with
regard to outpatient follow up of elective in¬
patients. The data do not in general show such
an effect, except for ENT. In this specialty the
effect seems to be that higher elective inpatient
follow up is associated with a higher new to
old ratio, suggesting that "recycling" of out¬
patients is inhibited by the relatively high pro¬
portions of follow up of inpatients in the ENT
workload.
In summary, there is substantial variation
which requires explanation. The components
of variance analyses suggest that some variation
is attributable to features of provider units and
some to individual consultant behaviour. The
absolute variation attributable to consultants is
greater in surgical specialties than non-surgical
specialties (table 2). A number of possible ex¬
planations can be suggested. Surgeons may in
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general pursue more independent, individual
styles of practice than physicians due to differ¬
ences in self selection into the specialties,
education, or professional socialisation. De¬
velopment of special interests within the sur¬
gical specialties may be greater than in the
medical specialties. There was some suggestion
that this was the case in gynaecology. A con¬
sultant with one of the lowest rates of new
patient attendance had a particular interest in
subfertility, investigation and management of
which requires repeated visits. On the other
hand, checking of a sample of the consultant
firms in the other specialties at the extremes
of the ranges of mean re-attendance did not
suggest that generalist consultants (for ex¬
ample, general physicians) with particular
specialist interests (for example, gastro¬
enterology) tended to occupy the extremes. We
conclude that this explanation does not apply
generally.
A further possible explanation for inter-con¬
sultant variation is systematic variation in clin¬
ical judgement. It may be that the clinical
knowledge base in the surgical specialties is less
well rooted in clear evidence of effectiveness,
is more complex, and is less amenable to stand¬
ard-setting than is the case for medical spe¬
cialties. There, is certainly evidence from the
south west to suggest that many more clinical
guidelines have been developed in the medical
than in the surgical specialties (D Baker, per¬
sonal communication).
Effects at the level of the provider unit group
are also substantial, the greatest being observed
in gynaecology (table 2 and table 3). It is
unlikely that this variation can be wholly at¬
tributed to underlying morbidity differences;
the appropriate morbidity data are not avail¬
able, but a study of factors predicting high
mean re-attendance in another region in one
specialty found that diagnosis and disease se¬
verity combined were able to account for only
a small percentage (<20%) of the variance
found.20 In gynaecology, uncertain man¬
agement of conditions such as menorrhagia
and dysmenorrhoea may lead to hospital based
conventions of practice.16 It is likely that in¬
stitutional effects are operating. The hypothesis
of a consultant "signature"17 is not sufficient
to account for the total variance found in these
data; there are to some degree at least "in¬
stitutional signatures" which are worthy of fur¬
ther examination.
The currently published routine data are
generally unhelpful in analysing profiles of out¬
patient workloads.18 Measures specific to the
complex dynamics of outpatient workloads are
needed if a clear understanding of the reasons
for variation in outpatient practice in different
specialties is to develop. New data are not
required to enable the crucial distinction to
be drawn between the three key elements of
outpatient workload: inpatient follow up, new
referrals and clinic initiated re-attendances.
These data are already available within the
contract minimum data set for outpatient ser¬
vices. It would be straightforward to collate,
present, and publish them in this form.
The existing research record has not sys¬
tematically identified the key factors accounting
for the high degrees of variation in the pro¬
portions of new referrals and recycled patients
in outpatient workloads, though a number of
contributory factors have been identified.1920 A
complex array of factors is clearly involved.
The systematic identification of these is the
topic of a follow up study. The analysis pre¬
sented here does not permit optimal follow up
patterns to be inferred, but it does give new
support to the view that substantial numbers
of patients are attending unnecessarily or not
frequently enough.
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Study objective - To assess the scope for
reducing unnecessary outpatient re¬
attendances, using as a benchmark an
acute specialty at a site recognised to have
an especially low ratio of repeat to new
attendances.
Design - This was a survey of the re-
attendance workload at general surgery
outpatient clinics over a three month
period. Patient re-booking and discharge
rates for different grades of staff; clini¬
cians' perception of the ability of the GP
to have managed the patient; perception
of the value of individual re-attendances;
reasons given for discharging/re-booking;
and outcome of attendance for patients in
relation to diagnostic category were de¬
termined.
Setting - General surgery outpatient clin¬
ics with re-attendance rates that were 50%
below average, in Taunton and Somerset
Hospital, a non-teaching district general
hospital.
Patients - Altogether 454 patients who
made 470 second or subsequent visits (re-
attendances) within the same episode of
outpatient care.
Main results - Thirty eight percent (178/
470) ofvisits were perceived asmanageable
by the GP, 45% (79, 17% of total re-
attendances) of which were also thought
to have been ofmarginal or little value. A
substantial group of patients was being
followed up largely for reasons of con¬
vention and traditional policy. Re-booking
rates were higher among junior staff. Sub¬
jective views of the value of attendance
at the hospital outpatient clinic and the
ability of the GP to have seen the patient
varied systematically between consultants
and junior staff. Judgements varied to
some extent according to the diagnostic
group.
Conclusion - The numbers of patients
being followed up equivocally at most gen¬
eral surgical outpatient departments will
be 50% more on average than those in this
benchmark department. A department
seeing 2000 new patients per annum will
have 3600 reattendances, 25-5% (918) of
which may be avoidable on the basis of
these results. A variety of approaches can
be used to increase the proportion of
patients seen appropriately by GPs. In
some cases this might be achieved without
the intensive commitment required to plan
and develop shared care protocols or new
formal discharge guidelines, but by en¬
couraging GPs to manage some patients,
increasing of hospital clinicians' access to
knowledge of local general practices, and
internal clinic review of 'routine' follow
up policies as shown in this study. This
type of review of outpatient practice can
also help prioritise conditions likely to
repay the effort of developing and im¬
plementing clinical management guide¬
lines and local protocols.
(J Epidemiol Community Health 1995;49:599-605)
It is well known that repeat visits to outpatient
clinics account for between 75% and 80%
of all attendances recorded for this form of
healthcare.1 Perennial doubts have been ex¬
pressed within the medical profession over the
value of repeated reattendances both to patient
and clinician. The policy issues have been high¬
lighted by the recent National Audit Office
study,2 and subsequent review by the Par¬
liamentary Committee of Public Accounts.3
Innovation in National Health Service or¬
ganisation, notably general practitioner (GP)
fundholding, is leading to an increased scrutiny
of the legitimacy of outpatient re-bookings. In
spite of the many assertions, however, there
has been a relative lack of research or audit
based evidence about causes, reasons, and pos¬
sible justifications for the high levels of patients
invited to return for follow up. This type of
evidence is a prerequisite of attempts to design
and progress toward viable alternatives to tra¬
ditional outpatient reattendance or substitute
care arrangements involving primary care.
No published study has examined these is¬
sues in the high volume specialty of general
surgery, with its particular case mix and typical
reasons for re-attendance. Diagnostic cat¬
egories within specialties have generally not
been taken into account in previous analysis of
reasons for reattendance, although diagnosis
has been identified as one predictor of the
probability of discharge after the first at¬
tendance.4 A recent randomised trial of im¬
mediate discharge of selected surgical patients
from a teaching hospital to general practice has
concluded that primary care was of at least
equal clinical effectiveness, and was less costly
than traditional outpatient follow up.5 This
enhances the need to base discussions of al-
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ternatives to traditional follow up on an im¬
proved understanding of the dynamics of the
outpatient clinic.
A number of possible generic explanations
have been put forward for high reattendance
and rebooking rates in outpatient clinics on
the basis of studies in other specialties. In
particular, the influential role played by junior
hospital doctors in needlessly inflating out¬
patient clinic reattendance rates is frequently
asserted. There is evidence that they do recall
patients in higher proportions than do their
consultants,46"10 although some studies show
no difference.""13 This suggests that there is
no simple explanation ofobserved reattendance
rates and that other factors impinging upon
decisions to offer repeat visits should receive
more attention. The role of clinician status
in relation to the management of patients in
different diagnostic categories, and clinicians'
opinions on alternative management require
more in depth exploration.
This study describes the casemix of the out¬
patient workload in general surgical clinics,
explores the relationship between case specific
opinions about routine follow up as expressed
by members of the surgical team and their
actual management decisions, and analyses the
stated reasons why clinicians re-book patients
whom they believe could have been managed
by their GP.
The study took place in general surgery out¬
patient clinics at a non-teaching district general
hospital which had already introduced a policy
of not offering routine follow up appointments
to patients after uncomplicated surgery.14 This
odtpatient facility was staffed by consultants,
registrars, and senior house officers, organised
into four consultant "firms". The ratio of new
to reattending patients at the time of the study
was low (1:1-2). This compares with a ratio
of approximately 1:1-8 for general surgery
across the South Western Health Region as a
whole at the time of the study (KH09 returns).
The data analysed here thus refer to a de¬
partment in a high volume acute specialty, with
an exceptionally low proportion of re-
attendances compared with the norm, in which
only marginal scope for further planned re¬
duction in reattendances might be expected. If
however, there were shown to be substantial
scope for further reduction, then the im¬
plications for the nature and volume of out¬
patient practice in general surgery would be
very large indeed.
vey sample were cross checked against case
notes. The records of non-attenders and
patients for whom a questionnaire was not
completed were checked to validate the com¬
pleted questionnaire data; they were found to
be representative of the broad diagnostic cat¬
egories in the sample.
The questionnaire asked clinicians to in¬
dicate the main objective of each appointment,
the actions taken, the type of continuation of
care, and to rate, firstly, their perception of
whether or not the patient's GP could have
managed care and, secondly, their opinion of
the overall necessity of the visit on a four point
scale: "essential", "desirable but not essential",
"ofmarginal benefit", or "not particularly use¬
ful". An open ended question then asked them
to give in their own words a brief reason for
the latter two judgements. During the study
period, 559 follow up visits were planned. Forty
seven patients (8-4%) failed to attend; ques¬
tionnaires were not completed for 42 (7-5%).
Data were thus obtained for 470 second or
subsequent visits within the same episode of
care, by 454 separate patients. These 470 re-
attendances form the basis for the analysis
presented here.
Analysis of numeric data was by frequency
counts, cross tabulation, and descriptive sum¬
mary statistics (using the Epi-Info software
package). The association of qualitative vari¬
ables (grade ofstaff and clinician opinion; clini¬
cian opinion and perceived necessity of
outpatient visit) was analysed by means of the
X2 test with Yate's correction for two by two
tables. This analysis was not extended to case
mix, where aggregate of diagnostic groups
would have been inappropriate. The reported
textual data produced by the open ended ques¬
tions were transcribed, classified by content,
and hand counted by the first author (AF)
and the classification decisions of the verbatim
statements were checked by a second author
(MW) to ensure consistency and reas¬
onableness of interpretation.
Methods
All follow up attendances at the general surgical
outpatient clinics between July and September
1990 were surveyed. Examining doctors filled
in a self completion questionnaire for each
patient after the consultation, and further
patient details were obtained from the case
notes by one of the authors (A S-T). The
questionnaire was developed in collaboration
with the consultants in general surgery in the
unit. It was piloted on 30 patients and ap¬
propriate changes were made to ensure face
validity. All relevant clinical details for the sur-
Results
Three main clinical objectives accounted for
79-2% of outpatient reattendances in this
sample:
• Postoperative follow up;
• Returning for results/continuing investi¬
gations; and
• The monitoring or treatment of chronic or
malignant disease. Details of all objectives
are given in table 1.
The mean number of reattendances per
patient was 3-54, with a median of 2. Sixteen
patients had each made more than 14 re¬
attendances (with a maximum of 41). Table 2
gives the median (and range) reattendances for
each clinical objective. It also shows for each
objective the three main outcomes of ap¬
pointments, namely placement on a waiting
list, discharge to the GP, and a further invitation
to reattend. This illustrates, notably, that
patients with the stated objective of returning
for results or continuing investigations are
placed on a waiting list in the highest pro-
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Table 1
clinic
Main clinical objectivres for reattending patients in general surgical outpatient
Main clinical objective No (%)
Post-operative follow-up 114 (24-5)
Continuing investigations/returning for results 103 (21-9)
Monitoring or treatment of chronic/malignant condition 154 (32-8)





Miscellaneous 18 ( 3-8)
Total 470 1000
portions, and that patients attending for moni¬
toring or treatment of chronic/malignant
conditions are discharged at a relatively low
rate and have the highest proportion of re¬
booking.
One would expect the number of re-
attendances per patient to be related to the
diagnosis, and this is the case. Diagnoses have
been grouped according to ICD-9 codes. Table
3 illustrates the variation. Patients with the
highest mean re-attendances at the clinic are
those suffering from malignant neoplasms, col¬
itis or enteritis, and vascular disease. Those
with hernia, other bowel disease (motility dis¬
orders, ulceration or inflammatory changes re¬
lated to oesophagus, stomach or duodenum,
irritable colon or appendicitis), perianal con¬
ditions (haemorrhoids, pilonidal cyst, pruritis)
and venous conditions are recalled, in general,
on a more short term basis. Table 3 also shows
the number of cases, analysed by diagnosis, for
the extremes of reattendances and man¬
agement, namely patients discharged on their
first or second reattendance, and patients with
between three and nine reattendances who have
been asked to come again. It is clear that some
conditions tend to be associated with long term
attendance and that others have a much faster
"turnaround". The table confirms that in the
former category are, most clearly, malignant
neoplasms and vascular disease, and to a lesser
extent colitis/enteritis; and in the latter are the
specified types ofbowel disease, hernia, benign
neoplasms, and perianal conditions.
CLINICAL OPINIONS ON MANAGEMENT BY GP
In the survey period, reattending patients were
seen in the following proportions by each grade
of staff: consultants - 22-3% (105), registrars
- 52-6% (247), and senior house officers -
25-1% (118). Additionally, a consultant opin¬
ion was sought during one in four appointments
with registrars and one in three with senior
house officers.
Overall, clinicians judged that 38% (178) of
their appointments could have been seen by the
patient's GP. There was no notable difference
between the mean number of reattendances by
patients who could have been seen by their
GPs and those who could not (3-59; 3-61
visits), suggesting that the frequency of a
patient's attendance is not in itself a criterion
of appropriateness of reattendance for clini¬
cians. Of the patients stated to be returning for
results of tests (not for continuing in¬
vestigation), it was felt that the results could
have gone direct to the GP, thus avoiding the
appointment, in 33% (29/88) of the cases. Of
the patients returning for treatment, none was
deemed substitutable for GP care. Of the post¬
operative patients, it was considered that 47%
(54/114) could have been seen by their GP
instead, as could 40% (62/154) of those with
malignant or chronic conditions.
These figures differed critically according to
clinician status. Figure 1 indicates the mag-
Table 2 Reattendances and appointment outcomes for each clinical objective
Main clinical objective Reattendances Outcome of appointment
Median No Waiting list Discharged re-booked Other








Postoperative follow up 2 (1-30) 114 11-4 430 421 3-5
Continuing investigations/returning for results 1 (1-19) 103 27-2 42-7 24-3 5-8
Monitoring or treatment of chronic/malignant 3 (1-41) 154 7-8 23-4 64-9 3-9
condition
Treatment 1 (1-11) 41 4.9 36-6 561 2-4
Surgeon's interest
Patient's request
2 (1-20) 29 6-9 37-9 51-7 3-5
2 (1-25) 11 18-2 18-2 63-6 00
Miscellaneous 1 d-31) 18 22-2 55-6 16-7 5-5
2 (1-41) 470 13*4 35-5 47-0 40
* Including 3 missing
Table 3 ICD9 outcomes of reattendance and total numbers of consultations within episodes of care in relation to diagnostic group
Diagnostic group ICD9 codes Mean no of Median Discharged Discharged Rebooked Rebooked 10 + reattendances Other Total no of
reattend¬ reattend- 1st or 2nd 3rd-9th 1st or 2nd 3rd-9th (Discharge Rebook) outcomes* patients
ances ances reaitendance reattendance reattendance reattendance
Colitis/enteritis (555-558) 7-24 4 2 0 5 6 6 6 25
Malignant neoplasm (150-151, 153-154, 157, 172-174,
194, 199, 230-234) 5-32 3 8 3 31 37 5 11 13 108
Vascular (441, 442, 443^148) 412 2 9 4 16 13 2 4 12 60
Skin/breast (non malignant) (707-709, 611-7) 2-71 1 4 1 6 1 0 5 17
Benign neoplasm (210-238) 2-53 2 15 4 7 4 1 3 34
Perianal (455, 685, 698) 2-23 2 17 4 15 4 1 2 43
Hernia (550-553) 208 1 5 1 1 1 0 4 12
Venous (451^154, 456-459) 1-63 1 9 0 8 2 0 19
Bowel disease (530-537, 560-569, 570-579, 540-543) 2-20 1 32 4 5 4 0 20 65
Miscellaneous (240-242, 285, 392, 474, 527, 590-608,
619, 741-999) 1-98 1 14 6 13 4 1 8 46
No diagnosis 3-54 2 16 2 7 5 2 9 41
Overall mean \ 3-54 2 131 (28%) 29 (6%) 114 (24%) 81 (17%) 33 (7%) 82 (17%) 470 (100%)
* Outcome values were missing for one each case of "vascular", "hernia", and "no diagnosis".
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Figure 1 Outcome in relation to seniority of doctor and whether or not the patient could




Wailing list Discharged Re-booked Other
Consultants:
GP could have seen 3 12 5 0
GP could not have seen 15 21 34 7
97+8
Registrars:
GP could have seen 5 61 62 1
GP could not have seen 22 28 57 5
241 +6
Senior house officer (SHO):
GP could have seen 1 15 13 0
GP could not have seen 14 21 47 1
112 +6
X: waiting list =1-12, p =NS (0-5717); discharged = 13-82, p<0-001;
re-booked = 27-56, p<0001
nitude of the variation. Regardless of the out¬
come of the attendance, registrars felt the GP
could have seen the patient in 54% (129/241)
of reattendances overall, whereas for con¬
sultants the proportion was 21% (20/97) and
that for senior house offers was 26% (29/112).
The difference between the different grades
of staff was statistically significant for both
discharged and re-booked patients. For the two
objectives of postoperative follow up and of
monitoring chronic/malignant conditions, the
percentages which registrars assessed as being
appropriately seen by GPs were 65% (45/69)
and 60% (47/78) respectively. Only in cases of
colitis/enteritis and perianal conditions were
the views of registrars similar to those of con¬
sultants and senior house officers in assessing
that it would rarely have been appropriate for
the GP to have seen them. For all other diag¬
nostic groups, registrars viewed over half the
reattendances as possibly being manageable by
the GP. For patients returning for results of
investigations the three grades of staff were
consistent in estimating 20%-30% to have been
manageable by the GP. Of those deemed to
have been manageable by the general prac¬
titioner, 71% (15/21) were in fact discharged.
There is, however, some suggestion that they
saw a higher than average proportion of certain
conditions, especially in the case of enteritis/
colitis (44%, 11/25, seen by consultants, al¬
though these cases amounted to less than 10%
of consultants' workload in this study) and
benign and malignant neoplasms (29% (10/
34) and 24% (26/108), respectively, seen by
consultants). Many of these patients were long
term reattenders. For patients reattending for
their fifth time or more (n = 96), consultants'
proportion increased to 30% and registrars
reduced to 44%. Within this group, proportions
are the same for attendances with the explicitly
stated purpose of monitoring or treatment of
chronic or malignant conditions.
Of the 178 patients whom "the GP could
have seen", 5% (9) were nevertheless put onto
the waiting list, 49% (88) were discharged, and
45% (80) were asked to reattend again. For
those who were discharged, the average number
ofprevious attendances was 2-4; for those asked
to reattend it was 4-9 visits. In other words,
patients with a longer history of visits were
more likely to be asked to come again. For
those who clinicians felt could have been seen
by the GP but who were nevertheless re-booked
(80), the mean interval to the new repeat visit
was 32-4 weeks (median 26); for those re-
booked and not deemed manageable by the
GP the interval was only 20-6 weeks (median
12).
This study does not reproduce unequivocally
the common finding that junior staff discharge
patients at lower rates than consultants, al¬
though the trend is in this direction. Figure 1
shows the main outcomes of appointments for
each clinician status separately, with the pro¬
portions for each outcome which were assessed
as manageable by a GP. The ratio of those
discharged compared with those asked to re¬
attend varies somewhat between each clinician
status (consultants 1:1-1, registrars 1:1-3, se¬
nior house officers 1:1-6). On the other hand,
of the patients discharged by registrars, those
they assessed as capable of having been seen
by the GP outnumber those whom the GP
could not have seen by more than two to one
(68%, 61/89). Even among the appointments
with registrars who were asked to re-attend,
over Half (52%, 62/119) were nevertheless felt
to have been manageable by the GP. This phe¬
nomenon was much less marked in the case of
consultants and senior house officers. For con¬
sultants, of those discharged 36% (12/33) and
ofthose reattending again only 13% (5/39) were
felt to have been appropriate for the GP. For
senior house officers the corresponding per¬
centages were 42% (15/36) and 22% (13/60).
OUTCOMES OF ATTENDANCE: RATES OF
DISCHARGE AND RE-BOOKING
Consultants saw only a marginally higher pro¬
portion of newer patients in their workload,
than other grades of staff. Patients reattending
for the first or second occasion constituted 68%
of consultants' (71/105), 65% of registrars'
(161/247), and 61% of senior house officers
(72/118) workloads.
OPINIONS OF VALUE OF ATTENDANCE
In order to explain why a proportion ofpatients
whom clinicians felt could be seen by their
GP were nevertheless asked to reattend, the
subjective views of the clinicians in the context
of their working environment have been ana¬
lysed. Figure 2 indicates the outcomes cf con¬
sultation for patients assessed by the clinicians
either as capable or not capable of having been
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Figure 2 Outcome in relation to necessity of reattendance and whether or not the GP
could have seen the patient




GP could have seen:
Waiting list 3 4 2 0
Discharged* 12 28 29 18
Re-booked* 14 37 21 8
Other 0 0 0 0
176 (2)
GP could not have seen:
Waiting list 40 9 1 1
Discharged! 31 30 9 0





* X2 = 4-213 p<0-05 (essential/desirable v marginal/not particularly useful)
fX* = 1-54, p =NS (0-214); (essential/desirable v marginal/not particularly useful)
seen by their GP, and shows, for each of the
three key outcomes, their opinion of the value
of the attendance.
Of those reattendances which the hospital
clinicians felt could have been undertaken by
the GP, the current hospital outpatient ap¬
pointment was considered essential or desirable
for 46% of the discharged patients' ap¬
pointments (40/87) and 63-8% of those invited
to reattend (51/80). In other words, the cor¬
relation between the perceived ability of the
GP to have seen the patient and the clinician's
rating of the necessity of the appointment was
low. This varied systematically according to
clinician status. Consultants felt a hospital out¬
patient appointment to be essential/desirable
regardless of whether they felt that the general
practitioner could have seen the patient or not:
in 93% (90/97) of cases. On the other hand,
of the 128 appointments which registrars felt
appropriate for GP, they rated 44% (56) as of
marginal or little value, and for senior house
officers die corresponding percentage was 69%
(20/29).
There was some variation in these judge¬
ments according to diagnostic group, as shown
in table 4. Nearly one third (10/34) of the
visits of cases of malignant neoplasm deemed
manageable by the GP, but nevertheless asked
to reattend again, were rated as of marginal
value; conversely, none of this diagnostic group
(0/44), asked to. reattend and not manageable
by the GP, was regarded as of marginal value.
Of those reaUeiidances discharged and rated as
not manageable by the GP, only nine overall
were regarded as of marginal or little value; of
those discharged and rated as GP-manageable,
bowel disease stands out with 15/20 at¬
tendances regarded as ofmarginal or little value
(these 15 comprised diverticulitis (3), irritable
colon (3), oesophagitis (3), cholelithiasis cal¬
culus of gall bladder without cholecystitis (1),
acute pancreatitis (1), gall bladder - other ch¬
olecystitis (1), peptic ulcer unspecified (1), dys¬
pepsia/other stomach disorder (1), and anal
fissure (1)). None of the attendances of the six
discharged patients deemed GP manageable
with malignant neoplasm was regarded as
necessary. On the other hand, most of the
reattendances in this group for perianal con¬
ditions were regarded as desirable (8/11); the
balance of perceived necessity for outpatient
attendance among the other diagnostic groups
was more even.
REASONS FOR RE-BOOKING PATIENTS WHOM THE
GP COULD HAVE SEEN
The most critical group in this analysis is those
who were asked to re-attend even though they
were assessed as suitable for management by
the GP. Of this 38% (178), 55% (98) were
nevertheless regarded at least as desirable clinic
attenders, and 51 of these were re-booked.
Overall, 80 (45%) patients whom the clinicians
felt the GP could have seen were re-booked
Table 4 Perceived necessity of reattendance* for different diagnosis categories in relation to outcome of reattendance
fand perceived ability of GP to have seen patient
Diagnostic group Outcome = discharge Outcome = rebooked Total
GP could have seen GP could not have seen GP could have seen GP could not have seen
Necessary Marginal Necessary Marginal Necessary Marginal Necessary Marginal
Colitis/enteritis 0 1 0 1 1 0 13 3 19
Malignant neoplasm 0 6 9 0 24 10 44 0 93
Vascular 4 1 8 0 11 5 16 1 46
Skin/breast
(non-malignant) 0 1 4 0 2 2 2 1 12
Benign neoplasm 4 5 8 2 3 1 6 0 30
Perianal 8 3 8 1 2 1 14 1 38
Hernia 2 2 2 0 0 1 1 0 8
Venous 4 2 3 0 2 1 7 0 19
Bowel disease 5 15 11 4 0 1 11 4 43
Miscellaneous 7 6 4 0 5 1 11 1 35
No diagnosis 6 5 4 1 1 4 7 2 30
Total 40 47 61 9 51 29 127 9 373
* Perceived necessity has been summarised as follows: "essential" or "desirable but not essential" = "necessary", "of marginal
value" or not particularly useful" = "Marginal".
f Discharge and rebooking outcomes only are included in this table; of these, values were missing in 3 cases for "perceived
necessity" and in 12 cases for "Could GP see?".
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(figs 1 and 2). Analysis of the brief reasons
given in this survey by clinicians for re-booking
patients who could have been seen by the GP,
reveals a mixture of practical considerations,
routine, tradition, and policy underlying the
observed rates. Actual reasons included: "lack
of a request (either from the patient or the GP)
for the GP to see the patient", "tradition to
follow up breast cancer forever", "education
for ourselves and to keep the morale of the
patient up", "I didn't ask GP to", "we like in
this instance to see the result of our work", "we
like to follow up abdominal aortic aneurysms
ourselves", "GP did see, but we wanted to
also", "we like to follow up vascular cases for
a while"," GP lack of sigmoidoscope", "follow
up of graft patency", and other more vague
reasons, such as "routine", "requested for close
follow up", and "agreed to attend".
It is not possible to calculate absolutely clear
proportions for the different categories of
reason given, because interpretation of some
of the verbatim written responses was open to
doubt (for example "not requested" leaves it
unclear whether the GP, patient, or clinician is
being referred to). However, two types of
reason stood out as the most common. They
can be summarised as firstly: a lack of a request
either from the GP or the clinician for the GP
to manage the patient: at least 22/80 responses
(it is likely that some of those cases where no
reason was given (n = 16) also fall into this
category); secondly, routine or tradition (at
least 15 cases, of whom all except one had
diagnoses of malignancy, peripheral vascular
disease, or aneurysm). It is worth noting also
that although cumbersome discharge pro¬
cedures have often been suggested as the reason
for many unnecessarily re-booked patients, this
reason was not offered in any case by the
clinicians in this group.
Discussion
This study has implications for several im¬
portant aspects of the phenomenon of re-
attendance at outpatient clinics. Firstly, a high
performing, hospital outpatient service in gen¬
eral surgery was re-booking a significant pro¬
portion of patients for whom the appropriate
mode of management was open to doubt. The
low ratio of re-bookings to new attendances in
this unit suggests that the proportion of these
patients being recalled in most departments of
general surgery will be some 50% larger than
that reported in this study. The analysis was
able to show particular diagnostic categories
which would be candidates for review. A pro¬
portion of cases of bowel disease in particular,
amongst the diagnostic categories, might have
been reviewed as possible candidates for al¬
ternative management.
The difference in reattendance ratios be¬
tween this and other departments, and the
proportion of patients whose appropriate man¬
agement was open to doubt and were po¬
tentially dischargeable, can be used to estimate
the numbers of patients potentially dis¬
chargeable in an average department. As¬
suming a ratio of reattendances to new referral
attendances of 1-8:1 in a general surgery d
partment seeing 2000 new referrals per annui
there would be 3600 ieattendances. Mt
tiplying the proportion found in this study
be both manageable by die GP and rated as
marginal value or less (17%; 79/470) by 1
(proportion of reattendances 50% higher
average departments) gives an esdmate of 91
patient reattendances per annum (1-5x17%
25-5%; 25-5% x 3600) the necessity of who:
visit is likely to be equivocal amongst the clin
cians themselves.
Secondly, the outpatient management of
small but not negligible proportion of patien
seemed to be perpetuated simply for lack (
either part at the primary/secondary interfac
making positive moves to take active tt
sponsibility for changing the care arrange
ments.
Thirdly, some patients who had had surger
for malignant or life threatening condition
were being followed up essentially as a matter o
routine or tradition, as the consultants involvee
were well aware. These patients typically hac
long intervals between appointments - si:
months or more. Questions of alternativt
methods of follow up of patients with some o
these conditions are now actively being con¬
sidered in the United Kingdom.
Fourthly, the study shows the complex re¬
lationships between clinical case based opin¬
ions, clinical management practices, diagnostic
categories, and the primary/secondary care in¬
terface in influencing the outcome ofoutpatient
reattendance. Some 45% of the 178 patients
rated by clinicians as manageable by the GP
were nevertheless rebooked. This phenomenon
has been reported previously be Leitch et al in
respiratory medicine15 and Armstrong et al in
gynaecology and general medicine.10 The pres¬
ent study has been able to show in addition
that many of such attendances in general sur¬
gery are, in fact, regarded as desirable by clini¬
cians, and it has been able to describe and
analyse by diagnostic category the stated
reasons given for retaining patients who in
principle seem to be dischargeable. Account
must, therefore, be taken of clinical opinions
and reasons for retaining patients in addressing
the question of substituting GP care for the
clinic. Subjective assessments of the ability of
GPs to manage patients may not be entirely
consistent, but this study does indicate some
broad regularities. Data such as these provide
the basis for internal audit of clinical practices
and policies as well as for informed discussion
between clinicians, managers, and GPs. In¬
volvement ofGPs in research, development, or
audit activities in this complex area will be of
benefit in strengthening the basis upon which
practical changes to patterns of care might
be made. The extent of GPs' willingness to
participate in innovative developments can be
expected to depend in part upon their in¬
volvement in this type of review process, as well
as upon workloads and experience in particular
conditions.
Fifthly, the study provides evidence that re¬
gistrars, in particular, place high value on a
relatively small proportion of their attendances
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in comparison with consultants and senior
house officers. Consultants exhibited extremely
conservative, case-specific opinions. The
reasons for this are unknown. It may be that
consultants have experienced instances ofmis¬
management by GPs, or they may be out of
touch with general practice. Alternatively this
may reflect the commitment generated by pro¬
fessional specialisation, clinical authority and
responsibility, and relatively long term local ties
to the hospital. In some cases, registrars may
have more confidence in general practice be¬
cause of greater contact with GPs through
mutual education programmes, although in
many instances registrars are likely to see more
"routine" cases because of case selection within
the clinic. Lack ofcontactwith GPs, and greater
contact with consultants in clinic may also
explain why senior house officers' perceptions
were closer to those of the consultants than to
the registrars. Given the uncertainties in these
interpretations, there is a strong case for eval¬
uating experimentally the effect upon the
patient re-booking and discharge behaviour of
junior hospital doctors of experience in general
practice.
A number of practical approaches to im¬
proving the "appropriateness" of reattendance
at outpatient clinics have been proposed. These
include making discharge policy more explicit
and organising training for juniors,10 improving
the content of discharge letters to GPs espe¬
cially for chronic conditions,15 increasing con¬
sultant review of casenotes with directive plans
clipped to them,8 and the introduction of writ¬
ten guidelines for reattendance and discharge.16
All these types ofmeasures have been reported
as successful, and this study provides evidence
to support extension of their application in
general surgery.
Further practical measures and productive
avenues for research and development are sug¬
gested on the basis of the analysis presented
here. The study site provides a reference point
for discussion.between GPs and hospital clini¬
cians of the potential scope for discharging
patients to general practitioners, which could
be applied to other general surgical de¬
partments. Specific measures to consider in¬
clude: the feasibility of increasing practical
contact between clinic and GPs through means
such as educational activities; stimulating GPs'
ability and willingness to request discharge of
some patients;making better information about
local general practices' facilities and training of
GPs readily available to clinicians; and de¬
velopment ofmore explicit, agreed procedures
for the management of patients with particular
conditions. Given the typically long interval
until the re-booked appointment, it might be
possible to book selected repeat appointments
on a "pending GP intervention" basis, and
notify the GP with an invitation to consider
assuming responsibility for the patient.
The clear disparity between the perceptions
of consultants and registrars about the value of
repeat appointments and GPs' ability to see
patients suggests that there is potential for
general surgical departments to consider locally
the issues of both formal and informal clinical
policies on reattendance and discharge, and for
shared interval review of clinical criteria for
"routine" repeat appointments between con¬
sultants and junior staff. More generally, it
suggests that there is a strong case for com¬
parative research to examine the specific factors
which may account for the discharge and re¬
booking behaviour of junior staff in clinics with
different (high versus low) reattendance and
discharge performance.
In summary, clinicians in a general surgery
outpatient department perceived that there was
a large proportion of re-attending patients who
could appropriately have been seen by the GP,
but in many cases they were equivocal in
judging the appropriate site of care and acting
upon these judgments. There will doubtless
always be come discrepancy between the ag¬
gregate of clinicians' opinions and their clinical
actions. The method of review demonstrated
in this study can help prioritise conditions
which may be candidates for development of
alternative care arrangements across the prim¬
ary/secondary care interface. Indicators of pos¬
sible levels of "inappropriateness" should be
taken as the opportunity to review practices
in a manner sensitive to the complexities of
hospital outpatient practice as shown in this
study.
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Abstract
An interpretive qualitative study was carried out as part of a large cohort study of factors affecting outpatient re-
attendance. Individuals from three groups involved in the provision of care across the primary-secondary interface
were interviewed: patients, general practitioners and consultants. The aim was to explore understandings concerning
referral to and re-attendance at outpatients, and to elicit detailed descriptions of the complexities of the outpatient
experience for both providers and recipients of care at the primary/secondary interface, given the policy
commitment to a 'primary-care led National Health Service'. Semi-structured interviews were carried out with nine
individuals currently attending outpatients, ten general practitioners, and ten consultants. Transcripts were analysed
individually and cross-checked between analysts for validity of interpretation, to identify key themes and sub-
themes. Data were compared across the three groups. Negative case analysis was employed. Seven major issues were
identified, some of which could be identified with interests and experience of the three obvious groupings, and some
of which were common. The three groupings are not as homogeneous as is often supposed. From the cross-group
analysis common themes included: interpersonal communication, knowledge, power relations and anxiety/
reassurance. Issues of trust, social status, funding and consumerism/litigation were also highlighted. The analysis has
implications for altering the balance of care across the interface, for example in the finding of what could be termed
a dissonance in power perceptions, in that consultants perceived general practitioners as relatively powerful and
'able to influence things', whereas general practitioners often expressed themselves as relatively powerless and unable
to be proactive in 'reclaiming' their patients. The analysis highlights the complexity of the outpatient experience,
drawing attention to detailed areas of contradiction, irony and conflict in the total context of outpatient care. These
areas should be addressed in policy development designed to shift the balance of care further towards the primary
sector. © 1998 Elsevier Science Ltd. All rights reserved.
Keywords: Outpatient care; Primary-care led NHS; Primary-secondary care interface; Qualitative study
1. Background
The notion of a primary-care led NHS is the most
radical idea shaping current policy for health service
provision in the United Kingdom. It promises a
* Corresponding author. Tel.: +44-117-928-7282; Fax:
+ 44-117-928-7340; E-mail: m.somerset@bristol.ac.uk.
revolution in the organisation of healthcare which
has major implications for conventional hospital-
based service provision and consumption (NHS
Executive, 1994). It envisages a shift in power and
resources from secondary to primary care, with the
aim of bringing the planning and provision of care
'closer to patients'. The White Paper, 'The New
NHS' (Department of Health, 1997) provides a
framework for the development of Primary Care
0277-9536/98/$ - see front matter © 1998 Elsevier Science Ltd. All rights reserved.
PII: S0277-9536(98)00338-4
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Groups which will commission services for local
patients and improve the health of local people.
Until recently outpatient services, which lie at the
interface between primary and secondary care, have
received relatively little direct consideration in
national policy statements and debate about this rad¬
ical concept for restructuring healthcare (e.g.
Department of Health, 1996).
In contrast to other countries such as the USA or
France where patients may self-refer to consultant
specialists, in the United Kingdom, as in Australia and
Canada, the General Practitioner (GP) is the gate¬
keeper to outpatient services. As healthcare costs have
risen, policymakers in all the advanced industrialised
countries have begun to examine the appropriateness
of the site of healthcare delivery. The transfer of
patient care from the secondary to the primary sector
has been expected to contain costs and to parallel
other movements toward devolution and patient
empowerment.
The National Health Service (NHS) deals with ap¬
proximately 40 million outpatient attendances per year
in England and Wales, costing around £2.4 billion
(National Audit Office, 1991), and about 20%-25% of
these are new GP referrals. Attendance at specialist
outpatient clinics in the UK has remained a relatively
invisible issue in health services policy generally. While
waiting times for inpatient services have been the sub¬
ject of many research and government funding initiat¬
ives, waiting for outpatient services has until very
recently been a neglected issue (Pope, 1993). There is
no evidence to date from national routine data that
restructuring in the NHS has had a notable effect
upon outpatient discharge or re-attendance rates. Total
attendances at outpatient clinics in England alone,
having declined from more than 37 million in the mid-
1980s to just over 36 million in the late 1980s, rose
again from 1991, reaching 37.5 million in 1992-1993
and 38.2 million in 1993-1994 (Department of Health,
1993, 1994).
The White Paper 'Working For Patients' (Secretary
of State for Health, 1989) attempted to highlight the
idea of health professionals working in partnership in
order to 'streamline' patient care, as have later state¬
ments (NHS Executive, 1996). Further NHS policy
guidance has suggested mechanisms for improving the
flow of patients through the outpatient system (NHS
Executive, 1994). In the mid-1990s, the newly consti¬
tuted NHS R&D initiative has also begun to focus
some attention upon outpatient services, devoting a
large programme of research to the 'balance of care' at
the primary-secondary care interface. The more or less
explicit agenda of this programme is to examine the
feasibility and consequences of tipping the balance of
care further in the direction of the primary and com¬
munity sector, away from the hospital sector.
However, the benefits in terms of quality or effi¬
ciency of a primary-care led NHS are not unequivo¬
cally clear (Coulter, 1995, 1996). Both Coulter (1995)
and Szecsenyi (1996) have emphasised a need to under¬
stand patients' needs, values, perceptions and attitudes
in considering policy measures to improve care at
the primary-secondary care interface. To this, one can
add that the health professional's own values and
attitudes must be considered, for example in terms
of job satisfaction and perceptions of professional
responsibilities.
The problem of 'unnecessary' outpatient attendance
has been widely recognised (Marsh, 1982; Hartog,
1988; Samanta et al., 1991; Cartwright and Windsor,
1992; Dodd et al., 1994; Dunn et al., 1994; Ember,
1995, Neal et al., 1996; Reeve et al., 1997), and many
reasons for the recycling of outpatients have been
identified. While there may seem to be good clinical
reasons to discharge an outpatient to general practice,
in a busy outpatient clinic there may also be 'good or¬
ganisational reasons' (Garfinkel, 1967) not to do so.
While formal policy debate about services focuses
upon clinical or economic rationale for decision mak¬
ing, it- must also be acknowledged that outpatient ser¬
vices are embedded in a network of possibly
competing incentives for different parties, this is likely
to include non-clinical and non-economic 'real reasons'
(Emerson, 1991).
It has been conventional in some studies of outpati¬
ent care to focus upon relevant issues from the per¬
spectives of the three obvious parties involved:
patients, GPs and specialists. A number of studies
have examined the views and attitudes of these groups
(Grace and Armstrong, 1986, 1987; Cartwright and
Windsor, 1992; Dodd et al., 1994). It is unsurprising
that the general conclusion of these studies is that the
perspectives of the three groups diverge. However,
there has been an overemphasis upon this divergence
and the impasse between entrenched positions which it
suggests. This has tended to lead to a portrayal of
each of the groups as being relatively homogeneous
and resilient to change. In this study we attempt to
examine the issues which affect people involved in pro¬
viding and receiving care at the primary^secondary
care interface, as well as to identify different interests
or perspectives which are important in shaping the out¬
come of attempts to move towards a primary-care led
NHS.
The study explored the views and experience of out¬
patient attendance held by patients, hospital clinicians
and GPs and the professional interaction between clini¬
cians across the primary-secondary care interface,
within the context of shifting resources. The study
formed the preparatory hypothesis-generating phase of
a cohort study of which the aim was to identify the
key modifiable factors associated with long as opposed
we
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to short sequences of outpatient care following referral
from general practice. This involved observation of
patients newly referred from primary care to hospital
outpatient specialties of general surgery, general medi¬
cine, gynaecology, ENT and paediatrics.
2. Methods
2.1. Participants
Recruitment was purposeful, the aim being to
select a sample that would include participants best
able to address the central research question
(Marshall, 1996). A sampling framework, which
identified the variables most likely to provide rich
and relevant data, based on previous research experi¬
ence, was drawn up. Participants were then recruited
accordingly.
GPs and consultants were identified from Health
Authority lists. Those who matched the selection cri¬
teria were contacted by the research team and invited
to take part. There were 29 participants. This total
comprised:
1. Ten GPs from a range of practice sizes (single-
handed/multi-partnered), locations (urban/rural)
and fund-holding status. All the GPs at times
referred patients to the participating hospitals.
2. Ten consultants from a range of specialities,
although working in the participating hospitals,
none contributed to the main study.
3. Nine patients, all recently referred by their GP to
one of the participating hospitals. Three were wait¬
ing to attend, the others had attended once or sev¬
eral times. Patients were recruited via their referring
GP (who took part in the main study) and did not
subsequently take part in the main study.
The three parties were not linked, rather the sample
comprised 'critical cases' that is people who had
specific, relevant experience. It was envisaged that the
variation would result in greater insight and under¬
standing of the scope of difficulties encountered
throughout the referral process.
2.2. Interviews
A central principle of interpretative qualitative
research is that the participant's perspective on the
topic of interest is uncovered as viewed by the partici¬
pant rather than the researcher (Marshall and
Rossman, 1995). The interviews were semi-structured
as there was a very specific focus to the study, namely
the requirement to explore particular aspects of out¬
patient attendance. By eliciting the participant's own
views and emphases while maintaining a focus on
specific aspects, the semi-structured interviews com¬
prised a bound piece of qualitative work (Miles and
Huberman, 1994).
A list of broad issues to be covered was drawn up
on the basis of a previous review of outpatient ser¬
vices research (Faulkner and Frankel, 1993). The
schedule included issues relating to the initial refer¬
ral, expectations and experiences of outpatient at¬
tendance, and discharge to general practice. However
respondents, to a certain extent, guided the agenda
of the interview by demonstration of their enthu¬
siasm or lack of enthusiasm for topics. Later inter¬
views were informed by themes and issues raised by
other participants. By the ninth or tenth interview it
became apparent that no new themes were emerging.
The interviews were shared between three inter¬
viewers and lasted between 20 and 45 min. They
were carried out in the workplace in the case of the
hospital clinicians and GPs and at home for the
patients. They were tape-recorded and transcribed,
each interviewer transcribing those she had con¬
ducted.
2.3. Analysis of interviews
Initially transcriptions of the sets of interviews
with patients, consultants and GPs were examined
separately, each of the three researchers reading and
coding her own interviews. In order to enhance val¬
idity of the process of analysis, the researchers dis¬
cussed their readings and codings, and exchanged
transcripts to compare codes, themes, and interpret¬
ations of the text to ensure consistency of approach.
The interviews were read several times, and as seg¬
ments relating either directly or indirectly to aspects
of outpatient attendance were identified, they were
highlighted. Gradually repeated readings enabled
topics to be coded. Each researcher checked the cod¬
ings and themes of the other two, and a single set
of codes was finally agreed for all transcripts. The
manuscripts with the marked segments and codes
were then scrutinised again to identify broader
themes under which the marked segments were then
classified. The themes and segments were then re¬
considered in context and the insight they provided
on the respondent's perspective concerning each par¬
ticular topic was recorded. Interpretations were
checked against the transcribed texts in order to
evaluate their plausibility. Negative instances were
sought and by integrating further material into each
theme, the emergent framework was strengthened.
In the context of the larger cohort study, the
themes arising from the data were used to develop
hypotheses about factors influencing outpatient re-at-
tendance.
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The themes and interpretations resulting from this
process, as presented below, illustrate the diversity of
the range of issues, perceptions and views within and
across the three groups, the central aim of qualitat¬
ive research being to reach improved understanding
about the complexity of issues (Marshall, 1996) and
their range, rather than necessarily attempting to
demonstrate representativeness of a wider population
to which quantitative generalisations might be
drawn.
3. Findings
Participants were invited to consider their experience
and views of outpatient attendance beginning with the
initial referral from general practice and concluding
with discharge to GP care. Several themes which were
important to participants across the groups emerged
from this process. These themes are presented in
Table 1 below in turn, together with an interpretative
commentary and illustrative extracts from the inter¬
view data.
3.1. Trust and knowledge: who is the expert?
There was a consensus amongst the patients that
they had been referred appropriately to outpatients.
Essentially this was because they believed that their
condition required specialist advice which was best
provided by a hospital consultant, rather than the
GP who was trained to provide general care. To
some extent, a lack of trust in the GP's knowledge
was linked to the severity of the condition; that is
for patients who perceived their condition to be
serious, it was increasingly important to be referred.
Patients often contrasted the knowledge of the GP
and consultant, seeing the consultant as the 'expert
able to delve deeper', in contrast to the GP who
'relies on past experience rather than knowledge of
the condition'.
If it's anything of a serious nature, I certainly
wouldn't take the GP's word for it (P:S2)
You need specialist input for some things, I don't
think that GPs have enough knowledge (P:R2)
The GP can only touch the surface ... the consult¬
ants are the ones with expertise [they] can look into
it deeper (P:N1)
However, once patients had accessed the hospital
outpatient services there was a range of views relating
to doctors other than the consultants. The experience
of some patients led them to express great confidence
in the abilities of registrars and house officers, but
others implied they were unhappy with levels of knowl¬
edge and expertise:
Very competent, very much abreast with the con¬
sultant (P:R1)
I had the impression that the registrar was not ex¬
perienced because he had to leave to speak to the
consultant (P:R3)
GPs acknowledged the specialist knowledge of the
consultant, for example referrals were usually initiated
in order to access diagnostic procedures, treatment, or
management advice from a hospital clinician. Some
GPs maintained they would be more likely to refer to
a consultant who was known to them personally. In
addition it was recognised that referral to a consultant
was often a means of satisfying the patient's desire for
a second opinion from an 'expert'. Trust between hos¬
pital clinicians and GPs was important when the care
of a patient was transferred from one setting to
another. This was particularly the case where the hos¬
pital clinician had a limited knowledge of the commu¬
nity setting and was uncertain of the abilities of the
GP. Some GPs proposed that if consultants had more
belief in their capabilities, patients could be more
readily discharged back into primary care.
Table 1
Themes
Theme 1 trust and knowledge: who is the expert?
Theme 2 inter-professional communication: the key to attitudes between GPs and consultants?
Theme 3 communication with patients: a need for information?
Theme 4 non-clinical influences: do patient personality and social status count?
Theme 5 personal and professional anxiety: who needs reassurance?
Theme 6 power relations: who is in control?
Theme 7 changes in practice: is the price too high?
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You would just be slightly more cautious about
referring to people who you've never met because I
suppose you're not so confident in their knowledge
and expertise (GP8)
A significant minority [of my patients] will not
accept anything you say until they have had the lay¬
ing on of hands by the consultant (GP10)
I think generally consultants feel the need to hang
onto patients. I assume that's because they're not
confident that treatment will be followed-up ade¬
quately in general practice (GP2)
[re-attendance] is to do with trust between the con¬
sultants and the GPs and knowing the GPs and
their competence (GP10)
The views presented by the consultants largely con¬
firmed the perceptions of the GPs in relation to con¬
sultants' confidence in standards of primary care. As
anticipated by the GPs, there were some reservations
about levels of knowledge in general practice, some
consultants conceding they would be uncertain that
follow-up would be carried out satisfactorily if the
patient was discharged:
You lose control if you send them back to the GP
for something that the GP won't have the expertise
to deal with (C5)
You don't know what's out there, there are some
GPs you trust more than others (C4)
At the same time, there was some acknowledgment
of the advantages of the GP's knowledge, linked to the
perception that patients could overestimate the out¬
comes of referral to the clinic and hold unrealistic ex¬
pectations of hospital follow-up:
[The patients] may think they will be assuaged by
coming into hospital. That is a touching faith, but
it is probably better that continuity is handled by
someone who knows the family background (CI)
3.2. Inter-professional communication: the key to
attitudes between GPs and consultants?
While GPs identified clinical competence as a central
factor in the decision to refer a patient to a particular
consultant, this could only be ascertained through
their knowledge of the clinician. Thus, communication
was the key issue underpinning the choice of consult¬
ant for each patient. Information relating to a consult¬
ant was frequently derived from the GP's experience of
referral to that individual, so the manner in which a
consultant communicated with both patients and GPs
was crucial.
Certain consultants are more receptive to different
types of people (GP9)
The way they talk to people (GP2)
Does [that consultant take] my questions seriously
as well as the patient's (GP4)
Some GPs said specifically that the information that
filtered back from the hospital was frequently in¬
adequate and they would like more detailed manage¬
ment advice. They pointed to the difficulties in taking
over follow-up care for patients if there was a lack of
such advice from the specialist. The increase in detailed
management plans from clinicians at the senior regis¬
trar level, which comprised 'recipes to follow', was
favoured by the GPs who had received them. The GPs
also perceived the lack of communication between
members of the consultant team to be a problem, with
poor feedback between the consultant and junior
doctors being identified as a source of inappropriate
follow-up appointments.
There's absolutely no clinical information in the hos¬
pital letters whatsoever. It's completely useless (GP2)
I'm happy to have those kinds of [management]
guidelines to follow (GP10)
[re-attendance] is to do with how much feedback
there is from the junior members of the team to the
consultant (GP5)
there's a chemistry between the consultant and his
team and the patient which is working or not work¬
ing and that chemistry generates a repeat appoint¬
ment (GP4)
Communication was also a key issue for consultants.
The main mode of communication for hospital clini¬
cians was the GP's referral letter. On the whole, they
felt that referral letters provided them with adequate
information, although a minority were felt to be
"bland, non-committal ... and sometimes positively
unhelpful". Some consultants criticised the lack of
background details which could help the consultant
in the context of 'heavy-pressed clinics'. Others ident¬
ified two main types of referral, for specific pro¬
cedures or for diagnosis, each of which require
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different types and amount of information from the
GP. Information from the GP was felt to be less
adequate in the latter type of referral which 'often
will have a psychological basis which is difficult to
tease out'.
it's often peripheral but relevant information which
may not be in the hospital notes ... I think some¬
times they're frightened of committing to paper
things which are relevant but not strictly associated
with the primary complaint (C4)
they still haven't told me what's wrong from the
first consultation (P.N3)
[the consultant] is referring me back to the physio
again, but I've already been there and they said
they couldn't do anything ... it makes you wonder
what direction they're working in regarding my
complaint (P:R1)
it depends in your personality, whether you actively
want to be involved in your health or whether you
sit back and think "What will be will be" (P:R2)
3.3. Communication with patients: a needfor
information?
For many of the patients, the information they had
been given by their GP had not been adequate to
satisfy their questions about their illness. They priori¬
tised the need to obtain more information from the
hospital clinician. Several expressed the hope that
during the outpatient consultation they would be given
instructions to guide their behaviour at home. Usually,
they expected verbal information, although some felt
they would have liked written guidance from the hospi¬
tal clinicians:
a lot of the GPs have said, when I've gone up to
ask about things, they've said they don't have the
knowledge and they'll have to ring up and find out
things (P:R2)
Hopefully [the consultant] will tell me what I can
do and what I can't do (P:N1)
I'll probably get verbal information and the doctor
will get written ... leaflets wouldn't be a bad idea
though (P:N3)
Some re-attending patients were disappointed at
the lack of information they had received at the out¬
patient clinic. This was intensified by a frustration
that while investigations implied nothing was wrong,
their symptoms persisted. Others expressed uncer¬
tainty about the management decisions made at the
hospital, not knowing why the hospital clincians had
taken certain courses of action in relation to their
care. Some patients felt that the amount of infor¬
mation given by clinicians was partly dependent on
patient 'type', specifically people who are proactive
in their health and ask questions are provided with
better quality information.
they say it is not active but then why am I getting
these hellish pains? ... they've never really explained
it to me (P:R1)
3.4: Non-clinical influences: do patient personality and
social status count?
The GPs commented on the influence of explicit and
implicit patient demands on their decisions to refer.
The patient's social status and ability to articulate
verbally were put forward as tacit influences which
affect the liklihood of referral. The reason a patient
may wish to re-attend outpatients was linked to the
patient's perception of the consultant as 'Dr. Big'.
The patient factor or demand ... it's partly intelli¬
gence and that's of course linked to social status
(GP4)
the seeing of the consultant for the patients is actu¬
ally the important statement ... seeing The Man
(GP7)
The GPs also felt that consultants sometimes influ¬
ence patient attendances at the outpatient clinic for
non-clinical reasons. Specifically, whether a patient was
asked to re-attend at the outpatient clinic was partly
dependent on the nature of the relationship between
the patient and consultant. Patients who were 'nice'
and liked by the consultant would be more likely to be
seen again in the outpatient setting:
I have to say that with one or two patients you feel
it's because they've got such nice personalities and
the consultants enjoy seeing them (GP10)
We've all got our rotten patients. I'm sure the con¬
sultants have got them too, I bet the rotten ones
who get up your nose don't get re-attended (GP4)
The consultants similarly talked about non-clinical
factors which might influence the care patients
received. They recognised the implicit influence that
patient demands may have on the referral process.
However, some consultants acknowledged that an im¬
portant and appropriate service provided by outpati-
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ents is to give GPs a break from more 'difficult'
patients:
it almost seems they've been slung up to hospital
because the parents are sort of moaning and groan¬
ing philosophy (C2)
Sometimes it is clear that I'm just being asked to
take the patient off the GP's hands for a while and
that's an appropriate function of specialist care
(C9)
Interestingly, all three groups of participants,
patients, GPs and consultants, indicated that patients'
perceptions of their illness could in part be defined by
the care they receive. For the patients, the hospital
clinician's decision to discharge them to general prac¬
tice was interpreted as meaning de facto that the clini¬
cal condition was at least under control. In short the
prevailing view was that 'if you have been discharged
you must be all right'. Similarly, both the GPs and
consultants described how patients may define the
extent of their illness according to their attendance at
either the GP's surgery or the hospital outpatients. A
common perception was that for some people outpati¬
ent attendance lends credibility to their illness:
Hospital follow-up creates an illness mentality "I'm
ill because I'm seen at the hospital all the time"
(GP7)
Many patients like to be seen at the hospital, it gives
a certain credibility that they have a disease that has
progressed sufficiently severely that they have to
remain under surveillance at the hospital (C6)
3.5. Personal and professional anxiety: who needs
reassurance?
Some patients acknowledged that one outcome of
referral to outpatients was reassurance and optimism.
It was assumed that if several opinions were gained
this would be followed by a superior outcome, even
when some of the opinions were those of medical stu¬
dents. Similarly being discharged back to primary care
implied that the condition was improving and this
again provided comfort.
I was reassured by that because I thought, well
there's 25 more opinions about me (P:N3)
I was just relieved to be signed off because ... you
think I must be alright, they're letting me out
(P:N3)
GPs recognised the reassuring effect of referral and
suggested that they would be more likely to refer an
anxious patient, or one who was unable to accept the
explanation given to them in the primary care setting.
Many of the consultants also appreciated this feature
of outpatient attendance:
There are the patients who transmit anxiety to me
and therefore I refer them on (GP2)
They either don't have the confidence in me or I
can't put my message across (GP4)
I give a lot of patients the opportunity to say
whether they would like to come back [to outpati¬
ents] or not, because I think re-attendance is to
some extent reassurance (C7)
The consultants also agreed that it was appropriate
for GPs to use outpatients to lessen their own anxiety
about patients, with the proviso that the GP should
explain in the referral letter that this is the main reason
for requesting a consultation. This was described as a
'benign role' for them, which they were on the whole
entirely happy to fulfil:
There is nothing wrong with [the GP wanting reas¬
surance] as long as the GP acknowledges that in the
referral letter (C9)
in general I have a very strong feeling that if a GP
is worried about a patient, that is an appropriate
referral, even if when I see them I am not worried
about them ... that's what specialists are for (C7)
However in some cases outpatient attendance also
served to alleviate the concerns of the consultant. For
specialties such as gynaecology, where follow-up is less
common, the paucity of re-attending patients was a po¬
tential source of anxiety as the full implications of treat¬
ment may not filter back to the hospital consultant:
We do need feedback on what we are doing. I
assume that women given hysterectomies by me go
on to have a normal sex life, but would anyone tell
me if this was not the case? (C8)
3.6. Power relations: who is in control?
The power relation between doctors and patients
was a common theme in patients' discussions about
their experiences of outpatient attendance. Many of
them talked about the degree of influence they believed
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they had exerted in the decision to refer. Responses
ranged from those who believed the decision rested
entirely with the GP through to those who thought
that they were primarily responsible for the referral.
Appreciation was expressed by those patients who had
been asked for their opinion. When considering the
extent to which they were able to influence events
during their outpatient attendances, some patients
maintained that they would actively seek information
if they were left in any doubt about their care follow¬
ing discharge to general practice. However, there was
general acknowledgement that they did not have a suf¬
ficiently rich knowledge base from which to generate
appropriate questions. So for many patients there was
a general acceptance of the doctor's word, whether GP
or consultant. While this was total for some, others
expressed the desire to be more proactive in the de¬
cisions made about their care.
My GP initiated everything (P:R1)
Everything they have told me I have carried out, I
always have done (P:S 1)
But on the other hand:
I asked my GP if I could see someone else (P:S2)
My GP gave me a choice, so that was really good
(P:N1)
I want to be involved all along, I want to know
everything, to be told everything and go over it
time and time again (P:R2)
The power relation between GPs and consultants
was a contentious issue for GPs. For many, there was
a perceived inequality in the distribution of power
between primary and secondary care clinicians. While
GPs agreed with the principles of sharing patient care
with hospital clinicians, there were misgivings about
the extent to which this could take place. Some GPs
did not feel themselves to be equal partners in the pro¬
vision of shared care, but flather believed that they
were viewed as the 'second rate service'. The consult¬
ant was frequently seen as the powerful figure, and
there was a suggestion that the re-attendance of
patients in the outpatient setting was associated with
'empire building' on the behalf of some consultants:
The theory would be that we're on the same level
[but] the consultant's up there in the clouds, we're
somewhere down there on earth and the patient is
sub-terranean (GP4)
They like having a number of people ... I think they
get a buzz out of it ... I'm sure that's a factor that's
under-recognised in medicine (GP4)
I don't mind shared care so long as we're treated as
equals (GP5)
shared care brings the tier in ... whereby I'm defi¬
nitely number two ... you do tend to be seen as the
second rate service within shared care (GP2)
Conversely, there was a consensus among the con¬
sultants that the GP was a relatively powerful partner.
GPs were perceived to have the potential to exercise a
considerable amount of authority in decisions about
their patients. Indeed, some consultants expressed their
own feelings of powerlessness when discharging
patients back to general practice. However, while some
maintained that GPs were in a good position to
'reclaim' their patients from outpatient care, GPs were
also perceived as failing to exercise this power.
GPs have that much power, and like to influence
things ... You lose control if you send them back to
the GP (C5)
But on the other hand:
If nobody's stopping me seeing them again ... I
carry on ... I've never met anyone trying to control
the number of times I see the patient (C2)
3.7. Changes in practice: is the price too high?
For both the GPs and consultants, two recurring
sub-themes in relation to perceived changes in practice
were pressures associated with resource or funding
issues, and the threat of litigation. Some of the GPs,
particularly non-fund-holders, expressed concerns
about the impact of the fund-holding system on
patient care. The focus on finance over and above
clinical reasons for referral or outpatient attendance
was the key source of concern: that fund-holding could
result in 'inappropriate' medical practice. Patients of
fund-holding GPs were often felt to be at an unfair ad¬
vantage in gaining access to hospital services. Some
non-fund-holding GPs perceived themselves and their
patients to be on the bottom tier of a 'two tier health
service'. However, most of the fund-holding GPs
claimed that funding arrangments had not influenced
their practice with regard to referral or outpatient fol¬
low-up, although acknowledging that reductions in the
use of hospital services were financially beneficial for
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their practice. Nevertheless, the consultants recognised
an impact of funding on the practice of GPs, specifi¬
cally fund-holders, which was seen potentially to affect
the extent of re-attendance at outpatients:
one is always concerned that fund-holding will lead
to inappropriate medicine (GP4)
if you're a fundholder you sharpen your focus on
the kind of service you're getting a bit more, but
that focus is financial rather than necessarily clinical
(GP7)
I am not a fund-holding practice, and I do have
very strong feelings about what I see as the devel¬
opment of a two tier health service ... patients of
fund-holding practices are seen sooner, my patients
have to wait, I feel very resentful about that (GP2)
fund-holding ... hasn't altered my policy as regards
referral and follow-ups, but certainly our fund-hold¬
ing manager is pleased that people aren't being fol¬
lowed up long term in the hospital because it saves
money for the fund (GP5)
From the consultant's point of view:
if patients come to see me at the hospital the pay¬
ment has to be made, so particularly the fund-hold¬
ing general practitioners are going to look very
critically at the number of attendances (C6)
I perceive a gradual swing away from the amount
of re-attendance because GPs' minds have been
concentrated on trying to save money (C7)
The resource implications of moving care from out¬
patients to the primary care setting was a commonly
recurring issue for GPs. The majority of the GPs
expressed willingness to take over the routine follow-
up care of patients discharged from secondary care.
However there was an important caveat: would the
resumption of care of a large number of patients lead
to excessive work for already overstretched GPs?
I should be able to say I can take over again, [but]
one's always slightly concerned that generates work
for oneself (GP9)
there would be this slight concern on the GP's
behalf that he is going to increase his workload by
saving the hospital workload (GP4)
there is a large chunk of secondary care which is
moving to primary care ... it makes a lot of sense
for the patients and administratively for this to hap¬
pen, but it does have major workload implications
(GP7)
Concern about litigation was another important
issue for both GPs and consultants. The majority of
the clinicians acknowledged that the perceived or real
threat of legal action from a patient had some impact
on their practice. For many of the GPs, this affected
their referral behaviour. They would be more likely to
refer a patient if they felt there was a risk of legal
action. Some of the GPs perceived consultants to be
influenced by the legal implications of their practice,
resulting in an increase in investigations and follow-up
outpatient care. However, a minority of the GPs main¬
tained that the threat of legal action had little impact
on their practice, arguing that they did not practice
'defensive medicine'.
I might be defensive in some positions, if you
demanded a Cardiologist appointment for your
nebulous chest pain, I'd be hard placed to say
"Don't be daft" because I'm taking a thousand to
one risk of ending up in the high court (GP4)
I think we would tend to refer because of the fear
of missing and having the medical legal implications
of that ... and I would be very surprised if the con¬
sultant's investigations and follow-ups weren't
affected by that as well (GP8)
But on the other hand:
I don't feel that I practice medicine looking over
my shoulder ... I don't think defensive medicine
(GPIO)
Many of the consultants talked at length about the
effects of litigation on their work. Some of them
identified a sharp increase in the amount of legal
action taken against hospital clinicians, and pointed
to the negative impact on the way they think about
patient care. Some drew on their personal experience
of official complaints to argue that the threat of liti¬
gation was leading to clinicians practising defen¬
sively. The consultants also recognised that GPs
referring patients for specialist advice may be 'cover¬
ing their backs':
it's become horrendous, this has increased exponen¬
tially, I think it's having a serious effect on the way
we think about our patients and our practice ... I
think we're protecting ourselves more and more,
and I think it's disillusioning some of us (C7)
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I'm sorry to have to say and admit freely that
many of my actions are taken to try and limit the
possibility of litigation or complaint, because I've
experienced it (C4)
GPs feel they lack sometimes a little bit in the way
of expertise and they want the cover of someone
more senior to them ... there is an element of prac¬
tising defensive medicine (C2)
There was a consensus in the accounts given by both
groups of clinicians that the key factor in this per¬
ceived increase in the threat of litigation was the cre¬
ation of a 'consumerist culture' within the NHS.
Patients were held to have become customers or cli¬
ents, who purchase a service, and complain when
things go wrong. Public awareness about patients'
rights to complain and the means for doing so were
felt to have been greatly heightened. Government pol¬
icy developments, as well as advertising by legal firms
in hospitals, were all perceived to fuel a growth in
patient expectations, which may have become unrealis-
tically high:
people are becoming more litigation conscious,
more consumerist in their view ... they buy off the
shelf and I think the tendency for people to com¬
plain ... could be a major problem ... You only
need to have one complaint against you to have the
whole of your clinical view coloured by that (GP7)
the government is fermenting complaint by charter
attitudes and so on, and litigation is encouraged.
Our outpatient cards have a statement saying "If
you have any complaints or worries please contact
us" and on the back there's an address of a local
solicitor (C4)
the expectations of the patient are very high, maybe
unrealistically high (GP10)
4. Conclusions
Our analysis of outpatient care identifies some of the
obstacles which need to be negotiated if policy initiat¬
ives proposing a move towards a primary-care led
health service are to be implemented. An important
theme concerns the status of the GP. The traditional
perception of hospital consultants as the premier
source of knowledge about disease was largely upheld
by patients and GPs. Furthermore, some consultants
expressed concern about the level of expertise in the
general practice setting. This stereotypical picture
should however be tempered by the recognition that
there is acknowledgement of the distinctive skills and
understanding which GPs can provide, for example
their knowledge regarding patients' social and family
circumstances.
In agreement with previous research (Audit
Commission, 1994; Bowling et al., 1991; Jacobs and _
Pringle, 1990; Lloyd and Barnett, 1993; Ong et al.,
1995; Westerman et al., 1990), communication between
GPs and consultants was acknowledged to be a pro¬
blem, each party suggesting that the remedy rested
with the other. As it would seem that the quality of
communication was responsible for the opinions GPs
and consultants derived of one another, poor com¬
munication resulted not only in lack of information
about a particular patient but also created negative
attitudes for future working relationships. This seems
of crucial importance at a time when the need for
health professionals to work effectively together to
streamline patient care has been highlighted (Secretary
of State for Health, 1989).
Patients' hopes that hospital doctors would amend
the lack of information provided within general prac¬
tice were frequently not fulfilled. These expectations
seem to have been based on the belief that the hospital
doctor had more expert knowledge than the GP.
However, some patients felt they had been given a lot
of information about their condition from hospital
clinicians and this was often related to the extent to
which they perceived they were proactive in their care.
Others seemed to have little knowledge about their
condition and expressed great uncertainty about their
management by both GPs and hospital doctors.
Patients often felt that they lacked the necessary
knowledge to pose questions, were unclear who they
had seen at outpatients, and (sometimes) expressed
their frustration about contradictions between infor¬
mation from the GP and hospital.
In addition to clinical rationale, GPs and consultants
agreed that reasons for referral included responding to
patients' demands and expectations. This finding lends
support to previous research indicating that doctors
perceive pressure from patients to be a factor contri¬
buting to referral (Armstrong et al., 1991; Wilkie,
1992; Williams et al., 1995). However, each prac¬
titioner tended to identify the other party as the most
likely to be influenced by a patient's personality over
and above their physical condition. For many patients,
outpatient attendance was regarded as an indication of
more serious illness, and similarly discharge back to
primary care was seen as a sign of progress. The con¬
ventional view held by doctors that outpatient attend¬
ance was a source of reassurance to patients was thus
confirmed, but in addition GPs and consultants
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acknowledged they themselves drew comfort from
their patient's outpatient attendance. If people are
increasingly to be managed within primary care (NHS
Management Executive, 1991), this extra buffer of
reassurance may cease to exist.
Reservations have been expressed regarding the suc¬
cess of policies (Department of Health, 1992) directed
towards transferring power from secondary to primary
care and giving more power to patients (Coulter, 1995,
1996). The unequal and variable power relations which
emerged from our data between and within the three
groups, and the disparity in perceptions of relative
power, support the case for caution regarding the pace
of change.
Unequal power relations were felt particularly
acutely in the context of shared care. GPs perceived
consultants as the most powerful party in the GP-con-
sultant relationship and expressed feelings of power-
lessness in 'reclaiming' their patients back from
secondary care. There was also perceived powerlessness
to control their own workload. In contrast, the con¬
sultants did see GPs as powerful, although they
suggested that GPs often failed to exercise that power.
In terms of patient empowerment, although there
was evidence of proactive patients who felt they had
exercised choice in the initial decision to refer, there
were also passive patients who seemed content to relin¬
quish control to their doctors. Patients might often be
unaware of the extent to which they were able to influ¬
ence events concerning them. In several cases, they
were unquestioning of decisions because they regarded
the consultant, in particular, as highly knowledgeable.
This apparent discrepancy in status resulted in a lack
of power which further determined the care they
received. It appears that one type of measure required
to foster a primary-care led NHS is to support patients
and GPs in exercising the power over care which they
have, but of which they may not be aware (Faulkner
et ah, 1995).
Recent policy developments have focused on the
role of funding arrangements in the provision of effi¬
cient and effective health care (NHS Executive, 1994).
In terms of perceived changes in practice related to
funding issues, GPs regarded fundholding status differ¬
ently according to their level of involvement. Fund-
holders acknowledged that they examined services
more carefully for their financial costs, but maintained
that the clinical needs of patients remained paramount.
Meanwhile non-fund-holding GPs were concerned
about the development of a two tier health service,
contending that fund-holders were able to get a 'better
deal' from the hospitals. Hospital consultants were
aware of these issues, recognising that fund-holding
GPs in particular may be less willing to pay for some
hospital services, including follow-up in the outpatient
setting. Consultants and GPs also acknowledged that
there were resource implications for the 'sharing out'
of patient care. Once more, the implications for the
transfer of care to the primary sector were highlighted
by both parties. While GPs expressed willingness to
take over some patient care traditionally managed
within the hospital setting, they were again concerned
about the resource and workload implications of such
changes.
Litigation by dissatisfied patients was an issue raised
by both GPs and consultants, and they acknowledged
that the perceived increase in legal actions had influ¬
enced their practice. However, it did not seem an im¬
portant issue for the patients in our sample. This raises
the question of the extent to which litigation is a threat
for health professionals in today's NHS. Changes in
practice brought about by fears of legal action could
be a result of the broader policy changes within the
NHS which emphasise patients' rights to complain
about the quality of the service they receive, or they
could be a reflection of wider movements towards a
consumer society. In any case, the importance attached
to these issues by consultants and GPs indicates a con¬
siderable resistance to systems of care which would
reduce the capacity for second opinions, availability of
tests or doctor-initiated referrals and repeat consul¬
tations.
From the perspective of outpatient service policy in
the NHS, the high volume of outpatient attendances,
and especially re-attendances, appears irrational.
Certainly many attendances are unnecessary from a
strictly clinical point of view, however, as this study
has shown, every outpatient attendance is embedded in
a network of social and professional relationships and
meanings. Individual experiences of outpatient care
vary widely, be they patients, GPs or consultants.
Some exercise more power than others; some gain reas¬
surance; some give or receive more effective infor¬
mation; patients' subjective concepts of their illness
and the experience of care are intertwined; some
doctors fear legal repercussions of not offering care;
some deplore inequalities in access to services. It
would seem that experiences of outpatient care are
affected by many more or less conscious incentives -
reassurance, funding, relative power and authority,
consumerist culture, interpersonal perceptions, infor¬
mation and communication needs, professionalism and
perceived authority and trust.
A move toward an NHS in which primary care
plays a more pivotal role would need to bring with it
major changes in attitudes, power relations and organ¬
isational responsibilities. Funding arrangements and
the promotion of patients' rights to access information
and receive a good quality service have effected some
transfer of power, and encouraged some clinicians to
be creative in their use of both primary and secondary
care resources. However, while traditional views about
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the relative status and expertise of secondary and pri¬
mary care clinicians endure and the breakdown of
communication at the interface remains a barrier to
effective partnerships, the transfer of more substantial
power across the interface will not be fully realised. In
some aspects such as litigation, obstacles to increasing
the role of primary care are actually growing. As
Coulter (1996) has implied, change in culture among
health professionals and the public is required if
further transfer is to take place. But there may be a
fundamental contradiction between the traditionally
perceived trust, expertise and authority of the hospital-
based consultant, and the concept of an NHS built
around a consumer-oriented locally-driven system of
care planning and provision.
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